Sponsor,Study Title,Medicine or Vaccine (generic name),Sponsor Identification Number,Trial Registry Identification Number(s),Medical Condition,Phase,Link to Sponsor Study Registry,Link to study details on ClinicalTrials.gov (if available),Link to study details on EudraCT (if available),Analysis-ready dataset,Annotated case report form,Clinical study report,Dataset specifications,Protocol with any amendments,Raw dataset,Reporting and analysis plan,Additional Information about the data and documents available for this study,Date Added to this Site
GSK,"U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects with Acne",benzoyl peroxide/salicylic acid,STF114550,NCT01706250,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114550,http://clinicaltrials.gov/show/NCT01706250,,N,Y,Y,Y,N,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A protocol is not available for this study because only a draft version was located; no final version found in archives.,1-Aug-2015
GSK,"GSK1550188, A randomised, single-blind, placebo controlled, dose ascending, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE)",belimumab,BEL114243,NCT01381536,Systemic Lupus Erythematosus,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114243,http://clinicaltrials.gov/show/NCT01381536,,N,Y,Y,Y,N,Y,Y,An analysis-ready dataset is not available for this study. A protocol is not available for this study because an English language version was not created.,1-Jul-2015
GSK,"A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, versus Vehicle in Subjects with Plaque-type Psoriasis","calcipotriol, calcipotriene",STF114741,NCT00688519,Psoriasis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114741,http://clinicaltrials.gov/show/NCT00688519,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (clindamycin 1% and benzoyl peroxide 5%) to ACANYA™ Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) Topical Acne Medications,benzoyl peroxide/clindamycin phosphate,STF114546,NCT01015638,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114546,http://clinicaltrials.gov/show/NCT01015638,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2014
GSK,"A single-blind, randomized, comparative split-face study evaluating the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of acne vulgaris.",benzoyl peroxide/clindamycin phosphate,STF114547,NCT00964223,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114547,http://clinicaltrials.gov/show/NCT00964223,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Aug-2014
GSK,"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream when used in Combination with Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris",benzoyl peroxide/clindamycin phosphate,STF114566,NCT01016977,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114566,http://clinicaltrials.gov/show/NCT01016977,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Aug-2014
GSK,"A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris",benzoyl peroxide/clindamycin phosphate,STF114677,NCT00776919,Acne Vulgaris,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114677,http://clinicaltrials.gov/show/NCT00776919,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Aug-2014
GSK,"A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis","calcipotriol, calcipotriene",STF114743,NCT01139580,Psoriasis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114743,http://clinicaltrials.gov/show/NCT01139580,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and lisinopril,carvedilol,CFD109701,NCT00508365,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/CFD109701,http://clinicaltrials.gov/show/NCT00508365,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy",carvedilol,COR111096,NCT00624065,Hypertension,Phase 3,http://www.gsk-clinicalstudyregister.com/study/COR111096,http://clinicaltrials.gov/show/NCT00624065,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer",casopitant,NKV100781,NCT00440128,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV100781,http://clinicaltrials.gov/show/NCT00440128,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A single-blind, randomized, comparative pilot study evaluating the tolerability of two topical combination therapies in the treatment of acne vulgaris",benzoyl peroxide/clindamycin phosphate,STF114544,NCT00887484,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114544,http://clinicaltrials.gov/show/NCT00887484,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset is not available for this study.  An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2014
GSK,Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.,clobetasol,STF115054,NCT01323673,"Dermatitis, Chronic",Phase 4,http://www.gsk-clinicalstudyregister.com/study/115054,http://clinicaltrials.gov/show/NCT01323673,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days.",darotropium bromide,AC2108378,NCT00453479,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/AC2108378,http://clinicaltrials.gov/show/NCT00453479,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD,darotropium bromide,AC2110664,NCT00676052,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/AC2110664,http://clinicaltrials.gov/show/NCT00676052,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD",vilanterol/darotropium bromide,DB1111581,NCT00749411,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/DB1111581,http://clinicaltrials.gov/show/NCT00749411,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis",fluticasone furoate,FFR101782,NCT00570492,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFR101782,http://clinicaltrials.gov/show/NCT00570492,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis",fluticasone furoate,FFR110537,NCT00682643,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFR110537,http://clinicaltrials.gov/show/NCT00682643,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis",fluticasone furoate,FFR111158,NCT00730756,"Rhinitis, Allergic, Perennial",Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFR111158,http://clinicaltrials.gov/show/NCT00730756,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis",fluticasone furoate,FFU105924,NCT00539006,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFU105924,http://clinicaltrials.gov/show/NCT00539006,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis",fluticasone furoate,FFU105927,NCT00519636,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFU105927,http://clinicaltrials.gov/show/NCT00519636,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis,fluticasone furoate,FFU109047,NCT00502775,"Rhinitis, Allergic, Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFU109047,http://clinicaltrials.gov/show/NCT00502775,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)",fluticasone furoate,FFU111439,NCT00609674,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFU111439,http://clinicaltrials.gov/show/NCT00609674,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A randomised, double-blind, placebo-controlled, 4-period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 g, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids",fluticasone propionate,NSG110341,NCT00848965,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/110341,http://clinicaltrials.gov/show/NCT00848965,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma",fluticasone propionate/salmeterol,ADA109055,NCT00452699,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ADA109055,http://clinicaltrials.gov/show/NCT00452699,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma",fluticasone propionate/salmeterol,ADA109057,NCT00452348,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ADA109057,http://clinicaltrials.gov/show/NCT00452348,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season.",fluticasone propionate/salmeterol,ADA113872,NCT01192178,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/113872,http://clinicaltrials.gov/show/NCT01192178,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,ADC111114,NCT00784550,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/111114,http://clinicaltrials.gov/show/NCT00784550,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50mcg twice-daily in subjects with COPD",fluticasone propionate/salmeterol,ADC111117,NCT00633217,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/111117,http://clinicaltrials.gov/show/NCT00633217,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,ADC112355,NCT00857766,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/112355,http://clinicaltrials.gov/show/NCT00857766,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A study of fluticasone propionate/salmeterol DISKUS combination product 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease,fluticasone propionate/salmeterol,ADC113877,NCT01124422,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/113877,http://clinicaltrials.gov/show/NCT01124422,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma",fluticasone propionate/salmeterol,SFA106484,NCT00441441,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFA106484,http://clinicaltrials.gov/show/NCT00441441,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,FondaparinUx Trial with Unfractionated Heparin (UFH) during Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with Unstable Angina/Non ST segment elevation myocardial infarction (UA/NSTEMI) initially treated with subcutaneous fondaparinux and referred for early coronary angiography (OASIS 8),fondaparinux sodium,AR1108888,NCT00790907,Acute Coronary Syndrome,Phase 4,http://www.gsk-clinicalstudyregister.com/study/108888,http://clinicaltrials.gov/show/NCT00790907,,Y,Y,Y,Y,Y,Y,Y,The raw dataset is included within the analysis-ready dataset.,1-May-2013
GSK,Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE),fondaparinux sodium,AR3106206,NCT00981409,"Embolism, Pulmonary",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106206,http://clinicaltrials.gov/show/NCT00981409,,N,Y,N,Y,N,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Jul-2015
GSK,Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT),fondaparinux sodium,AR3111436,NCT00911157,"Thrombosis, Venous",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111436,http://clinicaltrials.gov/show/NCT00911157,,N,Y,N,Y,N,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Jul-2015
GSK,"An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)",GSK256066,IPR110723,NCT00612820,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/IPR110723,http://clinicaltrials.gov/show/NCT00612820,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asthmatic response in subjects with mild asthma",GW870086,SIG110762,NCT00857857,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110762,http://clinicaltrials.gov/show/NCT00857857,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder,lamotrigine,LBI108884,NCT00579982,Mood Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/LBI108884,http://clinicaltrials.gov/show/NCT00579982,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Lamotrigine Extended-Release in Elderly Patients with Epilepsy,lamotrigine,LEP105972,NCT00516139,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/LEP105972,http://clinicaltrials.gov/show/NCT00516139,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients",lamotrigine,SCA104779,NCT00550407,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA104779,http://clinicaltrials.gov/show/NCT00550407,,N,Y,N,Y,N,Y,Y,An extension study SCA106052 was conducted. An analysis-ready dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Jul-2015
GSK,"Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))",lamotrigine,SCA106052,NCT00566020,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA106052,http://clinicaltrials.gov/show/NCT00566020,,N,Y,N,Y,N,Y,Y,This is an extension study of SCA104779. An analysis-ready dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Jul-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects",omega-3-acid ethyl esters,LOV111819,NCT00435045,Hypertriglyceridemia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/OM9L,http://clinicaltrials.gov/show/NCT00435045,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in adult subjects with newly diagnosed type 1 diabetes mellitus,otelixizumab,OTX113390,NCT01222078,"Diabetes Mellitus, Type 1",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113390,http://clinicaltrials.gov/show/NCT01222078,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND,otelixizumab,OTX115495,NCT00678886,"Diabetes Mellitus, Type 1",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115495,http://clinicaltrials.gov/show/NCT00678886,,Y,Y,Y,Y,Y,Y,Y,A follow-up study OTX115496 was conducted.,1-Jun-2014
GSK,"A randomised, single-blind, placebo-controlled, study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending administration of otelixizumab in subjects with Type 1 Diabetes Mellitus",otelixizumab,RAO112438,NCT00946257,"Diabetes Mellitus, Type 1",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112438,http://clinicaltrials.gov/show/NCT00946257,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study -",paroxetine,PIR109164,NCT00557622,Post-Traumatic Stress Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/PIR109164,http://clinicaltrials.gov/show/NCT00557622,,N,Y,N,Y,N,Y,Y,An analysis-ready dataset is not available for this study.,1-Jul-2015
GSK,"A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study>",paroxetine,PIR112487,NCT00812812,Depressive Disorder,Phase 4,http://www.gsk-clinicalstudyregister.com/study/112487,http://clinicaltrials.gov/show/NCT00812812,,N,Y,N,Y,N,Y,Y,An analysis-ready dataset. A clinical study report and a protocol are not available for this study because English language versions were not created.,1-Jul-2015
GSK,"Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus",retapamulin,ALB110247,NCT00539994,"Infections, Bacterial",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ALB110247,http://clinicaltrials.gov/show/NCT00539994,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months",retapamulin,TOC106489,NCT00555061,"Skin Infections, Bacterial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/TOC106489,http://clinicaltrials.gov/show/NCT00555061,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL",retapamulin,TOC110977,NCT00684177,"Skin Infections, Bacterial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/TOC110977,http://clinicaltrials.gov/show/NCT00684177,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus",retapamulin,TOC110978,NCT00852540,"Skin Infections, Bacterial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110978,http://clinicaltrials.gov/show/NCT00852540,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open label, single-dose, fixed sequence, two treatment period study to assess the effect of haemodialysis on the pharmacokinetics of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR).","retigabine, ezogabine",RTG115214,NCT01480609,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115214,http://clinicaltrials.gov/show/NCT01480609,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIa study using 18F fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on macrophage activity in subjects with atherosclerosis",rilapladib,LP2105521,NCT00695305,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/LP2105521,http://clinicaltrials.gov/show/NCT00695305,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius,ronacaleret,CR9108914,NCT00548496,Fracture Healing,Phase 2,http://www.gsk-clinicalstudyregister.com/study/CR9108914,http://clinicaltrials.gov/show/NCT00548496,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Study CR9108963: A 12-month, randomized, double-blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with osteoporosis",ronacaleret,CR9108963,NCT00471237,Osteoporosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/CR9108963,http://clinicaltrials.gov/show/NCT00471237,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Clinical Evaluation of ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in subjects with advanced Parkinson’s disease,ropinirole,ROP106066,NCT00823836,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106066,http://clinicaltrials.gov/show/NCT00823836,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because an English language version was not created.,1-Oct-2015
GSK,"An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.",ropinirole,ROP109087,NCT00460148,Parkinson Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/ROP109087,http://clinicaltrials.gov/show/NCT00460148,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration),ropinirole,ROR113079,NCT00996944,Restless Legs Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113079,http://clinicaltrials.gov/show/NCT00996944,,Y,Y,N,Y,N,N,Y,A raw dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Jul-2015
GSK,"Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory",ropinirole,ROX107846,NCT00530790,Restless Legs Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107846,http://clinicaltrials.gov/show/NCT00530790,,Y,Y,N,Y,N,N,Y,A raw dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Jul-2015
GSK,An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4).,rosiglitazone,AVA102675,NCT00490568,Alzheimer's Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVA102675,http://clinicaltrials.gov/show/NCT00490568,,Y,N,Y,Y,Y,Y,Y,"This is a follow-up study to AVA 102670,  and AVA102672. An annotated case report form is not available for this study. A blank will be provided.",1-May-2013
GSK,An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5),rosiglitazone,AVA102677,NCT00550420,Alzheimer's Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVA102677,http://clinicaltrials.gov/show/NCT00550420,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to AVA105640.,1-May-2013
GSK,"A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)",rosiglitazone,AVA105640,NCT00428090,Alzheimer's Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105640,http://clinicaltrials.gov/show/NCT00428090,,Y,Y,Y,Y,Y,Y,Y,A follow-up study AVA102677 was conducted.,1-May-2013
GSK,An open label single oral dose study in patients with mild Alzheimer's disease to assess the pharmacokinetics of extended release formulation of Rosiglitazone (RSG XR) in this population,rosiglitazone,AVA109941,NCT00688207,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AVA109941,http://clinicaltrials.gov/show/NCT00688207,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus",rosiglitazone,AVD111179,NCT00679939,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/AVD111179,http://clinicaltrials.gov/show/NCT00679939,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease,rosiglitazone,AVD111960,NCT00879970,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/111960,http://clinicaltrials.gov/show/NCT00879970,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administered alone or in conjunction with intranasal fluticasone propionate on the symptoms of rhinitis in the Vienna allergen challenge chamber",SB705498,VR1111924,NCT01424397,Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111924,http://clinicaltrials.gov/show/NCT01424397,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2",sumatriptan/naproxen,TRX109011,NCT01812408,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX109011,http://clinicaltrials.gov/show/NCT01812408,,Y,Y,Y,Y,Y,Y,Y,The results of this study have been pooled with study TRX109013 and summarised on the GSK Clinical Study Register.,1-May-2013
GSK,"A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2",sumatriptan/naproxen,TRX109013,NCT00599157,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX109013,http://clinicaltrials.gov/show/NCT00599157,,Y,Y,Y,Y,Y,Y,Y,The results of this study have been pooled with study TRX109011 and summarised on the GSK Clinical Study Register.,1-May-2013
GSK,"Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults",sumatriptan/naproxen,TXA110948,NCT00792636,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110948,http://clinicaltrials.gov/show/NCT00792636,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris",tazarotene,STF114575,NCT01017146,Acne Vulgaris,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114575,http://clinicaltrials.gov/show/NCT01017146,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris",tazarotene,STF114576,NCT01017120,Acne Vulgaris,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114576,http://clinicaltrials.gov/show/NCT01017120,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia",vestipitant,NKI110334,NCT00606697,Sleep Initiation and Maintenance Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKI110334,http://clinicaltrials.gov/show/NCT00606697,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients",vestipitant,NKI111364,NCT00992160,Sleep Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111364,http://clinicaltrials.gov/show/NCT00992160,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects.,Human Papillomavirus Types 16 and 18 Vaccine,110168,NCT00492544,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110168,http://clinicaltrials.gov/show/NCT00492544,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109507,NCT00463437,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109507,http://clinicaltrials.gov/show/NCT00463437,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and reactogenicity study of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine administered as a booster dose to 18-23 months old children,"Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",110478,NCT00611559,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110478,http://clinicaltrials.gov/show/NCT00611559,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 3 and 4 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",112157,NCT00970307,Acellular Pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112157,http://clinicaltrials.gov/show/NCT00970307,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine administered as a booster dose in 12-18 months old healthy children,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",113978,NCT01171989,Acellular Pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113978,http://clinicaltrials.gov/show/NCT01171989,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of Kinrix® co-administered with Varivax®,"Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",111852,NCT00871117,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111852,http://clinicaltrials.gov/show/NCT00871117,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 3, 5 and 11 months of age.","Combined Diphtheria, Tetanus, Pertussis, HepB, Polio, Hib and Neisseria meningitis serogroup C tetanus toxoid conjugate vaccine",111761,NCT00871741,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Neisseria Meningitidis; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111761,http://clinicaltrials.gov/show/NCT00871741,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",104977,NCT00473668,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104977,http://clinicaltrials.gov/show/NCT00473668,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals’ GSK2036874A vaccine in healthy toddlers,"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",113264,NCT01106092,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113264,http://clinicaltrials.gov/show/NCT01106092,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age.","Combined Measles, Mumps, Rubella, Varicella Vaccine",110058,NCT00578175,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110058,http://clinicaltrials.gov/show/NCT00578175,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity & safety study of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine 208136,"Combined Measles, Mumps, Rubella, Varicella Vaccine",110876,NCT00751348,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110876,http://clinicaltrials.gov/show/NCT00751348,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase IIIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course","Combined Measles, Mumps, Rubella, Varicella Vaccine",109995,NCT00969436,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/109995,http://clinicaltrials.gov/show/NCT00969436,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix) when administered to healthy chinese children 6-8 years of age.","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",107924,NCT00406562,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107924,http://clinicaltrials.gov/show/NCT00406562,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix (dTpa) vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",108638,NCT00452686,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/108638,http://clinicaltrials.gov/show/NCT00452686,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Evaluation of GSK Biologicals’ dTpa booster vaccine in adults, given 10 years after previous dTpa boosting.","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110804,NCT00548171,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110804,http://clinicaltrials.gov/show/NCT00548171,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluation of GSK Biologicals’ dTpa booster vaccine in young adults 10 years after previous dTpa boosting.,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110806,NCT00610168,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110806,http://clinicaltrials.gov/show/NCT00610168,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluation of GSK Biologicals’ Boostrix® vaccine when compared with Decavac™ in adults aged 65 years or older.,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",BTX111413,NCT00835237,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111413,http://clinicaltrials.gov/show/NCT00835237,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Evaluation of GSK Biological’s dTpa-IPV booster vaccine in children and adolescents, 5 years after previous dTpa-IPV boosting.","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine",110947,NCT00635128,Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110947,http://clinicaltrials.gov/show/NCT00635128,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 5 to 6-year-old children.,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine",111815,NCT00871000,Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111815,http://clinicaltrials.gov/show/NCT00871000,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals’ combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites.","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",104567,NCT00412854,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104567,http://clinicaltrials.gov/show/NCT00412854,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and reactogenicity study of GlaxoSmithKline Biologicals' Infanrix™/Hib vaccine administered as a booster dose to 18-24 months old children,"Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",111535,NCT00696423,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111535,http://clinicaltrials.gov/show/NCT00696423,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine challenge in 7-8 year old children, previously vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals' HBV vaccine.","Hepatitis B Vaccine, Recombinant",110474,NCT00519649,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110474,http://clinicaltrials.gov/show/NCT00519649,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Immunogenicity and safety study of a GSK influenza vaccine candidate GSK 2115160A in adults.,Influenza Vaccine (Quadrivalent),111295,NCT00714285,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111295,http://clinicaltrials.gov/show/NCT00714285,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,Safety and immunogenicity study of GSK Biologicals’ cell culture-based influenza virus vaccine 1388442A compared with US licensed TIV in healthy adults,GSK1388442A,110127,NCT00693706,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110127,http://clinicaltrials.gov/show/NCT00693706,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A trial to evaluate the safety & immunogenicity of investigational influenza vaccine GSK1557484A in adults 18-64 yrs of age,H5N1 Pandemic Influenza Vaccine,111729,NCT00771615,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111729,http://clinicaltrials.gov/show/NCT00771615,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly adults.,Influenza Vaccine,112662,NCT00938392,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112662,http://clinicaltrials.gov/show/NCT00938392,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Non-inferiority study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A using different formulations.,Influenza Vaccine,111454,NCT00633074,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111454,http://clinicaltrials.gov/show/NCT00633074,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GSK Biologicals’ influenza vaccine Arepanrix™ (GSK2340274A) in adults 65 years of age or older,H1N1 Pandemic Influenza Vaccine,114270,NCT01114620,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114270,http://clinicaltrials.gov/show/NCT01114620,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340273A and GSK2340274A in adults aged 18 years and older,H1N1 Pandemic Influenza Vaccine,113440,NCT00985088,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113440,http://clinicaltrials.gov/show/NCT00985088,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years,H1N1 Pandemic Influenza Vaccine,113456,NCT00968539,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113456,http://clinicaltrials.gov/show/NCT00968539,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above,H1N1 Pandemic Influenza Vaccine,113459,NCT00968526,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113459,http://clinicaltrials.gov/show/NCT00968526,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 6 to 35 months,H1N1 Pandemic Influenza Vaccine,113462,NCT00971321,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113462,http://clinicaltrials.gov/show/NCT00971321,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in adults aged 18 years and older",H1N1 Pandemic Influenza Vaccine,113480,NCT00979602,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113480,http://clinicaltrials.gov/show/NCT00979602,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,A study to evaluate immune responses following A/California/7/2009 (H1N1)v-like virus vaccination given 4 months following seasonal influenza vaccination in adults 19 to 40 years of age,H1N1 Pandemic Influenza Vaccine,113483,NCT01059617,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113483,http://clinicaltrials.gov/show/NCT01059617,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ influenza candidate vaccine GSK2340274A,H1N1 Pandemic Influenza Vaccine,113519,NCT00989612,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113519,http://clinicaltrials.gov/show/NCT00989612,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Immunogenicity, safety and reactogenicity of GSK Biologicals’ influenza GSK2340272A and Fluarix™ 2009-2010 vaccines when co-administered in elderly subjects aged 61 years and older",H1N1 Pandemic Influenza Vaccine,113525,NCT00968890,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113525,http://clinicaltrials.gov/show/NCT00968890,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years,H1N1 Pandemic Influenza Vaccine,113528,NCT00964158,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113528,http://clinicaltrials.gov/show/NCT00964158,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunological equivalence between GSK2340272A and GSK2340274A influenza vaccines in adults aged 18 to 60 years,H1N1 Pandemic Influenza Vaccine,113535,NCT00979407,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113535,http://clinicaltrials.gov/show/NCT00979407,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,A study to evaluate the safety and immunogenicity of an A/California/7/2009 (H1N1)v-like vaccine GSK2340274A or GSK2340273A co-administered with trivalent inactivated seasonal influenza vaccine in adults 19 to 40 years of age.,H1N1 Pandemic Influenza Vaccine,113536,NCT00985673,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113536,http://clinicaltrials.gov/show/NCT00985673,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety of GSK Biologicals’ pandemic influenza candidate vaccine GSK2340272A,H1N1 Pandemic Influenza Vaccine,113572,NCT00971425,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113572,http://clinicaltrials.gov/show/NCT00971425,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years,H1N1 Pandemic Influenza Vaccine,113574,NCT00951041,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113574,http://clinicaltrials.gov/show/NCT00951041,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 8 to 12 weeks,H1N1 Pandemic Influenza Vaccine,113629,NCT01003418,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113629,http://clinicaltrials.gov/show/NCT01003418,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study.,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above,H1N1 Pandemic Influenza Vaccine,113630,NCT00975884,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113630,http://clinicaltrials.gov/show/NCT00975884,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years,H1N1 Pandemic Influenza Vaccine,113638,NCT00972517,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113638,http://clinicaltrials.gov/show/NCT00972517,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Immunological non-inferiority between two process-manufactured influenza vaccines in adults aged 18 to 60 years,H1N1 Pandemic Influenza Vaccine,113809,NCT00992511,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113809,http://clinicaltrials.gov/show/NCT00992511,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years,H1N1 Pandemic Influenza Vaccine,113810,NCT01014091,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113810,http://clinicaltrials.gov/show/NCT01014091,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in Japanese children aged 6 months to 17 years,H1N1 Pandemic Influenza Vaccine,113847,NCT01001169,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113847,http://clinicaltrials.gov/show/NCT01001169,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years,H1N1 Pandemic Influenza Vaccine,113866,NCT00989287,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113866,http://clinicaltrials.gov/show/NCT00989287,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety of Fluarix™/ Influsplit SSW® 2010/2011 or Pandemrix™,H1N1 Pandemic Influenza Vaccine,114454,NCT01160237,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114454,http://clinicaltrials.gov/show/NCT01160237,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,An observer-blind safety and immunogenicity study of GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340272A in children 3 to less than 10 years old,H1N1 Pandemic Influenza Vaccine,114495,NCT01161160,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114495,http://clinicaltrials.gov/show/NCT01161160,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.",H5N1 Pandemic Influenza Vaccine,107066,NCT00502593,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107066,http://clinicaltrials.gov/show/NCT00502593,,Y,Y,Y,Y,Y,Y,Y,The results of this study are summarised with studies 108498 (second cohort study) and 108500 (third cohort study) on the GSK Clinical Study Register.,1-May-2013
GSK,Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules,H5N1 Pandemic Influenza Vaccine,107495,NCT00430521,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107495,http://clinicaltrials.gov/show/NCT00430521,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years,H5N1 Pandemic Influenza Vaccine,109630,NCT00449670,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/109630,http://clinicaltrials.gov/show/NCT00449670,,Y,Y,Y,Y,Y,Y,Y,The results of this study are summarised with long term immunogenicity study 109873 on the GSK Clinical Study Register.,1-May-2013
GSK,A trial to evaluate the safety and immunogenicity of an investigational vaccination regimen in adults aged ≥18 years,H5N1 Pandemic Influenza Vaccine,110464,NCT00616928,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110464,http://clinicaltrials.gov/show/NCT00616928,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A trial to evaluate the safety and immunogenicity of monovalent H5N1 vaccine in adults >=18 yrs of age,H5N1 Pandemic Influenza Vaccine,110624,NCT00719043,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110624,http://clinicaltrials.gov/show/NCT00719043,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and safety of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine GSK 1557484A.,H5N1 Pandemic Influenza Vaccine,111756,NCT00742885,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111756,http://clinicaltrials.gov/show/NCT00742885,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluate the reactogenicity & immunogenicity of 1 or 2 booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in primed adults aged between 19 & 61 years,H5N1 Pandemic Influenza Vaccine,109817,NCT00506350,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/109817,http://clinicaltrials.gov/show/NCT00506350,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant",H5N1 Pandemic Influenza Vaccine,110028,NCT00510874,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110028,http://clinicaltrials.gov/show/NCT00510874,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules,H5N1 Pandemic Influenza Vaccine,111443,NCT00652743,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111443,http://clinicaltrials.gov/show/NCT00652743,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111443 are summarised with studies 111470, 111471, and 111472 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,A trial to evaluate the immunogenicity of accelerated primary vaccination with monovalent A/Indonesia/5/05 (H5N1) vaccine antigen in association with AS03 adjuvant in adults aged 18-64.,H5N1 Pandemic Influenza Vaccine,111626,NCT00695669,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111626,http://clinicaltrials.gov/show/NCT00695669,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Non-inferiority study of GSK Biologicals’ Pandemic influenza vaccine 1562902A.,H5N1 Pandemic Influenza Vaccine,111954,NCT00812981,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111954,http://clinicaltrials.gov/show/NCT00812981,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Hib-MenCY-TT vaccine compared to monovalent Hib control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",105988,NCT00345683,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105988,http://clinicaltrials.gov/show/NCT00345683,,Y,Y,Y,Y,Y,Y,Y,The results of this study 105988 are summarised with study 105987 on the GSK Clinical Study Register.,1-May-2013
GSK,"Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",110215,NCT00586612,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110215,http://clinicaltrials.gov/show/NCT00586612,,Y,Y,Y,Y,Y,Y,Y,A booster study 110217 was conducted. The results of this study are summarised with 110217 on the GSK Clinical Study Register.,1-May-2013
GSK,"Study in healthy children of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine, GSK2197870A, co-administered with Prevenar™ as a three-dose primary vaccination course in infancy followed by a booster dose of Menitorix™ at 12 months of age","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",111709,NCT00871338,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111709,http://clinicaltrials.gov/show/NCT00871338,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix™-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix™-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months.","Hepatitis B Vaccine, Recombinant",108984,NCT00456625,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/108984,http://clinicaltrials.gov/show/NCT00456625,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Long-term persistence of hepatitis B antibodies and immune response to a hepatitis B vaccine challenge in 12-13 year old adolescents, vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals’ HBV vaccine (Engerix™-B)","Hepatitis B Vaccine, Recombinant",112682,NCT00984139,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/112682,http://clinicaltrials.gov/show/NCT00984139,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"Antibody persistence and immune memory against the hepatitis B antigen in 11-12 year old children, previously vaccinated with DTPa-HBV-IPV/Hib vaccine in study 217744/031","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",113954,NCT01138098,Diphtheria; Tetanus; Acellular Pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b,Phase 4,http://www.gsk-clinicalstudyregister.com/study/113954,http://clinicaltrials.gov/show/NCT01138098,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Immunogenicity and safety study of GSK Biologicals' HPV vaccine (GSK-580299) co-administered with a commercially available vaccine in healthy female adolescents,Human Papillomavirus Types 16 and 18 Vaccine,110886,NCT00578227,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110886,http://clinicaltrials.gov/show/NCT00578227,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV vaccine GSK580299 in healthy female subjects aged 10-25 years,Human Papillomavirus Types 16 and 18 Vaccine,106069,NCT00481767,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106069,http://clinicaltrials.gov/show/NCT00481767,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly in healthy female subjects aged 15 – 25 years",Human Papillomavirus Types 16 and 18 Vaccine,107291,NCT00485732,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107291,http://clinicaltrials.gov/show/NCT00485732,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Safety and immunogenicity study of the HPV vaccine (GSK-580299) in healthy, Chinese, female subjects",Human Papillomavirus Types 16 and 18 Vaccine,107336,NCT00549900,"Infections, Papillomavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/107336,http://clinicaltrials.gov/show/NCT00549900,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV vaccine (580299) Co-administered with Boostrix Polio (dTpa-IPV) in healthy female subjects aged 10–18 years,Human Papillomavirus Types 16 and 18 Vaccine,108464,NCT00426361,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/108464,http://clinicaltrials.gov/show/NCT00426361,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]",Human Papillomavirus Types 16 and 18 Vaccine,108933,NCT00423046,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/108933,http://clinicaltrials.gov/show/NCT00423046,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15-25 years,Human Papillomavirus Types 16 and 18 Vaccine,109179,NCT00552279,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109179,http://clinicaltrials.gov/show/NCT00552279,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Safety and immunogenicity study of an additional dose of HPV vaccine (580299) in young, adult women in North America.",Human Papillomavirus Types 16 and 18 Vaccine,109628,NCT00546078,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109628,http://clinicaltrials.gov/show/NCT00546078,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluation of the safety and immunogenicity of GSK Biologicals' HPV vaccine 580299 when administered in healthy females aged 9 - 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing,Human Papillomavirus Types 16 and 18 Vaccine,110659,NCT00541970,"Infections, Papillomavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/110659,http://clinicaltrials.gov/show/NCT00541970,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (580299) co-administrated with a commercially available vaccine in healthy female adolescents,Human Papillomavirus Types 16 and 18 Vaccine,111507,NCT00652938,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111507,http://clinicaltrials.gov/show/NCT00652938,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects.,Human Papillomavirus Types 16 and 18 Vaccine,111567,NCT00637195,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111567,http://clinicaltrials.gov/show/NCT00637195,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female subjects.,Human Papillomavirus Types 16 and 18 Vaccine,111712,NCT00811798,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111712,http://clinicaltrials.gov/show/NCT00811798,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects,Human Papillomavirus Types 16 and 18 Vaccine,112022,NCT00996125,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112022,http://clinicaltrials.gov/show/NCT00996125,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Observer-blind superior efficacy trial with GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in elderly subjects,Influenza Vaccine,106372,NCT00753272,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106372,http://clinicaltrials.gov/show/NCT00753272,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in people aged 18 years or above,"Influenza Vaccine (Split Virion, Inactivated)",110221,NCT00476307,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110221,http://clinicaltrials.gov/show/NCT00476307,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥67 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference.,Influenza Vaccine,110223,NCT00538473,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110223,http://clinicaltrials.gov/show/NCT00538473,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥66 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference,Influenza Vaccine,110263,NCT00538213,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110263,http://clinicaltrials.gov/show/NCT00538213,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over,Influenza Vaccine,110620,NCT00532298,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110620,http://clinicaltrials.gov/show/NCT00532298,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656,Influenza Vaccine,110674,NCT00545025,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110674,http://clinicaltrials.gov/show/NCT00545025,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study.,1-May-2013
GSK,"Immunogenicity, safety and reactogenicity of GSK Biologicals' influenza vaccine GSK1247446A with various formulations in subjects aged 18-64 years",Influenza Vaccine,110794,NCT00540228,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110794,http://clinicaltrials.gov/show/NCT00540228,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,Observer blind immunogenicity and safety study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A with various formulations in adults aged 65 years and above,Influenza Vaccine,110847,NCT00540592,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110847,http://clinicaltrials.gov/show/NCT00540592,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in people aged 18 years or above,"Influenza Vaccine (Split Virion, Inactivated)",111631,NCT00706563,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111631,http://clinicaltrials.gov/show/NCT00706563,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects.,Influenza Vaccine,111737,NCT00760617,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111737,http://clinicaltrials.gov/show/NCT00760617,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Safety and immunogenicity of the influenza vaccine GSK2186877A in the elderly,Influenza Vaccine,111738,NCT00772889,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111738,http://clinicaltrials.gov/show/NCT00772889,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety of GSK Biologicals’ thimerosal-free TIV flu vaccine versus a licensed comparator in children,"Influenza Vaccine (Split Virion, Inactivated)",111751,NCT00764790,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111751,http://clinicaltrials.gov/show/NCT00764790,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,Observer-blind immunogenicity study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly subjects,Influenza Vaccine,112147,NCT00765076,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112147,http://clinicaltrials.gov/show/NCT00765076,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,A Phase III study for evaluation of immunogenicity and reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in people aged 18 years or above,"Influenza Vaccine (Split Virion, Inactivated)",113018,NCT00920374,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113018,http://clinicaltrials.gov/show/NCT00920374,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects,Influenza Vaccine,113094,NCT00992784,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113094,http://clinicaltrials.gov/show/NCT00992784,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of a GlaxoSmithKline Biologicals’ candidate influenza vaccine GSK2321138A in healthy children,Influenza Vaccine (Quadrivalent),113237,NCT00985790,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113237,http://clinicaltrials.gov/show/NCT00985790,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Safety and immunogenicity of GSK2186877A candidate seasonal influenza vaccine in healthy children 6 to 35 months of age.,Influenza Vaccine,114182,NCT01096056,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114182,http://clinicaltrials.gov/show/NCT01096056,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,A phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™/Influsplit SSW® 2010/2011 in people aged 18 years or above,"Influenza Vaccine (Split Virion, Inactivated)",114292,NCT01144299,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114292,http://clinicaltrials.gov/show/NCT01144299,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"Observer blind study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A administered to adults over 65 years previously vaccinated with the same vaccine, compared to Fluarix™",Influenza Vaccine,109821,NCT00529516,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/109821,http://clinicaltrials.gov/show/NCT00529516,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007 – 2008 Season) in Adults Ranging in Age from 18 to 60 Years and 61 Years and Over","Influenza Vaccine (Split Virion, Inactivated, Fluviral)",110502,NCT00505453,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110502,http://clinicaltrials.gov/show/NCT00505453,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of a single injection of GSK Biologicals' Trivalent Split virion Influenza vaccine Fluviral® (2008 - 2009 Season) in adults aged 18 to 60 years and over 60 years.,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",110584,NCT00718120,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110584,http://clinicaltrials.gov/show/NCT00718120,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GSK Biologicals’ (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",110628,NCT01153685,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110628,http://clinicaltrials.gov/show/NCT01153685,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age from 18 to 60 Years","Influenza Vaccine (Split Virion, Inactivated, Fluviral)",111258,NCT00586469,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/111258,http://clinicaltrials.gov/show/NCT00586469,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",110586,NCT00929331,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110586,http://clinicaltrials.gov/show/NCT00929331,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax™ ACWY or naïve to meningococcal vaccination.,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",107408,NCT00661557,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/107408,http://clinicaltrials.gov/show/NCT00661557,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109067,NCT00453986,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109067,http://clinicaltrials.gov/show/NCT00453986,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Study to assess immunogenicity, reactogenicity and safety of primary vaccination with GSK Biologicals' MenACWY vaccine (GSK134612) given as 1 or 2 doses to healthy toddlers 9-12 months of age","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109375,NCT00471081,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109375,http://clinicaltrials.gov/show/NCT00471081,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 112021 was conducted.,1-May-2013
GSK,"Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109377,NCT00454909,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109377,http://clinicaltrials.gov/show/NCT00454909,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Non-inferiority of GSK Biologicals' Meningococcal vaccine GSK134612 versus Mencevax™ in healthy subjects aged 2 through 10 years of age,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109495,NCT00514904,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109495,http://clinicaltrials.gov/show/NCT00514904,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109835,NCT00508261,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109835,http://clinicaltrials.gov/show/NCT00508261,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of one dose of GSK Biologicals’ meningococcal vaccine GSK 134612 (blinded lots) versus one dose of Menactra® in healthy subjects aged 10-25 years,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",MEN114249,NCT01165242,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114249,http://clinicaltrials.gov/show/NCT01165242,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108658,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"This study is summarised with long term immunogenicity studies 108660 (year 1), 108661 (year 2), 108663 (year 3) and 108665 (year 4) on the GSK Clinical Study Register.",1-May-2013
GSK,Non-inferiority of GSK Biologicals’ meningococcal vaccine 134612 given concomitantly with GSK Biologicals’ Twinrix™ versus 134612 alone and Twinrix™ alone in healthy subjects aged 11 through 17 years.,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109063,NCT00465816,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109063,http://clinicaltrials.gov/show/NCT00465816,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Primary vaccination study in subjects aged 11-17 years to demonstrate the non-inferiority of GSK Biologicals' Meningococcal vaccine GSK134612 vaccine versus Mencevax™ ACWY,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109069,NCT00464815,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109069,http://clinicaltrials.gov/show/NCT00464815,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",109670,NCT00474266,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109670,http://clinicaltrials.gov/show/NCT00474266,,Y,Y,Y,Y,Y,Y,Y,A follow on study 112036 was conducted.,1-May-2013
GSK,Immunogenicity & safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers.,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",110870,NCT00614614,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110870,http://clinicaltrials.gov/show/NCT00614614,,Y,Y,Y,Y,Y,Y,Y,A booster study 110871 was conducted. The results of this study 110870 are summarized with 110871 on the GSK Clinical Study Register.,1-Jun-2015
GSK,Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 when co-administered with GSK Biologicals’ pneumococcal vaccine GSK1024850A in healthy 12-23-month-old children previously primed with GSK1024850A,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",111393,NCT00758264,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111393,http://clinicaltrials.gov/show/NCT00758264,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 109661 and 109861.,1-May-2013
GSK,Non-inferiority of GSK Biologicals’ meningococcal vaccine (GSK134612) compared to licensed MenC-CRM197 conjugate vaccine in healthy children,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",111414,NCT00674583,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111414,http://clinicaltrials.gov/show/NCT00674583,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety study of one dose of GSK Biologicals’ meningococcal vaccine GSK 134612 (blinded lots) versus one dose of Mencevax™ ACWY in healthy subjects aged 18-25 years,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",MEN114248,NCT01154088,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114248,http://clinicaltrials.gov/show/NCT01154088,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Prophylactic antipyretic treatment in children receiving booster dose of pneumococcal vaccine GSK1024850A and DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) and assessment of impact of pneumococcal vaccination on nasopharyngeal carriage,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107137,NCT00496015,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107137,http://clinicaltrials.gov/show/NCT00496015,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 107017,1-May-2013
GSK,"Booster vaccination course with the pneumococcal vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in children who completed the primary vaccination course in study 107007",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109509,NCT00547248,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109509,http://clinicaltrials.gov/show/NCT00547248,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Safety, reactogenicity and immunogenicity following booster dose of GSK Biologicals´ pneumococcal conjugate vaccine when co-administered with a booster dose of Infanrix-IPV/Hib in preterm born children at 16-18 months of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109621,NCT00609492,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109621,http://clinicaltrials.gov/show/NCT00609492,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109661,NCT00489554,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109661,http://clinicaltrials.gov/show/NCT00489554,,Y,N,Y,Y,Y,Y,Y,A follow-on study 111393 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,"Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children.",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),110031,NCT00513409,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/110031,http://clinicaltrials.gov/show/NCT00513409,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A co-administered with Zilbrix™ Hib and Polio Sabin™,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),110521,NCT00678301,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110521,http://clinicaltrials.gov/show/NCT00678301,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A or Prevenar™ co-administered with Hiberix™,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),110808,NCT00680914,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110808,http://clinicaltrials.gov/show/NCT00680914,,Y,Y,Y,Y,Y,Y,Y,A booster study 112933 was conducted,1-May-2013
GSK,"Primary vaccination course in healthy children receiving the pneumococcal vaccine GSK 1024850A co-administered with Tritanrix™-HepB/Hib at 6, 10 and 14 weeks of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111188,NCT00814710,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111188,http://clinicaltrials.gov/show/NCT00814710,,Y,Y,Y,Y,Y,Y,Y,A booster study 112909 was conducted.,1-May-2013
GSK,Evaluation of effectiveness of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A against invasive disease,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111442,NCT00861380,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111442,http://clinicaltrials.gov/show/NCT00861380,,Y,Y,Y,Y,Y,Y,Y,A nested study 112595 was conducted.,1-Sep-2015
GSK,Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112801,NCT00950833,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112801,http://clinicaltrials.gov/show/NCT00950833,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Booster vaccination with pneumococcal vaccine GSK1024850A or Prevenar™ co-administered with Hiberix™ in children primed with the same vaccines,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112933,NCT00911144,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112933,http://clinicaltrials.gov/show/NCT00911144,,Y,Y,Y,Y,Y,Y,Y,This is a booster study of 110808.,1-May-2013
GSK,"Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Malian children",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),113166,NCT00985465,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113166,http://clinicaltrials.gov/show/NCT00985465,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian children",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),113199,NCT01153893,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113199,http://clinicaltrials.gov/show/NCT01153893,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Evaluation of immunological persistence following 3-dose priming with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine in study NCT00808444 and safety and immunogenicity following a booster dose of the same vaccine,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),113266,NCT01119625,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113266,http://clinicaltrials.gov/show/NCT01119625,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up of primary study 111654.,1-Jun-2015
GSK,"An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vaccination course at 2, 3 and 4 months of age in healthy infants in China.",Poliomyelitis Vaccine (Inactivated),112581,NCT00937404,Poliomyelitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112581,http://clinicaltrials.gov/show/NCT00937404,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This is primary study with booster study 112683,1-Mar-2017
GSK,Immunogenicity and safety of GSK Biologicals’ IPV (Poliorix™) in infants,Poliomyelitis Vaccine (Inactivated),112679,NCT01021293,Poliomyelitis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112679,http://clinicaltrials.gov/show/NCT01021293,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healthy toddlers in China.,Poliomyelitis Vaccine (Inactivated),112683,NCT00920439,Poliomyelitis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112683,http://clinicaltrials.gov/show/NCT00920439,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This study is a booster of study 112581,1-Mar-2017
GSK,"A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.",Rotavirus Vaccine,106260,NCT00396630,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106260,http://clinicaltrials.gov/show/NCT00396630,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants",Rotavirus Vaccine,106481,NCT00420745,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106481,http://clinicaltrials.gov/show/NCT00420745,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants",Rotavirus Vaccine,107625,NCT00480324,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107625,http://clinicaltrials.gov/show/NCT00480324,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants.,Rotavirus Vaccine,109216,NCT00432380,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109216,http://clinicaltrials.gov/show/NCT00432380,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109861,NCT00533507,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109861,http://clinicaltrials.gov/show/NCT00533507,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 111393 was conducted.,1-May-2013
GSK,Non-inferiority of a commercial lot of the pneumococcal vaccine GSK1024850A compared to a clinical lot.,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111654,NCT00808444,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111654,http://clinicaltrials.gov/show/NCT00808444,,Y,Y,Y,Y,Y,Y,Y,A follow-up study 113266 was conducted.,1-Jun-2015
GSK,"Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV",Rotavirus Vaccine,112269,NCT00969228,"Infections, Rotavirus",Phase 4,http://www.gsk-clinicalstudyregister.com/study/112269,http://clinicaltrials.gov/show/NCT00969228,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2013
GSK,"Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants",Rotavirus Vaccine,113518,NCT01107587,"Infections, Rotavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113518,http://clinicaltrials.gov/show/NCT01107587,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563) in healthy adults,Rotavirus Vaccine,113545,NCT01162590,"Infections, Rotavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113545,http://clinicaltrials.gov/show/NCT01162590,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563) in healthy children,Rotavirus Vaccine,113552,NCT01086436,"Infections, Rotavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113552,http://clinicaltrials.gov/show/NCT01086436,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,Immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose.,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",111344,NCT00627458,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111344,http://clinicaltrials.gov/show/NCT00627458,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD)",zanamivir,NAI30008,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12.",zanamivir,NAI30009,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30009,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families.",zanamivir,NAI30010,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30010,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years.",zanamivir,NAI30012,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30012,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel.",zanamivir,NAI30015,,"Influenza, Human",Phase 4,http://www.gsk-clinicalstudyregister.com/study/NAI30015,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients",zanamivir,NAI30020,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30020,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children.",zanamivir,NAI30028,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30028,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households",zanamivir,NAI30031,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30031,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk …",zanamivir,NAI30034,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30034,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.",zanamivir,NAIA3002,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIA3002,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks",zanamivir,NAIA3003,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIA3003,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks.",zanamivir,NAIA3004,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIA3004,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults.",zanamivir,NAIA3005,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIA3005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults.",zanamivir,NAIB3001,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIB3001,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.",zanamivir,NAIB3002,,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAIB3002,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris",benzoyl peroxide/clindamycin phosphate,STF115902,NCT01132443,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115902,http://clinicaltrials.gov/show/NCT01132443,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency,"retigabine, ezogabine",VRX-RET-E22-101,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-101,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2013
GSK,Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment,"retigabine, ezogabine",VRX-RET-E22-102,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-102,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia","retigabine, ezogabine",VRX-RET-E22-NP201,NCT00612105,"Neuralgia, Postherpetic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-NP201,http://clinicaltrials.gov/show/NCT00612105,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.",H5N1 Pandemic Influenza Vaccine,108498,NCT00502593,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107066,http://clinicaltrials.gov/show/NCT00502593,,Y,Y,Y,Y,Y,Y,Y,Second cohort study of study 107066. The results of this study are summarised with studies 107066 and 108500 (third cohort study) on the GSK Clinical Study Register.,1-May-2013
GSK,"A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.",H5N1 Pandemic Influenza Vaccine,108500,NCT00502593,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107066,http://clinicaltrials.gov/show/NCT00502593,,Y,Y,Y,Y,Y,Y,Y,Third cohort study of study 107066. The results of this study are summarised with studies 107066 and 108498 (second cohort study) on the GSK Clinical Study Register.,1-May-2013
GSK,Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules,H5N1 Pandemic Influenza Vaccine,111470,NCT00652743,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111443,http://clinicaltrials.gov/show/NCT00652743,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111470 are summarised with studies 111443, 111471, and 111472 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules,H5N1 Pandemic Influenza Vaccine,111471,NCT00652743,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111443,http://clinicaltrials.gov/show/NCT00652743,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111471 are summarised with studies 111443, 111470, and 111472 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules,H5N1 Pandemic Influenza Vaccine,111472,NCT00652743,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111443,http://clinicaltrials.gov/show/NCT00652743,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111472 are summarised with studies 111443, 111470, and 111471 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",110217,NCT00586612,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110215,http://clinicaltrials.gov/show/NCT00586612,,Y,Y,Y,Y,Y,Y,Y,This is a booster study of 110215. The results of this study are summarised with 110215 on the GSK Clinical Study Register.,1-May-2013
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108660,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"Long term immunogenicity (year 1) of the primary study (108658). The results of this study are summarised with studies 108658, 108661, 108663, 108665 on the GSK Clinical Study Register.",1-May-2013
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108661,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"Long term immunogenicity (year 2) of the primary study (108658). The results of this study are summarised with studies 108658, 108660, 108663, 108665 on the GSK Clinical Study Register.",1-May-2013
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108663,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"Long term immunogenicity (year 3) of the primary study (108658). The results of this study are summarised with studies 108658, 108660, 108661, 108665 on the GSK Clinical Study Register.",1-May-2013
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108665,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"The results of this study 108665 (Y4) are summarised with studies 108658, 108660 (Y1), 108661 (Y2), 108663 (Y3), and 108668 (Y5) on the GSK Clinical Study Register.",1-Mar-2014
GSK,Immunogenicity and safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers.,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",110871,NCT00614614,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110870,http://clinicaltrials.gov/show/NCT00614614,,Y,Y,Y,Y,Y,Y,Y,This is a booster study to 110870. The results of this study 110871 are summarized with 110870 on the GSK Clinical Study Register.,1-Jan-2017
GSK,"An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects",casopitant,NKV110483,NCT00511823,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV110483,http://clinicaltrials.gov/show/NCT00511823,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers.",darotropium bromide,AC2106213,NCT00500461,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AC2106213,http://clinicaltrials.gov/show/NCT00500461,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers",darotropium bromide,AC2108380,NCT00453687,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AC2108380,http://clinicaltrials.gov/show/NCT00453687,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects",GSK932121,PFM111319,NCT00811356,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111319,http://clinicaltrials.gov/show/NCT00811356,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers",lamotrigine,LAM105379,NCT00412191,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM105379,http://clinicaltrials.gov/show/NCT00412191,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"An open-label, randomised, single-dose, parallel-group study to demonstrate bioequivalence of two formulations and the effect of food and water on one formulation of lamotrigine in healthy male and female volunteers",lamotrigine,LBI108617,NCT00449774,Mental Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LBI108617,http://clinicaltrials.gov/show/NCT00449774,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A randomised, double-blind study in healthy volunteers to compare the properties and characteristics of an investigational formulation of lamotrigine with placebo",lamotrigine,LBI111649,NCT01607086,Mental Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111649,http://clinicaltrials.gov/show/NCT01607086,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects",lamotrigine,LEP108937,NCT00627575,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LEP108937,http://clinicaltrials.gov/show/NCT00627575,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A pivotal single-dose, randomised, parallel-group, open-label study to demonstrate bioequivalence of 250mg lamotrigine XR relative to 200mg + 50mg lamotrigine XR and to demonstrate lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers",lamotrigine,LEP111102,NCT00605371,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LEP111102,http://clinicaltrials.gov/show/NCT00605371,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"An open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of retigavine given as the Market Image tablet compared to the retigavine clinical trial tablets.","retigabine, ezogabine",RTG113287,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113287,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2013
GSK,"An open label study conducted in healthy subjects to demonstrate bioequivalence between ropinirole prolonged release tablets (ropinirole XL, marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) manufactured at Crawley and Aranda",ropinirole,ROP112771,NCT01371682,Parkinson Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112771,http://clinicaltrials.gov/show/NCT01371682,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM)",rosiglitazone,DIX110434,NCT00551564,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/DIX110434,http://clinicaltrials.gov/show/NCT00551564,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
GSK,"A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",tazarotene,STF114571,NCT01112787,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114571,http://clinicaltrials.gov/show/NCT01112787,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",tazarotene,STF114572,NCT01114841,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114572,http://clinicaltrials.gov/show/NCT01114841,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",tazarotene,STF114573,NCT01115322,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114573,http://clinicaltrials.gov/show/NCT01115322,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,"A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",tazarotene,STF114574,NCT01119651,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114574,http://clinicaltrials.gov/show/NCT01119651,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2013
GSK,Carvedilol Prospective Randomized Cumulative Survival Trial.,carvedilol,105517/287,,"Heart failure, Congestive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105517/287,,,Y,Y,Y,Y,Y,Y,N,This study also known as 287-COPERNICUS. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Compare immunogenicity & reactogenicity of 2 formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects,"Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",105910,NCT00320463,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105910,http://clinicaltrials.gov/show/NCT00320463,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A phase III, double-blind, randomized, multicenter primary vaccination study to bridge the DTPa-HBV-IPV vaccine manufactured according to the large scale manufacturing process with the DTPa-HBV-IPV vaccine manufactured by the small scale manufacturing process when administered intramuscularly to infants at 2, 4 and 6 months of age, co-administered with Merck's Hib conjugate vaccine (Liquid PedvaxHIB®) in a separate injection at 2 and 4 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/077 (DTPa-HBV-IPV-077),,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/077,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A phase III, open labeled, randomized, multicenter, clinical study of the safety of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepB-IPV combined candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B®+ IPOL® + HibTITER + Prevnar","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/084 (DTPa-Hep B-IPV-084),,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/084,,,Y,N,Y,Y,Y,Y,N,A separate reporting and analysis plan was not created for this study and is therefore not available. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepBIPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/085 (DTPa-Hep B-IPV-085),,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/085,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine,"Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/097 (DTPa-HBV-IPV-097),NCT00352963,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/097,http://clinicaltrials.gov/show/NCT00352963,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Open, primary vaccination study to assess safety and reactogenicity of GSK Biologicals’ DTPa/Hib vaccine when administered to healthy chinese infants at 3, 4 and 5 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Haemophilus influenzae Type b Conjugate Vaccine",106345,NCT00379977,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106345,http://clinicaltrials.gov/show/NCT00379977,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",101518 (DTPa-HBV-IPV-103),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/101518,,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"Phase IIIb, open, randomized, multicenter study to assess the immunogenicity & safety of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in Indian infants when given at 6-10-14 weeks of age or at 2-4-6 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",104005,NCT00316147,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104005,http://clinicaltrials.gov/show/NCT00316147,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),105555,NCT00307567,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/105555,http://clinicaltrials.gov/show/NCT00307567,,Y,N,Y,Y,Y,Y,Y,This is a follow-up study to 103488. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,"A study to evaluate the immunogenicity and safety of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine as compared to the currently licensed Infanrix hexa in healthy infants (2,3,4 M)","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",106786,NCT00376779,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106786,http://clinicaltrials.gov/show/NCT00376779,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle’s meningococcal group C conjugate vaccine.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/076 (DTPa-HBV-IPV-076),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/076,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open, multicentre, phase IV clinical trial to assess the immunogenicity and reactogenicity of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, when co-administered at 3-4-5 Mth of age with Wyeth-Lederle's seven-valent pneumococcal conjugate vaccine at a different injection site during the same visit","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/078 (DTPa-HBV-IPV-078),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/078,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of a 4th dose of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, co-administered with Wyeth's seven-valent Pneumococcal conjugate vaccine at a different injection site during the same visit in healthy children","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/081 (DTPa-HBV-IPV-081),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/081,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Study to assess immunogenicity and reactogenicity of GSK Bio’s combined DTPa-HBV-IPV/Hib vaccine in pre-term infants in comparison with term infants, administered as a booster dose to children who previously were primed with 3 doses of GSK Biologicals combined DTPa-HBV-IPV/Hib vaccine","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/083 (DTPa-HBV-IPV-083),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/083,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Single-blind, multicentre, phase IV clinical trial to assess and compare the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) and Aventis Pasteur’s DTPa-HBV-IPV-Hib vaccine (Hexavac™) given as a primary vaccination course at 2, 4 and 6 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/086 (DTPa-HBV-IPV-086),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/086,,,Y,N,Y,Y,Y,Y,N,A booster study 217744/095 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa() given as a primary vaccination course at 2, 4 and 6 months of age to pre-term infants.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/090 (DTPa-HBV-IPV-090),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/090,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Study to assess and compare the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD’s DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) given at 3, 5 and 11-12 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/094,NCT01457547,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/094,http://clinicaltrials.gov/show/NCT01457547,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"An open, multicentric, post-marketing surveillance study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months of age, in healthy infants.","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",100917,NCT00325156,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100917,http://clinicaltrials.gov/show/NCT00325156,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",213503/049 (DTPa-IPV-049),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/213503/049,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",213503/050 (DTPa-IPV-050),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213503/050,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Assess safety & reactogenicity of DTPa-IPV/Hib vaccine admnd at 3 & 4 mths & DTPa-HBV-IPV/Hib vaccine admnd at 5 mths, followed by DTPa-IPV/Hib vaccine at 18 mths in infants who received hepatitisB vaccine at birth & at one month of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",217744/100,NCT00325143,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/100,http://clinicaltrials.gov/show/NCT00325143,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,An open prospective study of immunogenicity and reactogenicity of DTPa vaccine (Infanrix) given as a booster to healthy school children 10 to 12 years of age,"Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",100484 (DTPa),,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100484,,,Y,N,Y,Y,N,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A report and analysis plan and protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age.","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",101197 (DTPa -127),,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/101197,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",102038 (DTPa-130),,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/102038,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",104871,NCT00290342,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104871,http://clinicaltrials.gov/show/NCT00290342,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa vaccine or GSK Biologicals’ DTPa vaccine or Chiron Behring’s Td vaccine + either Pasteur Merieux’s Pa vaccine or GSK Biologicals’ pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118)","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",208355/124 (APV-124),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208355/124,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created for this study and is therefore not available. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A phase III, open, multicenter study of the safety of Infanrix® when administered as a booster dose at 15 to 18 months of age following primary immunization in studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085)","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",208355/125 (APV-125),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208355/125,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Evaluation of safety and efficacy through Post Market Surveillance for Infanrix™, the DTaP mixed vaccine","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",208355/128,NCT00908115,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208355/128,http://clinicaltrials.gov/show/NCT00908115,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Study to compare immunogenicity and reactogenicity of GSK Bio’s DTPa-IPV vaccine, with GSK Bio’s DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",213503/045 (DTPa-IPV-045),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213503/045,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ DTaP-IPV vaccine, with GSK Biologicals’ DTaP and Aventis Pasteur MSD’s IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals’ MMR vaccine","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",213503/046 (DTaP-IPV-046),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213503/046,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age.","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",213503/047,NCT00263692,Acellular pertussis; Diphtheria; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/213503/047,http://clinicaltrials.gov/show/NCT00263692,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",213503/048,NCT00148941,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213503/048,http://clinicaltrials.gov/show/NCT00148941,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer",dutasteride,ARI40006,NCT00056407,"Neoplasms, Prostate",Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40006,http://clinicaltrials.gov/show/NCT00056407,,Y,Y,Y,Y,Y,Y,Y,A follow-up study ARI103094 was conducted.,1-Sep-2013
GSK,"A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia",dutasteride,ARI40005,NCT00090103,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40005,http://clinicaltrials.gov/show/NCT00090103,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management",dutasteride,AVO105948,NCT00363311,"Neoplasms, Prostate",Phase 4,http://www.gsk-clinicalstudyregister.com/study/AVO105948,http://clinicaltrials.gov/show/NCT00363311,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC102871,NCT01009463,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102871,http://clinicaltrials.gov/show/NCT01009463,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects",fluticasone furoate,HZA102928,NCT00522678,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HZA102928,http://clinicaltrials.gov/show/NCT00522678,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects.",fluticasone furoate,HZA102932,NCT01213849,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/102932,http://clinicaltrials.gov/show/NCT01213849,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects",fluticasone furoate,HZA102936,NCT01209026,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/102936,http://clinicaltrials.gov/show/NCT01209026,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects",fluticasone furoate,HZA102940,NCT00625196,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HZA102940,http://clinicaltrials.gov/show/NCT00625196,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800?g) with and without magnesium stearate, in mild/moderate asthmatic patients.",fluticasone furoate,HZA108799,NCT00444509,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HZA108799,http://clinicaltrials.gov/show/NCT00444509,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent an",fluticasone furoate,FFA109684,NCT00603746,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFA109684,http://clinicaltrials.gov/show/NCT00603746,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy",fluticasone furoate,FFA109685,NCT00603278,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFA109685,http://clinicaltrials.gov/show/NCT00603278,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy",fluticasone furoate,FFA109687,NCT00603382,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFA109687,http://clinicaltrials.gov/show/NCT00603382,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment",fluticasone furoate,HZA111789,NCT01266941,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111789,http://clinicaltrials.gov/show/NCT01266941,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.",fluticasone furoate,HZA112018,NCT00972673,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112018,http://clinicaltrials.gov/show/NCT00972673,,N,N,Y,Y,N,Y,N,"An analysis-ready data set, a reporting and analysis plan, and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jul-2015
GSK,"A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma",fluticasone furoate,FFA112202,NCT00766090,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112202,http://clinicaltrials.gov/show/NCT00766090,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC112206,NCT01053988,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112206,http://clinicaltrials.gov/show/NCT01053988,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC112207,NCT01054885,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112207,http://clinicaltrials.gov/show/NCT01054885,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC113107,NCT01342913,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113107,http://clinicaltrials.gov/show/NCT01342913,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects",fluticasone furoate,HZA113477,NCT01000597,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113477,http://clinicaltrials.gov/show/NCT01000597,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects",fluticasone furoate/vilanterol,HZA102934,NCT01299558,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/102934,http://clinicaltrials.gov/show/NCT01299558,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents",fluticasone furoate/vilanterol,HZA106829,NCT01134042,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106829,http://clinicaltrials.gov/show/NCT01134042,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma",fluticasone furoate/vilanterol,HZA106839,NCT01018186,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106839,http://clinicaltrials.gov/show/NCT01018186,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics,fluticasone furoate/vilanterol,HZA106851,NCT01086410,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106851,http://clinicaltrials.gov/show/NCT01086410,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents",fluticasone furoate/vilanterol,HZA113091,NCT01147848,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113091,http://clinicaltrials.gov/show/NCT01147848,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD).",fluticasone propionate,FLTA3025,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FLTA3025,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,HZC102970: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC102970,NCT01017952,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102970,http://clinicaltrials.gov/show/NCT01017952,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID",fluticasone propionate/salmeterol,ADA103575,NCT00296491,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ADA103575,http://clinicaltrials.gov/show/NCT00296491,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID",fluticasone propionate/salmeterol,ADA103578,NCT00296530,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ADA103578,http://clinicaltrials.gov/show/NCT00296530,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,ADC105931,NCT00346749,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/ADC105931,http://clinicaltrials.gov/show/NCT00346749,,Y,Y,Y,Y,Y,Y,N,A full reporting and analysis plan for this study is not available as the study was terminated early.,1-Sep-2013
GSK,"A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks.",fluticasone propionate/salmeterol,SAM40031,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40031,,,N,N,Y,Y,Y,Y,N,An annotated case report form and reporting and analysis plan are not available for this study. A blank case report form will be provided. The statistical analysis for this study did not create a separate Analysis-ready dataset and this is therefore not available. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics",fluticasone propionate/salmeterol,SAM40056,NCT00479739,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40056,http://clinicaltrials.gov/show/NCT00479739,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Sep-2013
GSK,"A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic)",fluticasone propionate/salmeterol,SAM40065,NCT01324362,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40065,http://clinicaltrials.gov/show/NCT01324362,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Sep-2013
GSK,"A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic)",fluticasone propionate/salmeterol,SAM40086,NCT00920543,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40086,http://clinicaltrials.gov/show/NCT00920543,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Sep-2013
GSK,"Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily.",fluticasone propionate/salmeterol,SAM40100,NCT00169546,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40100,http://clinicaltrials.gov/show/NCT00169546,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Sep-2013
GSK,"A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years.",fluticasone propionate/salmeterol,SAM40101,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40101,,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily",fluticasone propionate/salmeterol,SAM40104,NCT00370591,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40104,http://clinicaltrials.gov/show/NCT00370591,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Sep-2013
GSK,"A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus",fluticasone propionate/salmeterol,SAS10006,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10006,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant",fluticasone propionate/salmeterol,SAS10007,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10007,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg)",fluticasone propionate/salmeterol,SAS10016,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10016,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma",fluticasone propionate/salmeterol,SAS10019,NCT00364442,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10019,http://clinicaltrials.gov/show/NCT00364442,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma",fluticasone propionate/salmeterol,SAS104449,NCT00369993,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SAS104449,http://clinicaltrials.gov/show/NCT00369993,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily",fluticasone propionate/salmeterol,SAS105519,NCT00400608,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS105519,http://clinicaltrials.gov/show/NCT00400608,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma",fluticasone propionate/salmeterol,SAS30021,NCT00920959,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30021,http://clinicaltrials.gov/show/NCT00920959,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg Twice Daily with Salmeterol Diskus 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease",fluticasone propionate/salmeterol,SCO100250,NCT00115492,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO100250,http://clinicaltrials.gov/show/NCT00115492,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A randomized, double-blind placebo-controlled study of treatments with salmeterol, fluticasone propionate and their combination to evaluate novel endpoints in patients with chronic obstructive pulmonary disease",fluticasone propionate/salmeterol,SCO104925,NCT00358358,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO104925,http://clinicaltrials.gov/show/NCT00358358,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE® inhaler) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the DISKUS®/ACCUHALER® inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment",fluticasone propionate/salmeterol,SCO30003,NCT00268216,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCO30003,http://clinicaltrials.gov/show/NCT00268216,,N,Y,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,SCO30005,NCT00268177,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCO30005,http://clinicaltrials.gov/show/NCT00268177,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double Blind, Placebo Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone/Salmeterol Combination Product 250/50mcg twice daily via DISKUS and Salmeterol 50 mcg twice daily via DISKUS on Lung Hyperinflation in Subjects with COPD.",fluticasone propionate/salmeterol,SCO40030,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40030,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS® inhaler versus salmeterol 50mcg twice daily via DISKUS® inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,SCO40041,NCT00355342,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40041,http://clinicaltrials.gov/show/NCT00355342,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 250/50mcg twice daily with Salmeterol DISKUS® inhaler 50mcg twice daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,SCO40043,NCT00144911,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40043,http://clinicaltrials.gov/show/NCT00144911,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"Randomized, Double-Blind Comparison of ADVAIR® medication 100/50 Twice Daily vs Salmeterol Twice Daily vs Albuterol QID in subjects with ARG/ARG genotype 12 years of Age and Older with Presistent Asthma on Short-Acting Beta2-Agonists Alone",fluticasone propionate/salmeterol,SFA100062,NCT00102882,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SFA100062,http://clinicaltrials.gov/show/NCT00102882,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm",fluticasone propionate/salmeterol,SFA100314,NCT00118716,Bronchospasm,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SFA100314,http://clinicaltrials.gov/show/NCT00118716,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm",fluticasone propionate/salmeterol,SFA100316,NCT00118690,Bronchospasm,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SFA100316,http://clinicaltrials.gov/show/NCT00118690,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Sep-2013
GSK,"A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® Inhaler Twice Daily or Fluticasone Propionate 100mcg DISKUS® Inhaler Twice Daily Alone.",fluticasone propionate/salmeterol,SFA103153,NCT00102765,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SFA103153,http://clinicaltrials.gov/show/NCT00102765,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the Salmeterol/Fluticasone combination product (50/500mg strength) twice daily with Salmeterol 50mg twice daily alone and Fluticasone Propionate 500mg twice daily alone, all delivered via the Diskus/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease.",fluticasone propionate/salmeterol,SFCB3024,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFCB3024,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients.",fluticasone propionate/salmeterol,SFCA3007,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFCA3007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulations of salmeterol 50mcg twice daily and fluticasone propionate 500mcg twice daily individually and in combination as compared to placebo in COPD patients.",fluticasone propionate/salmeterol,SFCA3006,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFCA3006,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).",fluticasone propionate/salmeterol,SCO100470,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/100470,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD",fluticasone propionate/salmeterol,SCO30002,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCO30002,,,N,Y,Y,Y,Y,Y,Y,All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An Analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects.",fluticasone propionate/salmeterol,SAS10013,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10013,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open-label, randomised, crossover study to assess the relative bioavailability of different 2mg formulations of GSK2018682(S1P1 agonist) in healthy volunteers",GSK2018682,P1A114919,NCT01466322,"Multiple Sclerosis, Relapsing-Remitting",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114919,http://clinicaltrials.gov/show/NCT01466322,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"To assess reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) at 2, 4 and 6 months of age.",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),106208,NCT00338351,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/106208,http://clinicaltrials.gov/show/NCT00338351,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs,"Hepatitis B Vaccine, Recombinant",101695,NCT00343915,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101695 Ext. Mth30,http://clinicaltrials.gov/show/NCT00343915,,Y,N,Y,Y,Y,Y,N,"The results of this study 101695 (Ext HBV-280 M30) are summarised with studies 103860/280 (HBV-280), 101696 (Ext HBV-280 M42), 101697 (Ext HBV-280 M54) and 101698 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Sep-2013
GSK,Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs,"Hepatitis B Vaccine, Recombinant",101696,NCT00343915,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101695 Ext. Mth30,http://clinicaltrials.gov/show/NCT00343915,,Y,N,Y,Y,Y,Y,N,"The results of this study 101696 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101697 (Ext HBV-280 M54) and 101698 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Sep-2013
GSK,Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs,"Hepatitis B Vaccine, Recombinant",101697,NCT00343915,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101695 Ext. Mth30,http://clinicaltrials.gov/show/NCT00343915,,Y,N,Y,Y,Y,Y,N,"The results of this study 101697 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101696 (Ext HBV-280 M42) and 101698 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Sep-2013
GSK,Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs,"Hepatitis B Vaccine, Recombinant",101698,NCT00343915,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101695 Ext. Mth30,http://clinicaltrials.gov/show/NCT00343915,,Y,N,Y,Y,Y,Y,N,"The results of this study 101698 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101696 (Ext HBV-280 M42), and 101697 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Sep-2013
GSK,"Phase II study to compare immunogenicity, reactogenicity and safety of 3 different experimental formulations of GSK Biologicals’ hepatitis B vaccine compared to that of Engerix™-B administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years.","Hepatitis B Vaccine, Recombinant",103860/275 (HBV-275),,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/103860/275,,,Y,N,Y,Y,Y,Y,N,The reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs,"Hepatitis B Vaccine, Recombinant",103860/280,NCT00343915,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101695 Ext. Mth30,http://clinicaltrials.gov/show/NCT00343915,,Y,N,Y,Y,Y,Y,N,"The results of this study 103860/280 (HBV-280) are summarised with studies 101695 (Ext HBV-280 M30), and 101696 (Ext HBV-280 M42), and 101697 (Ext HBV-280 M54) on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Sep-2013
GSK,"Phase III study to evaluate immunogenicity, reactogenicity and safety of GSK preservative free Engerix™-B comparing aged lot and, as reference, new lot when admind intramuscularly according to a 0,1,6 month schedule in healthy volunteers","Hepatitis B Vaccine, Recombinant",103860/282 (HBV-282),,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103860/282,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Phase IV study to demonstrate the non-inferiority in terms of immunogenicity of multidose ENGERIX-B with 2-phenoxyethanol as preservative to that elicited by multidose ENGERIX™-B with thiomersal as preservative, when administered according to a 0, 1, 6 month schedule in healthy adults","Hepatitis B Vaccine, Recombinant",103860/283,,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/103860/283,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created and is therefore not available. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, multidose Engerix™-B to that of monodose Engerix™-B when administered according to 0,1,6 mths schedule in healthy adults aged ≥ 18 yrs","Hepatitis B Vaccine, Recombinant",104387,NCT00197158,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/104387,http://clinicaltrials.gov/show/NCT00197158,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Evaluate the anti-HBs antibody persistence, in subjects who received GSK Biologicals’ preservative-free or thiomersal-free Engerix™-B or Engerix™-B containing thiomersal, approximately 5 to 6 yrs earlier","Hepatitis B Vaccine, Recombinant",106640,NCT00329576,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106640,http://clinicaltrials.gov/show/NCT00329576,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created for this study and is therefore not available.,1-Sep-2013
GSK,Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 7 to 9 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine,"Hepatitis B Vaccine, Recombinant",106744,NCT00356564,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106744,http://clinicaltrials.gov/show/NCT00356564,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 4 to 6 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine,"Hepatitis B Vaccine, Recombinant",106745,NCT00335881,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106745,http://clinicaltrials.gov/show/NCT00335881,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,Assess long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children aged 4-5 yrs (previously primed & boosted in the 1st 2 yrs of life with DTPa-HBV-IPV/Hib vaccine),"Hepatitis B Vaccine, Recombinant",106789,NCT00411697,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106789,http://clinicaltrials.gov/show/NCT00411697,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,Administration of a challenge dose of hepatitis B vaccine in subjects who previously received Engerix™-B vaccine.,"Hepatitis B Vaccine, Recombinant",108988,NCT00524576,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/108988,http://clinicaltrials.gov/show/NCT00524576,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created for this study and is therefore not available.,1-Sep-2013
GSK,"Immune response to a hepatitis B vaccine challenge dose in healthy subjects who received primary vaccination of GlaxoSmithKline Biologicals' hepatitis B vaccine, approximately 20 years ago.","Hepatitis B Vaccine, Recombinant",110071,NCT00657657,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110071,http://clinicaltrials.gov/show/NCT00657657,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Study to evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals’ Engerix™-B vaccine, approximately 20 years ago.","Hepatitis B Vaccine, Recombinant",110073,NCT00774995,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110073,http://clinicaltrials.gov/show/NCT00774995,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,Immunogenicity and safety of GSK Biological’s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers,"Hepatitis B Vaccine, Recombinant",217744/069,NCT00880477,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/069,http://clinicaltrials.gov/show/NCT00880477,,Y,N,Y,Y,Y,Y,N,A separate reporting and analysis plan was not created for this study and is therefore not available. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age","Hepatitis B Vaccine, Recombinant",217744/075 (DTPa-HBV-IPV-075),NCT00366366,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/075,http://clinicaltrials.gov/show/NCT00366366,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A Double-blind, Double-dummy, Parallel-group Comparison of Lamotrigine and Divalproex Sodium Initial Monotherapy in Patients with Epilepsy",lamotrigine,SCAA4001,,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCAA4001,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to a 2-4-11 months vaccination schedule",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),105539,NCT00307034,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105539,http://clinicaltrials.gov/show/NCT00307034,,Y,N,Y,Y,Y,Y,Y,A follow on study 111736 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),105554,NCT00307541,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105554,http://clinicaltrials.gov/show/NCT00307541,,Y,Y,Y,Y,Y,Y,Y,Follow on studies 106623 and 112807 were conducted.,1-Mar-2015
GSK,Multicentre immune memory study in healthy children following a 3 dose primary vaccination with Prevenar or GSK Biologicals' pneumococcal conjugate vaccine via the administration of a single booster dose of Pneumovax 23,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),106623,NCT00333450,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106623,http://clinicaltrials.gov/show/NCT00333450,,Y,Y,Y,Y,Y,Y,Y,This is a follow up study to 105554. Follow on study 112807 was conducted.,1-Mar-2015
GSK,"Evaluate immunogenicity, safety & reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine given as catch-up immunization in children older than 7 mo of age or as 3-dose primary immunization in children before 6 mo of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107058,NCT00345358,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107058,http://clinicaltrials.gov/show/NCT00345358,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"To assess safety, reactogenicity & immunogenicity of a booster dose of pneumococcal conjugate vaccine, co-admin with GSK Biologicals’ MMRV vaccine in children (2nd yr of life) primed with the pneumococcal conjugate vaccine in study 105553.",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107706,NCT00370227,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107706,http://clinicaltrials.gov/show/NCT00370227,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,Study to assess the safety and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine when Co-administered with DTPa-HBV-IPV/Hib (Infanrix-Hexa) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107737,NCT00390910,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107737,http://clinicaltrials.gov/show/NCT00390910,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib.,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),110142,NCT00652951,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110142,http://clinicaltrials.gov/show/NCT00652951,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111736,NCT00792909,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111736,http://clinicaltrials.gov/show/NCT00792909,,Y,N,Y,Y,Y,Y,Y,This is a follow up study to 105539. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,Vaccination with the pneumococcal vaccine GSK 1024850A or Prevenar™ at approximately 4 years of age in children primed with 3 doses of GSK 1024850A vaccine or Prevenar™ and boosted with 23-valent pneumococcal plain polysaccharide vaccine,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112807,NCT00907777,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112807,http://clinicaltrials.gov/show/NCT00907777,,Y,Y,Y,Y,Y,Y,Y,This is a follow up study to 105554 and 106623.,1-Mar-2015
GSK,"Primary vaccination course with the pneumococcal vaccine GSK 1024850A, in healthy infants in Vietnam when co-administered with GSK Biologicals’ Infanrix hexa™ (DTPa-HBV-IPV/Hib) vaccine",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),113151,NCT01153841,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113151,http://clinicaltrials.gov/show/NCT01153841,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open label, randomized, up-titration study to assess the effect of urine sample handling procedures on the safety results of urine obtained from healthy subjects receiving repeat doses of ezogabine/retigabine.","retigabine, ezogabine",RTG114137,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114137,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study as it was not sponsored by GSK and is not required to be registered.,1-Sep-2013
GSK,"A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus",rosiglitazone,49653/048,NCT00279045,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/048,http://clinicaltrials.gov/show/NCT00279045,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects with Type 2 Diabetes Mellitus,rosiglitazone,49653/137,NCT00500955,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/BRL-49653/137,http://clinicaltrials.gov/show/NCT00500955,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II),rosiglitazone,49653/211,,"Heart failure, Congestive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/211,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia",rosiglitazone,49653/231,NCT00379769,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/BRL-049653/231,http://clinicaltrials.gov/show/NCT00379769,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Rosiglitazone in Combination with Glimepiride Compared to Glimepiride Plus Placebo for 24 Weeks in Subjects with Type 2 DiabetesMellitus Who are Inadequately Controlled on Non-TZD Oral Monotherapy",rosiglitazone,49653/325,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/325,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis",rosiglitazone,49653/330,,Psoriasis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/330,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis",rosiglitazone,49653/331,,Psoriasis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/331,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes,rosiglitazone,49653/334,NCT00306644,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/334,http://clinicaltrials.gov/show/NCT00306644,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Sep-2013
GSK,A Study to Investigate the Mechanism of Fluid Retention with AVANDIA™ in Combination with a Euglycaemic/Hyperinsulinaemic Clamp.,rosiglitazone,49653/339,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/339,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,A Randomised study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated with Avandia,rosiglitazone,49653/342,NCT00306696,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/342,http://clinicaltrials.gov/show/NCT00306696,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin",rosiglitazone,49653/347,NCT00329225,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/347,http://clinicaltrials.gov/show/NCT00329225,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A 12 month randomized, double-blind, placebo-controlled, magnetic resonance imaging study to evaulate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes",rosiglitazone,49653/351,,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/351,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A 16 Week Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Rosiglitazone on Myocardial Glucose Uptake in Subjects with Type 2 Diabetes Mellitus and Stable Coronary Heart Disease",rosiglitazone,49653/352,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/352,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A 16-week, randomised, double-blind, placebo-controlled, single-centre study to investigate fluid retention in insulin-treated subjects with type 2 diabetes mellitus and varying degrees of autonomic neuropathy when administered rosiglitazone 4mg twice daily",rosiglitazone,49653/376,NCT00422955,"Neuropathy, Diabetic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/376,http://clinicaltrials.gov/show/NCT00422955,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,A Study to Evaluate the Effect of Single and Repeat Doses of Rosiglitazone on the Pharmacokinetics of Methotrexate in Patients Receiving Methotrexate for Psoriasis,rosiglitazone,49653/411,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/411,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,A study to evaluate the effect of repeat doses of rosiglitazone on the pharmacokinetics of repeat doses of acitretin in patients receiving acitretin for psoriasis.,rosiglitazone,49653/413,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/413,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open-label, non-randomized, two period study to investigate the pharmacokinetics of rosiglitazone and glibenclamide when administered alone and concomitantly in healthy male Japanese and Caucasian subjects.",rosiglitazone,49653/414,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/414,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,An Open-Label Study to Obtain Clinical Experience with BRL49653C with Concurrent Alpha-glucosidase Therapy in Patients with Type 2 Diabetes Mellitus,rosiglitazone,49653/423,,Diabetes Mellitus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/423,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Apr-2017
GSK,"A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS)",rosiglitazone,49653/452,,"Multiple Sclerosis, Relapsing-Remitting",Phase 2,http://www.gsk-clinicalstudyregister.com/study/49653/452,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilization and cognition in subjects with mild to moderate Alzheimer's Disease (AD)",rosiglitazone,49653/461,NCT00265148,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/BRL-49653/461,http://clinicaltrials.gov/show/NCT00265148,,N,Y,Y,Y,Y,Y,Y,A follow-on study AVA104617 was conducted.,1-Sep-2013
GSK,"An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosiglitazone when Co-administered with Gemfibrozil in Healthy Adult Subjects",rosiglitazone,49653/902,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/902,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A randomized, open-label, two-period crossover study to demonstrate the bioequivalence of twice-daily immediate release and once-daily extended release rosiglitazone dosing over five days in healthy volunteers.",rosiglitazone,49653/903,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/903,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis",rosiglitazone,ARA102198,NCT00379600,"Arthritis, Rheumatoid",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ARA102198,http://clinicaltrials.gov/show/NCT00379600,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease",rosiglitazone,AVA100193,,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/100193,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease",rosiglitazone,AVA100468,,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/100468,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A 54-week, study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-3)",rosiglitazone,AVA102670,NCT00348140,Alzheimer's Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVA102670,http://clinicaltrials.gov/show/NCT00348140,,Y,Y,Y,Y,Y,Y,Y,A follow-on study AVA102675 was conducted.,1-Sep-2013
GSK,"An open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease",rosiglitazone,AVA104617,NCT00381238,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/AVA104617,http://clinicaltrials.gov/show/NCT00381238,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 49653/461.,1-Sep-2013
GSK,"A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)",rosiglitazone,AVD100521,NCT00116831,Atherosclerosis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVD100521,http://clinicaltrials.gov/show/NCT00116831,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,Clinical evaluation of Rosiglitazone Malate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo,rosiglitazone,AVD104742,NCT00297063,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVD104742,http://clinicaltrials.gov/show/NCT00297063,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Combination Therapy with Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study,rosiglitazone,AVD105248,NCT00432679,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVD105248,http://clinicaltrials.gov/show/NCT00432679,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,Clinical evaluation of Rosiglitazone Malate (BRL49653C) in patients with type 2 diabetes mellitus -Long-term study of Rosiglitazone Maleate,rosiglitazone,AVD105720,NCT00523913,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVD105720,http://clinicaltrials.gov/show/NCT00523913,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo.,rosiglitazone,RES104385,NCT00318630,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/104385,http://clinicaltrials.gov/show/NCT00318630,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Single-Blind, Placebo-Controlled, Parallel Group, Exploratory Research Study to Describe the Pharmacodynamic Effects of Glyburide, Metformin, and Rosiglitazone versus Placebo for 8 Weeks in Adult Subjects with Type 2 Diabetes Mellitus",rosiglitazone,RES11098,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/RES11098,,,N,Y,N,Y,Y,Y,N,"An analysis-ready dataset, a reporting and analysis plan, and a clinical study report are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Sep-2013
GSK,"Multicentre study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GSK Biologicals’ 10-valent pneumococcal conjugate, Infanrix hexa and Rotarix vaccines",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107017,NCT00370318,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107017,http://clinicaltrials.gov/show/NCT00370318,,Y,N,Y,Y,Y,Y,Y,A follow on study 107137 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2013
GSK,"A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants",Rotavirus Vaccine,444563/023,NCT00140673,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/023,http://clinicaltrials.gov/show/NCT00140673,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A Randomized, Double-Blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin®) in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SLGA4005,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SLGA4005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Randomized, Double-blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin) in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SLGA4004,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SLGA4004,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects with Acne Vulgaris",tazarotene,STF114565,NCT01019603,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114565,http://clinicaltrials.gov/show/NCT01019603,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Sep-2013
GSK,"A double-blind, randomized, placebo-controlled, repeat dose, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following administration of fluticasone furoate/GW642444M Inhalation Powder with ketoconazole",fluticasone furoate/vilanterol,HZA105548,NCT01165125,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105548,http://clinicaltrials.gov/show/NCT01165125,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma",vilanterol,B2C109575,NCT00600171,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C109575,http://clinicaltrials.gov/show/NCT00600171,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A three-way incomplete block crossover study to investigate the 24-hour pulmonary function of three dosage strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in subjects with Chronic Obstructive Pulmonary Disease (COPD)",vilanterol,HZC110946,NCT01072149,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110946,http://clinicaltrials.gov/show/NCT01072149,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)",fluticasone furoate/vilanterol,HZC111348,NCT00731822,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/HZC111348,http://clinicaltrials.gov/show/NCT00731822,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma",fluticasone furoate/vilanterol,HZA113090,NCT01128569,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113090,http://clinicaltrials.gov/show/NCT01128569,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma",fluticasone furoate/vilanterol,HZA113126,NCT01128595,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113126,http://clinicaltrials.gov/show/NCT01128595,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry powder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma",vilanterol,HZA113310,NCT00980200,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113310,http://clinicaltrials.gov/show/NCT00980200,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,"An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment.",fluticasone furoate/vilanterol,HZA113970,NCT01266980,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113970,http://clinicaltrials.gov/show/NCT01266980,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
GSK,Phase III Clinical Study of GG167: An open trial of GG167 in the treatment of influenza viral infection in children (open-label study). A survey on time course of influenza-like symptoms in pediatric patients with influenza viral infection treated without an influenza antiviral.,zanamivir,167T3-11,N/A,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/167T3-11,,,N,Y,Y,Y,Y,Y,Y,All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled zanamivir Treatment on Workplace Attendance Due to Influenza A and B Infections",zanamivir,NAI30011,N/A,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NAI30011,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness.,zanamivir,NAIA1009,,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1009,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 in the Treatment of Influenza A and B Viral Infection",zanamivir,NAIA2005,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIA2005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 (zanamivir) Therapy in the Prevention of Progression of Influenza A and B Viral Infections",zanamivir,NAIA2006,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIA2006,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections",zanamivir,NAIA2008,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIA2008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections",zanamivir,NAIA2009,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIA2009,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Efficacy of zanamivir (GG167) In Controlling Nursing Home Influenza Outbreaks,zanamivir,NAIA2010,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIA2010,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,Pharmacoscintigraphic Evalutaion of Lung Deposition of GG167 Inhaled from the Diskhaler and the Free Flow Powder System (FFPS) in Healthy Volunteers.,zanamivir,NAIB1001,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIB1001,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects,zanamivir,C94-085 (NAIB1002),,"Hyperreactivity, Bronchial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIB1002,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,A GG167 Pharmacokinetic Study to Select a Regimen for Prophylaxis.,zanamivir,NAIB1007,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIB1007,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Intranasal GG167 in the Treatment of Influenza A and B Viral Infections",zanamivir,NAIB2005,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIB2005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Double-Blind,Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of inhaled zanamivir in Preventing Progression of Influenza",zanamivir,NAIB2006,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIB2006,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Double-Blind, Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Inhaled plus Intranasal GG167 in the Treatment of Influenza A and B Viral Infections",zanamivir,NAIB2007,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIB2007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections.",zanamivir,NAIB2008,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIB2008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections",zanamivir,NAIB2009,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NAIB2009,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,A randomized double-blind placebo-controlled study to evaluate the inhibitory effect against the onset of influenza virus-infected patients,zanamivir,PE-01,N/A,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/PE-01,,,N,Y,Y,Y,Y,Y,Y,All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,ARI103094-Follow-Up Study for REDUCE Study Subjects,dutasteride,ARI103094,NCT00883909,"Neoplasms, Prostate",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103094,http://clinicaltrials.gov/show/NCT00883909,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to ARI40006.,1-Jan-2014
GSK,"A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects",fluticasone furoate,HZA105871,NCT00538057,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HZA105871,http://clinicaltrials.gov/show/NCT00538057,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma",fluticasone propionate/salmeterol,SAS40020,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40020,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma",fluticasone propionate/salmeterol,SAS40021,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40021,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase",paroxetine,BRL-029060/329: Acute Phase,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/329,,,Y,N,Y,Y,Y,N,Y,This study was conducted in 2 phases - an acute phase and a continuation phase. A comprehensive dataset for the complete study is available. The data from this study is provided in a combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers,"retigabine, ezogabine",RTG116216,NCT01583036,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116216,http://clinicaltrials.gov/show/NCT01583036,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Three Dose Levels of Rosiglitazone Maleate in the Treatment of Moderate to Severe Plaque Psoriasis.",rosiglitazone,49653/292,,Psoriasis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/49653/292,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV",Rotavirus Vaccine,101555,,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/101555,,,Y,N,N,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa",Rotavirus Vaccine,444563/013,NCT00383903,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/013,http://clinicaltrials.gov/show/NCT00383903,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine",Rotavirus Vaccine,444563/022,NCT00263666,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/022,http://clinicaltrials.gov/show/NCT00263666,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants",Rotavirus Vaccine,444563/024,NCT00139347,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/024,http://clinicaltrials.gov/show/NCT00139347,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants",Rotavirus Vaccine,444563/028,NCT00197210,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/028/029/030,http://clinicaltrials.gov/show/NCT00197210,,Y,N,Y,Y,Y,Y,Y,"The results of this study 444563/028 are summarised with studies 444563/029, 444563/030, 107070, 107072, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.",Rotavirus Vaccine,107070,NCT00329745,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107070,http://clinicaltrials.gov/show/NCT00329745,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107070 are summarised with studies 444563/028, 444563/029, 444563/030, 107072, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants",Rotavirus Vaccine,444563/029,NCT00197210,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/028/029/030,http://clinicaltrials.gov/show/NCT00197210,,Y,N,Y,Y,Y,Y,Y,"The results of this study 444563/029 are summarised with studies 444563/028, 444563/030, 107070, 107072, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.",Rotavirus Vaccine,107072,NCT00329745,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107070,http://clinicaltrials.gov/show/NCT00329745,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107072 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants",Rotavirus Vaccine,444563/030,NCT00197210,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/028/029/030,http://clinicaltrials.gov/show/NCT00197210,,Y,N,Y,Y,Y,Y,Y,"The results of this study 444563/030 are summarised with studies 444563/028, 444563/029, 107070, 107072, and 107076 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.",Rotavirus Vaccine,107076,NCT00329745,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107070,http://clinicaltrials.gov/show/NCT00329745,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107076 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107072 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jan-2014
GSK,Study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age,Rotavirus Vaccine,444563/033,NCT00757770,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/444563/033,http://clinicaltrials.gov/show/NCT00757770,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines",Rotavirus Vaccine,102247,NCT00140686,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102247/036,http://clinicaltrials.gov/show/NCT00140686,,Y,Y,Y,Y,Y,Y,Y,A follow-up study 109810 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247).,Rotavirus Vaccine,109810,NCT00420316,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109810,http://clinicaltrials.gov/show/NCT00420316,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 102247. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants",Rotavirus Vaccine,102248,NCT00241644,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102248,http://clinicaltrials.gov/show/NCT00241644,,Y,Y,Y,Y,Y,Y,Y,The results of this study 102248 are summarised with study 111274 on the GSK Clinical Study Register. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants",Rotavirus Vaccine,111274,NCT00241644,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102248,http://clinicaltrials.gov/show/NCT00241644,,Y,N,Y,Y,Y,Y,Y,The results of this study 111274 are summarised with study 102248 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus",Rotavirus Vaccine,103477,NCT00169455,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103477,http://clinicaltrials.gov/show/NCT00169455,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus",Rotavirus Vaccine,103478,NCT00134732,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103478,http://clinicaltrials.gov/show/NCT00134732,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,"Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh",Rotavirus Vaccine,103992,NCT00139334,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/103992,http://clinicaltrials.gov/show/NCT00139334,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,"Compare the immunogenicity, reactogenicity & safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV",Rotavirus Vaccine,104480,NCT00137930,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104480,http://clinicaltrials.gov/show/NCT00137930,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,"A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam",Rotavirus Vaccine,105722,NCT00345956,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105722,http://clinicaltrials.gov/show/NCT00345956,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV",Rotavirus Vaccine,107077,NCT00363545,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107077,http://clinicaltrials.gov/show/NCT00363545,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
GSK,"Assess the immunogenicity of 3 doses of Pediarix®, Prevnar® & ActHIB® given to healthy infants when administered with GSK Biologicals’ 2 dose oral live attenuated human rotavirus vaccine given during the same vaccination visit or separately",Rotavirus Vaccine,107531,NCT00334607,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107531,http://clinicaltrials.gov/show/NCT00334607,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,Study to evaluate clinical consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate liquid formulation compared to lyophilised formulation of the HRV vaccine administered as a two-dose primary vaccination.,Rotavirus Vaccine,107876,NCT00382772,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107876,http://clinicaltrials.gov/show/NCT00382772,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2014
GSK,"A dose ranging study to assess the effect of pre-treatment with a single dose of inhaled fluticasone propionate (2 mg, 0.5 mg) on lung inflammation following challenge with inhaled ozone and intermittent exercise in healthy volunteers, relative to placebo.",fluticasone propionate,CR219039,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/CR219039,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
Roche,"A randomized, double-blind, phase ii trial of paclitaxel plus carboplatin plus bevacizumab with or without apomab in patients with previously untreated, advanced-stage non-small cell lung cancer",apomab (Anti-DR5; PRO95780),APM4074g,NCT00480831,advanced-stage non-small cell lung cancer,Phase 2,,http://clinicaltrials.gov/show/NCT00480831,,Y,Y,Y,Y,Y,Y,N,,1-Jan-2014
Roche,"A multicenter, open-label, phase III, randomized, active-controlled trial evaluating the efficacy, safety, and pharmacokinetics of rhuMAb VEGF (bevacizumab), in combination with capecitabine chemotherapy, in subjects with previously treated metastatic breast cancer",bevacizumab,AVF2119G,NCT00262067,refractory metastatic breast cancer,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00109239?term=avf2119g&rank=2,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind study of the effect of first line treatment with Avastin (bevacizumab) in combination with docetaxel on progression-free survival and disease response in patients with HER2 negative metastatic breast cancer",bevacizumab,BO17708,NCT00333775,malignant neoplasm of breast,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00333775?term=BO17708&rank=1,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer",bevacizumab,AVF3694G,NCT00262067,malignant neoplasm breast unspecified site,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00262067?term=avf3694g&rank=1,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy in patients with mCRC and disease progression under first-line standard CTx/Bevacizumab combination",bevacizumab,ML18147,NCT00700102,malignant neoplasm of colon/rectum,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00700102,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III, multicenter, randomized, active-controlled clinical trial to evaluate the efficacy and safety of rhumab vegf (bevacizumab) in combination with standard chemotherapy in subjects with metastatic colorectal cancer",bevacizumab,AVF2107g,NCT00109070,metastatic colorectal cancer,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00109070,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase II, multicenter, double-blind, randomized, active-controlled clinical trial to evaluate the efficacy and safety of rhumab vegf (bevacizumab), a recombinant humanized monoclonal antibody to vascular endothelial growth factor, in combination with 5-fluorouracil and leucovorin chemotherapy in subjects with metastatic colorectal cancer who are not optimal candidates for first-line cpt-11",bevacizumab,AVF2192g,NCT00109226,metastatic colorectal cancer,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT00109226,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind multicenter 2-stage phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy",bevacizumab,BO17704 (AVAIL),NCT00806923,locally advanced metastatic or recurrent non-squamous non-small cell lung cancer,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00806923,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (roferon) versus interferon alfa-2a and placebo as first line treatment administered to nephrectomized patients with metastatic clear cell renal cell carcinoma",bevacizumab,BO17705 (AVOREN),NCT00738530,renal cell carcinoma,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00738530,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"2 x 2 Factorial randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (q3w) (""XELOX"") with/without intravenous bevacizumab (q3w) versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin (q2w) (""FOLFOX-4"") with/without intravenous bevacizumab (q2w) as first-line treatment for patients with metastatic colorectal cancer.",capecitabine,NO16966,NCT00069095,metastatic colorectal cancer,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00069095,,Y,Y,Y,N,N,Y,N,,1-Jan-2014
Roche,"A phase III open-label, randomized, controlled study assessing the efficacy and safety of T-20/Ro 29-9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in triple class (nucleoside reverse transcriptase, non-nucleoside reverse tanscriptase and protease inhibitors) experienced patients or patients naive to one class",enfuvirtide,BV16052,,hiv disease,Phase 3,,,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
Roche,"A phase III open-label, randomized, controlled study assessing the efficacy and safety of T-20/Ro 29-9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in triple class (nucleoside reverse transcriptase, non-nucleoside reverse transcri[tase and protease inhibitors) experienced patients",enfuvirtide,NV16054,,hiv disease,Phase 3,,,,Y,N,Y,N,Y,Y,N,,1-Jan-2014
Roche,"A double-blind, randomized, placebo-controlled study of oral Ro 64-0796 (GS4104) in the treatment of influenza infection",oseltamivir,WV15670,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, randomized, placebo controlled study of GS4104 (Ro 64-0796) in the treatment of influenza infection",oseltamivir,WV15671,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double blind,randomised, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection",oseltamivir,WV15730,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, stratified, randomized, placebo controlled study of Ro 64-0796 (GS4104) in the treatment of influenza infection in elderly adults",oseltamivir,WV15707,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind, placebo-controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64-0796 (also known as GS4104)",oseltamivir,M76001,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, stratified, randomized, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza in chronically ill adults",oseltamivir,WV15812,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, stratified, randomized, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza in chronically ill adults",oseltamivir,WV15872,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, randomized, stratified, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection in elderly patients",oseltamivir,WV15819,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, randomized, stratified, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection in elderly patients",oseltamivir,WV15876,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, randomized, stratified, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection in elderly patients",oseltamivir,WV15978,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A double-blind, randomized, stratified, placebo-controlled study of oseltamivir in the treatment of influenza infection in patients",oseltamivir,WV16277,,influenza,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase II open label study evaluating safety and efficacy of PEG-Interferon alpha-2a (PEG-IFN, Ro 25-8310) versus Interferon (IFN alpha-2a, Roferon-A) in interferon have patients with chronic hepatitis B.",peg-interferon alpha-2a,NV16037,,chronic hepatitis b,Phase 2,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III partially double blind study evaluating the efficacy and safety of 40KD branched pegylated interferon alfa-2a (PEG-IFN, RO0258310) combined with  placebo or lamivudine versus lamivudine in HBeAg positive patients with chronic hepatitis B",peg-interferon alpha-2a,WV16240,NCT00048945,chronic hepatitis b,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00048945?term=WV16240&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III partially double blinded study evaluating the efficacy and safety of 4okD branched pegylated inteferon alfa-2a (PEG-IGFN, Ro 25-8310) combined with placebo or lamivudine versus lamivudine in anti-HBe positive patients with chronic hepatitis B",peg-interferon alpha-2a,WV16241,,chronic hepatitis b,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind study of the effect of treatment duration and dose of PEGASYS on HBeAg seroconversion and safety in patients with HBeAg positive chronic hepatitis B.",peg-interferon alpha-2a,WV19432,NCT00435825,chronic hepatitis b,Phase 4,,http://clinicaltrials.gov/ct2/show/NCT00435825?term=NCT00435825&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III, randomized, multicenter, efficacy and safety study examining the effects of the duration of treatment and the daily dose of ribavirin in patients with chronic hepatitis C virus infection treated with the combination of pegylated-interferon alpha-2a and ribavirin",peg-interferon alpha-2a,NV15942,,chronic hepatitis c,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III, randomized, multicenter, efficacy and safety study comparing the combination of PEG-IFN alfa-2a (Ro 25-8310) and ribavirin to IFN alfa-2b and ribavirin in the treatment of patients with chronic hepatitis C",peg-interferon alpha-2a,NV15801,,chronic hepatitis c,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,An exploratory single-arm study to evaluate the effect of pertuzumab in combination with Herceptin on response rate in patients with HER2-positive metastatic breast cancer,pertuzumab,BO17929,NCT01674062,malignant neoplasm of breast,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT01674062,,Y,N,Y,N,N,Y,N,,1-Jan-2014
Roche,"A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Herceptin + docetaxel + pertuzumab versus Herceptin + docetaxel + placebo in previously untreated HER2-positive metastatic breast cancer",pertuzumab,WO20698 (CLEOPATRA),NCT00567190,malignant neoplasm of breast,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00567190,,Y,N,Y,N,N,N,N,,1-Jan-2014
Roche,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment with Rituximab in Subjects with Rheumatoid Arthritis Receiving Background Methotrexate",Rituximab,U3384G,NCT00266227,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00266227?term=U3384G&rank=1,,Y,N,Y,N,Y,Y,N,,1-Oct-2015
Roche,"A randomized, open-label study of the effect of MabThera, with and without  fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia",Rituximab,ML17102,NCT00281918,lymphoid leukaemia,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00281918?term=ML17102&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomised, double dummy controlled, parallel group study of the efficacy and safety of Mabthera (rituximab) alone or in combination with either cyclophosphamide or methotrexate, in patients with rheumatoid arthritis.",Rituximab,WA16291,,rheumatoid arthritis,Phase 2,,,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab versus placebo, in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis",tocilizumab,WA17822,NCT00106548,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00106548?term=WA17822&rank=2,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A randomized, double-blind study of safety and prevention of structural joint damage during treatment with tocilizumab versus placebo, in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis",tocilizumab,WA17823,NCT00106535,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00106535?term=WA17823&rank=2,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe active rheumatoid arthritis",tocilizumab,WA17824,NCT00109408,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00109408?term=WA17824&rank=2,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis and inadequate response to anti-TNF therapy",tocilizumab,WA18062,NCT00106522,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00106522?term=WA18062&rank=2,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"A randomized, double-blind study of the effect of tocilizumab on reduction in signs and symptoms in patients with moderate to severe active rheumatoid arthritis and inadequate response to DMARD therapy",tocilizumab,WA18063,NCT00106574,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00106574?term=WA18063&rank=2,,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,Long-term extension study of safety during treatment with tocilizumab in rheumatoid arthritis patients completing treatment in WA17822,tocilizumab,WA18695,NCT00721123,rheumatoid arthritis,Phase 3,,"http://clinicaltrials.gov/ct2/show/NCT00721123?term=WA18695&rank=1

other title",,Y,N,Y,N,Y,N,N,,1-Jan-2014
Roche,"Long-term extension study of safety during treatment with tocilizumab in rheumatoid arthritis patients completing treatment in tocilizumab core studies WA18062, WA18063 and WA17824",tocilizumab,WA18696,NCT00720798,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00720798?term=WA18696&rank=2,,Y,N,Y,N,N,N,N,,1-Jan-2014
Roche,"A randomized, placebo-controlled study to evaluate the effect of tocilizumab on disease response in patients with active systemic juvenile idiopathic arthritis, with an open-label extension to examine the long term use of tocilizumab",tocilizumab,WA18221,NCT00642460,rheumatoid arthritis (juvenile),Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00642460?term=WA18221&rank=1,,Y,N,Y,N,N,N,Y,,1-Jan-2014
Roche,"A 24 week randomized, double-blind, placebo-controlled withdrawal trial with a 16 week open-label lead-in phase, and 64 week open-label follow-up, to evaluate the effect on clinical response and the safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis",tocilizumab,WA19977,NCT00988221,rheumatoid arthritis (juvenile),Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00988221?term=WA19977&rank=5,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind, parallel-group, comparison study of three doses (placebo, MRA 4 mg/kg, or MRA 8 mg/kg) in patients with rheumatoid arthritis",tocilizumab,MRA009JP,NCT00144651,rheumatoid arthritis,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT00144651?term=MRA009JP&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A phase III randomised, parallel-group study of MRA in patients with rheumatoid arthritis",tocilizumab,MRA012JP,NCT00144547,rheumatoid arthritis,Phase 3,,http://clinicaltrials.gov/ct2/show?term=MRA012JP&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
Roche,An open-label randomized multicentre Phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2-positive advanced gastric cancer.,trastuzumab,BO18255 (ToGA),NCT01041404,HER2-positive  metastatic  breast cancer,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT01041404,,Y,N,Y,N,N,N,N,,1-Jan-2014
Roche,"A multicenter, open-label, single-arm phase II study of safety and efficacy of a once three-weekly regimen of Herceptin monotherapy in patients with HER2-overexpressing  metastatic breast cancer",trastuzumab,WO16229,,HER2-positive  metastatic  breast cancer,Phase 2,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
Roche,"A Phase II, single-arm, open-label study, of Trastuzumab-MCC-DM1 adminstered intravenously to patients with HER2-positive metastatic breast cancer",trastuzumab emtansine,TDM4374g,NCT00679211,metastatic breast cancer,Phase 2,,http://clinicaltrials.gov/show/nct00679211,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
Roche,"A phase II, single-arm, open-label study of Trastuzumab-MCC-DM1 administered intravenously to patients with HER2-positive metastatic breast cancer who have progressed while receiving HER2-directed therapy",trastuzumab emtansine,TDM4258g,NCT00509769,metastatic breast cancer,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT00509769,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
Roche,"A phase II, open-label study to evaluate corrected QT interval effects of Trastuzumab-MCC-DM1 (T-DM1) in patients with HER2-positive recurrent locally advanced or metastatic breast cancer and to evaluate the safety and tolerability of combined T-DM1 and Pertuzumab in patients with early disease progression while receiving T-DM1 alone.",trastuzumab emtansine,TDM4688g,NCT00943670,locally advanced or metastatic breast cancer,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT00943670,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, double-blind study to compare the effect of up to 100 days, and up to 200 days, of treatment with Valcyte (valganciclovir) on prevention of cytomegalovirus disease in high-risk kidney allograft recipients",valganciclovir,NT18435,NCT00294515,transplanted organ and tissue status (excl. complications),Phase 3,,http://clinicaltrials.gov/ct2/show/NCT00294515?term=NT18435&rank=1,,Y,N,Y,N,N,N,N,,1-Jan-2014
Roche,"A randomized, double-blind, double-dummy, active-comparator controlled multi-center study of the efficacy and safety of valganciclovir (Ro 107-9070) vs. oral ganciclovir for prevention of cytomegalovirus disease in high_risk heart, liver and kidney allograft recipients",valganciclovir,PV16000,,cytomegaloviral disease,Phase 3,,,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
Roche,"A randomized, open-label, controlled, multicenter, global study on progression-free and overall survival in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF mutation receiving RO5185426 or dacarbazine",vemurafenib,NO25026 (BRIM3),NCT01006980,malignant melanoma of skin,Phase 3,,http://clinicaltrials.gov/ct2/show/NCT01006980,,Y,N,Y,N,N,N,Y,,1-Jan-2014
Roche,An open-label multicenter study on the efficacy of continuous oral dosing of RO5185426 on tumour response in previously treated patients with metastatic melanoma,vemurafenib,NP22657 (BRIM2),NCT00949702,malignant melanoma of skin,Phase 2,,http://clinicaltrials.gov/ct2/show/NCT00949702,,Y,N,Y,N,N,N,N,,1-Jan-2014
ViiV,"Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",abacavir,CNA109586,NCT00549198,"Infection, Human Immunodeficiency Virus I",Phase 4,http://www.viiv-clinicalstudyregister.com/study/CNA109586,http://clinicaltrials.gov/show/NCT00549198,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects",abacavir,EPZ104057,NCT00244712,"Infection, Human Immunodeficiency Virus I",Phase 4,http://www.viiv-clinicalstudyregister.com/study/EPZ104057,http://clinicaltrials.gov/show/NCT00244712,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients",abacavir,CAL30001,NCT00044577,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/CAL30001,http://clinicaltrials.gov/show/NCT00044577,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity",abacavir,CNA106030,NCT00340080,"Infection, Human Immunodeficiency Virus",Phase 4,http://www.viiv-clinicalstudyregister.com/study/CNA106030,http://clinicaltrials.gov/show/NCT00340080,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects",abacavir/lamivudine,EPZ113734,NCT01102972,"Infection, Human Immunodeficiency Virus",Phase 4,http://www.viiv-clinicalstudyregister.com/study/113734,http://clinicaltrials.gov/show/NCT01102972,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.",abacavir/lamivudine,ESS30008,NCT00046176,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/ESS30008,http://clinicaltrials.gov/show/NCT00046176,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects.",abacavir/lamivudine,ESS30009,NCT00053638,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/ESS30009,http://clinicaltrials.gov/show/NCT00053638,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.",abacavir/lamivudine/zidovudine,AZL30006,NCT00043888,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/AZL30006,http://clinicaltrials.gov/show/NCT00043888,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)",abacavir/lamivudine/zidovudine,ESS 30005,NCT00038506,"Infection, Human Immunodeficiency Virus I",Phase 4,http://www.viiv-clinicalstudyregister.com/study/ESS%2030005,http://clinicaltrials.gov/show/NCT00038506,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks",abacavir/lamivudine/zidovudine,100327,NCT00082394,"Infection, Human Immunodeficiency Virus",Phase 4,http://www.viiv-clinicalstudyregister.com/study/100327,http://clinicaltrials.gov/show/NCT00082394,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults",dolutegravir,ING111762,NCT01231516,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/111762,http://clinicaltrials.gov/show/NCT01231516,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)",dolutegravir,ING111521,NCT00708110,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/111521,http://clinicaltrials.gov/show/NCT00708110,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,A Phase IIb study to select a once daily dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naive adult subjects,dolutegravir,ING112276,NCT00951015,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/112276,http://clinicaltrials.gov/show/NCT00951015,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen.,dolutegravir,ING112574,NCT01328041,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/112574,http://clinicaltrials.gov/show/NCT01328041,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance",dolutegravir,ING112961,NCT00950859,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/112961,http://clinicaltrials.gov/show/NCT00950859,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects",dolutegravir,ING113086,NCT01227824,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/113086,http://clinicaltrials.gov/show/NCT01227824,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects",dolutegravir,ING114467,NCT01263015,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/114467,http://clinicaltrials.gov/show/NCT01263015,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects,fosamprenavir,APV30005,NCT00296504,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/APV30005,http://clinicaltrials.gov/show/NCT00296504,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-Jan-2014
ViiV,"A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks",fosamprenavir,ESS100290,NCT00094523,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/100290,http://clinicaltrials.gov/show/NCT00094523,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks",fosamprenavir,APV100732,NCT00085943,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/100732,http://clinicaltrials.gov/show/NCT00085943,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.",fosamprenavir,APV109141,NCT00450580,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/APV109141,http://clinicaltrials.gov/show/NCT00450580,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)",fosamprenavir,LEX106430,NCT00363142,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/LEX106430,http://clinicaltrials.gov/show/NCT00363142,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure",fosamprenavir,APV102002,NCT00144833,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/APV102002,http://clinicaltrials.gov/show/NCT00144833,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults",fosamprenavir,APV30001,N/A,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/APV30001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
ViiV,"A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects",fosamprenavir,APV30002,N/A,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/APV30002,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
ViiV,"A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure",fosamprenavir,APV30003,N/A,"Infection, Human Immunodeficiency Virus",Phase 3,,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2014
ViiV,Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase,lamivudine,EPZ108859,NCT00440947,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/EPZ108859,http://clinicaltrials.gov/show/NCT00440947,,Y,Y,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study),lamivudine,ESS101822,NCT00094367,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/101822,http://clinicaltrials.gov/show/NCT00094367,,Y,N,Y,N,Y,Y,Y,,1-Jan-2014
ViiV,"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients",maraviroc,A4001078,NCT00827112,"Infection, Human Immunodeficiency Virus",Phase 2,N/A,http://ClinicalTrials.gov/show/NCT00827112,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2014
ViiV,"Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",maraviroc,A4001015,NCT00634959,"Infection, Human Immunodeficiency Virus",Phase 2,N/A,http://ClinicalTrials.gov/show/NCT00634959,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.",1-Jan-2014
ViiV,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",maraviroc,A4001029,NCT00098748,"Infection, Human Immunodeficiency Virus",Phase 2/Phase 3,N/A,http://ClinicalTrials.gov/show/NCT00098748,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patie",1-Jan-2014
ViiV,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",maraviroc,A4001028,NCT00098722,"Infection, Human Immunodeficiency Virus",Phase 2/Phase 3,N/A,http://ClinicalTrials.gov/show/NCT00098722,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patie",1-Jan-2014
ViiV,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",maraviroc,A4001027,NCT00098306,"Infection, Human Immunodeficiency Virus",Phase 2/Phase 3,N/A,http://ClinicalTrials.gov/show/NCT00098306,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patie",1-Jan-2014
ViiV,"Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",maraviroc,A4001007,NCT00643643,"Infection, Human Immunodeficiency Virus",Phase 2,N/A,http://ClinicalTrials.gov/show/NCT00643643,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patie",1-Jan-2014
ViiV,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",maraviroc,A4001026,NCT00098293,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/A4001026,http://ClinicalTrials.gov/show/NCT00098293,,Y,Y,Y,Y,Y,Y,Y,"An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patie",1-Jan-2014
Boehringer Ingelheim,Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD,tiotropium bromide,205.249,NCT00239447,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239447?term=205.249&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.25,NCT00281567,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00281567?term=205.250&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD",tiotropium bromide,205.251,NCT00239473,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239473?term=205.251&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD",tiotropium bromide,205.252,NCT00240435,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00240435?term=205.252&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Tiotropium / Respimat One-Year Study,tiotropium bromide,205.254,NCT00168844,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00168844?term=205.254&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Tiotropium / Respimat One-Year Study,tiotropium bromide,205.255,NCT00168831,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00168831?term=205.255&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Tiotropium / Respimat One Year Study in COPD.,tiotropium bromide,205.372,NCT00387088,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00387088?term=205.372&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate",nadroparin calcium,FRX106365,NCT00312013,"Thrombosis, Venous",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FRX106365,http://clinicaltrials.gov/show/NCT00312013,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2014
GSK,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)",belimumab,HGS1006-C1056,NCT00410384,Systemic Lupus Erythematosus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HGS1006-C1056,http://clinicaltrials.gov/show/NCT00410384,,Y,Y,Y,Y,Y,Y,Y,"This study was not originally sponsored by GSK. The results summary and publications are available on ClinicalTrials.gov: <a href=""http://clinicaltrials.gov/show/NCT00410384"">http://clinicaltrials.gov/show/NCT00410384</a>. GSK reference study ID: 110751.  Raw data are included within the analysis-ready data for this study and are not provided separately",1-Feb-2014
GSK,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)",belimumab,HGS1006-C1057,NCT00424476,Systemic Lupus Erythematosus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HGS1006-C1057,http://clinicaltrials.gov/show/NCT00424476,,Y,Y,Y,Y,Y,Y,Y,"This study was not originally sponsored by GSK. The results summary and publications are available on ClinicalTrials.gov: <a href=""http://clinicaltrials.gov/show/NCT00424476"">http://clinicaltrials.gov/show/NCT00424476</a>. GSK reference study ID: 110752.  Raw data are included within the analysis-ready data for this study and are not provided separately",1-Feb-2014
GSK,"Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life","Hepatitis B Vaccine, Recombinant",103860/277,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103860/277,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2013
GSK,"Safety & immunogenicity of a booster dose of dTPa vaccine (Boostrix®) co-admnd. with Aventis Pasteur’s meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra™) vs admn. of either vaccine alone in healthy adolescents","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",105753,NCT00282295,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/105753,http://clinicaltrials.gov/show/NCT00282295,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",100406,NCT00263679,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100406/004,http://clinicaltrials.gov/show/NCT00263679,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,"Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/034,NCT01294605,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/263855/034,http://clinicaltrials.gov/show/NCT01294605,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR)","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/035,NCT00544271,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/263855/035,http://clinicaltrials.gov/show/NCT00544271,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Open, phase IIIb, multicentric, safety and reactogenicity study of GSK Biologicals’ reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine administered as a booster dose to healthy children according to the international recommended prescribing information","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/036,,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/263855/036,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine",711866/006 (dTpa-IPV-006),,Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/711866/006,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A double-blind, placebo-controlled, randomized, parallel group study to investigate the changes in corrected QT interval following repeat oral doses of GI198745 in healthy male subjects",dutasteride,ARI10019,,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARI10019,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART™ 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects",dutasteride,ARI109882,NCT00537654,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARI109882,http://clinicaltrials.gov/show/NCT00537654,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"An open label, randomized, repeat dose, 3 period crossover study to determine the bioequivalence of 3 different formulations of tamsulosin at steady state in healthy male volunteers",dutasteride,ARI111402,NCT00609596,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARI111402,http://clinicaltrials.gov/show/NCT00609596,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy of GI198745 0.5mg Once Daily versus finasteride 5mg Once Daily for 12 months in the treatment of subjects with benign prostatic hyperplasia (BPH). (EPICS)",dutasteride,ARI40001 -Open-Label,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40001,,,N,N,Y,Y,Y,Y,N,This study was conducted in 2 phases - Year 1 and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A pilot multi-centre, double-blind, parallel group, randomised study to investigate the effect on symptoms 3 months after discontinuing tamsulosin, following 6 months combination treatment with 0.5mg GI198745 and 0.4mg tamsulosin daily in patients with symptomatic Benign Prostatic Hyperplasia (BPH).",dutasteride,ARI40002,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40002,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,An Investigation of the Pharmacokinetics of GI198745 and of the Effects of GI198745 on Semen Characteristics When Administered Daily for 12 Months to Healthy Male Subjects,dutasteride,ARIA1009,,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARIA1009,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,Investiagtion of the Metabolic Fate and Routes of Excretion of GI198745 at Steady State in Healthy Male Subjects,dutasteride,ARIA1012,,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARIA1012,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia",dutasteride,ARIA3002 (Year 1),,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3002,,,N,Y,Y,Y,Y,Y,Y,The data relating to this record represents an interim analysis of a 4 year study. A comprehensive dataset is available within ARIA3002 Year 4. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia",dutasteride,ARIB3003 (Year 1),,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIB3003,,,N,N,Y,Y,Y,Y,Y,Follow up analyses ARIB3003 (Year 2) and ARIB3003 (Year 4) were conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension",dutasteride,ARIB3004 Double-blind Phase,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIB3004,,,N,N,Y,Y,Y,Y,Y,This study was conducted in 2 phases - a Double-blind Phase and an Open-label Extension. A comprehensive dataset is available within the Open-Label Extension. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist.",fiboflapon,LPA112186,NCT01147744,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112186,http://clinicaltrials.gov/show/NCT01147744,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age",fiboflapon,LPA114255,NCT01156792,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114255,http://clinicaltrials.gov/show/NCT01156792,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma,fluticasone propionate,FAS106533,NCT00370097,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAS106533,http://clinicaltrials.gov/show/NCT00370097,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics,fluticasone propionate,FAP10001,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAP10001,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy",fluticasone propionate,FAP30007,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAP30007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy",fluticasone propionate,FAP30008,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAP30008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma",fluticasone propionate,FAP30010,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAP30010,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms.",fluticasone propionate,FAS30007,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAS30007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms.",fluticasone propionate,FAS30009,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAS30009,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months.",fluticasone propionate,FAS30030,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FAS30030,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, open label, 4-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of single inhaled and intravenous doses of fluticasone propionate and mometasone furoate in healthy subjects",fluticasone propionate,FMS10026,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FMS10026,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A repeat dose study of inhaled budesonide, FP and MF to assess drug accumulation in adipose tissue",fluticasone propionate,FMS10030,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FMS10030,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2014
GSK,A study to compare PK of a single doe of fluticasone propionate in healthy male Japanse and Caucasian subjects,fluticasone propionate,FMS10032,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FMS10032,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, single-blind, placebo-controlled study with 5-way cross-over design to investigate the systemic pharmacokinetics and pharmacodynamics of single inhaled doses (800mcg and 1600mcg) of Fluticasone Propionate and Mometasone Furoate in healthy subjects.",fluticasone propionate,FMS10033,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FMS10033,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 24 months to 47 months",fluticasone propionate,FMS30058,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FMS30058,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 6 months to 2 years",fluticasone propionate,FMS30059,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FMS30059,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, double-blind, double-dummy, parallel group, multicentre study to compare the effect on growth measured by stadiometry of fluticasone propionate (100µg bd) administered via DISKUS™ with budesonide (200µg bd) administered via Turbuhaler in prepubescent children.",fluticasone propionate,FMS40001,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FMS40001,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"An open study to investigate the nasal bioavailability of intra-nasally administered fluticasone propionate administered as a solution formulation, HFA nasal MDI formulation and as the aqueous nasal spray during charcoal block in healthy subjects.",fluticasone propionate,FNM10003,,Rhinitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FNM10003,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"An open, three-period, balanced, incomplete block crossover study in healthy subjects to investigate the effect of 7 days co-administration of fluticasone propionate aqueous nasal spray (FPANS) with ritonavir, ketoconazole, or erythromycin on serum cortisol levels",fluticasone propionate,FNM10004,,Rhinitis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FNM10004,,,N,Y,Y,Y,Y,Y,N,An Analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Systems Commonly Associated with Allergic Rhinitis",fluticasone propionate,FNM30033,,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FNM30033,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis",fluticasone propionate,FNM30034,,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FNM30034,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multi-Center, Randomized, Double-Blind, Parallel Gruop Study to Assess the Potential Growth Effects of a One-year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) versus Placebo in Pre-pubescent, Pediatric Subjects with Perennial Allergic Rhinitis",fluticasone propionate,FNM40017,,"Rhinitis, Allergic, Perennial",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FNM40017,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)",fluticasone propionate,FNM40194,,"Rhinitis, Allergic, Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FNM40194,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)",fluticasone propionate,FNM40195,,"Rhinitis, Allergic, Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FNM40195,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A single centre, randomised, double blind, parallel group study to determine the efficacy and tolerability of Fluticasone propionate nasal drops (Nasules) 400mcg bd, 400mcg od and placebo nasal drops in adult patients with bilateral polyposis.",fluticasone propionate,FNP40010,,"Polyps, Nasal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FNP40010,,,N,Y,Y,Y,N,Y,Y,An analysis-ready dataset and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone",fluticasone propionate,FPD40009,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FPD40009,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids",fluticasone propionate,FPD40010,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/FPD40010,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 Years of Age with Persistant Asthma",fluticasone propionate,FPD40012,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FPD40012,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Proprionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 with Persistant Asthma",fluticasone propionate,FPD40013,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FPD40013,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind 12-Week Comparative Trial of Fluticasone Propionate DISKUS 100mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID And Oral Montelukast 10mg QD In Adults With Persistent Asthma.",fluticasone propionate,FPD40014,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FPD40014,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Open-Label, Cross Over Trial, Assessing Ease of Use, Correctness of Use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the Diskus versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone",fluticasone propionate,FPD40015,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FPD40015,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the DISKUS™ versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone.",fluticasone propionate,FPD40016,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FPD40016,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover, study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine 5-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects.",fluticasone propionate,SIG103337,NCT00400855,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SIG103337,http://clinicaltrials.gov/show/NCT00400855,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,An exploratory study to evaluate the response of salmeterol plus fluticasone propionate vs fluticasone propionate alone to experimental nasal inoculation with rhinovirus,fluticasone propionate/salmeterol,HZA109895,NCT00503009,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HZA109895,http://clinicaltrials.gov/show/NCT00503009,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval",fluticasone propionate/salmeterol,HZA109912,NCT00517634,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HZA109912,http://clinicaltrials.gov/show/NCT00517634,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A Multicentre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination diskus (Accuhaler) dry powder inhaler compared with fluticasone propionate Diskus alone in adults and adolescents.",fluticasone propionate/salmeterol,SAM40027,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40027,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects",fluticasone propionate/salmeterol,SAM40036,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAM40036,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma",fluticasone propionate/salmeterol,SAM40040,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40040,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment",fluticasone propionate/salmeterol,SAM40042,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40042,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks.",fluticasone propionate/salmeterol,SAM40058,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40058,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Muticenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day versus Montelukast 10mg every day in Adolescent and Adult subjects with Asthma and Seasonal allergic rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg twice daily",fluticasone propionate/salmeterol,SAM40066,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40066,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects,fluticasone propionate/salmeterol,SAS10014,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10014,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics",fluticasone propionate/salmeterol,SAS10015,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS10015,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy",fluticasone propionate/salmeterol,SAS30017,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30017,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years.",fluticasone propionate/salmeterol,SAS30019,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30019,,,N,Y,Y,Y,Y,Y,N,An Analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy",fluticasone propionate/salmeterol,SAS30022,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30022,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects",fluticasone propionate/salmeterol,SAS30023,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30023,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma",fluticasone propionate/salmeterol,SAS30031,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30031,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age",fluticasone propionate/salmeterol,SAS30033,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30033,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma.",fluticasone propionate/salmeterol,SAS30039,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30039,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks",fluticasone propionate/salmeterol,SAS30040,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30040,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Versus Fluticasone Propinate 250 mcg twice daily Diskus in Adolescents and Adults With Moderate To Persistent Asthma",fluticasone propionate/salmeterol,SAS40026,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40026,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma",fluticasone propionate/salmeterol,SAS40027,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40027,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"An Open-Label, 12-Week Study to Evaluate the Effects of a Corticosteroid-Sparing Dose of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Via the DISKUS Inhaler on Airway Inflammation, Airway Remodeling, and Bronchial Hyperresponsiveness in Adults with Persistent Asthma",fluticasone propionate/salmeterol,SAS40028,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40028,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescent and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day",fluticasone propionate/salmeterol,SAS40036,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40036,,,N,N,Y,Y,Y,Y,Y,An Analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day",fluticasone propionate/salmeterol,SAS40037,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40037,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Open Label, Pilot Crossover Trial, Assessing Patient Preference for Efficacy of Advair Diskus 100/50 (Fluticasone Propionate 100mcg and Salmeterol 50mcg Combination Product 100/50mcg twice daily) and Singulair (Montelukast 10mg every day) in Subjects>15 years of Age with Persistent Asthma",fluticasone propionate/salmeterol,SAS40066,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40066,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A randomised, double-blind, double dummy, 3 way crossover study evaluating the effects of a combination of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual agents (tiotropium bromide 18mcg alone and Seretide50/500mcg alone) in the treatment of subjects with COPD",fluticasone propionate/salmeterol,SCO104962,NCT00325169,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104962,http://clinicaltrials.gov/show/NCT00325169,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,SCO40011,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40011,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol Xinafoate (250/50mcg twice daily via Diskus) to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmondary Disease (COPD)",fluticasone propionate/salmeterol,SCO40012,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40012,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma.",fluticasone propionate/salmeterol,SFCA3002,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFCA3002,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma.",fluticasone propionate/salmeterol,SFCA3003,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SFCA3003,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children,Influenza Vaccine (Quadrivalent),113275,NCT01196988,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113275,http://clinicaltrials.gov/show/NCT01196988,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)",Human Papillomavirus Types 16 and 18 Vaccine,102115,NCT00231413,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/102115,http://clinicaltrials.gov/show/NCT00231413,,Y,N,Y,Y,Y,Y,Y,The results of this study 102115 are summarised with studies 107919 and 108052 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)",Human Papillomavirus Types 16 and 18 Vaccine,107919,NCT00231413,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/102115,http://clinicaltrials.gov/show/NCT00231413,,Y,N,Y,Y,Y,Y,N,The results of this study 107919 are summarised with studies 102115 and 108052 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2014
GSK,"Primary and long-term follow-up study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 10-14 years.","Hepatitis A Vaccine, Inactivated",104902,,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104902,,,Y,N,Y,Y,Y,Y,Y,"The results of studies 104896, 104902 and 104904 are summarised with study 580299/013 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2014
GSK,"Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs",Human Papillomavirus Types 16 and 18 Vaccine,104951,NCT00290277,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104951,http://clinicaltrials.gov/show/NCT00290277,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years","Hepatitis B Vaccine, Recombinant",580299/011,NCT00309166,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/580299/011,http://clinicaltrials.gov/show/NCT00309166,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",Human Papillomavirus Types 16 and 18 Vaccine,105880,NCT00196937,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103514,http://clinicaltrials.gov/show/NCT00196937,,Y,N,Y,Y,Y,Y,Y,The results of this study 105880 are summarised with studies 103514 and 105881 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",Human Papillomavirus Types 16 and 18 Vaccine,105881,NCT00196937,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103514,http://clinicaltrials.gov/show/NCT00196937,,Y,N,Y,Y,Y,Y,Y,The results of this study 105881 are summarised with studies 103514 and 105880 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",Human Papillomavirus Types 16 and 18 Vaccine,105926,NCT00345878,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105926,http://clinicaltrials.gov/show/NCT00345878,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A phase III, double-blind, randomized, controlled study to evaluate immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly (0, 1, 6 month schedule) in healthy females aged 18 – 35 years",Human Papillomavirus Types 16 and 18 Vaccine,106001,NCT00306241,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/106001,http://clinicaltrials.gov/show/NCT00306241,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",Human Papillomavirus Types 16 and 18 Vaccine,103514,NCT00196937,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103514,http://clinicaltrials.gov/show/NCT00196937,,Y,Y,Y,Y,Y,Y,Y,The results of this study 103514 are summarised with studies 105880 and 105881 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly at 0, 1, 6 months in healthy Indian female subjects aged 18–35 yrs",Human Papillomavirus Types 16 and 18 Vaccine,104479,NCT00344032,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104479,http://clinicaltrials.gov/show/NCT00344032,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"Assess lot-to-lot consistency of GSK Biologicals' HPV-16/18 L1/AS04 vaccine following manufacturing adjustments administered intramuscularly according to a 0,1,6-mth schedule in healthy female subjects (18-25 y)",Human Papillomavirus Types 16 and 18 Vaccine,104772,NCT00250276,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104772,http://clinicaltrials.gov/show/NCT00250276,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years.",Human Papillomavirus Types 16 and 18 Vaccine,104798,NCT00316693,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104798,http://clinicaltrials.gov/show/NCT00316693,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above",Human Papillomavirus Types 16 and 18 Vaccine,104820,NCT00294047,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104820,http://clinicaltrials.gov/show/NCT00294047,,Y,N,Y,Y,Y,Y,Y,"This study is still ongoing, however data related to the publication(s) is available. A follow-on study 109801 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Mar-2014
GSK,"Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)",Human Papillomavirus Types 16 and 18 Vaccine,104896,NCT00196924,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/013,http://clinicaltrials.gov/show/NCT00196924,,Y,Y,Y,Y,Y,Y,Y,"The results of studies 104896, 104902 and 104904 are summarised with study 580299/013 on the GSK Clinical Study Register.",1-Mar-2014
GSK,"Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)",Human Papillomavirus Types 16 and 18 Vaccine,104904,NCT00196924,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/013,http://clinicaltrials.gov/show/NCT00196924,,Y,N,Y,Y,Y,Y,Y,"The results of studies 104896, 104902 and 104904 are summarised with study 580299/013 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2014
GSK,"Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",Human Papillomavirus Types 16 and 18 Vaccine,107476,NCT00169494,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/012,http://clinicaltrials.gov/show/NCT00169494,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107476 (M18) are summarised with studies 580299/012, 107477 (M24), and 107479 (M36) on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Mar-2014
GSK,"Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",Human Papillomavirus Types 16 and 18 Vaccine,107477,NCT00169494,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/012,http://clinicaltrials.gov/show/NCT00169494,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107477 (M24) are summarised with studies 580299/012, 107476 (M18), and 107479 (M36) on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Mar-2014
GSK,"Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",Human Papillomavirus Types 16 and 18 Vaccine,107479,NCT00169494,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/012,http://clinicaltrials.gov/show/NCT00169494,,Y,N,Y,Y,Y,Y,Y,"The results of this study 107479 (M36) are summarised with studies 580299/012, 107476 (M18), and 107477 (M24) on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Mar-2014
GSK,"A randomized, open study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV vaccine Co-administered intramuscularly with Boostrix® and/or Menactra™ in healthy female subjects aged 11–18 years",Human Papillomavirus Types 16 and 18 Vaccine,107682,NCT00369824,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107682,http://clinicaltrials.gov/show/NCT00369824,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,"A long-term, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ novel HPV vaccine in healthy female subjects vaccinated in the primary study",Human Papillomavirus Types 16 and 18 Vaccine,108052,NCT00359619,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108052 (FU month 18),http://clinicaltrials.gov/show/NCT00359619,,Y,N,Y,Y,Y,Y,N,The results of this study 108052 are summarised with studies 102115 and 107919 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2014
GSK,Complementary testing to further evaluate the immunogenicity of a GSK Biologicals’ HPV vaccine (580299) in healthy female subjects aged over 26 years enrolled in study 104820.,Human Papillomavirus Types 16 and 18 Vaccine,109801,NCT00456807,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109801,http://clinicaltrials.gov/show/NCT00456807,,Y,N,Y,Y,Y,Y,Y,This is a follow-on study to 104820. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,A multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ HPV vaccine (GSK1674330A) in healthy female subjects aged 18–25 years.,Human Papillomavirus Types 16 and 18 Vaccine,109836,NCT00478621,"Infections, Papillomavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/109836,http://clinicaltrials.gov/show/NCT00478621,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2014
GSK,Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001,Human Papillomavirus Types 16 and 18 Vaccine,580299/007,NCT00120848,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/580299/007,http://clinicaltrials.gov/show/NCT00120848,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 580299/001.,1-Mar-2014
GSK,"A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age.",Human Papillomavirus Types 16 and 18 Vaccine,580299/008,NCT00122681,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/008,http://clinicaltrials.gov/show/NCT00122681,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",Human Papillomavirus Types 16 and 18 Vaccine,580299/012,NCT00169494,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/012,http://clinicaltrials.gov/show/NCT00169494,,Y,Y,Y,Y,Y,Y,Y,"The results of this study 580299/012 are summarised with studies 107476 (M18), 107477 (M24), and 107479 (M36) on the GSK Clinical Study Register.",1-Mar-2014
GSK,"Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)",Human Papillomavirus Types 16 and 18 Vaccine,580299/013,NCT00196924,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/013,http://clinicaltrials.gov/show/NCT00196924,,Y,Y,Y,Y,Y,Y,Y,"The results of this study 580299/013 are summarised with studies 104896 (M18), 104902 (M24),  104904 (M36) and 104918 (M48) on the GSK Clinical Study Register.",1-Mar-2014
GSK,"An open, phase IV study on the immunogenicity and tolerability of Influsplit SSW® 2005/2006 in children aged 6 – 13 years","Influenza Vaccine (Split Virion, Inactivated)",106252,NCT00372255,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106252,http://clinicaltrials.gov/show/NCT00372255,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study.,1-Mar-2015
GSK,Phase III study to determine immunogenicity and reactogenicity of investigational influenza vaccine formulation I compared to the standard influenza vaccine of GSK Biologicals’ Influsplit SSW®/Fluarix™2003/2004 and compared to an investigational influenza vaccine formulation II in subjects aged over 18 years,"Influenza Vaccine (Split Virion, Inactivated)",100349-054,,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100349-054,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A phase III double-blind randomized multicentric study to determine the reactogenicity of an investigational influenza vaccine compared to the standard influenza vaccine of GlaxoSmithKline Biologicals’ Influsplit SSW®/ Fluarix™ 2003/2004 in subjects aged over 18 years.,"Influenza Vaccine (Split Virion, Inactivated)",100350-055,,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100350-055,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,To determine the immunogenicity and reactogenicity of a thiomersal free trivalent influenza split vaccine 2003/2004 or of GSK Biologicals’ standard formulation Influsplit SSW®/Fluarix™ 2003/2004 in children aged from 6 months until 6 years,"Influenza Vaccine (Split Virion, Inactivated)",100351,NCT00731393,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100351,http://clinicaltrials.gov/show/NCT00731393,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,Open immunization study to determine the reactogenicity and immunogenicity of Fluarix™/Influsplit SSW® 2004/2005 in persons as of 18 years of age.,"Influenza Vaccine (Split Virion, Inactivated)",102151 (Flu-058),,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/102151,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age","Influenza Vaccine (Split Virion, Inactivated)",102499,NCT00306995,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/102499,http://clinicaltrials.gov/show/NCT00306995,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. There is no GSK Clinical Study Register Results Summary record for this study.,1-Aug-2015
GSK,"A phase III, observer-blind, randomized study to evaluate the immunogenicity and safety of Fluarix™ (GlaxoSmithKline Biologicals) compared with Fluzone® (Aventis Pasteur) administered intramuscularly in adults 18 years and older in the U.S.","Influenza Vaccine (Split Virion, Inactivated)",104437,NCT00197288,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104437,http://clinicaltrials.gov/show/NCT00197288,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults.","Influenza Vaccine (Split Virion, Inactivated)",104438,NCT00197223,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104438,http://clinicaltrials.gov/show/NCT00197223,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People age 18 or beyond,"Influenza Vaccine (Split Virion, Inactivated)",104745,NCT00306943,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104745,http://clinicaltrials.gov/show/NCT00306943,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2015
GSK,"A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals) compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older)","Influenza Vaccine (Split Virion, Inactivated)",104858,NCT00383123,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104858,http://clinicaltrials.gov/show/NCT00383123,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influsplit SSW®) 2006/2007 in people aged 18 years or above,"Influenza Vaccine (Split Virion, Inactivated)",107507,NCT00345904,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107507,http://clinicaltrials.gov/show/NCT00345904,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2015
GSK,"A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age.","Influenza Vaccine (Split Virion, Inactivated, Fluviral)",109249,NCT00380211,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/IDB-200-001,http://clinicaltrials.gov/show/NCT00380211,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2014
GSK,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108668,NCT00427908,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108658,http://clinicaltrials.gov/show/NCT00427908,,Y,Y,Y,Y,Y,Y,Y,"The results of this study 108668 (Y5) are summarised with studies 108658, 108660 (Y1), 108661 (Y2), 108663 (Y3), and 108665 (Y4) on the GSK Clinical Study Register.",1-Mar-2014
GSK,Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib.,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111053,NCT00652951,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/110142,http://clinicaltrials.gov/show/NCT00652951,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in healthy infants",Rotavirus Vaccine,113808,NCT01171963,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113808,http://clinicaltrials.gov/show/NCT01171963,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm.",salbutamol,SB020001,,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SB020001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ HFA MDI delivered TID with facemask and valved holding chamber Aerochamber Plus in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.",salbutamol,SB030001,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SB030001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airways disease",salbutamol,SB030002,NCT00144846,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SB030002,http://clinicaltrials.gov/show/NCT00144846,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Albuterol HFA with Counter in Asthma or COPD Subjects at Least 4 Years of Age.",salbutamol,SB030003,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SB030003,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2014
GSK,"Phase I study of GSK573719 -A randomized, double blind, placebo controlled, dose ascending, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 from a novel dry powder device in healthy Japanese male subjects",umeclidinium bromide,AC4113377,NCT01013974,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113377,http://clinicaltrials.gov/show/NCT01013974,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"Randomized, double-blind, 5 period cross over study assessing lung function in healthy volunteers following single inhalations of GSK573719 Inhalation Powder from two configurations of the Novel Dry Powder Inhaler",umeclidinium bromide,AC4115487,NCT01521390,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115487,http://clinicaltrials.gov/show/NCT01521390,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD",umeclidinium bromide/vilanterol,DB2113120,NCT01039675,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113120,http://clinicaltrials.gov/show/NCT01039675,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 and GW642444 as monotherapies and concurrently in healthy Japanese subjects",umeclidinium bromide/vilanterol,DB2113208,NCT00976144,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113208,http://clinicaltrials.gov/show/NCT00976144,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease",umeclidinium bromide/vilanterol,DB2113361,NCT01313637,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113361,http://clinicaltrials.gov/show/NCT01313637,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease",umeclidinium bromide/vilanterol,DB2113373,NCT01313650,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113373,http://clinicaltrials.gov/show/NCT01313650,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
GSK,"A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination with GW642444",umeclidinium bromide/vilanterol,DB2113950,NCT01128634,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113950,http://clinicaltrials.gov/show/NCT01128634,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2014
Boehringer Ingelheim,RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome,dabigatran etexilate,1160.67,NCT00621855,Coronary Disease,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00621855?term=1160.67&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention",dabigatran etexilate,1160.73,NCT00818753,Heart Catheterization,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00818753?term=1160.73&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin",dabigatran etexilate,1160.2,NCT01227629,Atrial Fibrillation,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01227629?term=1160.20&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin,dabigatran etexilate,1160.49,NCT01136408,Atrial Fibrillation,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01136408?term=1160.49&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone,linagliptin,1218.15,NCT00641043,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00641043?term=1218.15&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control,linagliptin,1218.16,NCT00621140,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00621140?term=1218.16&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,linagliptin,1218.17,NCT00601250,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00601250?term=1218.17&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes,linagliptin,1218.18,NCT00602472,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00602472?term=1218.18&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,linagliptin,1218.2,NCT00622284,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00622284?term=1218.20&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Japanese P III vs Voglibose and Placebo,linagliptin,1218.23,NCT00654381,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00654381?term=1218.23&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",linagliptin,1218.35,NCT00819091,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00819091?term=1218.35&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,linagliptin,1218.36,NCT00954447,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00954447?term=1218.36&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients,linagliptin,1218.37,NCT00716092,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00716092?term=1218.37&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,linagliptin,1218.4,NCT00736099,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00736099?term=1218.40&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive",linagliptin,1218.43,NCT00800683,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00800683?term=1218.43&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",linagliptin,1218.46,NCT00798161,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00798161?term=1218.46&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",linagliptin,1218.5,NCT00740051,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00740051?term=1218.50&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid,linagliptin,1218.52,NCT00915772,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00915772?term=1218.52&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes,linagliptin,1218.6,NCT00309608,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00309608?term=1218.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes,linagliptin,1218.62,NCT01012037,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01012037?term=1218.62&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes,linagliptin,1218.63,NCT01084005,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01084005?term=1218.63&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,linagliptin,1218.75,NCT01194830,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01194830?term=1218.75&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Comprehensive Add on Study in Japan,linagliptin,1218.78,NCT01204294,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01204294?term=1218.78&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"Efficacy, Safety, Tolerability of Pramipexole ER Versus Pramipexol IR Versus Placebo in Early PD Patients",pramipexole,248.524,NCT00479401,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00479401?term=248.524&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms,pramipexole,248.596,NCT00297778,"Parkinson Disease, Depression",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00297778?term=248.596&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients",pramipexole,248.622,NCT00402233,Parkinson Disease,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00402233?term=248.622&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",pramipexole,248.629,NCT00472199,Restless Legs Syndrome,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00472199?term=248.629&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson's Disease (PD),pramipexole,248.633,NCT00601523,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00601523?term=248.633&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD,pramipexole,248.634,NCT00577460,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00577460?term=248.634&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease,pramipexole,248.636,NCT00558025,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00558025?term=248.636&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Pivotal Study in Advanced Parkinson Disease Patients,pramipexole,248.525,NCT00466167,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00466167?term=248.525&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Study of (Mirapex) Pramipexole for the Early Treatment of Parkinson Disease (PD),pramipexole,248.595,NCT00321854,Parkinson Disease,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00321854?term=248.595&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"A 12-week Study of Pramipexole ER in Patients With Parkinson's Disease, Followed by a 52-week Long-term Treatment Period",pramipexole,248.61,NCT00560508,Parkinson Disease,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00560508?term=248.610&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS",pramipexole,248.627,NCT00390689,Idiopathic Restless Legs Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00390689?term=248.627&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria,pramipexole,248.644,NCT00558467,Tourette Syndrome,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00558467?term=248.644&rank=1,,N,N,Y,N,Y,N,N,,1-Apr-2014
Boehringer Ingelheim,Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension,telmisartan,502.55,NCT00926289,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00926289?term=502.550&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,telmisartan + amlodipine,1235.1,NCT00281580,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00281580?term=1235.1&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Filtered Trial for Amlodipine Non-responder,telmisartan + amlodipine,1235.13,NCT00558064,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00558064?term=1235.13&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,telmisartan + amlodipine,1235.2,NCT00860262,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00860262?term=1235.20&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,telmisartan + amlodipine,1235.21,NCT00877929,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00877929?term=1235.21&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,"An Eight-week Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy",telmisartan + amlodipine,1235.29,NCT01103960,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01103960?term=1235.29&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension,telmisartan + amlodipine,1235.5,NCT00558428,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00558428?term=1235.5&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,telmisartan + amlodipine,1235.6,NCT00553267,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00553267?term=1235.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Open Label Study Telmisartan and Amlodipine in Hypertension,telmisartan + amlodipine,1235.7,NCT00614380,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00614380?term=1235.7&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,tiotropium bromide,205.235,NCT00144339,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144339?term=205.235&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients,tiotropium bromide,205.325,NCT00359788,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00359788?term=205.325&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD,tiotropium bromide,205.334,NCT00530842,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00530842?term=205.334&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.365,NCT00523991,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00523991?term=205.365&rank=1,,N,Y,Y,N,Y,Y,N,,1-Apr-2014
Boehringer Ingelheim,Tiotropium In Exercise,tiotropium bromide,205.368,NCT00525512,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00525512?term=205.368&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
Boehringer Ingelheim,Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients,tiotropium bromide,205.389,NCT00563381,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00563381?term=205.389&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
GSK,"Efficacy study of GSK Biologicals’ quadrivalent influenza vaccine, GSK2282512A, (FLU Q-QIV) when administered in children",Influenza Vaccine (Quadrivalent),114541,NCT01218308,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114541,http://clinicaltrials.gov/show/NCT01218308,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
GSK,Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children,"Influenza Vaccine (Split Virion, Inactivated)",113314,NCT01198756,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113314,http://clinicaltrials.gov/show/NCT01198756,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
GSK,Immunogenicity & safety study of GSK Biologicals’ thimerosal-free trivalent influenza vaccine (TIV) versus a licensed comparator in children,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",112999,NCT00980005,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112999,http://clinicaltrials.gov/show/NCT00980005,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2014
GSK,An adaptive design study for the assessment of the pharmacokinetics of albiglutide in subjects with normal renal function and subjects with moderate-to-severe renal impairment and hemodialysis.,albiglutide,GLP108370,NCT00938158,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/108370,http://clinicaltrials.gov/show/NCT00938158,,Y,Y,Y,Y,Y,Y,Y,,1-May-2014
GSK,"A multicentre, double-blind, placebo-controlled, parallel group study of the efficacy and tolerability of long-term inhaled fluticasone propionate 500mg twice daily via a Volumatic Spacer device in patients with non-asthmatic chronic obstructive pulmonary disease, including…",fluticasone propionate,FLTB3054 (FLIT78) [ISOLDE],,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FLTB3054,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety",paroxetine,29060/785,,"Depressive Disorder, Major",Phase 4,http://www.gsk-clinicalstudyregister.com/study/29060/785,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder.",paroxetine,MY-1043/BRL-029060/115,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/115,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression.",paroxetine,BRL-029060/377,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/377,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression",paroxetine,29060/448,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/448,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression",paroxetine,29060/449,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/449,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A multi-center, double blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Paroxetine in children with major depression.",paroxetine,BRL-029060/701,,Major Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/701,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression.",paroxetine,29060/810,,"Depressive Disorder, Major",Phase 4,http://www.gsk-clinicalstudyregister.com/study/29060/810,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"Assessment of Paxil CR, 12.5 and 25 mg/day in treating elderly patients with major depression",paroxetine,29060/874,NCT00067444,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/874,http://clinicaltrials.gov/show/NCT00067444,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study.,1-May-2014
GSK,A multi-center trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPD,umeclidinium bromide,DB2113374,NCT01316913,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113374,http://clinicaltrials.gov/show/NCT01316913,,Y,Y,Y,Y,Y,Y,Y,,1-May-2014
GSK,A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD,umeclidinium bromide,DB2113360,NCT01316900,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113360,http://clinicaltrials.gov/show/NCT01316900,,Y,Y,Y,Y,Y,Y,Y,,1-May-2014
GSK,"Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients treated with IV zanamivir in the Relenza Compassionate Use Program",zanamivir,NAI115008,NCT01353768,"Infections, Respiratory Tract",N/A,http://www.gsk-clinicalstudyregister.com/study/115008,http://clinicaltrials.gov/show/NCT01353768,,N,Y,Y,Y,Y,Y,Y,The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.,1-May-2014
ViiV,"A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...",fosamprenavir,ESS40001,N/A,"Infection, Human Immunodeficiency Virus I",Phase 2,http://www.viiv-clinicalstudyregister.com/study/ESS40001,,,N,Y,Y,N,Y,Y,Y,"A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the analysis-ready dataset and dataset specification are not available.",1-Apr-2014
Lilly,A Dose Response Study of Duloxetine versus Placebo in Patients with Painful Diabetic Neuropathy,Duloxetine hydrochloride,F1J-MC-HMAW,Not available,Diabetic Peripheral Neuropathic Pain,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
Lilly,Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMBC,NCT00036309,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00036309?lead=Lilly&id=HMBC&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Lilly,Duloxetine Hydrochloride 60 mg or 120 mg Once Daily Compared With Placebo in Patients With Generalized Anxiety Disorder,Duloxetine hydrochloride,F1J-MC-HMBR,NCT00122824,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00122824?lead=Lilly&id=HMBR&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Lilly,Open-Label Safety Study of Duloxetine in Patients with Painful Diabetic Neuropathy,Duloxetine hydrochloride,F1J-MC-HMBT,Not available,Diabetic Peripheral Neuropathic Pain,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
Lilly,Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression,Duloxetine hydrochloride,F1J-US-HMFA,NCT00406848,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00406848?lead=Lilly&id=HMFA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Lilly,"Olanzapine Versus Placebo and Haloperidol in the
Treatment of Schizophrenia",Olanzapine,F1D-MC-HGAD,Not available,Schizophrenia,Phase 2,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the reporting and analysis plan and the annotated case report form are not available. A blank case report form will be provided.",1-Jun-2014
Lilly,"A Fixed-Dose Range Safety and Efficacy Study of Olanzapine
Versus Haloperidol in the Treatment of Schizophrenia",Olanzapine,F1D-EW-E003,Not available,Schizophrenia,Phase 2,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the reporting and analysis plan and the annotated case report form are not available. A blank case report form will be provided.",1-Jun-2014
Lilly,Olanzapine Relapse Prevention Versus Placebo in the Treatment of Schizophrenia,Olanzapine,F1D-MC-HGGI,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the reporting and analysis plan and the annotated case report form are not available. A blank case report form will be provided.",1-Jun-2014
Lilly,Olanzapine Versus Haloperidol in the Treatment of Acute Mania,Olanzapine,F1D-MC-HGHD,Not available,Acute Mania,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the reporting and analysis plan is not available.",1-Jun-2014
Lilly,A Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia,Olanzapine pamoate,F1D-MC-HGJZ,NCT00088478,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00088478?lead=lilly&id=HGJZ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Lilly,A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults (HypoCCS),Somatropin,B9R-MC-GDGA,NCT01088399,"Hypopituitarism;   Pituitary Insufficiency;   Growth Hormone Deficiency, Adult",Not applicable,Not available,http://clinicaltrials.gov/ct2/show/NCT01088399?lead=lilly&id=GDGA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,COPD prevalence estimation in Spanish population.,N/A,107335,,"Pulmonary Disease, Chronic Obstructive",N/A,,,,N,N,N,Y,N,Y,N,This is an observational study to determine the prevalence of COPD in residents of Spain aged 40 to 80 years. Only raw data is available for this study. The data labels for this study are in Spanish. The supporting documents are not in English and will not be provided. A link to the GSK Clinical Study Register entry for this study is not provided because the study was conducted before GSK policy requirements to register observational studies. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jun-2014
GSK,"A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus",albiglutide,GLP106073,NCT00354536,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/GLP106073,http://clinicaltrials.gov/show/NCT00354536,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal",albiglutide,GLP107030,NCT00537719,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/GLP107030,http://clinicaltrials.gov/show/NCT00537719,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers.",albiglutide,GLP105229,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105229,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects,albiglutide,GLP107032,NCT01077505,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/107032,http://clinicaltrials.gov/show/NCT01077505,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)",albiglutide,GLP107085,NCT01406262,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/107085,http://clinicaltrials.gov/show/NCT01406262,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects",albiglutide,GLP111680,NCT01147718,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111680,http://clinicaltrials.gov/show/NCT01147718,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects",albiglutide,GLP111681,NCT01147731,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111681,http://clinicaltrials.gov/show/NCT01147731,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus",albiglutide,GLP114179,NCT01128894,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114179,http://clinicaltrials.gov/show/NCT01128894,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jun-2014
GSK,"An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers",albiglutide,GLP107724,NCT00394030,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/GLP107724,http://clinicaltrials.gov/show/NCT00394030,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance,amoxicillin/clavulanic acid,25000/541,,Otitis Maedia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/541,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 7 days for the Treatment of Bacterial Community-Acquired Pneumonia in adults.",amoxicillin/clavulanic acid,25000/547,,"Pneumonia, Community-Acquired",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/547,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,Evaluating the Impact of Amoxicillin/Clavulanate Potassium Therapy on Carriage of Susceptible and Resistant Streptococcus pneumoniae.,amoxicillin/clavulanic acid,25000/555,,Streptococcus pneumoniae,Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/555,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension.,amoxicillin/clavulanic acid,25000/601,,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/601,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children.",amoxicillin/clavulanic acid,25000/611,,Otitis Maedia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/25000/611,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin.",amoxicillin/clavulanic acid,25000/620,,"Pneumonia, Community-Acquired",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/620,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis.",amoxicillin/clavulanic acid,25000/630,,"Bronchitis, Chronic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/630,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A),amoxicillin/clavulanic acid,25000/643,,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/643,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension.",amoxicillin/clavulanic acid,25000/665,,Streptococcus pneumoniae,Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/665,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days,amoxicillin/clavulanic acid,AUG102821,NCT00354965,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AUG102821,http://clinicaltrials.gov/show/NCT00354965,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study.,1-Jun-2014
GSK,"A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults.",amoxicillin/clavulanic acid,25000/557,,"Pneumonia, Community-Acquired",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/557,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.",amoxicillin/clavulanic acid,25000/592,,Sinusitis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/592,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers.",amoxicillin/clavulanic acid,25000/593,,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/593,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia.",amoxicillin/clavulanic acid,25000/600,,"Pneumonia, Community-Acquired",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/600,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis",amoxicillin/clavulanic acid,25000/627,,"Bronchitis, Chronic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/25000/627,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients",carvedilol,105517/367,,Hypertension,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105517/367,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An open, non-randomized comparison of pharmacokinetic profiles of carvedilol (SK&F-105517) MR and IR on repeat dosing in chronic CHF subjects and survivors of an acute MI and LVD",carvedilol,105517/369,,"Heart failure, Congestive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105517/369,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the B1-Blocking Effects of an investigational formulation of carvedilol to COREG Immediate Release Tablets at Steady-State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response to Bicycle Ergometry",carvedilol,105517/902,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105517/902,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An Open-label, Single Dose, Three Session, Partially Randomized, Crossover Study to Assess Morning and Evening Dosing of Carvedilol Phosphate MR Capsules in Healthy Adult Subjects",carvedilol,105517/906,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105517/906,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized, single-blind, placebo-controlled, three-period parallel-group study to assess the pharmacokinetic and pharmacodynamic relationship of a 50 mg single oral dose of immediate release carvedilol in healthy subjects",carvedilol,105517/908,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105517/908,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized, open-label, single-dose, four-period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-encapsulated Zestril to Zestril",carvedilol,CFD105533,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105533,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized, open-label, two period, period balanced, crossover study to estimate the relative bioavailability of an investigational drug compared to Coreg IR in healthy adult volunteers",carvedilol,CRV104257,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/104257,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR",carvedilol,CRV106904,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/106904,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG™ CR) or 10mg, 20mg, or 40mg QD doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication",carvedilol; carvedilol/lisinopril; lisinopril,CFD105453,NCT00347360,Hypertension,Phase 3,http://www.gsk-clinicalstudyregister.com/study/CFD105453,http://clinicaltrials.gov/show/NCT00347360,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A phase 3, open, randomized, controlled, multicentre study to evaluate the safety and reactogenicity profile of GSK Biologicals' Haemophilus influenzae type b–meningococcal serogroup C conjugate candidate vaccine given concomitantly with GSK Biologicals' diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine and to compare it with MenC-CRM197 conjugate vaccine co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine, when given as a 3-dose primary vaccination (at 2, 3, 4 months of age) to healthy infants.","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",811936/003,,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/811936/003,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels,dutasteride,ARI40014,NCT00062790,Prostatic Hyperplasia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ARI40014,http://clinicaltrials.gov/show/NCT00062790,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase,dutasteride,AVO108943,NCT00470834,"Neoplasms, Prostate",Phase 4,http://www.gsk-clinicalstudyregister.com/study/AVO108943,http://clinicaltrials.gov/show/NCT00470834,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.",fluticasone furoate,FFR20001,,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFR20001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Perennial Allergic Rhinitis (PAR)",fluticasone furoate,FFR30002,NCT00103454,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR30002,http://clinicaltrials.gov/show/NCT00103454,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the
 effect of fluticasone furoate aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis
 in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR)",fluticasone furoate,FFR20002,NCT00116818,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR20002,http://clinicaltrials.gov/show/NCT00116818,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis",fluticasone furoate,FFR30003,NCT00115622,"Rhinitis, Allergic, Seasonal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR30003,http://clinicaltrials.gov/show/NCT00115622,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A non-randomized, open label, two period cross-over study to determine the excretion balance and pharmacokinetics of [14C]-GW685698, administered as single doses of an oral solution and an intravenous infusion to healthy adult male subjects",fluticasone furoate,FFR10008,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFR10008,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.",fluticasone furoate,FFA112059,NCT01159912,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112059,http://clinicaltrials.gov/show/NCT01159912,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, repeat-dose, placebo-controlled, double-blind study to evaluate and compare the efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, when administered either in the morning or in the evening, in male and female asthmatic subjects",fluticasone furoate/vilanterol,HZA114624,NCT01287065,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114624,http://clinicaltrials.gov/show/NCT01287065,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects.",fluticasone furoate,FFR101888,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/101888,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, open label, 2-way cross-over study to assess the absolute bioavailability of GW685698X administered intranasally in healthy male and female subjects",fluticasone furoate,FFR10010,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFR10010,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and
 Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mg and 100mcg for
 12 Weeks in Pediatric Subjects Ages 2 to <12 Years with Perennial Allergic Rhinitis (PAR)",fluticasone furoate,FFR30008,NCT00108914,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR30008,http://clinicaltrials.gov/show/NCT00108914,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis",fluticasone furoate,FFR30006,NCT00117325,"Rhinitis, Vasomotor",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR30006,http://clinicaltrials.gov/show/NCT00117325,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis",fluticasone furoate,FFR30007,NCT00118703,"Rhinitis, Vasomotor",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR30007,http://clinicaltrials.gov/show/NCT00118703,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study",fluticasone furoate,FFR105693,NCT00346775,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR105693,http://clinicaltrials.gov/show/NCT00346775,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects 18 Years of Age with Perennial Allergic Rhinitis (PAR)",fluticasone furoate,FFR104503,NCT00224523,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR104503,http://clinicaltrials.gov/show/NCT00224523,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.",fluticasone furoate,FFA114496,NCT01431950,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114496,http://clinicaltrials.gov/show/NCT01431950,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 years of age and older) with Persistent Asthma",fluticasone furoate,FFA106783,NCT00398645,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFA106783,http://clinicaltrials.gov/show/NCT00398645,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients",fluticasone furoate,FFA10022,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10022,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients",fluticasone furoate,FFA10027,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10027,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients.",fluticasone furoate,FFA10028,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10028,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects.,fluticasone furoate,FFA10013,NCT00419237,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10013,http://clinicaltrials.gov/show/NCT00419237,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis.",fluticasone furoate,FFR102123,,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/102123,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 100ug (micrograms) in children aged 5-11 years with persistent asthma",fluticasone furoate,HZA102942,NCT01332292,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/102942,http://clinicaltrials.gov/show/NCT01332292,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2016
GSK,"A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 years of age and older) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber",fluticasone furoate,FFR101816,NCT00118729,"Rhinitis, Allergic, Seasonal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR101816,http://clinicaltrials.gov/show/NCT00118729,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe",fluticasone furoate,FFR103184,NCT00225823,"Rhinitis, Allergic, Seasonal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR103184,http://clinicaltrials.gov/show/NCT00225823,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg Once Daily on Short-Term Growth in Children Aged 6 to 11 Years with Seasonal and/or Perennial Allergic Rhinitis",fluticasone furoate,FFR101747,NCT00109486,"Rhinitis, Allergic, Perennial and Seasonal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR101747,http://clinicaltrials.gov/show/NCT00109486,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR).",fluticasone furoate,FFR100012,NCT00116883,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR100012,http://clinicaltrials.gov/show/NCT00116883,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,See Detailed Description,fluticasone furoate,FFR104861,NCT00197262,"Rhinitis, Allergic, Seasonal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR104861,http://clinicaltrials.gov/show/NCT00197262,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR)",fluticasone furoate,FFR100010,NCT00107757,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR100010,http://clinicaltrials.gov/show/NCT00107757,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)",fluticasone furoate,FFR106080,NCT00289198,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/FFR106080,http://clinicaltrials.gov/show/NCT00289198,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma",fluticasone furoate/vilanterol,HZA106837,NCT01086384,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106837,http://clinicaltrials.gov/show/NCT01086384,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents",fluticasone furoate/vilanterol,HZA106827,NCT01165138,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106827,http://clinicaltrials.gov/show/NCT01165138,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A two cohort, randomised, single-blind, two-way crossover design study to assess the effects of single doses of nasally administered fluticasone propionate (400 mcg) and a new chemical entity (NCE) on nuclear translocation of the glucocorticoid receptor, using biopsy, in male healthy volunteers.",fluticasone furoate; fluticasone propionate,FFR10006,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFR10006,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE),fondaparinux sodium,AR1104574,,Thromboembolism,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104574,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.,fondaparinux sodium,AR2103413,NCT00064428,Thromboembolism,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103413,http://clinicaltrials.gov/show/NCT00064428,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with Intermittent Pneumatic Compression (IPC) versus IPC used alone for the prevention of venous thromboembolic events in subjects at increased risk undergoing major abdomi",fondaparinux sodium,AR3103414,NCT00038961,Thromboembolism,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103414,http://clinicaltrials.gov/show/NCT00038961,,Y,N,Y,Y,Y,N,Y,A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes",fondaparinux sodium,AR1103420,NCT00139815,Thromboembolism,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103420,http://clinicaltrials.gov/show/NCT00139815,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,"A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS).",fondaparinux sodium,AR3104619,,"Thrombosis, Venous",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104619,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age,H1N1 Pandemic Influenza Vaccine,113482,NCT00976820,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113482,http://clinicaltrials.gov/show/NCT00976820,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Immunogenicity and safety study of GSK Biologicals’ monovalent pandemic H5N1 vaccine 1557484A in adults aged 18 – 64 years,H5N1 Pandemic Influenza Vaccine,112691,NCT01416571,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112691,http://clinicaltrials.gov/show/NCT01416571,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects",Haemophilus influenzae Type b Vaccine,208108/091,NCT01061541,Haemophilus influenzae type b,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208108/091,http://clinicaltrials.gov/show/NCT01061541,,Y,N,Y,Y,Y,Y,Y,The results of study 208108/091 are summarised with study 208108/092 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects",Haemophilus influenzae Type b Vaccine,208108/092,NCT01061541,Haemophilus influenzae type b,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208108/091,http://clinicaltrials.gov/show/NCT01061541,,Y,N,Y,Y,Y,Y,N,The results of study 208108/092 are summarised with study 208108/091 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-admind with Infanrix penta) compared to a booster dose of Menjugate (co-admind with Infanrix hexa)","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",100381,,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/100381,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",792014/001,NCT00127855,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/792014/001,http://clinicaltrials.gov/show/NCT00127855,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",792014/002,,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/792014/002,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for ths study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",792014/003,NCT00129116,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/792014/003,http://clinicaltrials.gov/show/NCT00129116,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",101858,NCT00129129,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101858,http://clinicaltrials.gov/show/NCT00129129,,Y,N,Y,Y,Y,Y,N,The results of study 101858 are summarised with study 102015 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",102015,NCT00129129,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101858,http://clinicaltrials.gov/show/NCT00129129,,Y,N,Y,Y,Y,Y,Y,The results of study 102015 are summarised with study 101858 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months,"Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",102370,NCT00134719,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/102370 (primary study),http://clinicaltrials.gov/show/NCT00134719,,Y,N,Y,Y,Y,Y,N,The results of study 102370 are summarised with study 102371 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months,"Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",102371,NCT00134719,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/102370 (primary study),http://clinicaltrials.gov/show/NCT00134719,,Y,N,Y,Y,Y,Y,N,The results of study 102371 are summarised with study 102370 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",103813,NCT00289783,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103813,http://clinicaltrials.gov/show/NCT00289783,,Y,N,Y,Y,Y,Y,N,The results of study 103813 are summarised with study 105067 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",105067,NCT00289783,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103813,http://clinicaltrials.gov/show/NCT00289783,,Y,N,Y,Y,Y,Y,N,The results of study 105067 are summarised with study 103813 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"A single-blind, randomized, controlled, multinational study for the evaluation of safety of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",105987,NCT00345579,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105987,http://clinicaltrials.gov/show/NCT00345579,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A study to evaluate the long-term antibody persistence at 1, 3 & 5 years after the administration of a fourth dose of Hib-MenCY-TT Vaccine compared to ActHIB in subjects boosted in a previous study.","Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine",107824,NCT00359983,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107824,http://clinicaltrials.gov/show/NCT00359983,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",102547,NCT00323050,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/102547,http://clinicaltrials.gov/show/NCT00323050,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Study to evaluate the safety, reactogenicity & immunogenicity of a booster dose of GSK Biologicals’ Hib-MenC given with Priorix™, vs Hib-MenC or Priorix™ only, in toddlers (13–14 m) primed with 3 doses of Hib (as part of a DTPa –containing vaccine) & MenC-CRM197 conjugate vaccines.","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",103954,NCT00263653,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103954,http://clinicaltrials.gov/show/NCT00263653,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",103974,NCT00258700,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103974 (primary study),http://clinicaltrials.gov/show/NCT00258700,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Study to demonstrate the non-inferiority of the meningococcal serogroup C immune response of GlaxoSmithKline Biologicals’ Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ vaccine,"Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",104056,,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104056,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106388,NCT00327184,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106388,http://clinicaltrials.gov/show/NCT00327184,,Y,N,Y,Y,Y,Y,Y,The results of study 106388 are summarised with study 106390 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106390,NCT00327184,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106388,http://clinicaltrials.gov/show/NCT00327184,,Y,N,Y,Y,Y,Y,N,The results of study 106390 are summarised with study 106388 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5 years after vaccination.","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106445,NCT00326118,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106445,http://clinicaltrials.gov/show/NCT00326118,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106672,NCT00322335,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106672,http://clinicaltrials.gov/show/NCT00322335,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Assessment of long-term antibody persistence after a booster dose of GSK Biologicals’ Hib & meningococcal C vaccine (Menitorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Menitorix™ at 2, 3, 4 months of age","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",109664,NCT00454987,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/109664,http://clinicaltrials.gov/show/NCT00454987,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,Evaluate the effect of risk factors that influence the immunogenicity of GSK Biologicals Twinrix compared to hepatitis A and hepatitis B vaccines given separately and to show the non-inferiority between the vaccines in adults,twinrix,111149,NCT00603252,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/111149,http://clinicaltrials.gov/show/NCT00603252,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Mar-2015
GSK,"Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose",twinrix,100566,NCT00197119,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100566,http://clinicaltrials.gov/show/NCT00197119,,Y,N,Y,Y,Y,Y,Y,"The results of study 100566 are summarised with studies 100567, 100568, 100569, and 100570 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose",twinrix,100567,NCT00197119,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100566,http://clinicaltrials.gov/show/NCT00197119,,Y,N,Y,Y,Y,Y,Y,"The results of study 100567 are summarised with studies 100566, 100568, 100569, and 100570 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose",twinrix,100568,NCT00197119,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100566,http://clinicaltrials.gov/show/NCT00197119,,Y,N,Y,Y,Y,Y,Y,"The results of study 100568 are summarised with studies 100566, 100567, 100569, and 100570 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose",twinrix,100569,NCT00197119,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100566,http://clinicaltrials.gov/show/NCT00197119,,Y,N,Y,Y,Y,Y,Y,"The results of study 100569 are summarised with studies 100566, 100567, 100568, and 100570 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose",twinrix,100570,NCT00197119,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100566,http://clinicaltrials.gov/show/NCT00197119,,Y,N,Y,Y,Y,Y,Y,"The results of study 100570 are summarised with studies 100566, 100567, 100568, and 100569 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",100576,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100576 are summarised with studies 100577, 100578, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",100577,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100577 are summarised with studies 100576, 100578, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",100578,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100578 are summarised with studies 100576, 100577, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",100579,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100579 are summarised with studies 100576, 100577, 100578, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",100580,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100580 are summarised with studies 100576, 100577, 100578, 100579, 111028, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",111028,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111028 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111029, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",111029,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111029 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111030, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",111030,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111030 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111031, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",111031,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111031 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111030, and 111032 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",100571,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100571 are summarised with studies 100572, 100573, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",100572,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100572 are summarised with studies 100571, 100573, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",100573,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100573 are summarised with studies 100571, 100572, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",100574,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100574 are summarised with studies 100571, 100572, 100573, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",100575,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100575 are summarised with studies 100571, 100572, 100573, 100574, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",110677,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 110677 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110678, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",110678,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 110678 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110679, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",110679,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 110679 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110680, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",110680,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 110680 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110679, and 110681 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2014
GSK,Long-term antibody persistence of hepatitis B antibodies and immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children previously vaccinated with Infanrix hexa vaccine,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",112688,NCT01333813,Diphtheria; Tetanus; Acellular Pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b,Phase 4,http://www.gsk-clinicalstudyregister.com/study/112688,http://clinicaltrials.gov/show/NCT01333813,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2015
GSK,Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.,Influenza Vaccine (Quadrivalent),114269,NCT01204671,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114269,http://clinicaltrials.gov/show/NCT01204671,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older",Influenza Vaccine (Quadrivalent),112963,NCT01196975,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112963,http://clinicaltrials.gov/show/NCT01196975,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"Clinical study in children, 6 months to 3 years of age, to assess the immunogenicity and safety of two dose levels of thimerosal-free Fluviral® vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control","Influenza Vaccine (Split Virion, Inactivated, Fluviral)",111635,NCT00778895,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111635,http://clinicaltrials.gov/show/NCT00778895,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A randomised, open-label, parallel-group design study to evaluate the pharmacokinetic characteristics, safety and tolerability of single oral doses of three prototype 300mg enteric coated - modified release formulations of Lamotrigine in healthy subjects.",lamotrigine,LAM105377,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105377,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A two-part, open label study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single and repeat oral doses of Lamictal SR/XR prototype formulations and to study the effects of food on pharmacokinetic parameters.",lamotrigine,LAM10005,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM10005,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,An open-label study in healthy male and female volunteers to evaluate the repeat dose pharmacokinetics and dose strength equivalence of lamotrigine enteric coated modified release tablets over the dose range 25-200 mg.,lamotrigine,LAM10017,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM10017,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"Open label, safety study for use of lamictal in patients with diabetic neuropathy",lamotrigine,NPP30006,,"Neuropathy, Diabetic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NPP30006,,,Y,Y,Y,Y,Y,Y,Y,This is a follow-on study to NPP30004 and NPP30005. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures",lamotrigine,LAM100036,NCT00104416,"Epilepsy, Tonic-Clonic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/LAM100036,http://clinicaltrials.gov/show/NCT00104416,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures",lamotrigine,LAM100034,NCT00113165,"Epilepsy, Partial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/LAM100034,http://clinicaltrials.gov/show/NCT00113165,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects",lamotrigine,LBI108614,NCT00410371,Mental Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LBI108614,http://clinicaltrials.gov/show/NCT00410371,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder",lamotrigine,SCA100223,NCT00274677,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA100223,http://clinicaltrials.gov/show/NCT00274677,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,Double blind placebo controlled study of lamictal in acute bipolar depression,lamotrigine,SCA30924,NCT00056277,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA30924,http://clinicaltrials.gov/show/NCT00056277,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,Lamictal in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: Trial to Assess and Refine Global Epilepsy Treatment),lamotrigine,LAM40091,,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40091,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy",lamotrigine,NPP30004,,"Neuropathy, Diabetic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NPP30004,,,N,Y,Y,Y,Y,Y,N,A follow-on study NPP30006 was conducted. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy",lamotrigine,NPP30005,,"Neuropathy, Diabetic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NPP30005,,,N,Y,Y,Y,Y,Y,Y,A follow-on study NPP30006 was conducted. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Fixed-dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Subjects with Bipolar I Disorder",lamotrigine,SCAB2003 (105-605),,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCAB2003,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"Open-Label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects Initiating Lamotrigine or Valproate Either as Monotherapy for Newly Diagnosed Epilepsy or as Adjunctive Therapy for Inadequately Controlled Epilepsy",lamotrigine,LAM30007,,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/LAM30007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",lamotrigine,LAM30055,NCT00355082,"Epilepsy, Partial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/LAM30055,http://clinicaltrials.gov/show/NCT00355082,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects wtih Primary Generalized Tonic-Clonic Seizures",lamotrigine,LAM40097,NCT00043901,"Epilepsy, Tonic-Clonic",Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40097,http://clinicaltrials.gov/show/NCT00043901,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa",lamotrigine,LEP103944,NCT00264615,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/LEP103944,http://clinicaltrials.gov/show/NCT00264615,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months)",lamotrigine,LAM20006,NCT00043875,Epilepsy,Phase 2,http://www.gsk-clinicalstudyregister.com/study/LAM20006,http://clinicaltrials.gov/show/NCT00043875,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,"An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age)",lamotrigine,LAM20007,NCT00044278,Epilepsy,Phase 2,http://www.gsk-clinicalstudyregister.com/study/LAM20007,http://clinicaltrials.gov/show/NCT00044278,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,Double-blind Randomized Trial of Cognitive Effects of LAMICTAL (lamotrigine) versus Topiramate in Epilepsy,lamotrigine,LAM40112,,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/LAM40112,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and risperidone in healthy, non-smoking, male volunteers.",lamotrigine,SCA101963,,Schizophrenia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101963,,,Y,N,Y,Y,Y,Y,N,An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A study to evaluate the effect of repeat oral doses of lamotrigine on cardiac conduction as assessed by 12-Lead ECG as compared to placebo and single oral doses of moxifloxacin.,lamotrigine,SCA104648,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/104648,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.,lamotrigine,SCA40917,NCT00067938,Bipolar Disorder,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCA40917,http://clinicaltrials.gov/show/NCT00067938,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study.,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Evaluation of LAMICTAL (lamotrigine) in Adult Subjects with HIV-Associated Peripheral Neuropathy",lamotrigine,LAM40006,,Peripheral Neuropathies,Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40006,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy",lamotrigine,LAM40013,NCT00043914,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40013,http://clinicaltrials.gov/show/NCT00043914,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,"A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and olanzapine in healthy, non-smoking, male volunteers.",lamotrigine,SCA10908,,Bipolar Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SCA10908,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and oxcarbazepine in healthy, non-smoking, male volunteers.",lamotrigine,SCA10910,,Bipolar Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SCA10910,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety, Efficacy, and Tolerability of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder",lamotrigine,SCA40910,,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA40910,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"Double blind, double-dummy, randomised, placebo controlled study to evaluate the effect of single doses of drug A (lamotrigine) and drug B (vofopitant) alone and in combination on resting motor threshold in healthy subjects",lamotrigine,LNK112676,NCT00907985,Bipolar Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112676,http://clinicaltrials.gov/show/NCT00907985,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents,lamotrigine,LAM100118,NCT00144872,"Seizure, Absence",Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM100118,http://clinicaltrials.gov/show/NCT00144872,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects with Schizophrenia",lamotrigine,SCA101464,NCT00086593,Schizophrenia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101464,http://clinicaltrials.gov/show/NCT00086593,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study.,1-Jun-2014
GSK,"A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia",lamotrigine,SCA30926,NCT00071747,Schizophrenia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA30926,http://clinicaltrials.gov/show/NCT00071747,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study.,1-Jun-2014
GSK,"An open, randomised, parallel group study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single oral does of new LAMICTAL™ formulations.",lamotrigine,LAM10004,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM10004,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An open-label, non-randomised, single-sequence study to investigate the effects of the combined oral contraceptive pill on the pharmacokinetics of lamotrigine and the effects of lamotrigine on the pharamcokinetics of the combined oral contraceptive pill in healthy young female subjects.",lamotrigine,LAM10016,,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LAM10016,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Phase IV, partially double-blind study to demonstrate non-inferiority of GSK Biologicals’ Mencevax™ ACWY (new process) versus Mencevax™ ACWY (current process) when administered as a single dose to subjects aged 2-30 yrs","Meningococcal Serogroups A, C, W-135 and Y Vaccine",102394,NCT00227422,"Infections, Meningococcal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/102394,http://clinicaltrials.gov/show/NCT00227422,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"Assess the immunogenicity, safety, reactogenicity of 1 dose of 4 different formulations of GSK Biologicals’ meningococcal conjugate vaccine (MenACWY) vs 1 dose of Mencevax™ ACWY in healthy subjects aged 15-19 yrs","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",103532,NCT00196963,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/103532,http://clinicaltrials.gov/show/NCT00196963,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2014
GSK,"Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",103533,NCT00196976,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/103533,http://clinicaltrials.gov/show/NCT00196976,,Y,N,Y,Y,Y,Y,Y,The results of study 103533 are summarised with study 103534 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided,1-Jun-2014
GSK,"Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",103534,NCT00196976,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/103533,http://clinicaltrials.gov/show/NCT00196976,,Y,Y,Y,Y,Y,Y,Y,The results of study 103534 are summarised with study 103533 on the GSK Clinical Study Register.,1-Jun-2014
GSK,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",104703,NCT00126984,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104703 (Primary study),http://clinicaltrials.gov/show/NCT00126984,,Y,N,Y,Y,Y,Y,Y,The results of study 104703 are summarised with study 104704 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",104704,NCT00126984,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104703 (Primary study),http://clinicaltrials.gov/show/NCT00126984,,Y,N,Y,Y,Y,Y,Y,The results of study 104704 are summarised with study 104703 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",107386,NCT00356369,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/107386,http://clinicaltrials.gov/show/NCT00356369,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,Assess long term persistence of a primary dose of GSK Biologicals' meningococcal vaccine 134612 versus one dose of Mencevax™ ACWY in healthy adolescents/young adults (15 to 19 years at vaccination),"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",108595,NCT00390143,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108595 Mth18,http://clinicaltrials.gov/show/NCT00390143,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2014
GSK,"A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage",ropinirole,RRL100013,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100013,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)",ropinirole,RRL100310,NCT00225862,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100310,http://clinicaltrials.gov/show/NCT00225862,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open-label, randomised, two part study to investigate the relative bioavailability of Ropinirole new and standard, marketed formulations and the effect of food on the pharmacokinetics of Ropinirole new formulation in early stage Parkinson’s disease subjects",ropinirole,101468/164,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/164,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies.",ropinirole,101468/165,,Parkinson Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101468/165,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies",ropinirole,SKF-101468/166,,Parkinson Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101468/166,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy",ropinirole,101468/168,,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/168,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa",ropinirole,101468/169,NCT00381472,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/169,http://clinicaltrials.gov/show/NCT00381472,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,A Study of the Maintained Efficacy and Safety of Ropinirole Versus Placebo in the Long Term Treatment of Restless Legs Syndrome (RLS),ropinirole,SKF-101468/188,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/188,,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 101468/192 was conducted. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).",ropinirole,SKF-101468/190,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/190,,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 101468/192 was conducted. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS)",ropinirole,SKF-101468/191,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/191,,,N,Y,Y,Y,Y,Y,Y,A follow-on study 101468/243 was conducted. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS),ropinirole,101468/192,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/192,,,N,Y,Y,Y,Y,Y,Y,"This is a follow up study to 101468/188, 101468/190, 101468/194 and 101468/218. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).",ropinirole,101468/194,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/194,,,N,N,Y,Y,Y,Y,Y,A follow-on study 101468/243 was conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164",ropinirole,101468/196,NCT00650104,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/196,http://clinicaltrials.gov/show/NCT00650104,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to 101468/164 and 101468/167.,1-Jun-2014
GSK,"An open study to compare the PK and tolerability of ropinirole administered as 5 different new formulations with the standard, marketed formulation in healthy volunteers",ropinirole,SKF-101468/197,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/197,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation",ropinirole,101468/198,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/198,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,An open label study conducted in healthy volunteers to characterize the pharmacokinetics of a new unmarketed formulation of ropinirole,ropinirole,101468/199,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/199,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Single Blind, Parallel Group, Up-titration, Phase 1 Study in Healthy Volunteers to Determine a Starting Dose and Select an Up-titration Regimen for a new Formulation of Ropinirole",ropinirole,101468/201,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/201,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS)",ropinirole,101468/204,NCT00314860,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/204,http://clinicaltrials.gov/show/NCT00314860,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome",ropinirole,101468/205,NCT00197080,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/205,http://clinicaltrials.gov/show/NCT00197080,,N,Y,Y,Y,Y,Y,Y,A follow-on study 101468/206 was conducted. An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,"A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS)",ropinirole,101468/206,NCT00355641,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/206,http://clinicaltrials.gov/show/NCT00355641,,Y,Y,Y,Y,Y,Y,Y,This is a Follow up study to 101468/205 and ROX104805,1-Jun-2014
GSK,"A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS).",ropinirole,SKF-101468/207,,Restless Legs Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101468/207,,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 101468/243 was conducted. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase IIa Study to Determine the Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)",ropinirole,SKF-101468/218,,Restless Legs Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101468/218,,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 101468/192 was conducted. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers",ropinirole,101468/219,,Parkinson Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/219,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.",ropinirole,101468/228,NCT00363727,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/228,http://clinicaltrials.gov/show/NCT00363727,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS),ropinirole,101468/243,,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/243,,,Y,Y,Y,Y,Y,Y,Y,"This is a follow up study to 101468/191, SKF-101468/194 and SKF-101468/207.  A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)",ropinirole,101468/249,NCT00363857,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/249,http://clinicaltrials.gov/show/NCT00363857,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open label, single dose, dose rising, multi-centre study to assess the tolerability and pharmacokinetics of Ropinirole Immediate Release in adolescent patients with RLS.",ropinirole,101468/253,NCT00140712,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/253,http://clinicaltrials.gov/show/NCT00140712,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,A study to evaluate the effect of repeated oral doses of ropinirole on cardiac conduction as assessed by 12-lead electrocardiogram compared to placebo and single oral doses of moxifloxacin (Bayer) as a positive control.,ropinirole,101468/902,,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101468/902,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome,ropinirole,99910/188,,Restless Legs Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/99910/188,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A randomised, double blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24 mg) administered once daily for 12 weeks in subjects with fibromyalgia",ropinirole,ROF102100,NCT00256893,"Fibromyalgia Syndrome, Primary",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ROF102100,http://clinicaltrials.gov/show/NCT00256893,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome.,ropinirole,ROR104836,NCT00329602,Restless Legs Syndrome,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ROR104836,http://clinicaltrials.gov/show/NCT00329602,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)",ropinirole,RRL103628,NCT00422994,Restless Legs Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/RRL103628,http://clinicaltrials.gov/show/NCT00422994,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep",ropinirole,RRL103660,NCT00373542,Restless Legs Syndrome,Phase 4,http://www.gsk-clinicalstudyregister.com/study/RRL103660,http://clinicaltrials.gov/show/NCT00373542,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicentre, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered to Patients With Type 2 Diabetes Mellitus.",rosiglitazone,49653/009,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/009,,,Y,Y,Y,Y,Y,Y,N,"This is an extension study to 49653/015, 49653/020, and 49653/025. Reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2014
GSK,"A 26 Week Randomised, Double-Blind, Multicentre Study to Investigate the Effects of Rosiglitazone on Insulin Requirements in Insulin-Treated Type 2 Diabetic Patients",rosiglitazone,49653/085,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/085,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)",rosiglitazone,49653/097,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/097,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)",rosiglitazone,49653/112,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/112,,,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Insulin to Patients with Type 2 Diabetes",rosiglitazone,49653/114,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/114,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Double-blind, Placebo-controlled, Parallel-group Study to Determine the Effect of BRL- 49653C Rosiglitazone, on Fat Distribution When Administered for 26 Weeks to Subjects With Impaired Glucose Tolerance (IGT)",rosiglitazone,BRL-049653/131,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/131,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine",sumatriptan,SUM30047,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SUM30047,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study).",sumatriptan,SUM30053,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SUM30053,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A randomized double-blind placebo-controlled crossover dose escalation study to examine the safety tolerability pharmacodynamics and pharmacokinetics of inhaled doses of GSK233719 in healthy normal volunteers (single and repeat dosing) and in healthy CYP2D6 poor metaboliser volunteers (single or repeat dosing).,umeclidinium bromide,AC4105209,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105209,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719 in healthy male volunteers.",umeclidinium bromide,AC4112008,NCT01110018,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112008,http://clinicaltrials.gov/show/NCT01110018,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open-label, two period study to determine the excretion balance and pharmacokinetics of 14C-GSK573719, administered as single dose of an oral solution and an intravenous infusion, to healthy male adults",umeclidinium bromide,AC4112014,NCT01362257,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112014,http://clinicaltrials.gov/show/NCT01362257,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 formulated with the excipient Magnesium Stearatein COPD subjects for 7 days",umeclidinium bromide,AC4105211,NCT00732472,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/105211,http://clinicaltrials.gov/show/NCT00732472,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as singledoses (750 μg and 1000 μg) and repeat doses over 14 days (250 μg–1000 μg once-daily) of GSK573719 in healthy male and female subjects.",umeclidinium bromide,AC4106889,NCT00475436,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AC4106889,http://clinicaltrials.gov/show/NCT00475436,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD",umeclidinium bromide,AC4113073,NCT00950807,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113073,http://clinicaltrials.gov/show/NCT00950807,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD",umeclidinium bromide,AC4113589,NCT01030965,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113589,http://clinicaltrials.gov/show/NCT01030965,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide,AC4115321,NCT01372410,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115321,http://clinicaltrials.gov/show/NCT01372410,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease",umeclidinium bromide,AC4115408,NCT01387230,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115408,http://clinicaltrials.gov/show/NCT01387230,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (250, 500 and 1000 μg) and tiotropium bromide (18 μg) via DPI in COPD patients.",umeclidinium bromide,AC4108123,NCT00515502,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/AC4108123,http://clinicaltrials.gov/show/NCT00515502,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers.",umeclidinium bromide,AC4110106,NCT00803673,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/110106,http://clinicaltrials.gov/show/NCT00803673,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection",valaciclovir,HS210916,,Varicella,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HS210916,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients",valaciclovir,HS2100275,NCT00158860,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HS2100275,http://clinicaltrials.gov/show/NCT00158860,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children.",valaciclovir,HS210914,NCT00297206,Herpes Simplex,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HS210914,http://clinicaltrials.gov/show/NCT00297206,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2014
GSK,"An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection",valaciclovir,HS210915,,Herpes Simplex,Phase 1,http://www.gsk-clinicalstudyregister.com/study/HS210915,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3.",valaciclovir,HS2100181,NCT00079911,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100181,http://clinicaltrials.gov/show/NCT00079911,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes",valaciclovir,HS230027,,Herpes Labialis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HS230027,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development",valaciclovir,HS230028,,Herpes Labialis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HS230028,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase)",valaciclovir,HS2AB3009,,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HS2AB3009,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects",valaciclovir,HS230018,,Herpes Genitalis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HS230018,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes",valaciclovir,HS2100273,,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100273,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection.",valaciclovir,VLX103596,NCT00116844,"Infections, Herpesviridae",Phase 4,http://www.gsk-clinicalstudyregister.com/study/VLX103596,http://clinicaltrials.gov/show/NCT00116844,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection,valaciclovir,VLX105832,NCT00306293,Herpes Labialis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/VLX105832,http://clinicaltrials.gov/show/NCT00306293,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
GSK,"A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes",valaciclovir,HS240017,,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HS240017,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes",valaciclovir,HS240018,,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HS240018,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes",valaciclovir,HS240021,,Herpes Genitalis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/HS240021,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects with asthma,vilanterol,HZA113989,NCT01244984,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113989,http://clinicaltrials.gov/show/NCT01244984,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Lilly,"A Double-Blind, Placebo- and Clomipramine-Controlled Study of Duloxetine in Patients with Major 
Depression",Duloxetine hydrochloride,F1J-MC-HMAI,Not available,Major Depressive Disorder,Phase 2,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the annotated case report form is not available. A blank case report form will be provided.",1-Jul-2014
Lilly,"Duloxetine Versus Placebo in the
Treatment of Major Depression",Duloxetine hydrochloride,F1J-MC-HMAQ(A),Not available,Major Depressive Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,"Duloxetine Versus Placebo in the
Treatment of Major Depression",Duloxetine hydrochloride,F1J-MC-HMAQ(B),Not available,Major Depressive Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,Duloxetine Versus Placebo and Paroxetine  in the Acute Treatment of Major Depression,Duloxetine hydrochloride,F1J-MC-HMAT(A),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression,Duloxetine hydrochloride,F1J-MC-HMAT(B),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,"Long-Term Open-Label Treatment  with Duloxetine Hydrochloride for Evaluation of Safety in Major 
Depression",Duloxetine hydrochloride,F1J-MC-HMAU,Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMDI,NCT00105989,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/results?term=HMDI&Search=Search,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Lilly,Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD,Duloxetine hydrochloride,F1J-US-HMFS,NCT00536471,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00536471?term=F1J-US-HMFS&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jul-2014
Lilly,"A Double-Blind Randomised Comparison of the Efficacy and Safety of Short Acting Intramuscular Olanzapine, Short Acting Intramuscular Haloperidol and Intramuscular Placebo in Patients with Schizophrenia",Olanzapine,F1D-MC-HGHB,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,"A Double-Blind Dose-Response Study Comparing Short Acting Intramuscular Olanzapine, Short Acting Intramuscular Haloperidol and Intramuscular Placebo in Patients with Schizophrenia",Olanzapine,F1D-MC-HGHV,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,"A Double-Blind Randomized Comparison of the Efficacy
and Safety of Short-Acting Intramuscular Olanzapine,
Short-Acting Intramuscular Lorazepam and Intramuscular Placebo in Acutely Agitated Patients Diagnosed with Mania Associated with Bipolar Disorder",Olanzapine,F1D-MC-HGHW,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,"A Double-Blind Placebo Controlled Comparison of the Efficacy and Safety of Short Acting Intramuscular Olanzapine, Short Acting Intramuscular Lorazepam and Intramuscular Placebo in Treating Agitation in Patients with Dementia of the Alzheimer’s Type, Vascular Dementia and Mixed Dementia",Olanzapine,F1D-MC-HGHX,Not available,Dementia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
Lilly,Efficacy and Safety of Olanzapine Versus Fluphenazine,Olanzapine,F1D-VI-HGCH,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. Due to the age of this study, the annotated case report form is not available. A blank case report form will be provided.",1-Jul-2014
Boehringer Ingelheim,Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification,afatinib,1200.26,NCT00748709,Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00748709?term=1200.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours,afatinib,1200.24,NCT00875433,Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00875433?term=1200.24&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),afatinib,1200.23,NCT00656136,"Carcinoma, Non-Small-Cell Lung",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00656136?term=1200.23&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer,afatinib,1200.1,NCT00425854,Breast Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00425854?term=1200.10&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy,afatinib,1200.11,NCT00431067,Breast Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00431067?term=1200.11&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,afatinib,1200.33,NCT00711594,"Carcinoma, Non-Small-Cell Lung",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00711594?term=1200.33&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme,dipyridamole + acetylsalicylic acid,9.178,NCT00311402,Cerebrovascular Accident,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00311402?term=9.178&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes,dipyridamole + acetylsalicylic acid,9.159,NCT00153062,Stroke,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00153062?term=9.159&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Actuation Indicator Trial in Patients With COPD,ipratropium bromide,244.2507,NCT00928746,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00928746?term=244.2507&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,ipratropium bromide + salbutamol,1012.62,NCT01019694,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01019694?term=1012.62&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients,linagliptin,1218.5,NCT00328172,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00328172?term=1218.5&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,linagliptin,1218.61,NCT00996658,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00996658?term=1218.61&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults,nevirapine,1100.147,NCT00389207,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00389207?term=1100.1470&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,nevirapine,1100.1486,NCT00561925,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00561925?term=1100.1486&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT),nevirapine,1100.1512,NCT00552240,HIV Infections,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00552240?term=1100.1512&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,nevirapine,1100.1526,NCT00819052,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00819052?term=1100.1526&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),tipranavir,1182.12,NCT00054717,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00054717?term=1182.12&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients,tipranavir,1182.107,NCT00530920,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00530920?term=1182.107&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Boehringer Ingelheim,Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI,tipranavir,1182.71,NCT00517192,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00517192?term=1182.71&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD)",casopitant,NKF100096,NCT00413023,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKF100096,http://clinicaltrials.gov/show/NCT00413023,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder",casopitant,NKF100110,NCT00273039,Anxiety Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKF100110,http://clinicaltrials.gov/show/NCT00273039,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis",casopitant,NKT102552,NCT00334152,"Nausea and Vomiting, Postoperative",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NKT102552,http://clinicaltrials.gov/show/NCT00334152,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis",casopitant,NKT102553,NCT00326248,"Nausea and Vomiting, Postoperative",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NKT102553,http://clinicaltrials.gov/show/NCT00326248,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment",casopitant,NKT102783,NCT00358813,Vomiting,Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKT102783,http://clinicaltrials.gov/show/NCT00358813,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment",casopitant,NKT102785,NCT00359177,Vomiting,Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKT102785,http://clinicaltrials.gov/show/NCT00359177,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
GSK,"A two-part, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of single intravenous doses of GW679769 when administered alone and in combination with intravenous or oral doses of dexamethasone in healthy adult subjects",casopitant,NKV100789,,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/100789,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2014
GSK,"A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique.",SB257049,257049/026,NCT00197041,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/257049/026,http://clinicaltrials.gov/show/NCT00197041,,Y,N,Y,Y,Y,Y,Y,A follow up study 104297 was conducted. The analysis-ready data from this study is provided in combined datasets with the analysis-ready data from 104297. An annotated case report form is not available for this study. A blank case report form will be provided,1-Jul-2014
GSK,"An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose.",SB257049,104297,NCT00323622,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104297,http://clinicaltrials.gov/show/NCT00323622,,Y,N,Y,Y,Y,Y,Y,This is a follow up study to 257049/026. The analysis-ready data from this study is provided in combined datasets with the analysis-ready data from 257049/026. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2014
ViiV,"A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects",dolutegravir,ING114915,NCT01449929,"Infection, Human Immunodeficiency Virus I",Phase 3,http://www.viiv-clinicalstudyregister.com/study/114915,http://clinicaltrials.gov/ct2/show/NCT01449929,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2014
Lilly,"A Randomized, Double-Blind Comparison of Atomoxetine versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder",Atomoxetine,B4Z-SB-LYDW,NCT00406354,Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00406354?term=lydw&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Aug-2014
Lilly,Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression,Duloxetine hydrochloride,F1J-AA-HMCV,NCT00489775,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00489775?term=hmcv&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,Comparison of Two Different Treatment Strategies in Patients With Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy,Duloxetine hydrochloride,F1J-EW-HMGD,NCT00810069,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00810069?id=F1J-EW-HMGD&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,Duloxetine Versus Placebo and Paroxetine in the Treatment of Major Depression,Duloxetine hydrochloride,F1J-MC-HMAY(A),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Duloxetine Versus Placebo and Paroxetine in the Treatment of Major Depression,Duloxetine hydrochloride,F1J-MC-HMAY(B),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,"Duloxetine Once-Daily Dosing
Versus Placebo in the Acute Treatment of Major Depression",Duloxetine hydrochloride,F1J-MC-HMBH(A),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,"Duloxetine Once-Daily Dosing
Versus Placebo in the Acute Treatment of Major Depression",Duloxetine hydrochloride,F1J-MC-HMBH(B),Not available,Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMBU,NCT00071695,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00071695?id=HMBU&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,"Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major
Depressive Disorder",Duloxetine hydrochloride,F1J-MC-HMCQ,NCT00067912,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00067912?term=hmcq&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,"Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",Duloxetine hydrochloride,F1J-US-HMBY,NCT00042575,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00042575?term=hmby&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression,Duloxetine hydrochloride,F1J-US-HMCR,NCT00073411,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00073411?term=hmcr&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,Validation of Daily Telephone Self-Assessment in the Study of Antidepressant Treatment Outcome,Duloxetine hydrochloride,H8I-MC-HQAC,Not available,Major Depressive Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Olanzapine Versus Placebo in the Treatment of Mania Associated with Bipolar I Disorder,Olanzapine,F1D-MC-HGEH,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Olanzapine Versus Placebo in the Prevention of Relapse in Bipolar Disorder,Olanzapine,F1D-MC-HGHL,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Prevention Of Bipolar Relapse With Olanzapine And Other Mood-Stabilizers. A Prospective Observational Study (PROTECT),Olanzapine,F1D-SB-B018,Not available,Bipolar Disorder,Phase 4,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated CRF is available in German only.  A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Boehringer Ingelheim,Case-Control Viramune (Nevirapine) Toxicogenomics Study,nevirapine,1100.1452,NCT00310843,HIV Infections,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00310843?term=1100.1452&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-Aug-2014
Boehringer Ingelheim,A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions,nevirapine,1100.1448,NCT00144248,HIV Infections; Hepatic Insufficiency,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144248?term=1100.1448&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,"An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects",nevirapine,1100.1426,NCT00144261,"HIV Infections; Metabolism, Lipids",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144261?term=1100.1426&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS),nevirapine,1100.1413,NCT00144183,Acquired Immunodeficiency Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144183?term=1100.1413&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS,pramipexole,248.615,NCT00349531,Restless Legs Syndrome,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00349531?term=248.615&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,"A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)",pramipexole,248.546,NCT00152958,Restless Legs Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00152958?term=248.546&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances,pramipexole,248.604,NCT00356096,Restless Legs Syndrome; Depression,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00356096?term=248.604&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome,pramipexole,248.557,NCT00152997,Restless Legs Syndrome,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00152997?term=248.557&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS),pramipexole,248.543,NCT00133198,Restless Legs Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00133198?term=248.543&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM (PRISMA),telmisartan,502.391,NCT00274612,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274612?term=502.391&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril,telmisartan,502.236,NCT00274118,"Hypertension; Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274118?term=502.236&rank=1,,Y,Y,N,N,N,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes,telmisartan,502.398,NCT00240422,"Diabetes Mellitus, Type 2; Hypertension",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00240422?term=502.398&rank=1,,Y,Y,Y,N,Y,Y,N,,1-Aug-2014
Boehringer Ingelheim,1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy,telmisartan,502.396,NCT00153023,Diabetic Nephropathies; Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00153023?term=502.396&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose,telmisartan,502.327,NCT00034840,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00034840?term=502.327&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy,telmisartan,502.413,NCT00153088,Diabetic Nephropathies,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00153088?term=502.413&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,"The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects",telmisartan,502.469,NCT00146289,Obesity; Insulin Resistance,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00146289?term=502.469&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN,telmisartan,502.392,NCT00274599,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274599?term=502.392&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,"A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)",telmisartan,502.397,NCT00168857,Hypertension; Diabetic Nephropathies,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00168857?term=502.397&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM),telmisartan + hydrochlorothiazide,502.387,NCT00274638,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274638?term=502.387&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,SMOOTH - Blood Pressure Control in Diabetic/Obese Patients,telmisartan + hydrochlorothiazide,502.399,NCT00239538,"Hypertension; Diabetes Mellitus, Type 2",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239538?term=502.399&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients,telmisartan + hydrochlorothiazide,502.491,NCT00267943,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00267943?term=502.491&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,"A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients",telmisartan + hydrochlorothiazide,502.421,NCT00240448,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00240448?term=502.421&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension,telmisartan + hydrochlorothiazide,502.439,NCT00153049,Hypertension,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00153049?term=502.439&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5,telmisartan + hydrochlorothiazide,502.48,NCT00239369,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239369?term=502.480&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study),telmisartan + hydrochlorothiazide,502.4,NCT00240474,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00240474?term=502.400&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal),tiotropium bromide,205.282,NCT00239408,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239408?term=205.282&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients,tiotropium bromide,205.223,NCT00274508,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274508?term=205.223&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders,tiotropium bromide,205.214,NCT00274014,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274014?term=205.214&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease,tiotropium bromide,205.294,NCT00106821,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00106821?term=205.294&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.287,NCT00239421,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239421?term=205.287&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Tiotropium (Spiriva) Rehabilitation Study,tiotropium bromide,205.23,NCT00274521,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274521?term=205.230&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.266,NCT00274547,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274547?term=205.266&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD,tiotropium bromide,205.256,NCT00274053,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274053?term=205.256&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol,tiotropium bromide,205.264,NCT00274560,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274560?term=205.264&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Spiriva® Assessment of FEV1 (SAFE),tiotropium bromide,205.259,NCT00277264,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00277264?term=205.259&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva,tiotropium bromide,205.258,NCT00274066,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274066?term=205.258&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity,tiotropium bromide,205.257,NCT00274573,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274573?term=205.257&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients,tiotropium bromide,205.346,NCT00388882,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00388882?term=205.346&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD),tiotropium bromide,205.281,NCT00144196,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144196?term=205.281&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.273,NCT00239499,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239499?term=205.273&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Boehringer Ingelheim,Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2),tipranavir,1182.48,NCT00144170,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144170?term=1182.48&rank=1,,N,N,Y,N,Y,N,N,,1-Aug-2014
Boehringer Ingelheim,Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients,tipranavir,1182.51,NCT00056641,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00056641?term=1182.51&rank=1,,N,N,Y,N,Y,N,N,,1-Aug-2014
GSK,"An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers.",bupropion,AK110022,,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AK110022,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.",bupropion,AK130939,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AK130939,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.",bupropion,WXL101497,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/101497,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers",bupropion,WXL103106,,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103106,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension",bupropion,WELL AK110021,,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AK110021,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension",bupropion,WELL ZYB40021,,Depressive Disorder,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40021,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin,casopitant,NKV103447,,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/103447,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects",casopitant,NKV103933,,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/103933,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769]",casopitant,NKV105093,NCT00404378,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV105093,http://clinicaltrials.gov/show/NCT00404378,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
GSK,"An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin when Co-administered with Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.",casopitant,NKV105097,NCT00404274,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV105097,http://clinicaltrials.gov/show/NCT00404274,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
GSK,"A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant [GW679769] in Healthy Subjects",casopitant,NKV109990,NCT00460707,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV109990,http://clinicaltrials.gov/show/NCT00460707,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
GSK,"A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease",ropinirole,SKF-101468/125,,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/125,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Multicentre, Double-Blind, Parallel Group Study to Determine the Effects of Rosiglitazone on Insulin Sensitivity, Endothelial Function and Vascular Reactivity in Comparison With Metformin and Placebo When Administered to Patients With Non-insulin Dependent Diabetes Mellitus.",rosiglitazone,49653/025,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/025,,,N,N,Y,Y,Y,Y,Y,Extension study 49653/009 was conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Lilly,Duloxetine 20/30 mg vs. Placebo in Major Depression,Duloxetine hydrochloride,F1J-MC-HMAH,Not available,Major Depressive Disorder,Phase 2,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.  Annotated and blank case report forms are not available.,1-Sep-2014
Lilly,Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients with Manic or Mixed Episode of Bipolar I Disorder,Olanzapine,F1D-JE-BMAC,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. The annotated case report form is not available. A blank case report form will be provided.,1-Sep-2014
Lilly,"Olanzapine Added to Mood
Stabilizers in the Treatment of Bipolar Disorder",Olanzapine,F1D-MC-HGFU,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,Open-label Trial of Olanzapine in Children and Adolescents with Bipolar Disorder,Olanzapine,F1D-MC-HGGC,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,"Olanzapine Versus Placebo in the Treatment of Bipolar Disorder, Manic or Mixed",Olanzapine,F1D-MC-HGGW,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,Placebo-Controlled Olanzapine Monotherapy in the Treatment of Bipolar I Depression,Olanzapine,F1D-MC-HGGY,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,Olanzapine Versus Lithium in Relapse Prevention in Bipolar Disorder,Olanzapine,F1D-MC-HGHT,Not available,Bipolar Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia,Olanzapine,F1D-MC-HGIN,NCT00051298,Schizophrenia,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00051298?term=HGIN&rank=6,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Lilly,Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder,Olanzapine,F1D-MC-HGIU,NCT00050206,Bipolar Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00050206?term=HGIU&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Lilly,Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder,Olanzapine,F1D-MC-HGKQ,NCT00094549,Bipolar Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00094549?term=HGKQ&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Sep-2014
Lilly,"Efficacy and Safety of Olanzapine in the Treatment of Patients with Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison with Placebo",Olanzapine,F1D-MC-HGMP,NCT00510146,Bipolar Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00510146?term=hgmp&rank=2,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Sep-2014
Lilly,"Open-label Study on the Efficacy and Safety of Olanzapine in Adolescent and Young Adult Patients with Schizophrenia, Schizoaffective and Schizophreniform Disorders",Olanzapine,F1D-SB-LOAY,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,Olanzapine Versus Divalproex in the Treatment of Acute Mania,Olanzapine,F1D-US-HGHQ,Not available,Acute Mania,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2014
Lilly,"A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia",Olanzapine pamoate,F1D-MC-HGKA,NCT00088491,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00088491?term=HGKA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Lilly,An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,Olanzapine pamoate,F1D-MC-HGKB,NCT00088465,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00088465?term=HGKB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease,ipratropium bromide,244.2484,NCT02177344,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02177344?term=244.2484&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus,linagliptin,1218.12,NCT02183324,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02183324?term=1218.12&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis,telmisartan,502.339,NCT02178306,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02178306?term=502.339&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension,telmisartan,502.26,NCT02177422,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02177422?term=502.260&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH),telmisartan,502.254,NCT02175355,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02175355?term=502.254&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension,telmisartan,502.317,NCT02177461,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02177461?term=502.317&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring,telmisartan,502.256,NCT02177396,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02177396?term=502.256&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy,telmisartan + hydrochlorothiazide,502.323,NCT02177500,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02177500?term=502.323&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2014
Boehringer Ingelheim,Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease,tiotropium bromide,205.44,NCT01072396,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01072396?term=205.440&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Year 1 Data)",dutasteride,ARIA3001_1,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3001_1,,,N,Y,Y,Y,Y,Y,Y,The data relating to this record represents an interim analysis of a 4 year study. A comprehensive dataset is available within ARIA3001 (Year 4). An Analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).",dutasteride,ARIA3001_2,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3001_2,,,N,Y,Y,Y,Y,Y,Y,The data relating to this record represents an interim analysis of a 4 year study. A comprehensive dataset is available within ARIA3001 (Year 4). An Analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).",dutasteride,ARIA3001_4,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3001_4,,,N,Y,Y,Y,Y,Y,Y,This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).",dutasteride,ARIA3002_2,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3002_2,,,N,Y,Y,Y,Y,Y,Y,The data relating to this record represents an interim analysis of a 4 year study. A comprehensive dataset is available within ARIA3002 (Year 4). An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).",dutasteride,ARIA3002_4,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIA3002_4,,,N,Y,Y,Y,Y,Y,Y,This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase).",dutasteride,ARIB3003_4,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIB3003_4,,,N,N,Y,Y,Y,Y,Y,This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension.",dutasteride,ARIB3004_1,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARIB3004_1,,,N,N,Y,Y,Y,Y,N,This study was conducted in 2 phases - a Double-blind Phase and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,"A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Compare the Efficacy of Dutasteride/GI198745 0.5mg Once Daily Versus Finasteride 5mg Once Daily for 12 Months in the Treatment of Subjects with Benign Prostatic Hyperplasia (BPH), Followed by an Optional 24 Months Open Label Phase.",dutasteride,ARI40001_1,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40001_1,,,N,N,Y,Y,Y,Y,N,This study was conducted in 2 phases - Year 1 and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
GSK,Study in adults aged between 18 and 45 years to evaluate the reactogenicity and the immunogenicity of an experimental administration of GlaxoSmithKline Biologicals Fluarix vaccine (known as a-Rix in Belgium). Standard intramuscular and subcutaneous vaccine administration will be used as references,"Influenza Vaccine (Split Virion, Inactivated)",104440-002,,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/104440-002,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2014
GSK,"A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients",paroxetine,29060/01/001,,Depressive Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/01/001,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients",paroxetine,29060/02/001,,Depressive Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/02/001,,,Y,N,Y,Y,Y,N,N,"This study has multiple results summaries on the GSK Clinical Study Register under the following clinical study identifiers: PAR 29060.02.001, PAR 29060.02.002, PAR 29060.02.003, and PAR 29060.02.004. This posting links only to PAR 29060.02.001. All other results summaries must be viewed directly from the GSK Clinical Study Register. The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2014
GSK,"A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients",paroxetine,29060/03/001,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/03/001,,,Y,N,Y,Y,Y,N,N,"This study has multiple results summaries on the GSK Clinical Study Register under the following clinical study identifiers: PAR 03 001, PAR 29060/03/002, PAR 29060.03.003, PAR 29060.03.004, PAR 29060.03.005, PAR 29060.03.006, and PAR03_001. This posting links only to PAR 03 001. All other results summaries must be viewed directly from the GSK Clinical Study Register. The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2014
GSK,"A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia",paroxetine,29060/07/001,,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/07/001,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine",paroxetine,29060/009,,Depressive Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/009,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression,paroxetine,29060/057,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/057,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD),paroxetine,29060/106,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/106,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder",paroxetine,29060/128,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/128,,,Y,N,Y,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. An annotated case report form, reporting and analysis plan, and a protocol are not available for this study.",1-May-2014
GSK,"A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety",paroxetine,29060/251,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/251,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression,paroxetine,26090/007,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/26090/007,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies.  A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo",paroxetine,29060/276,,Depressive Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/276,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin,paroxetine,29060/012_3,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/012_3,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design,paroxetine,29060/282,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/282,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia.",paroxetine,29060/327,,Depressive Disorder,Phase 2,http://www.gsk-clinicalstudyregister.com/study/29060/327,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients",paroxetine,29060/487,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/487,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression.",paroxetine,29060/625,,Major Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/625,,,Y,N,Y,Y,Y,N,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Continuation Phase.",paroxetine,29060/329_1,,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/329_1,,,Y,N,Y,Y,Y,Y,Y,This study was conducted in 2 phases - an acute phase and a continuation phase. A comprehensive dataset for the complete study is available. The data from this study is provided in a combined datasets containing data from other paroxetine studies. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2014
Boehringer Ingelheim,Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN),dabigatran etexilate,1160.113,NCT01452347,Heart Valve Diseases,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01452347?term=1160.113&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial,tenecteplase,1123.18,NCT00157261,Heart Arrest,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00157261?term=1123.18&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI),tenecteplase,1123.12,NCT00168792,Myocardial Infarction,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00168792?term=1123.12&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,"Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)",tenecteplase,1123.1,NCT02181985,Myocardial Infarction,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02181985?term=1123.10&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting,tenecteplase,1123.11,NCT02181998,Myocardial Infarction,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02181998?term=1123.11&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD),tiotropium bromide,205.137,NCT02173691,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02173691?term=205.137&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.218,NCT02172391,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172391?term=205.218&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.227,NCT02172430,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172430?term=205.227&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,"12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales",tiotropium bromide,205.215,NCT02172378,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172378?term=205.215&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,"Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)",tiotropium bromide,205.13,NCT02172287,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172287?term=205.130&rank=1,,N,N,Y,N,N,Y,N,,1-Oct-2014
Boehringer Ingelheim,HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.22,NCT02172404,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172404?term=205.220&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
GSK,Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label),"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",103812,NCT00228917,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103812,http://clinicaltrials.gov/show/NCT00228917,,Y,N,Y,Y,Y,Y,Y,The results of this study 103812 are summarised with study 104727 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label),"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",104171,NCT00228917,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103812,http://clinicaltrials.gov/show/NCT00228917,,Y,N,Y,Y,Y,Y,Y,The results of this study 104171 are summarised with study 104730 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Study to evaluate immunogenicity, reactogenicity and safety of an investigational vaccination regimen as compared to extemporaneously mixed GlaxoSmithKline Biological’s Hiberix and Tritanrix-HepB vaccines, when administered intramuscularly in infants at 6, 10 and 14 weeks of age","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",104430,NCT00612105,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104430,http://clinicaltrials.gov/show/NCT00612105,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax™ ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",104727,NCT00136604,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104727 (Booster - 15-24 mths),http://clinicaltrials.gov/show/NCT00136604,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",104733,NCT00197275,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104733,http://clinicaltrials.gov/show/NCT00197275,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib,"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",104065,NCT00169442,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104065,http://clinicaltrials.gov/show/NCT00169442,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Study to assess immunogenicity and safety of GlaxoSmithKline Biologicals' Kft’s DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs concomitant administration of CSL’s Triple Antigen and GlaxoSmithKline Biologicals’ Hiberix, to infants at 2, 4, 6 months of age, after a birth dose of hepatitis B","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",104489,NCT00316680,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104489,http://clinicaltrials.gov/show/NCT00316680,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals’ DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals’ DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",106602,NCT00332566,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106602,http://clinicaltrials.gov/show/NCT00332566,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life","Combined Measles, Mumps, Rubella, Varicella Vaccine",103388,NCT00127010,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103388,http://clinicaltrials.gov/show/NCT00127010,,Y,N,Y,Y,Y,Y,Y,A follow on study 104690 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life","Combined Measles, Mumps, Rubella, Varicella Vaccine",104020,NCT00126997,Measles; Mumps; Rubella; Varicella,Phase 4,http://www.gsk-clinicalstudyregister.com/study/104020,http://clinicaltrials.gov/show/NCT00126997,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life","Combined Measles, Mumps, Rubella, Varicella Vaccine",104389,NCT00127023,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104389,http://clinicaltrials.gov/show/NCT00127023,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,Comparative study evaluating the immunogenicity and safety of MeMuRu-OKA vaccine and measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with measles-mumps-rubella vaccine,"Combined Measles, Mumps, Rubella, Varicella Vaccine",105908,NCT00353288,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/105908,http://clinicaltrials.gov/show/NCT00353288,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Comparative study evaluating the immunogenicity & safety of MeMuRu-OKA vaccine & measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with both measles-mumps-rubella & varicella vaccines,"Combined Measles, Mumps, Rubella, Varicella Vaccine",105909,NCT00352898,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/105909,http://clinicaltrials.gov/show/NCT00352898,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Observer-blind monocentric study in adults aged between 18-60 years to evaluate reactogenicity and immunogenicity of 1 and 2 administrations of pandemic monovalent influenza vaccines administered at different antigen doses and adjuvanted or not,H5N1 Pandemic Influenza Vaccine,106750,NCT00309634,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/106750,http://clinicaltrials.gov/show/NCT00309634,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs,H5N1 Pandemic Influenza Vaccine,108251,NCT00397215,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108251,http://clinicaltrials.gov/show/NCT00397215,,Y,N,Y,Y,Y,Y,Y,"The results of this study 108251 are summarised with studies 108252, 111275, and 111276 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs,H5N1 Pandemic Influenza Vaccine,108252,NCT00397215,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108251,http://clinicaltrials.gov/show/NCT00397215,,Y,N,Y,Y,Y,Y,Y,"The results of this study 108252 are summarised with studies 108251, 111275, and 111276 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs,H5N1 Pandemic Influenza Vaccine,111275,NCT00397215,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108251,http://clinicaltrials.gov/show/NCT00397215,,Y,N,Y,Y,Y,Y,N,"The results of this study 111275 are summarised with studies 108251, 108252, and 111276 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs,H5N1 Pandemic Influenza Vaccine,111276,NCT00397215,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108251,http://clinicaltrials.gov/show/NCT00397215,,Y,N,Y,Y,Y,Y,N,"The results of this study 111276 are summarised with studies 108251, 108252, and 111275 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106673,NCT00322335,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106672,http://clinicaltrials.gov/show/NCT00322335,,Y,N,Y,Y,Y,Y,Y,"The results of this study 106673 are summarised with studies 106672, 106675, 106679, and 106680 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106675,NCT00322335,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106672,http://clinicaltrials.gov/show/NCT00322335,,Y,N,Y,Y,Y,Y,Y,"The results of this study 106675 are summarised with studies 106672, 106673, 106679, and 106680 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106679,NCT00322335,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106672,http://clinicaltrials.gov/show/NCT00322335,,Y,N,Y,Y,Y,Y,Y,"The results of this study 106679 are summarised with studies 106672, 106673, 106675, and 106680 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",106680,NCT00322335,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106672,http://clinicaltrials.gov/show/NCT00322335,,Y,N,Y,Y,Y,Y,Y,"The results of this study 106680 are summarised with studies 106672, 106673, 106675, and 106679 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",twinrix,100382,NCT00289731,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100382,http://clinicaltrials.gov/show/NCT00289731,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100382 are summarised with studies 100383, 100384, and 100385 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",twinrix,100383,NCT00289731,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100382,http://clinicaltrials.gov/show/NCT00289731,,Y,N,Y,Y,Y,Y,N,"The results of this study 100383 are summarised with studies 100382, 100384, and 100385 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",twinrix,100384,NCT00289731,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100382,http://clinicaltrials.gov/show/NCT00289731,,Y,N,Y,Y,Y,Y,N,"The results of this study 100384 are summarised with studies 100382, 100383, and 100385 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",twinrix,100385,NCT00289731,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100382,http://clinicaltrials.gov/show/NCT00289731,,Y,N,Y,Y,Y,Y,Y,"The results of this study 100385 are summarised with studies 100382, 100383, and 100384 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose",twinrix,100386,NCT00197171,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100386 (EXT Y5),http://clinicaltrials.gov/show/NCT00197171,,Y,N,Y,Y,Y,Y,N,The results of this study 100386 are summarised with study 100387 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Oct-2014
GSK,"Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose",twinrix,100387,NCT00197171,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100386 (EXT Y5),http://clinicaltrials.gov/show/NCT00197171,,Y,N,Y,Y,Y,Y,N,The results of this study 100387 are summarised with study 100386 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Oct-2014
GSK,"A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults",twinrix,100551,NCT00289770,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100551 (EXT Y11),http://clinicaltrials.gov/show/NCT00289770,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/119. The results of this study 100551 are summarised with studies 100552, 100553, 100554, 100555, and 112267 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults",twinrix,100552,NCT00289770,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100551 (EXT Y11),http://clinicaltrials.gov/show/NCT00289770,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/119. The results of this study 100552 are summarised with studies 100551, 100553, 100554, 100555, and 112267 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults",twinrix,100553,NCT00289770,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100551 (EXT Y11),http://clinicaltrials.gov/show/NCT00289770,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/119.The results of this study 100553 are summarised with studies 100551, 100552, 100554, 100555, and 112267 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults",twinrix,100554,NCT00289770,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100551 (EXT Y11),http://clinicaltrials.gov/show/NCT00289770,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/119. The results of this study 100554 are summarised with studies 100551, 100552, 100553,100555, and 112267 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,"A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults",twinrix,100555,NCT00289770,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100551 (EXT Y11),http://clinicaltrials.gov/show/NCT00289770,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/119. The results of this study 100555 are summarised with studies 100551, 100552, 100553, 100554, and 112267 on the GSK Clinical Study Register.  An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers,twinrix,100556,NCT00289718,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100556 (Y11),http://clinicaltrials.gov/show/NCT00289718,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/118. The results of this study 100556 are summarised with studies 100557, 100558, 100559, 100560, and 112266 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers,twinrix,100557,NCT00289718,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100556 (Y11),http://clinicaltrials.gov/show/NCT00289718,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/118. The results of this study 100557 are summarised with studies 100556, 100558, 100559,100560, and 112266 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers,twinrix,100558,NCT00289718,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100556 (Y11),http://clinicaltrials.gov/show/NCT00289718,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/118. The results of this study 100558 are summarised with studies 100556, 100557, 100559, 100560, and 112266  on the GSK Clinical Study Register.  An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers,twinrix,100560,NCT00289718,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100556 (Y11),http://clinicaltrials.gov/show/NCT00289718,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/118. The results of this study 100560 are summarised with studies 100556, 100557, 100558, and 100559 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
GSK,Challenge dose administration of Twinrix™ or comparator 4 years after primary vaccination.,twinrix,111572,NCT00684671,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/111572,http://clinicaltrials.gov/show/NCT00684671,,Y,N,Y,Y,Y,Y,Y,The results of this study 111572 are summarised with study 111149 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers","Hepatitis A Vaccine, Inactivated",110681,NCT00291876,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100571 (M138),http://clinicaltrials.gov/show/NCT00291876,,Y,N,Y,Y,Y,Y,Y,"The results of this study 110681 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110679, and 110680 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects","Hepatitis A Vaccine, Inactivated",111032,NCT00289757,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100576 (Y11),http://clinicaltrials.gov/show/NCT00289757,,Y,N,Y,Y,Y,Y,Y,"The results of this study 111032 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111030, and 111031 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers","Hepatitis B Vaccine, Recombinant",100448,NCT00240500,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100448,http://clinicaltrials.gov/show/NCT00240500,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Oct-2014
GSK,"Long-term Follow-Up studies at Years 16-20, to evaluate the persistence of immune response of GSK Biologicals’ hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group","Hepatitis B Vaccine, Recombinant",100449,NCT00240539,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100449,http://clinicaltrials.gov/show/NCT00240539,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Oct-2014
GSK,"Long-Term Follow-up Study at Years 16, 17, 18, 19 and 20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine Administered With or Without HBIG in Newborns of HBeAg+ Mothers","Hepatitis B Vaccine, Recombinant",100450,NCT00240526,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/100450,http://clinicaltrials.gov/show/NCT00240526,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)",Human Papillomavirus Types 16 and 18 Vaccine,104918,NCT00316706,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/580299/013,http://clinicaltrials.gov/show/NCT00316706,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects,Human Papillomavirus Types 16 and 18 Vaccine,107863,NCT00586339,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/107863,http://clinicaltrials.gov/show/NCT00586339,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil,Human Papillomavirus Types 16 and 18 Vaccine,109624,NCT00518336,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109616 (Y7),http://clinicaltrials.gov/show/NCT00518336,,Y,N,Y,Y,Y,Y,Y,This is a year 8 follow-up study to 580299/001. The results of this study 109624 are summarised with studies 109616 and 109625 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil,Human Papillomavirus Types 16 and 18 Vaccine,109625,NCT00518336,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109616 (Y7),http://clinicaltrials.gov/show/NCT00518336,,Y,N,Y,Y,Y,Y,Y,This is a year 9 follow-up study to 580299/001. The results of this study 109625 are summarised with studies 109616 and 109624 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil,Human Papillomavirus Types 16 and 18 Vaccine,109616,NCT00518336,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109616 (Y7),http://clinicaltrials.gov/show/NCT00518336,,Y,N,Y,Y,Y,Y,Y,This is a year 7 follow-up study to 580299/001. The results of this study 109616 are summarised with studies 109624 and 109625 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (adjuvanted split virus formulation) in adults aged 18 years and older","Influenza Vaccine (Split Virion, Inactivated)",107064,NCT00319098,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107064,http://clinicaltrials.gov/show/NCT00319098,,Y,N,Y,Y,Y,Y,Y,The results of this study 107064 are summarised with study 107217 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (adjuvanted split virus formulation) in adults aged 18 years and older","Influenza Vaccine (Split Virion, Inactivated)",107217,NCT00319098,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107064,http://clinicaltrials.gov/show/NCT00319098,,Y,N,Y,Y,Y,Y,Y,The results of this study 107217 are summarised with study 107064 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,A study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults,"Influenza Vaccine (Split Virion, Inactivated)",108134,NCT00363870,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/108134,http://clinicaltrials.gov/show/NCT00363870,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
GSK,"A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.","Meningococcal Serogroups A, C, W-135 and Y Vaccine",104730,NCT00136604,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104730,http://clinicaltrials.gov/show/NCT00136604,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007","Meningococcal Serogroups A, C, W-135 and Y Vaccine",104756,NCT00317109,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/104756,http://clinicaltrials.gov/show/NCT00317109,,Y,N,Y,Y,Y,Y,Y,This is a follow-up study to 759346/007. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study,"Meningococcal Serogroups A, C, W-135 and Y Vaccine",105239,NCT00291343,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105239 (mth24-30),http://clinicaltrials.gov/show/NCT00291343,,Y,Y,Y,Y,Y,Y,Y,This is a follow up study to 100478. The results are summarized with study 105245 on the GSK Clinical Study Register.,1-Oct-2014
GSK,Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study,"Meningococcal Serogroups A, C, W-135 and Y Vaccine",105245,NCT00291343,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105239 (mth24-30),http://clinicaltrials.gov/show/NCT00291343,,Y,N,Y,Y,Y,Y,Y,This is a follow up study to 100478. The results are summarized with study 105239 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided,1-Oct-2014
GSK,Assess lot-to-lot consistency of 3 lots (double blind design) of GlaxoSmithKline Biologicals' 10-valent pneumococcal vaccine and evaluate non-inferiority to Prevenar™ (single blind design) when administered as 3-dose primary immunization course before 6 months of age,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),105553,NCT00307554,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105553,http://clinicaltrials.gov/show/NCT00307554,,Y,N,Y,Y,Y,Y,Y,"Follow on studies 107046, 112640, 111345,111346, and 111347 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,"To assess safety, reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age.",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107005,NCT00334334,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107005,http://clinicaltrials.gov/show/NCT00334334,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107007,NCT00344318,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107007,http://clinicaltrials.gov/show/NCT00344318,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,"To assess the safety, reactogenicity & immunogenicity of a 4th dose of GSK Biologicals’ pneumococcal vaccine or Prevenar™ in children (12-18 months) previously vaccinated in the primary study 105553 with either pneumococcal vaccine or Prevenar™",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),107046,NCT00370396,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107046,http://clinicaltrials.gov/show/NCT00370396,,Y,N,Y,Y,Y,Y,Y,"This is a booster study of 105553. Follow on studies 112640, 111345, 111346, and 111347 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Oct-2014
GSK,Long-term follow-up study to assess antibody persistence in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study (105553) and booster vaccination study (107046),Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111345,NCT00624819,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111345 (Mth 12),http://clinicaltrials.gov/show/NCT00624819,,Y,N,Y,Y,Y,Y,Y,This is a Year 1 follow up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
GSK,Study of two formulations of GSK Biologicals' varicella vaccine given as a 2-dose course in the second year of life,Varicella Vaccine,109705,NCT00568334,Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/109705,http://clinicaltrials.gov/show/NCT00568334,,Y,Y,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2014
Roche,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",omalizumab,Q4881g,NCT01287117,chronic idiopathic urticaria (CIU),Phase 3,,http://clinicaltrials.gov/show/NCT01287117,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies. Xolair information appears on both Company websites.,1-Nov-2014
Roche,"A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)",omalizumab,Q4882g,NCT01292473,chronic idiopathic urticaria (CIU),Phase 3,,http://clinicaltrials.gov/show/NCT01292473,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies. Xolair information appears on both Company websites.,1-Nov-2014
Roche,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",omalizumab,Q4883g,NCT01264939,chronic idiopathic urticaria (CIU),Phase 3,,http://clinicaltrials.gov/show/NCT01264939,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies. Xolair information appears on both Company websites.,1-Nov-2014
Novartis,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",omalizumab,Q4883g,NCT01264939,Chronic Idiopathic Urticaria (CIU),Phase 3,http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4883g,https://clinicaltrials.gov/show/NCT01264939,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.,1-Jun-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine
Hydrochloride in Children and Adolescents with Attention-Deficit/Hyperactivity
Disorder and Comorbid Anxiety",Atomoxetine,B4Z-US-LYBP,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera,Atomoxetine,B4Z-US-LYCC,NCT00486122,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00486122?term=LYCC&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2014
Lilly,"A Randomized, Double-Blind Study of Tomoxetine Hydrochloride,
Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention Deficit/Hyperactivity Disorder",Atomoxetine,B4Z-MC-HFBD,Not available,Attention Deficit Hyperactivity Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in
Patients, 6 Years and Older",Atomoxetine,B4Z-MC-HFBF,Not available,Attention Deficit Hyperactivity Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Randomized, Double-Blind Study of Tomoxetine Hydrochloride,
Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder",Atomoxetine,B4Z-MC-HFBK,Not available,Attention Deficit Hyperactivity Disorder,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Phase III Randomized, Double-Blind Comparison of Placebo and
Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder.",Atomoxetine,B4Z-MC-LYAA,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Phase III Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Outpatients with ADHD, Ages 6 to 18 Years",Atomoxetine,B4Z-MC-LYAB,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety
Comparison of Fixed-Dose Ranges (mg/kg/day) of Tomoxetine with Placebo in Child and Adolescent Outpatients with ADHD, Aged 8 to 18 Years",Atomoxetine,B4Z-MC-LYAC,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,Relapse Prevention After 10-Week and 52-Week Treatment with Tomoxetine Hydrochloride in Children with Attention-Deficit/Hyperactivity Disorder,Atomoxetine,B4Z-MC-LYAF,Not available,Attention Deficit Hyperactivity Disorder,Phase 2/Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Phase III Randomized, Double-Blind Comparison of Placebo and
Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-
Deficit/Hyperactivity Disorder.",Atomoxetine,B4Z-MC-LYAO,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"Safety and Efficacy of Atomoxetine or Atomoxetine Plus Fluoxetine in the
Treatment of Mixed Attentional and Affective Disorders",Atomoxetine,B4Z-MC-LYAQ,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Randomized, Double-Blind Study of Tomoxetine Hydrochloride and Placebo
in Pediatric Outpatients with Attention Deficit/Hyperactivity Disorder and
Comorbid Tic Disorders",Atomoxetine,B4Z-MC-LYAS,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride versus Placebo in Children with Attention-Deficit/Hyperactivity Disorder",Atomoxetine,B4Z-MC-LYAT,Not available,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,A Phase 3 Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Pediatric Outpatients (6 to 18 Years) with ADHD,Atomoxetine,B4Z-MC-LYBB,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
Lilly,"A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder",Atomoxetine,B4Z-MC-LYCK,NCT00191906,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00191906?term=lyck&rank=2,Not available,Y,N,Y,Y,Y,Y,N,,1-Nov-2014
Lilly,"Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study",Atomoxetine,B4Z-MC-LYDO,NCT00700427,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00700427?term=B4Z-MC-LYDO&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available.  A blank case report form will be provided.,1-Nov-2014
Takeda,"A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/CCT-003,NCT01263483,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-003,https://clinicaltrials.gov/show/NCT01263483,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/CCT-004,NCT01318070,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-004,https://clinicaltrials.gov/show/NCT01318070,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/CCT-005,NCT01318083,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-005,https://clinicaltrials.gov/show/NCT01318083,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Metformin in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/CCT-006,NCT01318109,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-006,https://clinicaltrials.gov/show/NCT01318109,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"An Open-Label Study to Assess the Effect of Age on Pharmacokinetics, Safety and Pharmacodynamics of a Single-Dose of SYR-322 in Healthy Elderly and Non-Elderly Adult Male Subjects",alogliptin,SYR-322/CPH-003,Not available,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-003,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,An Open-Label Study to Assess the Effect of Voglibose on the Pharmacokinetics of SYR-322 in Healthy Male Subjects,alogliptin,SYR-322/CPH-004,Not available,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-004,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"An Open-Label, Randomized, Cross-Over Study to Determine the Food Effect on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose of the Commercial SYR-322 Tablets (12.5 mg and 25 mg) in Healthy Male Subjects",alogliptin,SYR-322/CPH-007,Not available,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-007,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 in Subjects with Type 2 Diabetes in Japan",alogliptin,SYR-322/OCT-001,NCT01263496,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322/OCT-001,https://clinicaltrials.gov/show/NCT01263496,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/OCT-004,NCT01318122,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/OCT-004,https://clinicaltrials.gov/show/NCT01318122,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Long-Term, Open-Label Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Rapid-Acting Insulin Secretagogues in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/OCT-901,NCT01456130,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/OCT-901,https://clinicaltrials.gov/show/NCT01456130,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients With Type 2 Diabetes, Who Are Either Receiving No Current Treatment or  Treated With Diet and Exercise, Sulfonylurea, Metformin or a Combination of Sulfonylurea and Metformin",alogliptin,SYR-322_003,NCT00755846,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322_003,https://clinicaltrials.gov/show/NCT00755846,,Y,Y,Y,Y,Y,N,Y,,1-Oct-2014
Takeda,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes",alogliptin,SYR-322_301,"NCT00655863
2007-000486-38","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322_301,https://clinicaltrials.gov/show/NCT00655863,https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000486-38/SE,Y,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes",alogliptin,SYR-322_303,"NCT00707993
2008-000959-10","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322_303,https://clinicaltrials.gov/show/NCT00707993,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000959-10/HU,Y,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes",alogliptin,SYR-322-INS-011,"NCT00286429
2005-004671-38","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-INS-011,https://clinicaltrials.gov/show/NCT00286429,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004671-38/HU,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes",alogliptin,SYR-322-MET-008,"NCT00286442
2005-004668-22","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-MET-008,https://clinicaltrials.gov/show/NCT00286442,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004668-22/GB,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes",alogliptin,SYR-322-OLE-012,"NCT00306384
2005-004672-20","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-OLE-012,https://clinicaltrials.gov/show/NCT00306384,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004672-20/CZ,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes",alogliptin,SYR-322-PLC-010,"NCT00286455 
2005-004670-24","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-PLC-010,https://clinicaltrials.gov/show/NCT00286455,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004670-24/GB,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes",alogliptin,SYR-322-SULF-007,"NCT00286468
2005-004667-36","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-SULF-007,https://clinicaltrials.gov/show/NCT00286468,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004667-36/GB,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Diabetes Mellitus, Type 2",alogliptin,SYR-322-TZD-009,"NCT00286494
2005-004669-40","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322-TZD-009,https://clinicaltrials.gov/show/NCT00286494,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004669-40/GB,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Ascending Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Effects of SYR110322 in Healthy Male Volunteers",alogliptin,SYR-322_001,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_001,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Repeat-Dose Study to Determine the Safety, Pharmacokinetic and Pharmacodynamic Effects, and Efficacy of SYR110322 in Patients with Type 2 Diabetes Who are Either Newly Diagnosed or Managed with Diet and Exercise Alone for the Past 3 Months",alogliptin,SYR-322_002,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_002,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of SYR110322 When Administered with Food and When Coadministered with Metformin or Cimetidine",alogliptin,SYR-322_005,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_005,Not available,,Y,Y,Y,Y,Y,N,Y,,1-Oct-2014
Takeda,"An Evaluator-Blinded, Active- and Placebo-Controlled, Multiple-Dose, Crossover Study to Assess the Effects of SYR110322 on the QTc Interval in Healthy Subjects",alogliptin,SYR-322_004,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_004,Not available,,Y,Y,Y,Y,Y,N,Y,,1-Oct-2014
Takeda,"An Open-Label, Parallel-Group Comparison Study of Single-Dose Pharmacokinetics of SYR110322 in Subjects with Mild or Moderate Renal Impairment and Healthy Volunteers",alogliptin,SYR-322_006,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_006,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Multiple-Dose Study to Assess the Drug-Drug Interaction Between SYR-322 and Caffeine, Tolbutamide, Dextromethorphan, Midazolam, and Fexofenadine Administered Concomitantly to Healthy Adult Subjects",alogliptin,SYR-322_015,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_015,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of SYR-322 Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women",alogliptin,SYR-322_019,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_019,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"The Effect of Multiple Doses of Fluconazole, Ketoconazole, or Gemfibrozil on the Single-Dose Pharmacokinetic Profile of SYR-322 in Healthy Subjects",alogliptin,SYR-322_016,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_016,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,An Open-Label Study to Assess the Effect of SYR-322 on Glyburide in Healthy Adult Subjects,alogliptin,SYR-322_018,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_018,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose of SYR-322 in an Ascending Dose Regimen in Healthy Male Subjects",alogliptin,SYR-322/CPH-001,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-001,Not available,,Y,Y,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Randomized, Multiple-Dose, Crossover Study to Assess the Drug-Drug Interaction of SYR-322 and Pioglitazone",alogliptin,SYR-322_017,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_017,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label Mass Balance and Excretion Study of [14C]SYR-322 Following Oral Administration in Healthy Male Subjects",alogliptin,SYR-322_014,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_014,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study to Determine the Effect of Cyclosporine (Neoral) on the Pharmacokinetics of SYR-322 in Healthy Male Subjects",alogliptin,SYR-322_020,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_020,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SYR-322 in an Ascending Dose Regimen in Healthy Male Subjects",alogliptin,SYR-322/CPH-002,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-002,Not available,,Y,Y,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 1, Single-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Possible Effects of Age, Gender, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of SYR-322 in Healthy Adult Subjects",alogliptin,SYR-322_022,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_022,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Randomized, Single-Blind, Placebo-Controlled Assessment of the Pharmacokinetics and Pharmacodynamics of Warfarin in the Presence of Multiple Doses of SYR-322 in Healthy Male and Female Subjects",alogliptin,SYR-322_021,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_021,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,The Effect of SYR-322 on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Norethindrone (Ortho-Novum® 1/35) in Healthy Adult Female Subjects,alogliptin,SYR-322_024,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_024,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,An Open-Label Evaluation of the Single Dose Pharmacokinetics of SYR-322 in Subjects With and Without Hepatic Impairment,alogliptin,SYR-322_023,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_023,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"Randomized, Open-Label Cross-over Study to Assess the Effects of Food on the Safety, Tolerability and Pharmacokinetics of Single-Dose SYR-322 in Healthy Male Subjects",alogliptin,SYR-322/CPH-006,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322/CPH-006,Not available,,N,Y,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Randomized, Multiple-Dose, Crossover Study to Assess the Drug-Drug Interaction of SYR-322 and Atorvastatin",alogliptin,SYR-322_025,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_025,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-label, Randomized, 2-Period Crossover Study to Determine the Bioequivalency of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) With the Commercial SYR-322 Tablets (12.5 and 25 mg) in Healthy Adult Subjects",alogliptin,SYR-322_027,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_027,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Multiple-Dose, Open-Label, Randomized, 3-Period Crossover Study to Evaluate the Effect of SYR-322 on the Pharmacokinetics of Digoxin in Healthy Subjects",alogliptin,SYR-322_029,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_029,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of SYR-322 in Healthy Male and Female Subjects",alogliptin,SYR-322_026,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_026,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Multiple-Dose, Randomized, Crossover Study to Determine the Pharmacokinetics and Pharmacodynamics of SYR-322 Twice Daily Versus Once-Daily Dosing in Healthy Male and Female Subjects",alogliptin,SYR-322_101,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_101,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Evaluate the Absolute Bioavailability of Alogliptin in Healthy Adult Subjects",alogliptin,SYR-322_103,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_103,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects",alogliptin,SYR-322_106,NCT01391663,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_106,https://clinicaltrials.gov/show/NCT01391663,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Single and Multiple-Dose Study of the Pharmacokinetics of Alogliptin 25 mg in Healthy Chinese Subjects",alogliptin,SYR-322_105,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322_105,Not available,,Y,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/OCT-003,NCT01263509,"Diabetes Mellitus, Type 2",Phase 2/3,http://takedaclinicaltrials.com/browse/summary/SYR-322/OCT-003,https://clinicaltrials.gov/show/NCT01263509,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/OCT-005,NCT01318135,"Diabetes Mellitus, Type 2",Phase 2/3,http://takedaclinicaltrials.com/browse/summary/SYR-322/OCT-005,https://clinicaltrials.gov/show/NCT01318135,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes",alogliptin/metformin,SYR-322MET_302,"NCT01023581
2009-012652-24","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322MET_302,https://clinicaltrials.gov/show/NCT01023581,https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012652-24/LT,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, 2-Cohort, 4-Sequence, 4-Period Crossover Study to Determine the Bioequivalence of Alogliptin 6.25 mg and 12.5 mg and Metformin 500 mg and 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet",alogliptin/metformin,SYR-322MET_101,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322MET_101,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Subjects",alogliptin/metformin,SYR-322MET_102,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322MET_102,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, 2-Cohort, 4-Sequence, 4-Period Crossover Study to Determine the Bioequivalence of Alogliptin 6.25 mg and 12.5 mg and Glucophage (Metformin HCl) 500 mg and 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet",alogliptin/metformin,SYR-322MET_103,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322MET_103,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS), in Subjects With Type 2 Diabetes",alogliptin/pioglitazone,01-05-TL-322OPI-001,"NCT00328627
2006-000694-30","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/01-05-TL-322OPI-001,https://clinicaltrials.gov/show/NCT00328627,https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000694-30/EE,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes",alogliptin/pioglitazone,01-06-TL-322OPI-002,"NCT00395512
2006-005492-17","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-322OPI-002,https://clinicaltrials.gov/show/NCT00395512,https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005492-17/HU,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg Versus Dose Titration From 30 mg to 45 mg of Pioglitazone HCl (ACTOS) in Subjects With Diabetes Mellitus, Type 2 Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy",alogliptin/pioglitazone,01-06-TL-322OPI-004,"NCT00432276
2006-006025-73","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-322OPI-004,https://clinicaltrials.gov/show/NCT00432276,https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006025-73/FI,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"An Open-Label, Randomized, 4-Period Crossover Study to Determine the Relative Bioavailability of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) and Pioglitazone (15 and 45 mg) When Administered as Commercial Tablets and as a Combination Product",alogliptin/pioglitazone,01-06-TL-322OPI-007,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-322OPI-007,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of the Proposed Commercial Formulation of a Fixed-Dose Combination of SYR-322 and Pioglitazone HCl in Healthy Male and Female Subjects",alogliptin/pioglitazone,01-06-TL-322OPI-006,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-322OPI-006,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, 4-Period Crossover Study to Determine the Bioequivalency of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) and Pioglitazone (15 and 45 mg) When Administered as Individual Tablets and as Combination Products",alogliptin/pioglitazone,SYR-322OPI_101,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322OPI_101,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"An Open-Label, Randomized, 2-Period Crossover Study to Determine the Bioequivalence of SYR-322 and AD-4833 Tablets When Administered as Individual Tablets and as Combination Product and to Determine the Effect of Food on the Pharmacokinetics of Combination Product",alogliptin/pioglitazone,SYR-322-4833/CPH-001,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322-4833/CPH-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"An Open-Label, Randomized, 2-Period Crossover Study to Determine the Bioequivalence of SYR-32  (12.5 mg) and AD-4833 (30 mg) Tablets When Administered as Individual Tablets and as a Combination Tablet and to Determine the Effect of Food on the Pharmacokinetics of the Combination Tablet",alogliptin/pioglitazone,SYR-322-4833/CPH-002,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-322-4833/CPH-002,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD),dexlansoprazole,T-GD05-137,NCT00321984,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GD05-137,https://clinicaltrials.gov/show/NCT00321984,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)",dexlansoprazole,T-GD07-170,NCT00627016,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GD07-170,https://clinicaltrials.gov/show/NCT00627016,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)",dexlansoprazole,T-GI04-088,NCT00255190,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GI04-088,https://clinicaltrials.gov/show/NCT00255190,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Dose, Four-Period Crossover Study Comparing the Pharmacokinetics of a 90 mg Modified-Release TAK-390 Formulation Administered Orally Under Fed and Fasting Conditions in Healthy Subjects",dexlansoprazole,T-P104-069,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P104-069,Not available,,N,N,Y,Y,Y,Y,N,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Four-Period Crossover, Multiple-Dose Single-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety Following Administration of 60 mg, 90 mg and 120 mg Oral Doses of a Modified Release Formulation of TAK-390 and 30 mg Oral Doses of Lansoprazole in Healthy Subjects",dexlansoprazole,T-P104-071,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P104-071,Not available,,N,N,Y,Y,Y,Y,N,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Double-Blind, Four-Period Crossover Study to Assess the Effects on the Cardiac QT Interval of a Single Dose of TAK-390MR (90 mg and 300 mg) with a Placebo Control and Avelox® 400 mg as an Active Control in Healthy Subjects",dexlansoprazole,T-P104-092,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P104-092,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Crossover, Single Center Study to Measure Plasma Gastrin Levels Following Administration of 90-mg and 120-mg Oral Doses of a Modified-Release Formulation of TAK-390 and a 30-mg Oral Dose of Lansoprazole in Healthy Subjects",dexlansoprazole,T-P104-100,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P104-100,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Parallel Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Dexlansoprazole MR (60 mg) in Subjects With Normal or Moderately Impaired Hepatic Function",dexlansoprazole,T-P105-115,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-115,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Parallel Study to Evaluate the Effect of Gender and Age on the Pharmacokinetics and Safety of a Single Oral Dose of Dexlansoprazole MR 60 mg",dexlansoprazole,T-P105-119,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-119,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Single-Center, Randomized, Open-Label, Three-Period Crossover, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety Following Administration of Oral Doses of TAK-390MR (30 mg and 60 mg) and Lansoprazole 15 mg in Healthy Subjects",dexlansoprazole,T-P105-122,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-122,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy",dexlansoprazole,T-GD08-178,NCT00847808,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GD08-178,https://clinicaltrials.gov/show/NCT00847808,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of TAK-390MR in Healthy Male Subjects",dexlansoprazole,TAK-390MR/CPH-001,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR/CPH-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase I, Randomized, Double-Blind, AG-1749 Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-390MR in Healthy Male Subjects",dexlansoprazole,TAK-390MR/CPH-002,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR/CPH-002,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects",dexlansoprazole,TAK-390MR_101,NCT00942175,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR_101,https://clinicaltrials.gov/show/NCT00942175,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed Release Capsules 30 mg Encapsulated at Osaka with Granules Manufactured by TIL and Osaka Relative to Reference Dexlansoprazole Delayed Release Capsules 30 mg Encapsulated at Osaka With Granules Manufactured by Osaka in Healthy Subjects",dexlansoprazole,TAK-390MR_102,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR_102,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed Release Capsules 60 mg Encapsulated at Osaka With Granules Manufactured by TIL and Osaka Relative to Reference Dexlansoprazole Delayed Release Capsules 60 mg Encapsulated at Osaka With Granules Manufactured by Osaka in Healthy Subjects",dexlansoprazole,TAK-390MR_103,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR_103,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Single-Center, Randomized, Open-Label, 2-Period Crossover, Single-Dose Study to Evaluate the Pharmacodynamics and Pharmacokinetics of Dexlansoprazole 60 mg Capsules and Esomeprazole 40 mg Capsules in Healthy Subjects",dexlansoprazole,TAK-390MR_105,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR_105,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Crossover Study to Assess the Bioavailability of Dexlansoprazole Delayed-Release 60 mg Capsule Granules Mixed With Water and Administered Via Nasogastric Tube or Oral Syringe, Relative to Administration of the Intact 60 mg Capsule in Healthy Subjects",dexlansoprazole,TAK-390MR_107,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-390MR_107,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease",dexlansoprazole,T-P107-163,NCT00847210,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P107-163,https://clinicaltrials.gov/show/NCT00847210,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Parallel Design, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Delayed Release Capsules in Pediatric Subjects Ages 1 to 11 Years Old With Symptomatic Gastroesophageal Reflux Disease",dexlansoprazole,T-P107-174,NCT01045096,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P107-174,https://clinicaltrials.gov/show/NCT01045096,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"Controlled, Study to Evaluate Cardiovascular Outcomes of",dexlansoprazole,T-EE04-084,"NCT00251693
2005-001187-31",Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-EE04-084,https://clinicaltrials.gov/show/NCT00251693,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001187-31/EE,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,TAK-875 50 mg in Addition to Standard of Care in Subjects,dexlansoprazole,T-EE04-085,"NCT00251719
2005-001188-70",Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-EE04-085,https://clinicaltrials.gov/show/NCT00251719,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001188-70/EE,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,with Type 2 Diabetes and with Cardiovascular Disease or,dexlansoprazole,T-EE04-086,"NCT00255164
2005-001189-15",Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-EE04-086,https://clinicaltrials.gov/show/NCT00255164,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001189-15/EE,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,Multiple Risk Factors for Cardiovascular Events,dexlansoprazole,T-EE04-087,"NCT00255151
2005-001190-10",Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-EE04-087,https://clinicaltrials.gov/show/NCT00255151,https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001190-10/EE,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis,dexlansoprazole,T-EE05-135,"NCT00321737
2006-000419-90",Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-EE05-135,https://clinicaltrials.gov/show/NCT00321737,https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000419-90/EE,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD),dexlansoprazole,T-GD04-082,NCT00251745,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GD04-082,https://clinicaltrials.gov/show/NCT00251745,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD),dexlansoprazole,T-GD04-083,NCT00251758,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/T-GD04-083,https://clinicaltrials.gov/show/NCT00251758,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Single-Center, Randomized, Open-Label, Parallel-Group, Multiple-Dose Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole MR (30 mg, 60 mg, and 90 mg) in Subjects with Symptomatic, Nonerosive Gastroesophageal Reflux Disease (GERD)",dexlansoprazole,T-P105-129,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-129,Not available,,N,N,Y,Y,Y,Y,N,,1-Oct-2014
Takeda,A Phase 1 Two-Way Crossover Study to Assess the Effect of Multiple Oral Doses of Dexlansoprazole MR (TAK-390MR) on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Warfarin,dexlansoprazole,T-P105-132,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-132,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Double-Blind, Placebo-Controlled, Two-way Crossover Study to Assess the Effect of Multiple Oral Doses of 90 mg Dexlansoprazole MR on the Pharmacokinetics of Phenytoin Following a Single Oral Dose of 250 mg Phenytoin",dexlansoprazole,T-P105-133,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-133,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Double-Blind, Placebo-Controlled, Two-Way Crossover Study to Assess the Effect of Multiple Oral Doses of Dexlansoprazole MR on Diazepam Pharmacokinetics Following a Single Oral Dose of Diazepam",dexlansoprazole,T-P105-134,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-134,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Double-Blind, Placebo-Controlled, Two-way Crossover Study to Assess the Effect of Multiple Oral Doses of Dexlansoprazole MR on the Pharmacokinetics of Theophylline Following a Single Intravenous Dose of Aminophylline",dexlansoprazole,T-P105-139,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P105-139,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label Study to Assess the Absorption, Distribution, Metabolism and Excretion of Orally Administered [14C]Dexlansoprazole in Healthy Subjects",dexlansoprazole,T-P106-141,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P106-141,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Single-Dose, Four-Way Crossover Study to Assess the Effect of the Timing of Food on the Pharmacokinetics and Intragastric pH of Dexlansoprazole Following a Single Oral Dose of 90-mg Dexlansoprazole MR",dexlansoprazole,T-P106-146,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P106-146,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open-Label, Two-Way Crossover Study to Assess the Bioavailability of Dexlansoprazole MR 90 mg When the Capsule Contents Are Administered Sprinkled Over Applesauce Relative to a Single, Oral Dose of Dexlansoprazole MR 90 mg Intact Capsule Administered Orally",dexlansoprazole,T-P106-148,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P106-148,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Open Label, Three-Way Crossover Study to Compare the Bioavailability, Pharmacokinetics, and Safety of Dexlansoprazole After Single Oral Doses of Three Dexlansoprazole MR 90 mg Capsule Formulations",dexlansoprazole,T-P106-149,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P106-149,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Four-Way Crossover Study to Assess the Effect of Time of Day on the Pharmacokinetics and Pharmacodynamics of Dexlansoprazole Following Daily Dosing of Dexlansoprazole MR 60 mg for 5 Days in Healthy Adult Subjects",dexlansoprazole,T-P107-164,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/T-P107-164,Not available,,N,N,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase Ib/IIa Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness of LDP-02 in Subjects with Severe Ulcerative Colitis",vedolizumab,L297-005,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1/2,http://takedaclinicaltrials.com/browse/summary/L297-005,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Single Dose Phase Ib/IIa Placebo Controlled, Randomized, Double Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness of LDP-02 in Patients with Moderately Severe Ulcerative Colitis",vedolizumab,L297-006,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1/2,http://takedaclinicaltrials.com/browse/summary/L297-006,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase I/II, Randomized, Placebo-Controlled, Double Blind, Parallel Group, Multicenter Study to Determine the Safety, Pharmacokinetics, and Effectiveness of Multiple Doses of LDP-02 in Patients with Mildly to Moderately Active Ulcerative Colitis",vedolizumab,M200-021,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1/2,http://takedaclinicaltrials.com/browse/summary/M200-021,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis",vedolizumab,C13006,"NCT00783718
2008-002782-32",Ulcerative Colitis; Crohn's Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/C13006,https://clinicaltrials.gov/show/NCT00783718,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002782-32/ES,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease",vedolizumab,C13007,"NCT00783692
2008-002783-33",Ulcerative Colitis; Crohn's Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/C13007,https://clinicaltrials.gov/show/NCT00783692,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002783-33/ES,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease",vedolizumab,C13011,"NCT01224171
2009-016488-12",Ulcerative Colitis; Crohn's Disease,Phase 3,http://takedaclinicaltrials.com/browse/summary/C13011,https://clinicaltrials.gov/show/NCT01224171,https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016488-12/NL,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"Phase 2, Randomized, Placebo-Controlled, Double-Blind Label Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis",vedolizumab,C13002,NCT01177228,Ulcerative Colitis; Crohn's Disease,Phase 2,http://takedaclinicaltrials.com/browse/summary/C13002,https://clinicaltrials.gov/show/NCT01177228,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease",vedolizumab,C13004,"NCT00619489
2008-002784-14",Ulcerative Colitis; Crohn's Disease,Phase 2,http://takedaclinicaltrials.com/browse/summary/C13004,https://clinicaltrials.gov/show/NCT00619489,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002784-14/EE,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
Takeda,"Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease",vedolizumab,L299-016,NCT00655135,Ulcerative Colitis; Crohn's Disease,Phase 2,http://takedaclinicaltrials.com/browse/summary/L299-016,https://clinicaltrials.gov/show/NCT00655135,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase II, Randomized, Placebo-Controlled, Double Blind, Parallel Group, Multicenter Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients with Mildly to Moderately Active Ulcerative Colitis",vedolizumab,M200-022,Not available,Ulcerative Colitis; Crohn's Disease,Phase 2,http://takedaclinicaltrials.com/browse/summary/M200-022,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Single Ascending Dose, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 in Healthy Subjects",vedolizumab,C13001,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/C13001,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Single Dose, Open-Label Study to Determine the Pharmacokinetics, Safety, and Tolerability of MLN0002 in Healthy Subjects Across a Range of Low and High Body Weights",vedolizumab,C13005,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/C13005,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1 Single Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Lyophilized Formulation (Process C Drug Product) of MLN0002 in Healthy Subjects",vedolizumab,C13009,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/C13009,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,A Phase 1 Single-Arm Study to Evaluate the Effects of a Single Intravenous Dose of Vedolizumab (MLN0002) on the CD4+:CD8+ Lymphocyte Ratio in the Cerebrospinal Fluid of Healthy Subjects,vedolizumab,C13012,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/C13012,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab",vedolizumab,C13013,NCT01981616,Ulcerative Colitis; Crohn's Disease,Phase 1,http://takedaclinicaltrials.com/browse/summary/C13013,https://clinicaltrials.gov/show/NCT01981616,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2014
Takeda,"Phase I, Multiple-dose Study of MLN0002 in Patients with Ulcerative Colitis",vedolizumab,MLN0002/CPH-001,Not available,Ulcerative Colitis; Crohn's Disease,Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Oct-2014
UCB,"A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)",Certolizumab Pegol,C87031,NCT00152490,Crohn's Disease,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00152490?term=NCT00152490&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,"Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).",Certolizumab Pegol,C87032,NCT00152425,Crohn's Disease,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00152425?term=NCT00152425&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis,Certolizumab Pegol,C87014,NCT00544154,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00544154?term=NCT00544154&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Certolizumab Pegol,C87050,NCT00160602,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00160602?term=NCT00160602&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Certolizumab Pegol,AKS001,NCT01087762,Axial Spondyloarthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT01087762?term=nCT01087762&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Jul-2014
UCB,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,Certolizumab Pegol,PsA001,NCT01087788,Psoriatic Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT01087788?term=NCT01087788&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Jul-2014
UCB,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel
Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/day, 400mg/day,
600mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without
Secondary Generalization",Lacosamide,SP667,Not available,Epilepsy,Phase 2,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,"Currently not available on Sponsor Clinical Study Registry  but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015). 

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only 

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements",1-Jul-2014
UCB,SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization,Lacosamide,SP754,NCT00136019,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00136019?term=NCT00136019&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization",Lacosamide,SP755,NCT00220415,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00220415?term=NCT00220415&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures,Levetiracetam,N01057,NCT00160550,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00160550?term=NCT00160550&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy,Levetiracetam,N01061,NCT00150735,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,http://clinicaltrials.gov/ct2/show/NCT00150735?term=NCT00150735&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy,Levetiracetam,N01274,NCT00535392,Epilepsy,Phase 2,http://www.ucb.com/rd/data-transparency,http://clinicaltrials.gov/ct2/show/NCT00535392?term=NCT00535392&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy,Levetiracetam,N01275,NCT00505934,Epilepsy,Phase 2,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00505934?term=NCT00505934&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group,
dose-ranging study to assess the efficacy, safety, and tolerability of escalating transdermal
doses of rotigotine (SPM 962) in subjects with early-stage Parkinson’s disease",Rotigotine,SP506,Not available,Parkinson's Disease,Phase 2,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,"Currently not available on Sponsor Clinical Study Registry  but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only 

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements",1-Jul-2014
UCB,"A multi-center, multinational, phase III, randomized, double-blind, placebocontrolled
trial, of the efficacy and safety of the rotigotine patch in subjects with earlystage,
idiopathic Parkinson?s disease",Rotigotine,SP512,Not available,Parkinson's Disease,Phase 3,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,"Currently not available on Sponsor Clinical Study Registry  but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only 

CRFs are seperate files per year 

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements",1-Jul-2014
UCB,"A multi-center, multinational, phase III, randomized, double-blind, doubledummy,
3-arm parallel group, placebo- and ropinirole-controlled trial of the efficacy and
safety of the rotigotine CDS patch in subjects with early-stage idiopathic Parkinson?s
disease",Rotigotine,SP513,Not available,Parkinson's Disease,Phase 3,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,"Currently not available on Sponsor Clinical Study Registry  but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only 

CRFs are seperate files per year 

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements",1-Jul-2014
UCB,"A multi-center, multinational, Phase 3, randomized, double-blind, parallel
group, placebo-controlled trial of the efficacy and safety of rotigotine CDS patch (2 target
doses) in subjects with advanced-stage, idiopathic Parkinson?s disease who are not well
controlled on levodopa",Rotigotine,SP650,Not available,Parkinson's Disease,Phase 3,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,"Currently not available on Sponsor Clinical Study Registry  but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only 

CRFs are seperate files per year 

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements",1-Jul-2014
UCB,"Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa",Rotigotine,SP515,NCT00244387,Parkinson's Disease,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00244387?term=NCT00244387&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome,Rotigotine,SP792,NCT00135993,Restless Legs Syndrome,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00135993?term=NCT00135993&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome,Rotigotine,SP790,NCT00136045,Restless Legs Syndrome,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00136045?term=NCT00136045&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
Boehringer Ingelheim,"LUX Lung 2 Phase II Single Arm BIBW 2992 ""Afatinib"" in NSCLC With EGFR Activating Mutations",afatinib,1200.22,NCT00525148,"Carcinoma, Non-Small-Cell Lung",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00525148?term=1200.22&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,afatinib,1200.32,NCT00949650,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00949650?term=1200.32&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR],afatinib,1200.72,NCT01003899,"Carcinoma, Non-Small-Cell Lung",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01003899?term=1200.72&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,BIBW 2992 (Afatinib) in Head & Neck Cancer,afatinib,1200.28,NCT00514943,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00514943?term=1200.28&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,12 / 48 wk Pivotal PFT vs PBO in COPD II,olodaterol,1222.12,NCT00782509,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00782509?term=1222.12&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,12 / 48 Week Pivotal PFT vs PBO in COPD I,olodaterol,1222.11,NCT00782210,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00782210?term=1222.11&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I,olodaterol,1222.13,NCT00793624,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00793624?term=1222.13&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease",olodaterol,1222.4,NCT01040728,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01040728?term=1222.40&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,olodaterol,1222.25,NCT00932646,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00932646?term=1222.25&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II,olodaterol,1222.14,NCT00796653,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00796653?term=1222.14&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease,olodaterol,1222.39,NCT01040689,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01040689?term=1222.39&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,olodaterol,1222.24,NCT00931385,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00931385?term=1222.24&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Nov-2014
Boehringer Ingelheim,"Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease",pramipexole,248.544,NCT02231905,Parkinson Disease,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02231905?term=248.544&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients,telmisartan,502.35,NCT00274105,Hypertension; Coronary Arteriosclerosis,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274105?term=502.350&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension",telmisartan,502.476,NCT00168779,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00168779?term=502.476&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM),telmisartan,502.343,NCT02200640,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02200640?term=502.343&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM),telmisartan,502.344,NCT02200653,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02200653?term=502.344&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension,telmisartan + amlodipine,1235.8,NCT00624052,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00624052?term=1235.8&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",tiotropium bromide,205.269,NCT00144326,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144326?term=205.269&rank=1,,N,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases,tiotropium bromide,205.234,NCT00274534,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274534?term=205.234&rank=1,,N,N,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients,tiotropium bromide,205.247,NCT00157235,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00157235?term=205.247&rank=1,,N,Y,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,"A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)",tiotropium bromide,205.291,NCT00292448,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00292448?term=205.291&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD,tiotropium bromide,205.284,NCT00239460,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00239460?term=205.284&rank=1,,N,N,Y,N,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,SPIRIVA in Usual Care,tiotropium bromide,205.276,NCT00274079,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00274079?term=205.276&rank=1,,N,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Boehringer Ingelheim,Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.131,NCT02172300,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02172300?term=205.131&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
Lilly,Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMBV,NCT00062673,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00062673?term=hmbv&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
Lilly,Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain,Duloxetine hydrochloride,F1J-US-HMCB,NCT00036335,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00036335?id=HMCB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2014
GSK,"A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus",albiglutide,GLP110125,NCT00518115,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/GLP110125,http://clinicaltrials.gov/show/NCT00518115,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment",albiglutide,GLP114130,NCT01098539,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114130,http://clinicaltrials.gov/show/NCT01098539,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Nov-2014
GSK,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus",albiglutide/metformin,GLP112753,NCT00838903,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112753,http://clinicaltrials.gov/show/NCT00838903,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Nov-2014
GSK,"A multicenter, randomized, parallel, placebo-controlled, one-year study of the efficacy and safety of bupropion hydrochloride sustained-release tablets versus placebo as an aid to smoking cessation treatment in adult cigarette smokers previously treated with bupropion",bupropion,ZYB40003,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40003,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking,bupropion,ZYB40005,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)",cilomilast,CIL103657,NCT00103922,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/CIL103657,http://clinicaltrials.gov/show/NCT00103922,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2014
GSK,"An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD",cilomilast,SB207499/180,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/180,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD).",cilomilast/salmeterol/fluticasone propionate,207499/125,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/125,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A 12-Week, Parallel-Group, Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose Ranging Study toEvaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45mg), AdministeredOrally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus foll ...",denagliptin,DPB100925,NCT00111800,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/100925,http://clinicaltrials.gov/show/NCT00111800,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma",fiboflapon,LPA111834,NCT00748306,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111834,http://clinicaltrials.gov/show/NCT00748306,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction.",fiboflapon,LPA112025,NCT00812929,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112025,http://clinicaltrials.gov/show/NCT00812929,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"An open-label, randomised, single-dose, multi-cohort, crossover bioavailability study of a solution formulation and three capsule formulations of GSK2190915 in healthy adult subjects followed by a repeat-dose, randomized, parallel group, double-blinded study of one selected capsule formulation and matched placebo in elderly healthy subjects",fiboflapon,LPA112071,NCT02224521,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112071,http://clinicaltrials.gov/show/NCT02224521,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"An open label, sequential, single cohort, repeat dose study to investigate the potential interaction of GSK2190915 on the pharmacokinetics of rosuvastatin in healthy adult subjects.",fiboflapon,LPA112362,NCT01411111,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112362,http://clinicaltrials.gov/show/NCT01411111,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomised, double-blind, placebo-controlled, cross-over study to evaluate the effect of treatment with repeat dose GSK2190915 as an add-on to current therapy on the percentage of neutrophils in induced sputum in asthmatic patients with elevated sputum neutrophils",fiboflapon,LPA115134,NCT01471665,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/115134,http://clinicaltrials.gov/show/NCT01471665,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"Randomised, open label, two period, crossover study to compare the steroid systemic exposure of Fluticasone Propionate (FP) from FP/Salmeterol (SALM) (500/50) DISKUS and Budesonide (BUD) from BUD/formoterol (FOR).(200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease.",fluticasone propionate/salmeterol,SAM100807,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/100807,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A single-blind, placebo-controlled, two part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682 in healthy volunteers",GSK2018682,P1A114070,NCT01387217,Multiple Sclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114070,http://clinicaltrials.gov/show/NCT01387217,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A single-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682 (S1P1 agonist) in healthy volunteers",GSK2018682,P1A114347,NCT01431937,"Multiple Sclerosis, Relapsing-Remitting",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114347,http://clinicaltrials.gov/show/NCT01431937,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects","retigabine, ezogabine",RTG115860,NCT01462669,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115860,http://clinicaltrials.gov/show/NCT01462669,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,A two part study to assess the pharmacokinetic performance of three retigabine modified release (MR) formulations after single dose and to assess the pharmacokinetics and tolerability of titration with retigabine MR,"retigabine, ezogabine",RTG113215,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113215,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"Open-Label Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Retigabine Following Single and Multiple Dose Administration of Two Different Modified Release Formulations Compared to Single Dose Administration of One Immediate Release Formula","retigabine, ezogabine",VRX-RET-E22-MR103,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-MR103,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users","retigabine, ezogabine",VRX-RET-E22-108,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-108,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol","retigabine, ezogabine",VRX-RET-E22-107,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-107,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers,"retigabine, ezogabine",VRX-RET-E22-106,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-106,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects","retigabine, ezogabine",VRX-RET-E22-105,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-105,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects","retigabine, ezogabine",VRX-RET-E22-104,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-104,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial,"retigabine, ezogabine",VRX-RET-E22-103,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-103,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects","retigabine, ezogabine",VRX-RET-E22-101SR,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-101SR,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy","retigabine, ezogabine",3065A1-214-EU/US,,Seizures,Phase 2,http://www.gsk-clinicalstudyregister.com/study/3065A1-214,,,Y,Y,Y,Y,Y,N,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205)","retigabine, ezogabine",3065A1-212,,Seizures,Phase 2,http://www.gsk-clinicalstudyregister.com/study/3065A1-212,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202)","retigabine, ezogabine",3065A1-208,,Seizures,Phase 2,http://www.gsk-clinicalstudyregister.com/study/3065A1-208,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2014
GSK,"A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects",rosiglitazone/metformin,712753/007,NCT00499707,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/712753/007,http://clinicaltrials.gov/show/NCT00499707,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus",rosiglitazone/metformin,712753/002,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/712753/002,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus",rosiglitazone/metformin,712753/003,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/712753/003,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET® (8.0mg / 2.0g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy",rosiglitazone/metformin,712753/009,NCT00069836,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/712753/009,http://clinicaltrials.gov/show/NCT00069836,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A two part randomized, double-blind, placebo controlled study to investigate the effects of topical doses of SB705498 oncapsaicin, histamine, and cowhage responses in healthy volunteers.",SB705498,VRD115246,NCT01673529,"Dermatitis, Atopic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115246,http://clinicaltrials.gov/show/NCT01673529,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"Two part study to investigate pharmacokinetics (PK) & pharamcodynamics (PD) of SB-705498 in cough. Part A:open label study in healthy subjects to determine exposure to SB-705498. Part B:double-blind, placebo controlled, cross over study to investigate effect of SB-705498 on capsaicin induced cough and 24 hour cough counts in cough patients",SB705498,VR1114693,NCT01476098,Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114693,http://clinicaltrials.gov/show/NCT01476098,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomised, double blind placebo controlled, 2 way cross over study in adults with non-allergic rhinits to evaluate the effect of once daily administration of intranasal SB-705498 12mg for two weeks and the response to a chamber challenge of cold dry air",SB705498,VR1114974,NCT01424514,Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114974,http://clinicaltrials.gov/show/NCT01424514,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100mg Tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who meet International Headache Society (IHS) Criteria for Migraine.",sumatriptan,SUM40312,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40312,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder International Headache Society (IHS) 1.7.",sumatriptan,SUM40299,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40299,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 50mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache.",sumatriptan,SUM40298,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40298,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening.",sumatriptan,SUM40286,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40286,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack",sumatriptan,SUM40285,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40285,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack",sumatriptan,SUM40282,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40282,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2014
GSK,A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease,umeclidinium bromide/vilanterol,DB2113359,NCT01316887,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113359,http://clinicaltrials.gov/show/NCT01316887,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomised, placebo-controlled, incomplete block, four period crossover , repeat dose study to evaluate the effect of the inhaled GSK573719/Vilanterol combination and GSK573719 monotherapy on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects.",umeclidinium bromide/vilanterol;umeclidinium bromide,DB2114635,NCT01521377,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114635,http://clinicaltrials.gov/show/NCT01521377,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"An open-label, non-randomized, pharmacokinetic and safety study of single dose GSK573719 + GW643444 (VI) combination and repeat doses of GSK573719 in healthy subjects and in subjects with moderate hepatic impairment",umeclidinium bromide/vilanterol;umeclidinium bromide,DB2114637,NCT01577680,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114637,http://clinicaltrials.gov/show/NCT01577680,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss",vestipant;vestipitant/paroxetine,NKP106254,NCT00394056,Tinnitus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKP106254,http://clinicaltrials.gov/show/NCT00394056,,Y,N,Y,Y,Y,Y,Y,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions.,1-Nov-2014
GSK,"A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD)",vestipitant/paroxetine,NKP103401,NCT00403962,Social Phobia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKP103401,http://clinicaltrials.gov/show/NCT00403962,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
GSK,"A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powder (GW642444) and salmeterol, compared with placebo in the treatment of persistent asthma in adults and adolescents uncontrolled on inhaled corticosteroids",vilanterol,B2C112060,NCT01181895,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112060,http://clinicaltrials.gov/show/NCT01181895,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2014
ViiV,A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir,abacavir,ABC107442,NCT00373945,"Infection, Human Immunodeficiency Virus I",Phase 4,http://www.viiv-clinicalstudyregister.com/study/abc107442,http://clinicaltrials.gov/show/NCT00373945,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Lilly,Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder,Duloxetine hydrochloride,F1J-MC-HMDT,NCT00475969,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00475969?term=HMDT&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Lilly,"A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder.",Duloxetine hydrochloride,F1J-MC-HMDU,NCT00122850,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00122850?id=F1J-MC-HMDU&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Lilly,"A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder",Duloxetine hydrochloride,F1J-MC-HMDW,NCT00122837,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00122837?id=F1J-MC-HMDW&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Lilly,A Double-Blind Placebo-Controlled Study of Fluoxetine and Clomipramine in the Treatment of Panic Disorder,Fluoxetine,B1Y-EW-HCHQ,Not available,Panic Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available.  A blank case report form will be provided.                                                     A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Dec-2014
Lilly,Fluoxetine vs Placebo in Obsessive Compulsive Disorder,Fluoxetine,B1Y-MC-HCEP,Not available,Obsessive Compulsive Disorder,Phase 2,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,"If requested, the data package for Study B1Y-MC-HCEP will provide data for two independent studies (Study 1 and Study 2).  A link to Clinicaltrials.gov and a NCT ID number are not available for these studies because the studies were conducted before regulatory requirements to register studies.",1-Dec-2014
Lilly,Fluoxetine versus Placebo in Panic Disorder,Fluoxetine,B1Y-MC-HCHG,Not available,Panic Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available.  A blank case report form will be provided.                                                     A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Dec-2014
Lilly,Fluoxetine versus Placebo in Panic Disorder,Fluoxetine,B1Y-MC-HCJB,Not available,Panic Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available.  A blank case report form will be provided.                                                     A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Dec-2014
Lilly,Fluoxetine versus Placebo in Panic Disorder,Fluoxetine,B1Y-MC-HCJC,Not available,Panic Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available.  A blank case report form will be provided.                                                     A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Dec-2014
Lilly,Humatrope and Low-Dose Estrogen in Turner Syndrome,Somatropin,B9R-MC-GDCI,Not available,Turner Syndrome,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available.  A blank case report form will be provided.                                                       A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Dec-2014
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-491 in Healthy Volunteers",azilsartan medoxomil,01-05-TL-491-002,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-002,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Single-Blind, Placebo-Controlled, Randomized, Parallel-Design Study to Evaluate the Possible Effects of Age, Gender, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of TAK-491 in Healthy Adult Subjects",azilsartan medoxomil,01-05-TL-491-003,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-003,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Multiple-Dose, Open-Label, Randomized, 6-Sequence, 3-Period, Crossover Study to Assess the Drug-Drug Interaction Between TAK-491 and Chlorthalidone (Thalitone®)",azilsartan medoxomil,01-05-TL-491-004,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-004,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension",azilsartan medoxomil,01-05-TL-491-005,NCT00362115,Hypertension,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-005,https://clinicaltrials.gov/show/NCT00362115,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension",azilsartan medoxomil,01-05-TL-491-006,NCT00695955,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-006,https://clinicaltrials.gov/show/NCT00695955,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Randomized, Double-Blind, Placebo and Positive Controlled, Crossover Study to Evaluate the Effect of TAK-491 on the QTc Interval in Healthy Adult Subjects",azilsartan medoxomil,01-05-TL-491-007,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-007,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension",azilsartan medoxomil,01-05-TL-491-008,NCT00696241,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-008,https://clinicaltrials.gov/show/NCT00696241,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension",azilsartan medoxomil,01-05-TL-491-009,NCT00591773,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-009,https://clinicaltrials.gov/show/NCT00591773,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Single-Dose, Double-Blind, Sequential-Panel, Randomized, Placebo-Controlled, Dose-Escalation Study to Examine the Safety, Tolerability, and Pharmacokinetics of TAK-491 in Healthy Male Volunteers",azilsartan medoxomil,01-05-TL-491-001,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-001,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension",azilsartan medoxomil,01-05-TL-491-010,NCT00591266,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-05-TL-491-010,https://clinicaltrials.gov/show/NCT00591266,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension",azilsartan medoxomil,01-06-TL-491-011,NCT00591253,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-011,https://clinicaltrials.gov/show/NCT00591253,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Open-Label Mass Balance and Excretion Study of [14C]TAK-491 Following Oral Administration in Healthy Male Subjects",azilsartan medoxomil,01-06-TL-491-012,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-012,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"An Open-Label, Multiple-Dose Study to Assess the Drug-Drug Interaction Between TAK-491 and Caffeine, Tolbutamide, Dextromethorphan, Midazolam, and Fexofenadine Administered Concomitantly to Healthy Adult Subjects",azilsartan medoxomil,01-06-TL-491-013,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-013,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"An Open-Label, Randomized, 3-Period, Crossover Study to Evaluate the Relative Bioavailability of TAK-491 Capsule and Tablet Formulations and Food Effect of the Tablet Formulation in Healthy Adult Subjects",azilsartan medoxomil,01-06-TL-491-015,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-015,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension",azilsartan medoxomil,01-06-TL-491-016,NCT00696384,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-016,https://clinicaltrials.gov/show/NCT00696384,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo Controlled, Sequential-Panel, Ascending Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of High Doses of TAK-491 in Healthy Volunteers",azilsartan medoxomil,01-06-TL-491-017,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-017,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension",azilsartan medoxomil,01-06-TL-491-019,NCT00696436,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-019,https://clinicaltrials.gov/show/NCT00696436,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension",azilsartan medoxomil,01-06-TL-491-020,"NCT00760214
2007-002583-10",Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-491-020,https://clinicaltrials.gov/show/NCT00760214,https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002583-10/NL,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,Phase 1 Study of TAK-491 in Japanese Healthy Male Subjects - Single Dose Study,azilsartan medoxomil,TAK-491/CPH-001,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491/CPH-001,Not available,,N,N,Y,Y,N,Y,N,,1-Nov-2014
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of 80 mg and 160 mg of TAK-491 in Healthy Male Subjects",azilsartan medoxomil,TAK-491/CPH-005,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491/CPH-005,Not available,,N,N,Y,Y,N,Y,N,,1-Nov-2014
Takeda,"A Phase 1, Randomized, Open-Label, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of 20, 40, and 80 mg of TAK-491 Tablets in Healthy Adult Subjects",azilsartan medoxomil,TAK-491_101,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_101,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,Open-Label Evaluation of the Single-Dose and Multiple-Dose Pharmacokinetics of TAK-491 in Subjects With and Without Hepatic Impairment,azilsartan medoxomil,TAK-491_102,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_102,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"An Open-Label, Parallel-Group Comparison Study of Single-Dose Pharmacokinetics of TAK-491 in Subjects With Varying Degrees of Renal Impairment and Their Healthy Matched Subjects",azilsartan medoxomil,TAK-491_103,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_103,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Multiple-Dose, Open-Label, Randomized, 3-Period Crossover Study to Evaluate the Effect of TAK-536 Formed From TAK-491 on the Pharmacokinetics of Digoxin in Healthy Subjects",azilsartan medoxomil,TAK-491_104,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_104,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,The Effect of Antacid on the Pharmacokinetic Profile of TAK-491,azilsartan medoxomil,TAK-491_107,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_107,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Phase 1, Multiple-Dose, Open-Label, Randomized, 3-Period Crossover Study to Assess the Drug-Drug Interaction of TAK-491 and Amlodipine in Healthy Subjects",azilsartan medoxomil,TAK-491_110,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_110,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Randomized, Open-Label, 2-Period Crossover Study in Healthy Adult Subjects to Determine the Relative Bioavailability of TAK-491 Granules for Reconstitution Compared to TAK-491 Tablets",azilsartan medoxomil,TAK-491_111,Not available,Hypertension,Phase 1,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension",azilsartan medoxomil,TAK-491_301,NCT00591578,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491_301,https://clinicaltrials.gov/show/NCT00591578,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Takeda,"A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Relative Bioavailability of TAK-491 and Amlodipine in Fixed-Dose Combination Following Oral Administration to Healthy Adult Subjects",azilsartan medoxomil/amlodipine,TAK-491CCB_101,Not available,Hypertension,Phase 1,Not available,Not available,,N,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2014
Boehringer Ingelheim,BI 10773 add-on to Metformin in Patients With Type 2 Diabetes,empagliflozin,1245.1,NCT00749190,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00749190?term=1245.10&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension",empagliflozin,1245.24,NCT00881530,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00881530?term=1245.24&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients,empagliflozin,1245.9,NCT00789035,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00789035?term=1245.9&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,empagliflozin,1245.23,NCT01159600,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01159600?term=1245.23&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,empagliflozin,1245.36,NCT01164501,"Diabetes Mellitus, Type 2; Renal Insufficiency",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01164501?term=1245.36&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,empagliflozin,1245.19,NCT01210001,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01210001?term=1245.19&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,empagliflozin,1245.48,NCT01370005,"Diabetes Mellitus, Type 2; Hypertension",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01370005?term=1245.48&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,empagliflozin,1245.2,NCT01177813,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01177813?term=1245.20&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA),meloxicam,107.208,NCT00279747,"Arthritis, Juvenile Rheumatoid",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00279747?term=107.208&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA),meloxicam,107.235,NCT00034853,"Arthritis, Juvenile Rheumatoid",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00034853?term=107.235&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Boehringer Ingelheim,"Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis",meloxicam,107.21,NCT02183064,Osteoarthritis,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02183064?term=107.210&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
GSK,Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder,paroxetine,BRL-029060/CPMS- 116,,Obsessive-Compulsive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/116,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder,paroxetine,MY- 1028/BRL-029060/1/CPMS-118,,Obsessive-Compulsive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/118,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.",paroxetine,MY1047/BRL-029060/1/CPMS-120,,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/120,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder.,paroxetine,MY-1037/BRL-029060/1/CPMS-136,,Obsessive-Compulsive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/136,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder.,paroxetine,MY-1036/BRL-029060/1/CPMS-187 (PAR187),,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/187,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder",paroxetine,MY-1048/BRL-029060/1/CPMS-223 (PAR 223),,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/223,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia",paroxetine,PAR 029060-382,,Social Phobia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/29060/382,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia.",paroxetine,PAR 454,,Social Phobia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/454,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder",paroxetine,29060-494,,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/494,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder",paroxetine,29060/495,,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/495,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder",paroxetine,29060/497,,Panic Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/497,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia",paroxetine,PAR 029060-502,,Social Phobia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/502,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD)",paroxetine,PAR 29060/627,,Post-Traumatic Stress Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/627,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD)",paroxetine,PAR 29060 637,,Anxiety Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/637,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder",paroxetine,BRL-029060/RSD-101336/1/CPMS-641,,Anxiety Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/641,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder",paroxetine,PAR 29060/642,,Anxiety Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/642,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD)",paroxetine,PAR 648,,Post-Traumatic Stress Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/648,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Post-traumatic Stress Disorder (PTSD).",paroxetine,PAR 29060 651 (BRL – 02960),,Post-Traumatic Stress Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/651,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder",paroxetine,BRL-029060/CPMS-790,,Social Phobia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/790,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD)",paroxetine,29060/791,,Anxiety Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/791,,,Y,N,N,Y,N,N,N,"The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Dec-2014
GSK,An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A,umeclidinium bromide/vilanterol,DB2114417,NCT01328444,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114417,http://clinicaltrials.gov/show/NCT01328444,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
GSK,An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study B,umeclidinium bromide/vilanterol,DB2114418,NCT01323660,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114418,http://clinicaltrials.gov/show/NCT01323660,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2014
Roche,"A Randomized, Double-blind Study of the Effect of Avastin Plus Gemcitabine and Erlotinib Compared With Placebo Plus Gemcitabine and Erlotinib on Overall Survival in Patients With Metastatic Pancreatic Cancer",Bevacizumab,BO17706,NCT01214720,malignant neoplasm of pancreas,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01214720?term=BO17706&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study",Bevacizumab,BO17920,NCT00112918,malignant neoplasm of colon/rectum,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00112918?term=BO17920&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.",Bevacizumab,BO20231,NCT00391092,malignant neoplasm of breast,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00391092?term=BO20231&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized, Open-label Study to Explore the Correlation of Biomarkers With Response Rate in Chemo-naive Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Who Receive Treatment With Avastin in Addition to Carboplatin-based Chemotherapy",Bevacizumab,BO21015,NCT00700180,malignant neoplasm of bronchus and lung,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00700180?term=BO21015&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer",Bevacizumab,AVF3693G,NCT00281697,malignant neoplasm of breast,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00281697?term=AVF3693G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma",Bevacizumab,AVF4095G,NCT00434642,malignant neoplasm of ovary,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00434642?term=AVF4095G&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jan-2015
Roche,An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis,Bevacizumab,ML21823,NCT00800202,malignant neoplasm of bronchus and lung,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00800202?term=ML21823&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jan-2015
Roche,A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer,Bevacizumab,AVF3752G,NCT00312728,malignant neoplasm bronchus & lung unspecified site,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00312728?term=AVF3752G&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jan-2015
Roche,"A Placebo-Controlled, Double-Blind, Multicenter, Randomized, Phase II Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer",Bevacizumab,AVF3995G,NCT00403403,malignant neoplasm bronchus & lung unspecified site,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00403403?term=AVF3995G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma",Bevacizumab,AVF2938G,NCT00081614,malignant neoplasm kidney except pelvis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00081614?term=AVF2938G&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized Phase II study of bevacizumab, Carboplatin and Paclitaxel plus Sutent (sunitinib) in patients with advanced, previously untreated,  non-small cell lung cancer",Bevacizumab,AVF3996G,NCT00434226,malignant neoplasm bronchus & lung unspecified site,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00434226?term=AVF3996G&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Roche,Effects of Two Doses of rhuMAB-VEGF Antibody in Combination w/Chemotherapy in Subjects With Locally Advanced or Metastatic Lung Cancer,Bevacizumab,AVF0757G,,malignant neoplasm bronchus & lung unspecified site,Phase 2,,,,Y,Y,Y,Y,Y,Y,N,,1-Jan-2015
Roche,Trial to Evaluate Safety and Efficacy of rhuMAb VEGF as Monotherapy in Subjects with Hormone Refractory Prostate Cancer,Bevacizumab,AVF0775G,,malignant neoplasm of prostate,Phase 2,,,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Roche,Trial to Evaluate Safety and Efficacy of rhuMAb VEGF as Monotherapy in Subjects with Hormone Refractory Breast Cancer,Bevacizumab,AVF0776G,,malignant neoplasm breast unspecified site,Phase 2,,,,Y,N,Y,Y,Y,Y,N,,1-Jan-2015
Roche,Trial of rhuMAb VEGF Antibody Combined With 5 Fluourouracil and Leucovorin in Subjects With Locally Advanced or Metastatic Colorectal Cancer,Bevacizumab,AVF0780G,,malignant neoplasm of colon/rectum,Phase 2,,,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Roche,"AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Bevacizumab,MO22224,NCT00976911,malignant neoplasm of ovary,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00976911?term=MO22224&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized, Open-label Study of the Effect of Intermittent Xeloda Versus iv Fluorouracil/Leucovorin, Both in Combination With Eloxatin, on Tumor Progression in Patients With Metastatic Colorectal Cancer Who Received Prior CPT-11 and 5-fluorouracil/Leucovorin",Capecitabine,NO16967,NCT00069108,malignant neoplasm of colon/rectum,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00069108?term=no16967&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A randomized, open-label study of the effect of intermittent Xeloda in combination with Eloxatin, versus fluorouracil/leucovorin, on disease-free survival in patients who have undergone surgery for colon cancer",Capecitabine,NO16968,NCT00069121,malignant neoplasm of colon/rectum,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00069121?term=NO16968&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer.",Capecitabine,NO17629,NCT00089479,malignant neoplasm of breast,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00089479?term=NO17629&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A randomised, double blind, parallel group, placebo controlled study of the effect of oseltamivir on ECG intervals in healthy subjects.",Oseltamivir,WP16263,,viral diseases,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A randomized, open-label, parallel group study of oseltamivir used for management of influenza in households.",Oseltamivir,WV16193,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater than or Equal to 13 Years.,Oseltamivir,NV25118,NCT01050257,influenza,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01050257?term=NV25118&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jan-2015
Roche,"A randomized, open-label study of the effect of different doses of pertuzumab on treatment response in patients with metastatic breast cancer with low HER2 expression",Pertuzumab,BO16934,,malignant neoplasm of breast,Phase 2,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Roche,"A randomized, multicenter phase II study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in patients with metastatic HER2-positive breast cancer who have not received prior therapy for metastatic disease.",trastuzumab emtansine,BO21976,NCT00679341,malignant neoplasm of breast,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00679341,,Y,Y,Y,Y,Y,Y,N,,1-Jan-2015
Roche,"A randomized, Multicenter, Phase III Open-Label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in patients with HER2-Positive locally advanced or metastic breast cancer who have received prior Trastuzumab-based therapy.",trastuzumab emtansine,BO21977,NCT00829166,malignant neoplasm of breast,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00829166,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study,Duloxetine hydrochloride,F1J-AY-HMCZ,NCT00191685,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00191685?id=F1J-AY-HMCZ&rank=1,Not available,Y,Y,Y,Y,Y,Y,N,,1-Jan-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy,Duloxetine hydrochloride,F1J-MC-HMAV(A and B),NCT00058968,Diabetic Peripheral Neuropathic Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00058968?id=HMAV&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMBO,Not available,Fibromyalgia,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,N,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jan-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMCA,NCT00489073,Fibromyalgia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00489073?term=F1J-MC-HMCA&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Lilly's Emotional and Physical Symptoms of Depression Study,Duloxetine hydrochloride,F1J-MC-HMCM,NCT00479414,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00479414?id=F1J-MC-HMCM&rank=1,Not available,Y,N,Y,Y,N,Y,Y,,1-Jan-2015
Lilly,Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression,Duloxetine hydrochloride,F1J-MC-HMDD,NCT00494377,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00494377?term=F1J-MC-HMDD&rank=1,Not available,Y,N,Y,Y,Y,Y,N,,1-Jan-2015
Lilly,Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,Duloxetine hydrochloride,F1J-MC-HMDV,NCT00122863,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00122863?term=F1J-MC-HMDV&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain,Duloxetine hydrochloride,F1J-MC-HMEN,NCT00424593,Chronic Lower Back Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00424593?term=F1J-MC-HMEN&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain,Duloxetine hydrochloride,F1J-MC-HMEO,NCT00408876,Chronic Lower Back Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00408876?term=F1J-MC-HMEO&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain,Duloxetine hydrochloride,F1J-MC-HMEP,NCT00408421,Osteoarthritis Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00408421?term=F1J-MC-HMEP&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain,Duloxetine hydrochloride,F1J-MC-HMFG,NCT00433290,Osteoarthritis Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00433290?term=F1J-MC-HMFG&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,"An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder",Duloxetine hydrochloride,F1J-MC-HMFN,NCT00529789,Major Depressive Disorder,Phase 2,Not available,http://clinicaltrials.gov/ct2/show/NCT00529789?term=F1J-MC-HMFN&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder,Duloxetine hydrochloride,F1J-MC-HMGF,NCT01118780,Anxiety Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT01118780?term=F1J-MC-HMGF&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression,Duloxetine hydrochloride,F1J-US-HMBZ,NCT00042562,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00042562?id=F1J-US-HMBZ&rank=1,Not available,Y,N,Y,Y,Y,Y,N,,1-Jan-2015
Lilly,A Comparison of Duloxetine Dosing Strategies in The Treatment of Patients With Major Depression,Duloxetine hydrochloride,F1J-US-HMDR,NCT00191061,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00191061?id=HMDR&rank=2,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Lilly,A European observational study of health outcomes associated with treatment for mania in Bipolar Disorder.,Olanzapine,F1D-EW-HGKV,Not available,Mania,Not applicable,Not available,Not available,Not available,Y,N,N,Y,N,Y,N,"A link to clinicaltrials.gov and a NCT ID number are not available for this study because the study is observational and not in scope for listing on clinicaltrials.gov. The annotated case report form is not available. A blank case report form will be provided.  The CSR is not available however, the findings of this study are in Vieta et al, Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.;Journal of Affective Disorders 106 (2008) 63–72",1-Jan-2015
Boehringer Ingelheim,"Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048",dabigatran etexilate,1160.42,NCT00157248,"Atrial Fibrillation, Stroke",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00157248?term=1160.42&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,dabigatran etexilate,1160.63,NCT00558259,Venous Thromboembolism,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00558259?term=1160.63&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Secondary Prevention of Venous Thrombo Embolism (VTE).,dabigatran etexilate,1160.47,NCT00329238,Thromboembolism,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00329238?term=1160.47&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),dabigatran etexilate,1160.46,NCT00680186,Thromboembolism,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00680186?term=1160.46&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,dabigatran etexilate,1160.53,NCT00291330,Thromboembolism,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00291330?term=1160.53&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,dabigatran etexilate,1160.26,NCT00262600,"Atrial Fibrillation, Stroke",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00262600?term=1160.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients,dipyridamole + acetylsalicylic acid,9.169,NCT00129038,Coronary Arteriosclerosis,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00129038?term=9.169&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder,duloxetine hydrochloride,1208.34,NCT00844194,"Diabetic Neuropathies; Depressive Disorder, Major",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00844194?term=1208.34&rank=1,,Y,Y,Y,Y,Y,Y,Y,The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.,1-Jan-2015
Boehringer Ingelheim,Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression,duloxetine hydrochloride,1208.24,NCT02229825,"Depressive Disorder, Major",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02229825?term=1208.24&rank=1,,Y,Y,Y,Y,Y,Y,Y,The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.,1-Jan-2015
Boehringer Ingelheim,Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain,duloxetine hydrochloride,1208.1,NCT02232555,"Depressive Disorder, Major",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02232555?term=1208.10&rank=2,,Y,Y,Y,Y,Y,Y,Y,The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.,1-Jan-2015
Boehringer Ingelheim,"A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women >= 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence",duloxetine hydrochloride,1208.22,NCT00244296,"Urinary Incontinence, Stress",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00244296?term=NCT00244296&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.,1-Jan-2015
Boehringer Ingelheim,Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome,pramipexole,248.642,NCT00681863,Tourette Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00681863?term=248.642&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients,pramipexole,248.671,NCT01191944,Parkinson Disease,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01191944?term=248.671&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Pramipexole ER vs. Placebo in Fibromyalgia,pramipexole,248.637,NCT00689052,Fibromyalgia,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00689052?term=248.637&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Profile of Depressive Symptoms in Parkinson Disease,pramipexole,248.597,NCT00349310,Parkinson Disease; Depression,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00349310?term=248.597&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients,pramipexole,248.52,NCT00275457,Restless Legs Syndrome,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00275457?term=248.520&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS,pramipexole,248.616,NCT00375284,Restless Legs Syndrome,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00375284?term=248.616&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS),pramipexole,248.6,NCT02231918,Restless Legs Syndrome,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02231918?term=248.600&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients,pramipexole,248.538,NCT00144300,Parkinson Disease,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144300?term=248.538&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease,pramipexole,248.342,NCT02233023,Parkinson Disease,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02233023?term=248.342&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis,meloxicam,107.258,NCT00042068,"Arthritis, Rheumatoid",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00042068?term=107.258&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Study to Compare the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar,meloxicam,107.197,NCT02183051,Pain,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02183051?term=107.197&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring,telmisartan,502.376,NCT02242318,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02242318?term=502.376&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,"Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension",telmisartan,502.403,NCT02242344,Hypertension,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02242344?term=502.403&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Telmisartan 80mg Non-responder Trial,telmisartan,1235.36,NCT01222520,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01222520?term=1235.36&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,Filtered Trial for Telmisartan 40mg Non-responder,telmisartan,1235.14,NCT00550953,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00550953?term=1235.14&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg),telmisartan + amlodipine,1235.37,NCT01286558,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01286558?term=1235.37&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination",telmisartan + amlodipine,1235.16,NCT00618774,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00618774?term=1235.16&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch,telmisartan + amlodipine,1235.33,NCT01134393,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01134393?term=1235.33&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension,telmisartan + hydrochlorothiazide,502.516,NCT00326768,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00326768?term=502.516&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy,telmisartan + hydrochlorothiazide,502.436,NCT00144222,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00144222?term=502.436&rank=1,,Y,N,Y,N,Y,Y,N,,1-Jan-2015
Boehringer Ingelheim,Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg,telmisartan + hydrochlorothiazide,502.472,NCT00146341,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT00146341?term=502.472&rank=1,,N,Y,Y,N,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Tiotropium Respimat Pharmacokinetic Study in COPD,tiotropium bromide,205.458,NCT01222533,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01222533?term=205.458&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,tiotropium bromide,205.452,NCT01126437,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT01126437?term=205.452&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Boehringer Ingelheim,Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects,tipranavir,1182.6,NCT02251223,HIV Infections,Phase 1/Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,http://clinicaltrials.gov/ct2/show/NCT02251223?term=1182.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
GSK,"A double-blind, placebo-controlled, randomised study of the efficacy of an HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in healthy adolescent and young adult women in North America and Brazil.",Human Papillomavirus Types 16 and 18 Vaccine,580299/001,NCT00689741,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/580299/001,http://clinicaltrials.gov/show/NCT00689741,,Y,N,Y,Y,Y,Y,Y,"Follow-up studies 580299/007, 109616, 109624, and 109625 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jan-2015
GSK,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease.",rosiglitazone,AVA102672,NCT00348309,Alzheimer's Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVA102672,http://clinicaltrials.gov/show/NCT00348309,,Y,Y,Y,Y,Y,Y,Y,A follow-on study AVA102675 was conducted.,1-Jan-2015
Roche,A Phase I/II Pharmacokinetic and Safety Study of T20 in combination with an optimized background in HIV infected Children and Adolescents,enfuvirtide,NV16056,NCT00022763,hiv disease,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00022763?term=nv16056&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A Phase II open-label, randomized, active-controlled study comparing the efficacy and safety of once daily enfuvirtide dosing versus the currently recommended twice daily dosing in HIV-1 infected treatment-experienced patients.",enfuvirtide,NV17658,NCT00089492,hiv disease,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00089492?term=nv17658&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Feb-2015
Roche,"A continuation protocol with open label pegylated-interferon alpha-2a (Ro 25-8310) for chronic hepatis C patients whose disease did not respond to roferon-a in the original studies (NV15495, NV15496, NV15497).",Peg-Interferon Alpha-2A,NV15909,,chronic hepatitis c,Phase 3,,,,Y,N,Y,N,Y,Y,N,,1-Feb-2015
Roche,A protocol for re-treatment with the combination of peginterferon alfa-2a and ribavirin for patients with chronic hepatitis C original study NV15942 who relapsed virologically after completing 24 weeks of treatment.,Peg-Interferon Alpha-2A,WV16143,,chronic hepatitis c,Phase 3,,,,Y,N,Y,N,Y,Y,N,,1-Feb-2015
Roche,An open-label study of the safety of PEGASYS alone or in combination with ribavirin in patients with chronic hepatitis C who have participated in previous studies,Peg-Interferon Alpha-2A,NV17590,NCT01853254,chronic hepatitis c,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01853254?term=NV17590&rank=1,,Y,N,Y,N,Y,Y,N,,1-Feb-2015
Roche,"A Randomized, Open-Label, Multicenter, Phase III Study Evaluating the Efficacy and Safety of Peginterferon alfa-2a (Ro 25-8310) in Combination with Ribavirin (Ro 20-9963) Given for 24 weeks Versus 48 Weeks Versus No Treatment in Patients with Chronic Hepatitis C and Persistently Normal ALT Levels.",Peg-Interferon Alpha-2A,NR16071,,chronic hepatitis b,Phase 3,,,,Y,N,Y,N,Y,Y,Y,,1-Feb-2015
Roche,"A Randomized, Open-Label, Multicenter, Phase III, Three Arm Study Evaluating the Efficacy and Safety of Pegylated-Interferon alfa-2a (Ro 25-8310) Monotherapy versus Combination Therapy of Pegylated-Interferon alfa-2a with Ribavirin (Ro 22-8181 with Ribavirin for 48 Weeks, and 24 Weeks of Follow-up in Patients with Chronic Hepatitis C Coinfected with Human Immunodeficiency Virus.",Peg-Interferon Alpha-2A,NR15961,,chronic hepatitis c,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A randomized, open-label study of the effect of PEGASYS combined with ribavirin on sustained virologic response in patients with chronic hepatitis C who did not respond to previous Pegintron/ribavirin combination therapy",Peg-Interferon Alpha-2A,MV17150,NCT00087646,chronic hepatitis c,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT00087646?term=MV17150&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A randomized, open-label study of the effect of PEGASYS and ribavirin combination therapy on sustained virologic response in interferon-naïve patients with chronic hepatitis C genotype 2 or 3 infection",Peg-Interferon Alpha-2A,NV17317,NCT00077636,chronic hepatitis c,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT00077636?term=nv17317&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A randomized, multicenter, double blinded study comparing the safety and efficacy of Pegasys® 180 ug plus Copegus® 1000 or 1200 mg to the currently approved combination of Pegasys® 180 ug plus Copegus® 800 mg in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection and HIV-1",Peg-Interferon Alpha-2A,NV18209,NCT00353418,chronic hepatitis c,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT00353418?term=nv18209&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A Ph II/III seamless adaptive, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and prevention of structural joint damage during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis who have failed  therapy",Tocilizumab,NA22823,NCT01209702,ankylosing spondylitis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01209702?term=NA22823&rank=2,,Y,N,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis",Tocilizumab,NA25220,NCT01232569,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01232569?term=NA25220&rank=3,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis (RA).",Tocilizumab,WA19923,NCT00535782,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00535782?term=WA19923&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"Multi-center, randomized, double-blind, parallel group study of the safety, disease remission & prevention of structural joint damage during treatment with tocilizumab as a monotherapy & in combination with methotrexate versus methotrexate in pts with early moderate to severe rheumatoid arthritis",Tocilizumab,WA19926,NCT01007435,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01007435?term=wa19926&rank=7,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A Phase III multicenter, double blind, placebo controlled, parallel group study of the safety and efficacy of a subcutaneous formulation of tocilizumab administered once or twice weekly versus an intravenous administration of tocilizumab administered once every four weeks.",Tocilizumab,WA22762,NCT01194414,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01194414?term=22762&rank=4,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Roche,"A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis (AS) who have had an inadequate response to previous TNF blocker therapy",Tocilizumab,WA22908,NCT01209689,ankylosing spondylitis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01209689?term=wa22908&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-Feb-2015
Roche,"A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis",Tocilizumab,WA19924,NCT01119859,rheumatoid arthritis,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT01119859?term=wa19924&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Lilly,A Randomized Phase III Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-small Cell Lung Cancer,Pemetrexed,H3E-MC-JMHD,NCT00762034,Nonsquamous Non-small Cell Lung Cancer (NSCLC).,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00762034?term=H3E-MC-JMHD&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Feb-2015
Takeda,"An Open-Label, Parallel-Group Comparison Study of Multiple-Dose Pharmacokinetics of TAK-536 in Hypertensive Patients With Varying Degrees of Renal Impairment",azilsartan,TAK-536/CPH-005,Not available,Hypertension,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-536/CPH-005,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Randomized, Open-Label, Three-Period, Three Treatment, Six Sequence Cross-Over Study to Evaluate the Bioavailability among Three Formulations (10 mg Tablet, 20 mg Tablet and 40 mg Tablet) of TAK-536 in Healthy Male Subjects",azilsartan,TAK-536/CPH-009,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536/CPH-009,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"An Open Label, Randomized, 2-Period Crossover Study to Determine the Effect of Food on the Pharmacokinetics of TAK-536 in Healthy Male Subjects",azilsartan,TAK-536/CPH-011,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536/CPH-011,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A single and multiple dose, double-blind, parallel-group, placebo controlled study to examine the safety, tolerabilit  and pharmacokinetics of TAK-536 in healthy volunteers",azilsartan,TAK-536/EC101,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536/EC101,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-label Study in Hypertensive Patients with Renal Impairment,azilsartan,TAK-536/OCT-002,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536/OCT-002,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,An Open-Label Study in Patients with Grade III Hypertension,azilsartan,TAK-536/OCT-003,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536/OCT-003,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"An Open-Label, Multiple-Dose Study to Assess the Drug Drug Interaction Between TAK-536 and Midazolam, Caffeine, Tolbutamide, Dextromethorphan, and Fexofenadine in Healthy Male and Female Subjects",azilsartan,01-04-TL-536-004,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-536-004,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,The Effect of Multiple Doses of Fluconazole or Ketoconazole on the Single-Dose Pharmacokinetic Profile of TAK-536 in Healthy Subjects,azilsartan,01-04-TL-536-005,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-536-005,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase 1, Open-Label, Randomized, Multiple-Dose, Crossover Study to Assess the Drug-Drug Interaction of TAK-536 and Pioglitazone HCl",azilsartan,01-04-TL-536-006,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-536-006,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase I, Single-Blind, Placebo-Controlled, Randomized, Parallel-Design Study to Evaluate the Possible Effects of Age, Gender, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of TAK-536 in Healthy Adult Subjects",azilsartan,01-05-TL-536-008,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-536-008,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Randomized, Single-Blind, Placebo-Controlled Assessment of the Pharmacokinetics and Pharmacodynamics of Warfarin in the Presence of Multiple Doses of TAK-536 in Healthy Male and Female Subjects",azilsartan,01-05-TL-536-009,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-536-009,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,A Placebo-Controlled Study of the Effect of Multiple Doses of TAK-536 on the Single-Dose Pharmacokinetic Profile of Glyburide in Healthy Adult Subjects,azilsartan,01-05-TL-536-010,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-536-010,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"An Open-Label, Randomized, Multiple-Dose, 3-Period Crossover Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between TAK-536 and Metformin in Healthy Adult Subjects",azilsartan,01-05-TL-536-011,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-536-011,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase 1, Open-Label, Mass Balance and Excretion Study of [14C]TAK-536 Following Oral Administration in Healthy Male Subjects",azilsartan,01-05-TL-536-014,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-536-014,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"An Open-Label, Randomized, Single-Dose, 3-Period Crossover Study to Evaluate the Absolute Bioavailability of TAK-536 and Relative Bioavailability of TAK-491 in Healthy Adult Subjects",azilsartan,01-06-TL-536-016,NCT01289132,Hypertension,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-06-TL-536-016,https://clinicaltrials.gov/ct2/show/NCT01289132?term=NCT01289132,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension",azilsartan,TAK-536/CCT-001,Not available,Hypertension,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-536/CCT-001,https://clinicaltrials.gov/show/NCT01289132,,Y,N,Y,Y,Y,Y,Y,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,A Phase 3 Study of TAK-536 (Comparative Study),azilsartan,TAK-536/CCT-005,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536/CCT-005,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Phase I, Single-dose, Double-Blind, Randomized, Placebo-controlled, Dose-escalation Study to Examine the Safety and Pharmacokinetics of TAK-536 in Healthy Male Subjects in Japan",azilsartan,TAK-536/CPH-001,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536/CPH-001,Not available,,Y,N,Y,Y,Y,N,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase I, Multiple-dose, Double-blind, Randomized, Placebo-controlled, Dose escalation Study to examine the Safety and Pharmacokinetics of TAK-536 in Healthy Male Subjects in Japan",azilsartan,TAK-536/CPH-002,Not available,Hypertension,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-536/CPH-002,Not available,,Y,N,Y,Y,Y,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,A Phase 3 Study of TAK-536 (Long-Term Study) (Up to Week 24),azilsartan/amlodipine,TAK-536/OCT-006,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536/OCT-006,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-536CCB as Compared to Those of TAK-536 Monotherapy and Amlodipine Besilate Monotherapy in Patients with Grade I or II Essential Hypertension",azilsartan/amlodipine,TAK-536CCB/CCT-001,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/CCT-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"An Open-Label, 2-Period Crossover Study to Evaluate the Pharmacokinetic Profiles of TAK-536 and Amlodipine in Fixed-Dose Combination",azilsartan/amlodipine,TAK-536CCB/CPH-001,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/CPH-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Phase 1, Single-Dose, Open-Label, Randomized, 3 Period Crossover Study to Assess the Drug-Drug Interactions of TAK-536 and Amlodipine in Healthy Subjects",azilsartan/amlodipine,TAK-536CCB/CPH-002,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/CPH-002,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Phase 1, Single-Dose, Open-Label, 2-Period Crossover Study to Evaluate the Food- Effect on the Pharmacokinetics and Safety of TAK-536CCB (TAK-536 40 mg/ amlodipine 5 mg) in Healthy Male Subjects",azilsartan/amlodipine,TAK-536CCB/CPH-004,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/CPH-004,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Phase 1, Single-Dose, Open-Label, 2-Period Crossover Study to Evaluate the Food- Effect on the Pharmacokinetics and Safety of TAK-536CCB (TAK-536 20 mg/amlodipine 5 mg) in Healthy Male Subjects",azilsartan/amlodipine,TAK-536CCB/CPH-005,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/CPH-005,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,"A Phase 3, Multicenter, Long-term, Open-label Study to Evaluate the Safety and Efficacy of TAK-536CCB in Patients with Grade I or II Essential Hypertension",azilsartan/amlodipine,TAK-536CCB/OCT-001,Not available,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-536CCB/OCT-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-Jan-2015
Takeda,Effect of Age and Gender on the Pharmacokinetics and Pharmacodynamics of TAK-375 in Healthy Adult Subjects,ramelteon,01-01-TL-375-003,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-003,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,Effect of Food on the Pharmacokinetics of TAK-375 in Healthy Male and Female Subjects,ramelteon,01-01-TL-375-004,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-004,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Efficacy, Safety, and Dose Response Study of TAK-375 in Subjects with Primary Chronic Insomnia",ramelteon,01-01-TL-375-005,Not available,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-005,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four-Period Crossover Evaluation of the Circadian Phase-Shifting Effects of TAK-375 in Normal Subjects",ramelteon,01-01-TL-375-006,Not available,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-006,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"An Open-Label, Crossover, Drug Interaction Study of the Effects of Ketoconazole on the Pharmacokinetics of TAK-375 in Normal, Healthy Male and Female Subjects",ramelteon,01-01-TL-375-007,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-007,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open-Label, Crossover, Drug Interaction Study of the Effects of Fluvoxamine on the Pharmacokinetics of TAK-375 in Normal Male and Female Subjects",ramelteon,01-01-TL-375-008,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-01-TL-375-008,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open-Label, Crossover, Drug Interation Study of the Effects of Fluconazole on the Single-Dose Pharmacokinetics of TAK-375 in Normal Healthy Male and Female Subjects",ramelteon,01-02-TL-375-009,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-009,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase I, Randomized, Single Center Double-blind, Pilot Dose Finding Study of the Acute Effects of TAK-375 On Subjective Ratings and Performance In a Well Characterized Group of Substance Abusers",ramelteon,01-02-TL-375-014,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-014,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse",ramelteon,01-02-TL-375-015,NCT00671632,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-015,https://clinicaltrials.gov/show/NCT00671632,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects With Chronic Insomnia",ramelteon,01-02-TL-375-017,NCT00671294,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-017,https://clinicaltrials.gov/show/NCT00671294,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of Ramelteon in Healthy Subjects",ramelteon,01-02-TL-375-018,NCT00671190,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-018,https://clinicaltrials.gov/show/NCT00671190,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adults With Chronic Insomnia",ramelteon,01-02-TL-375-020,NCT00671567,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-020,https://clinicaltrials.gov/show/NCT00671567,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase III, Randomized, Double-Blind Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults With Chronic Insomnia",ramelteon,01-02-TL-375-021,NCT00671125,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-021,https://clinicaltrials.gov/show/NCT00671125,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase 3, Open-label, Fixed-dose Study to Determine the Safety of Long-term Administration of TAK-375 in Subjects With Chronic Insomnia",ramelteon,01-02-TL-375-022,NCT00671086,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-022,https://clinicaltrials.gov/show/NCT00671086,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia",ramelteon,01-02-TL-375-023,NCT00671398,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-023,https://clinicaltrials.gov/show/NCT00671398,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,A Clinical Study to Investigate the Effect of Multiple Doses of TAK-375 on the Single-Dose Pharmacokinetic Profile of Midazolam in Healthy Adult Subjects,ramelteon,01-02-TL-375-024,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-024,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects With Chronic Insomnia",ramelteon,01-02-TL-375-025,NCT00671255,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-025,https://clinicaltrials.gov/show/NCT00671255,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open Label, Randomized, Three Period Crossover Study to Assess the Drug-Drug Interaction Between TAK-375 and Dextromethorphan in Healthy Female and Male Adult Subjects",ramelteon,01-02-TL-375-026,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-026,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open Label, Multiple Dose, Randomized, Two Period Crossover Study to Assess the Drug-Drug Interaction Between TAK-375 and Theophylline in Healthy Female and Male Adult Subjects",ramelteon,01-02-TL-375-027,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-027,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Pharmacodynamic Drug-Drug Interaction Between TAK-375 and Ethanol in Healthy Adult Subjects",ramelteon,01-02-TL-375-028,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-028,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,Clinical Protocol for a TAK-375 Single and Multiple Dose Pharmacokinetic Evaluation in Subjects With and Without Hepatic Impairment,ramelteon,01-02-TL-375-029,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-029,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,Evaluation of the Single and Multiple Dose Pharmacokinetics of TAK-375 in Subjects With and Without Renal Impairment,ramelteon,01-02-TL-375-030,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-030,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Phase I, Randomized, Double-Blind, Placebo Controlled, Parallel, Multi-Center, Safety Study to Evaluate the Short-Term Effects of TAK-375 on Endocrine Function in Healthy Adult Subjects",ramelteon,01-02-TL-375-031,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-031,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,A Phase III Safety Study to Evaluate the Long-term Effects of TAK-375 on Endocrine Function in Adult Subjects With Chronic Insomnia,ramelteon,01-02-TL-375-032,NCT00656994,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-032,https://clinicaltrials.gov/show/NCT00656994,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open-Label Assessment of the Pharmacokinetics and Pharmacodynamics of Warfarin in the Presence
of Multiple Doses of TAK-375 in Healthy Female and Male Adult Subjects",ramelteon,01-02-TL-375-033,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-02-TL-375-033,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open-Label, Multiple Dose, Drug Interaction Study of the Effects of Fluoxetine on the Pharmacokinetics of TAK 375 in Normal Healthy Male and Female Adult Subjects",ramelteon,01-03-TL-375-034,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-034,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"Phase I, Multiple Dose, Open-Label, Single-Center Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of TAK-375",ramelteon,01-03-TL-375-035,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-035,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"An Open-Label, Randomized, Multiple Dose, Crossover Study to Assess the Steady State Drug-Drug Interaction of Omeprazole with TAK-375",ramelteon,01-03-TL-375-036,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-036,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"Phase I, Open Label, Randomized, Multiple-Dose, Two Period Cross-Over, Single-Center Study to Assess the Effect of TAK-375 on the Pharmacokinetics of Digoxin in Healthy Subjects",ramelteon,01-03-TL-375-037,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-037,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease,ramelteon,01-03-TL-375-038,NCT00672802,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-038,https://clinicaltrials.gov/show/NCT00672802,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Obstructive Sleep Apnea,ramelteon,01-03-TL-375-039,NCT00672061,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-039,https://clinicaltrials.gov/show/NCT00672061,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Randomized, Single-Blind, Crossover, Phase I Evaluation of the Effect of TAK-375 on the QT Interval in Healthy Adult Subjects",ramelteon,01-03-TL-375-040,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-03-TL-375-040,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon in Adult Subjects With Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data",ramelteon,01-04-TL-375-041,NCT00672724,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-041,https://clinicaltrials.gov/show/NCT00672724,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Double-Blind, Randomized, 4-Period Crossover Study to Assess the Pharmacodynamic Interaction Between Ramelteon (TAK-375) 32 mg and Ethanol 0.6 g/kg in Healthy Adult Subjects",ramelteon,01-04-TL-375-043,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-043,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia Symptoms Associated With Eastward Bound Jet Lag Across 5 Time Zones in Healthy Adult Volunteers",ramelteon,01-04-TL-375-045,NCT00492011,Insomnia,Phase 4,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-045,https://clinicaltrials.gov/show/NCT00492011,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Fluvoxamine in Normal Healthy Male and Female Subjects,ramelteon,01-04-TL-375-049,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-049,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Sertraline (Zoloft®) in Normal Healthy Male and Female Subjects,ramelteon,01-04-TL-375-050,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-050,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction between Ramelteon and Venlafaxine (Effexor) in Normal Healthy Male and Female Subjects,ramelteon,01-04-TL-375-051,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-051,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Escitalopram in Normal Healthy Male and Female Subjects,ramelteon,01-04-TL-375-052,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-052,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Gabapentin in Normal Healthy Male and Female Subjects,ramelteon,01-05-TL-375-054,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-054,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study to Evaluate the Safety and Efficacy of ROZEREM™ Taken in Combination With Gabapentin for the Treatment of Subjects With Chronic Insomnia",ramelteon,01-05-TL-375-055,NCT00755508,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-055,https://clinicaltrials.gov/show/NCT00755508,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Donepezil in Normal Healthy Male and Female Subjects,ramelteon,01-05-TL-375-056,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-056,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,A Study of the Safety of Ramelteon in Elderly Subjects,ramelteon,01-05-TL-375-060,NCT00568789,Insomnia,Phase 4,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-060,https://clinicaltrials.gov/show/NCT00568789,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects",ramelteon,01-05-TL-375-061,NCT00325728,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-061,https://clinicaltrials.gov/show/NCT00325728,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon and Doxepin in Normal Healthy Male and Female Subjects,ramelteon,01-05-TL-375-066,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-066,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination With Doxepin for the Treatment of Subjects With Chronic Insomnia",ramelteon,01-05-TL-375-067,NCT00755495,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-067,https://clinicaltrials.gov/show/NCT00755495,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,A Study of the Safety of Ramelteon in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease,ramelteon,01-05-TL-375-068,NCT00316992,Insomnia,Phase 4,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-068,https://clinicaltrials.gov/show/NCT00316992,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep Questionnaire - Interactive Voice Response System (PSQ-IVRS) in an ""At-Home Setting"" in an Adult Population With Chronic Insomnia",ramelteon,01-05-TL-375-069,NCT00414102,Insomnia,Phase 4,http://takedaclinicaltrials.com/browse/summary/01-05-TL-375-069,https://clinicaltrials.gov/show/NCT00414102,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-Label Study to Assess the Drug-Drug Interaction Between Ramelteon 8 mg and Zolpidem 10 mg in Healthy Male and Female Subjects,ramelteon,01-06-TL-375-070,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-375-070,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"Randomized, Double Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien®) ≥10 mg Therapy in Subjects With Chronic Insomnia",ramelteon,01-06-TL-375-071,NCT00492232,Insomnia,Phase 4,http://takedaclinicaltrials.com/browse/summary/01-06-TL-375-071,https://clinicaltrials.gov/show/NCT00492232,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"An Open-Label, Randomized, 3-Period, 6-Sequence Crossover Study to Determine the Relative Bioavailability of 8 mg Ramelteon and 3 and 6 mg Doxepin When Coadministered Individually and Administered as Combination Tablets",ramelteon,01-06-TL-375-072,Not available,Insomnia,Phase 1,Not available,Not available,,N,Y,N,N,Y,N,N,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"An Open-Label Randomized, 3-Period 6-Sequence Crossover Study to Determine the Relative Bioavailability of 4 mg Ramelteon and 400 mg Gabapentin When Coadministered Individually and Administered as Combination Tablets",ramelteon,01-06-TL-375-073,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/01-06-TL-375-073,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia",ramelteon,01-06-TL-375-081,"NCT00756002
01-06-TL-375-081",Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/01-06-TL-375-081,https://clinicaltrials.gov/show/NCT00756002,https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000403-15/GB,Y,Y,Y,N,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase I, Randomised, Double-Blind, Placebo-Controlled, Ascending, Multiple Oral Dose Pharmacokinetic, Safety, Tolerability and Pharmacodynamic Study of TAK-375 in Healthy Adult Volunteers",ramelteon,TAK-375/EC002,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC002,Not available,,Y,Y,Y,Y,Y,Y,N,,1-Jan-2015
Takeda,"TAK-375 - A Phase I, Open-Label, Randomised, Balanced, Two-Period Crossover Study to Investigate the Absolute Bioavailability of a Single Oral Dose in Healthy Male Subjects",ramelteon,TAK-375/EC003,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC003,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"(14C)-TAK-375 - A Phase I, Open-Label Study of the Absorption, Metabolism and Excretion following a Single Oral Dose to Healthy Male Subjects",ramelteon,TAK-375/EC004,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC004,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Study to Investigate the Residual Effects of Ramelteon (8 mg), Zopiclone (7.5 mg) and Placebo on Actual Driving, Memory, Psychomotor Performance and Mood",ramelteon,TAK-375/EC103,NCT00319215,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC103,https://clinicaltrials.gov/show/NCT00319215,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,An Open-Label Study to Assess the Pharmacokinetic Drug-Drug Interaction Between Ramelteon and Lorazepam in Normal Healthy Male and Female Subjects,ramelteon,TAK-375/EC105,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC105,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"The Effect of Ramelteon (TAK-375) on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol (30 μg) and Levonorgestrel (150 μg) [Microgynon 30®], in Healthy Adult Female Subjects",ramelteon,TAK-375/EC106,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC106,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ramelteon Compared to Placebo With Zopiclone as a Reference Arm in Adults With Chronic Insomnia",ramelteon,TAK-375/EC301,"NCT00237497
2004-004350-91",Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC301,https://clinicaltrials.gov/show/NCT00237497,https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004350-91/GB,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Randomised, Double-blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia",ramelteon,TAK-375/EC302,"NCT00247390
2004-004351-20",Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/EC302,https://clinicaltrials.gov/show/NCT00247390,https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004351-20/DE,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Takeda,"A Phase 3, Single-Blind, Flexible Titration Study to Determine the Safety of Long-Term administration of TAK-375 in Subjects with Chronic Insomnia",ramelteon,TAK-375/OCT-002,Not available,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/OCT-002,Not available,,N,N,Y,N,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,"A Randomized, Double-Blind Placebo-Controlled, Ascending Single-Dose, Safety, Tolerance and Pharmacokinetic Study of Five Doses of TAK-375 in Healthy Adult Volunteers",ramelteon,TAK-375/PNFP-001,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/PNFP-001,Not available,,Y,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jan-2015
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Single-Dose First Night Effect Sleep Laboratory Study of Two Doses of TAK-375 in Healthy Adult Volunteers",ramelteon,TAK-375/PNFP-002,Not available,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-375/PNFP-002,Not available,,N,Y,Y,N,Y,N,Y,,1-Jan-2015
Takeda,"A Comparative Single Dose Pharmacokinetic and Safety Study of 4 or 8 mg Ramelteon in Adolescents with Insomnia Characterized by Difficulty with Sleep Onset, Children with Insomnia Associated with ADHD, and Healthy Adults",ramelteon,TAK-375_110,NCT00914862,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375_110,https://clinicaltrials.gov/show/NCT00914862,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2015
Astellas,"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects with Symptoms of Overactive Bladder.",mirabegron,178-CL-049,NCT00688688,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=25,https://clinicaltrials.gov/ct2/show/NCT00688688,,Y,Y,Y,Y,Y,Y,Y,Extension study of 178-cl-046 and 178-cl-047.,1-Feb-2015
Astellas,"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive bladder.",mirabegron,178-CL-074,NCT00912964,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=26,https://clinicaltrials.gov/ct2/show/NCT00912964,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Astellas,"A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy.",mirabegron,178-EC-001,NCT01638000,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=27,https://clinicaltrials.gov/ct2/show/NCT01638000,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Astellas,"A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.",mirabegron,178-CL-046,NCT00689104,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=35,https://clinicaltrials.gov/ct2/show/NCT00689104,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Astellas,"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.",mirabegron,178-CL-047,NCT00662909,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=36,https://clinicaltrials.gov/ct2/show/NCT00662909,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Astellas,"A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.",solifenacin succinate + tamsulosin,905-CL-055,NCT01018511,Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=38,https://clinicaltrials.gov/ct2/show/NCT01018511,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Astellas,"An open-label, long term, multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.",solifenacin succinate + tamsulosin,905-CL-057,NCT01021332,Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=39,https://clinicaltrials.gov/ct2/show/NCT01021332,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Sanofi,Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years,Quadrivalent Inactivated Influenza vaccine - intradermal,QID01,NCT01712984,"Influenza infection;  Influenza, Human",Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/QID01_Report_Summary.pdf,http://www.clinicaltrials.gov/ct2/show/study/NCT01712984?term=QID01&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jan-2015
GSK,"A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/099,,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/217744/099,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",759346/002,NCT00317174,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759346/002,http://clinicaltrials.gov/show/NCT00317174,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix™-HBV, its non-inferiority to Tritanrix™-HBV/Hiberix™ with or without Meningitec™, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",100480,NCT00317161,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100480,http://clinicaltrials.gov/show/NCT00317161,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Study to assess immunogenicity and non-inferiority of investigational vaccination regimen as compared to Tritanrix-HepB/Hiberix and as compared to Meningitec when administered to healthy infants,"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",100791,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,"http://www.gsk-clinicalstudyregister.com/study/100480, 759346/004 & 100791",,,Y,N,Y,Y,Y,Y,Y,The results of this study 100791 are summarised with 100480 and 759346/004 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",101222,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101222,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Study to assess the lot-to-lot consistency of the production method of GSK Biologicals' DTPw-HBV/ Hib Kft. vaccine and to compare to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",101223,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101223,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®.","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/039,NCT00406211,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/039,http://clinicaltrials.gov/show/NCT00406211,,Y,N,Y,Y,Y,Y,Y,This is a Year 1 follow up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/040,,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/040,,,Y,N,Y,Y,Y,Y,Y,This is a Year 2  follow up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/041,,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/041,,,Y,N,Y,Y,Y,Y,Y,This is a Year 3 follow up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,Immunogenicity & safety study of GSK Biologicals’ 208136 vaccine formulated with new measles and rubella working seeds,"Combined Measles, Mumps, Rubella, Varicella Vaccine",108760,NCT00892775,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108760,http://clinicaltrials.gov/show/NCT00892775,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/038,,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/038,,,Y,N,Y,Y,Y,Y,Y,"Follow on studies 208136/039, 208136/040, and 208136/041 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Feb-2015
GSK,"Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",113055,NCT01147900,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/113055,http://clinicaltrials.gov/show/NCT01147900,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ Boostrix™ vaccine using a new syringe presentation in healthy adolescents aged 10–15 years,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",114778,NCT01362322,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114778,http://clinicaltrials.gov/show/NCT01362322,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age)","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",776423/001,NCT00109330,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/776423/001,http://clinicaltrials.gov/show/NCT00109330,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Evaluation of GSK Biologicals’ Boostrix™ Polio in healthy adults, 10 years after a booster vaccination","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine",113060,NCT01323959,Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/113060,http://clinicaltrials.gov/show/NCT01323959,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 4 and 12 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",113615,NCT01090453,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Neisseria Meningitidis; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113615,http://clinicaltrials.gov/show/NCT01090453,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) when administered in children,Influenza Vaccine (Quadrivalent),116926,NCT01711736,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116926,http://clinicaltrials.gov/show/NCT01711736,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ cell culture derived pandemic influenza vaccines GSK2590066A and GSK2592984A administered to healthy adults 18 - 49 years old,GSK2590066A,114371,NCT01236040,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114371,http://clinicaltrials.gov/show/NCT01236040,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Safety and immunogenicity study of a prime-boost schedule of GSK Biologicals' influenza vaccine GSK1562902A in children aged 3 to 17 years,Influenza Vaccine,115115,NCT01379937,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115115,http://clinicaltrials.gov/show/NCT01379937,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,A Phase IIIA study of immunogenicity and safety of GSK Biologicals’ quadrivalent split virion influenza vaccine FLU-Q-QIV in adults aged 18 years and older,Influenza Vaccine,115418,NCT01440387,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115418,http://clinicaltrials.gov/show/NCT01440387,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™,H1N1 Pandemic Influenza Vaccine,114451,NCT01196026,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114451,http://clinicaltrials.gov/show/NCT01196026,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM,H1N1 Pandemic Influenza Vaccine,114452,NCT01190215,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114452,http://clinicaltrials.gov/show/NCT01190215,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in children aged 10 to less than 18 years,H1N1 Pandemic Influenza Vaccine,113883,NCT01035749,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113883,http://clinicaltrials.gov/show/NCT01035749,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,A study to evaluate the safety and efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children aged 6 months to less than 10 years of age,H1N1 Pandemic Influenza Vaccine,114000,NCT01051661,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114000,http://clinicaltrials.gov/show/NCT01051661,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Safety and immunogenicity of monovalent H5N1 vaccine GSK1557484A in children 6 months to < 18 years of age,H5N1 Pandemic Influenza Vaccine,114464,NCT01310413,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114464,http://clinicaltrials.gov/show/NCT01310413,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological’s Hiberix vaccine, extemporaneously mixed with GSK Biological’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age",Haemophilus influenzae Type b Vaccine,759346/009,,Haemophilus influenzae type b,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759346/009,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"Persistence of antibodies after full vaccination course with GSK Biologicals’ Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age","Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine",112830,NCT00891176,Haemophilus influenzae type b; Neisseria Meningitidis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112830,http://clinicaltrials.gov/show/NCT00891176,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline (GSK) Biologicals' combined hepatitis A / hepatitis B vaccine in healthy adult volunteers.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/118 (Ext-HAB-032 Month 120),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/118,,,Y,N,Y,Y,Y,Y,Y,"This is a follow-up study of 208127/022. Follow on studies 100556, 100557, 100558, 100560, and 112266 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Feb-2015
GSK,"Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose",twinrix,208127/132,NCT00197184,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/132 (EXT Y2),http://clinicaltrials.gov/show/NCT00197184,,Y,N,Y,Y,Y,Y,Y,"This is a long-term follow-up study to 208127/120. The results of this study 208127/132 are summarised with studies 208122/133, 208127/134 and 208127/137 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2015
GSK,"Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose",twinrix,208127/134,NCT00197184,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/132 (EXT Y2),http://clinicaltrials.gov/show/NCT00197184,,Y,N,Y,Y,Y,Y,Y,"This is a long-term follow-up study to 208127/120. The results of this study 208127/134 are summarised with studies 208127/132, 208127/133 and 208127/137 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2015
GSK,"Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose",twinrix,208127/137,NCT00197184,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/132 (EXT Y2),http://clinicaltrials.gov/show/NCT00197184,,Y,N,Y,Y,Y,Y,Y,This is a long-term follow-up study to 208127/120. The results of this study 208127/137 are summarised with studies 208127/132 and 208127/134 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"An open, multicentric, post-marketing surveillance study of GlaxoSmithKline Biologicals’ combined hepatitis A-hepatitis B vaccine (Twinrix™), injected as a three dose primary vaccination course according to the prescribing information, in healthy children and adults.",twinrix,208127/127 (HAB-127),,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208127/127,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A/hepatitis B vaccine in healthy children between 6 and 15 years of age.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",101040 (HAB-164 Ext-038 Y10),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101040,,,Y,N,Y,Y,Y,Y,Y,This is a 10 year follow-up of primary study HAB-038. A 90 month follow-up study 208127/125 was also conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A phase III, open, randomized, multicentre study to demonstrate the non-inferiority of GSK Biologicals' combined hepatitis A and hepatitis B vaccine according to a 0-1-6 month schedule, to the monovalent hepatitis A vaccine Havrix and hepatitis B vaccine Engerix separately administered, in healthy adults","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",101377,,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101377,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age","Hepatitis A Vaccine, Inactivated",208109/220,NCT00197002,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208109/220,http://clinicaltrials.gov/show/NCT00197002,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age","Hepatitis A Vaccine, Inactivated",208109/231,NCT00197015,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208109/231,http://clinicaltrials.gov/show/NCT00197015,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age,"Hepatitis A Vaccine, Inactivated",208109/232,NCT00197236,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208109/232,http://clinicaltrials.gov/show/NCT00197236,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Study to assess immunogenicity and reactogenicity of a booster dose of GSK Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to concomitant administration of CSL’s DTPw vaccine and GSK Biologicals' hepatitis B vaccine at separate injection sites and to GSK Biologicals' DTPw-HB vaccine,"Hepatitis B Vaccine, Recombinant",102144,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/102144,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A phase III, partially double blind, randomized, multicentric study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to Commonwealth Serum Laboratory’s (CSL’s) DTPwCSL (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B) administered concomitantly at separate injection sites and to GSK Biologicals’ DTPw-HB vaccine (Tritanrix™-HepB) when administered to healthy infants at 3, 4 and 5 months of age","Hepatitis B Vaccine, Recombinant",196131/001,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/196131/001,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine.","Hepatitis B Vaccine, Recombinant",104021,NCT00158756,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/104021,http://clinicaltrials.gov/show/NCT00158756,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase III, clinical trial comparing the immunogenicity and safety of SmithKline Beecham Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B, in pre-haemodialysis/haemodialysis patients (>=15 years of age)","Hepatitis B Vaccine, Recombinant",208129/047,NCT00383227,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208129/032,http://clinicaltrials.gov/show/NCT00383227,,Y,N,Y,Y,Y,Y,Y,The results of this study 208129/047 are summarised with 208129/032 and 208129/042 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Efficacy, immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV GSK 580299 vaccine in healthy Chinese female subjects",Human Papillomavirus Types 16 and 18 Vaccine,107638,NCT00779766,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/107638,http://clinicaltrials.gov/show/NCT00779766,,Y,Y,Y,Y,Y,Y,Y,A follow-up study 114590 was conducted.,1-Feb-2015
GSK,Long-term extension study of the efficacy of the 580299 vaccine in the prevention of HPV-16 and/or HPV-18 associated cervical intraepithelial neoplasia (CIN) in Japanese women vaccinated in the primary vaccination study NCT00316693,Human Papillomavirus Types 16 and 18 Vaccine,112949,NCT00929526,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112949,http://clinicaltrials.gov/show/NCT00929526,,Y,N,Y,Y,Y,Y,Y,This is a long-term follow-up study to 104798. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate adjuvanted vaccine in an elderly population aged over 65 years previously vaccinated in 2004 with the same candidate vaccine",Influenza Vaccine,104540,NCT00318058,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/104540,http://clinicaltrials.gov/show/NCT00318058,,Y,Y,Y,Y,Y,Y,N,A RAP is not available for this study.,1-Feb-2015
GSK,Demonstrate the non-inferiority in term of cellular mediated immune response of GSK Biologicals' influenza candidate vaccines containing various adjuvants administered in elderly population (aged 65 years & older) vs Fluarix™ (known as alpha-Rix™ in Belgium) administered in adults (18-40 years),Influenza Vaccine,104886,NCT00318149,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104886,http://clinicaltrials.gov/show/NCT00318149,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Evaluate reactogenicity & immunogenicity of adjuvanted influenza vaccine in elderly adults previously vaccinated with the same candidate vaccine. Fluarix™ administered in young & elderly adults will be used as reference,Influenza Vaccine,104887,NCT00386698,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104887,http://clinicaltrials.gov/show/NCT00386698,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™",Influenza Vaccine,104888,NCT00377585,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104888,http://clinicaltrials.gov/show/NCT00377585,,Y,N,Y,Y,Y,Y,Y,A follow-on study 107509 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™",Influenza Vaccine,107509,NCT00377585,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104888,http://clinicaltrials.gov/show/NCT00377585,,Y,N,Y,Y,Y,Y,Y,This is a follow-on study to 104888. The results of this study 107509 are summarised with study 104888 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months,"Influenza Vaccine (Split Virion, Inactivated)",114294,NCT01195779,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114294,http://clinicaltrials.gov/show/NCT01195779,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ influenza split vaccine FLUARIX™ administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination,"Influenza Vaccine (Split Virion, Inactivated)",218352/054,NCT00750360,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/218352/054,http://clinicaltrials.gov/show/NCT00750360,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",134612/003,NCT00196950,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/003,http://clinicaltrials.gov/show/NCT00196950,,Y,N,Y,Y,Y,Y,Y,"Follow-up studies 102252, 102253, and 102254 were conducted. The results of this study 134612/003 are summarised with studies 102252, 102253, and 102254 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2015
GSK,"Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",102254,NCT00196950,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/003,http://clinicaltrials.gov/show/NCT00196950,,Y,N,Y,Y,Y,Y,Y,"This is a year 3 follow-up study to 134612/003. The results of this study 102254 are summarised with studies 134612/003, 102252, and 102253 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2015
GSK,"A primary vaccination study to assess the immunogenicity, safety & reactogenicity of 1 dose of 4 different formulations of GSK Biologicals’ meningococcal conjugate vaccine (MenACWY) vs 1 dose of MENCEVAX™ ACWY in healthy subjects aged 15-19 years","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",104702,NCT00126945,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104702,http://clinicaltrials.gov/show/NCT00126945,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Persistence of antibodies after GSK Biologicals’ meningococcal vaccine GSK134612 in toddlers,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",112036,NCT00955682,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112036,http://clinicaltrials.gov/show/NCT00955682,,Y,N,Y,Y,Y,Y,Y,This is a follow up study to 109670. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,The long term antibody persistence study of GSK Biologicals’ meningococcal vaccine GSK 134612 administered as 1 or 2 doses to healthy toddlers at 9-12 months of age and as a booster dose at 5 years post-primary vaccination,"Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",112021,NCT00718666,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112021,http://clinicaltrials.gov/show/NCT00718666,,Y,N,Y,Y,Y,Y,Y,This is a follow-up study to 109375. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Phase IIIb immunogenicity, safety and reactogenicity study of GSK Biologicals’ meningococcal vaccine [GSK 134612] when given as one dose to healthy subjects aged 56 years or older","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",113807,NCT01235975,"Infections, Meningococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113807,http://clinicaltrials.gov/show/NCT01235975,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,COMPAS: A phase III study to demonstrate efficacy of GSK Biologicals' 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),109563,NCT00466947,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109563,http://clinicaltrials.gov/show/NCT00466947,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111346,NCT00624819,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111346,http://clinicaltrials.gov/show/NCT00624819,,Y,N,Y,Y,Y,Y,Y,This is a Year 2 follow up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age.,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111347,NCT00624819,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111347,http://clinicaltrials.gov/show/NCT00624819,,Y,N,Y,Y,Y,Y,Y,This is a Year 4 follow up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"Immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ pneumococcal vaccine GSK1024850A following primary and booster vaccination of healthy Japanese children",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112640,NCT01027845,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112640,http://clinicaltrials.gov/show/NCT01027845,,Y,N,Y,Y,Y,Y,Y,This is a follow up study to 105553. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,Booster vaccination with pneumococcal vaccine GSK1024850A in primed children and catch-up vaccination in unprimed children,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112909,NCT01030822,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112909,http://clinicaltrials.gov/show/NCT01030822,,Y,Y,Y,Y,Y,Y,Y,This is a booster study of 111188.,1-Feb-2015
GSK,"A study to compare the safety, reactogenicity & immunogenicity of GSK Biologicals pneumococcal vaccines vs the licensed 23-valent pneumococcal polysaccharide vaccine, in healthy elderly subjects",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),106068,NCT00327665,"Infections, Streptococcal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/106068,http://clinicaltrials.gov/show/NCT00327665,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2015
GSK,"A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes",rosiglitazone,49653/183,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/183,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus",rosiglitazone,AXR100723,,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/100723,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy",rosiglitazone,49653/135,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/135,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis).",rosiglitazone,49653/136,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/136,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.",rosiglitazone,49653/140,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/140,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg once daily) in Combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy",rosiglitazone,49653/143,NCT00333723,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/143,http://clinicaltrials.gov/show/NCT00333723,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
GSK,"A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA when added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy when Administered to Subjects with Type 2 Diabetes Mellitus",rosiglitazone,49653/284,NCT00501020,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/284,http://clinicaltrials.gov/show/NCT00501020,,Y,Y,Y,Y,Y,N,Y,An analysis-ready dataset is not available for this study.,1-Feb-2015
GSK,"A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients with Type 2 Diabetes Mellitus",rosiglitazone,49653/326,NCT00044460,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/326,http://clinicaltrials.gov/show/NCT00044460,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
GSK,A Double-Blind Feasibility Study to Estimate and Compare the Effect of Rosiglitazone in Parallel with Glyburide on Cognition in Patients with Type 2 Diabetes Mellitus,rosiglitazone,BRL-049653/282,,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/282,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.",rosiglitazone,BRL-049653/375,NCT00197132,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/375,http://clinicaltrials.gov/show/NCT00197132,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Feb-2015
GSK,A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects.,rosiglitazone/glimepiride,797620/001,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/797620/001,,,Y,N,Y,Y,Y,Y,Y,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects",rosiglitazone/glimepiride,797620/003,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/797620/003,,,Y,N,Y,Y,Y,Y,Y,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus",rosiglitazone/glimepiride,797620/004,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/797620/004,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,A Bioequivalence Study with a Combination Tablet Formulation of Rosiglitazone and Metformin (4mg/1000mg) Compared to the Commercial Tablet Formulation of AVANDAMET (2mg rosiglitazone/500mg metformin) and a Dose Proportionality Study Comparing the Combination Tablet Formulations of Rosiglitazone and Metformin (4mg/1000mg & 2mg/1000mg).,rosiglitazone/metformin,SB-712753/001,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/712753/001,,,Y,N,Y,Y,Y,N,Y,A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,"A study to estimate the pharmacokinetics of six extended release formulations of AVANDAMET (rosiglitazone maleate 4mg / metformin HCl 1000mg), compared to the commercial formulation of AVANDAMET (rosiglitazone maleate 2mg / metformin HCl 500mg, q12h), and concomitant dosing of Glucophage XR (metformin HCl 2 × 500mg) with AVANDIA (rosiglitazone maleate 4mg)",rosiglitazone/metformin,SB-712753/012,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/712753/012,,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Feb-2015
GSK,Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine,Varicella Vaccine,100388,NCT00226499,Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100388,http://clinicaltrials.gov/show/NCT00226499,,Y,N,Y,Y,Y,Y,Y,"Follow up studies 103494,104105, and 104106 were conducted. The results of this study 100388  are summarized with studies 103494, 104105,  and 104106 on the GSK Clinical Study Register. An annotated case report form is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2015
Roche,An open-label study of the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant patients,valganciclovir,WV16726,NCT00090766,cytomegaloviral disease,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00090766?term=wv16726&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder",Duloxetine hydrochloride,F1J-MC-HMCK,NCT00849901,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00849901?term=F1J-MC-HMCK&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder",Duloxetine hydrochloride,F1J-MC-HMCL,NCT00849693,Major Depressive Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00849693?term=F1J-MC-HMCL&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China,Duloxetine hydrochloride,F1J-MC-HMFJ,NCT00803361,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00803361?term=F1J-MC-HMFJ&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Mar-2015
Lilly,A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder,Duloxetine hydrochloride,F1J-MC-HMFL,NCT00960986,Major Depressive Disorder,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00960986?term=F1J-MC-HMFL&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Mar-2015
Lilly,Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain,Duloxetine hydrochloride,F1J-MC-HMGC,NCT00767806,Chronic Lower Back Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00767806?term=F1J-MC-HMGC&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,"A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia",Duloxetine hydrochloride,F1J-MC-HMGG,NCT00965081,Fibromyalgia,Phase 4,Not available,http://clinicaltrials.gov/ct2/show/NCT00965081?term=F1J-MC-HMGG&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Mar-2015
Lilly,"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder",Duloxetine hydrochloride,F1J-MC-HMGI,NCT01226511,Anxiety Disorder,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT01226511?term=F1J-MC-HMGI&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,"A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study",Duloxetine hydrochloride,F1J-MC-HMGP,NCT00945945,Osteoarthritis Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT00945945?term=F1J-MC-HMGP&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Mar-2015
Lilly,Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo,Duloxetine hydrochloride,F1J-MC-HMGV,NCT01179672,Diabetic Peripheral Neuropathic Pain,Phase 3,Not available,http://clinicaltrials.gov/ct2/show/NCT01179672?term=F1J-MC-HMGV&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Mar-2015
Lilly,Pharmacological Treatment of Fluoxetine-Associated Sexual Dysfunction,Fluoxetine,B1Y-MC-HCKB,Not available,Fluoxetine-Associated Sexual Dysfunction,Phase 4,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
Lilly,Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis,Raloxifene,H3S-MC-GGGK,NCT00670319,Osteoporosis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00670319?term=NCT00670319&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events (Ruth: Raloxifen Use for The Heart),Raloxifene,H3S-MC-GGIO,NCT00190593,Risk Reduction of Invasive Breast Cancer in Postmenopausal Women; Cardiovascular Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00190593?term=NCT00190593&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer,Raloxifene,H3S-MC-GGIY,Not available,Risk Reduction of Invasive Breast Cancer in Postmenopausal Women,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
Lilly,Continuing Outcomes Relevant to Evista® (CORE): A Study of Raloxifene HCl and Placebo In the Prevention of Invasive Breast Cancer In Postmenopausal Women With Osteoporosis,Raloxifene,H3S-MC-GGJY,Not available,Risk Reduction of Invasive Breast Cancer in Postmenopausal Women,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
Lilly,A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men,Testosterone MD-Lotion,I5E-MC-TSAH (MTE08),NCT00702650,Hypogonadism,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00702650?term=NCT00702650&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Lilly,A Phase III open-label extension of the MTE08 trial (A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men) to evaluate skin-safety,Testosterone MD-Lotion,I5E-MC-TSAI (MTE09),NCT00857454,Hypogonadism,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00857454?term=NCT00857454&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Takeda,"An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Liposomal Muramyltripeptide Phosphatidylethanolamine (L-MTP-PE) in Subjects with Mild or Moderate Chronic Renal Insufficiency Compared to Healthy, Adult Subjects",mifamurtide,C23001,Not available,Osteosarcoma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C23001,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Takeda,"An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Liposomal Muramyltripeptide Phosphatidylethanolamine (L-MTP-PE) in Subjects With Mild or Moderate Chronic Hepatic Impairment Compared to Healthy, Adult Subjects",mifamurtide,C23002,Not available,Osteosarcoma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C23002,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2015
Boehringer Ingelheim,BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC),afatinib,1200.34,NCT01121393,"Carcinoma, Non-Small-Cell Lung; Adenocarcinoma",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01121393?term=1200.34&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours,afatinib,1200.37,NCT00716417,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00716417?term=1200.37&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.,afatinib,1200.68,NCT00950742,Breast Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00950742?term=1200.68&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours,afatinib,1200.92,NCT01169675,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01169675?term=1200.92&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients,afatinib,1200.41,NCT00730925,"Carcinoma, Non-Small-Cell Lung",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00730925?term=1200.41&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer,afatinib,1200.74,NCT01152437,Colorectal Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01152437?term=1200.74&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients,afatinib,1200.4,NCT00796549,"Carcinoma, Non-Small-Cell Lung",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00796549?term=1200.40&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab,afatinib,1200.44,NCT00826267,Breast Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00826267?term=1200.44&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM),empagliflozin,1245.15,NCT00885118,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00885118?term=1245.15&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes,empagliflozin,1245.4,NCT00558571,"Diabetes Mellitus, Type 2",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00558571?term=1245.4&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment",empagliflozin,1245.12,NCT01907113,"Diabetes Mellitus, Type 2",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01907113?term=1245.12&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,linagliptin,1218.64,NCT01087502,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01087502?term=1218.64&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes",linagliptin,1218.83,NCT01512979,"Diabetes Mellitus, Type 2",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01512979?term=1218.83&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,olodaterol,1222.52,NCT01696058,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01696058?term=1222.52&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,olodaterol,1222.51,NCT01694771,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01694771?term=1222.51&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Boehringer Ingelheim,Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis,tiotropium bromide,205.339,NCT00737100,Cystic Fibrosis,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00737100?term=205.339&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects",albiglutide,GLP108366,NCT01147692,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/108366,http://clinicaltrials.gov/show/NCT01147692,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide,albiglutide,GLP114856,NCT01357889,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114856,http://clinicaltrials.gov/show/NCT01357889,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A multi-center, randomised, parallel-group, double-blind, placebo-controlled one year study (with a 7 week Treatment Phase) to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) versus placebo as an aid to smoking cessation in a population of smokers with established, stable cardiovascular disease",bupropion,ZYB40014,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40014,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 346) and A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 347)",carvedilol,346/347 (GEMINI),,Hypertension,Phase 4,http://www.gsk-clinicalstudyregister.com/study/105517/346; 105517/347,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)",cilomilast,207499/181,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/181,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)",cilomilast,207499/168,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/168,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD)",cilomilast,207499/157,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/157,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).",cilomilast,207499/156,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/156,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD)",cilomilast,207499/041,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/041,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).",cilomilast,207499/040,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/207499/040,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects.",darotropium bromide,AC2105333,NCT00376714,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/AC2105333,http://clinicaltrials.gov/show/NCT00376714,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease",darotropium bromide,AC2106956,NCT00422604,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/AC2106956,http://clinicaltrials.gov/show/NCT00422604,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.",darotropium bromide,AC2111509,NCT00671216,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/DB1111509,http://clinicaltrials.gov/show/NCT00671216,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"A single-centre, randomised, double-blind placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic and urinary pharmacokinetics of GSK233705 administered twice daily for 14 days in healthy male subjects",darotropium bromide,AC2105331,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105331,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy Japanese subjects",darotropium bromide; vilanterol; darotropium bromide/vilanterol,DB1112146,NCT00783003,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112146,http://clinicaltrials.gov/show/NCT00783003,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3),denagliptin,DPB102761,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/102761,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety And Preliminary Efficacy of Neoadjuvant Therapy With GI198745 in Subjects With Localized Prostate Cancer Undergoing Radical Prostatectomy.",dutasteride,ARIA2003,,"Neoplasms, Prostate",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ARIA2003,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A double blind, placebo controlled, single dose, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled reformulated FP (TIBAC) in comparison with the standard formulation FP.",fluticasone propionate,FPR10001,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FPR10001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A randomised, double blind, placebo controlled, cross over study to investigate the duration of action of inhaled doses of Fluticasone Propionate (1000mg) on airway responsiveness to adenosine-5'-monophosphate (AMP) in mild asthmatic patients",fluticasone propionate,FPR10006,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FPR10006,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler.",fluticasone propionate,FLIQ51 / DENB3002 / (FAS400012),,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FAS40012,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants",fluticasone propionate,FAP10006,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAP10006,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma,fluticasone propionate,FAP19052,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAP19052,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma.,fluticasone propionate,FAP19058,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAP19058,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks",fluticasone propionate,FAS10002,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FAS10002,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma",fluticasone propionate/salmeterol,SAS101877,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/101877,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics",fluticasone propionate/salmeterol,SAS10017,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10017,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?",fluticasone propionate/salmeterol,FAS40008 double blind period (1 year),,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/FAS40008,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults",fluticasone propionate/salmeterol,SAM40008,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40008,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) 50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4- 11 years with asthma",fluticasone propionate/salmeterol,SAM40012,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40012,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma",fluticasone propionate/salmeterol,SAM40062,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM40062,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC, 100/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma",fluticasone propionate/salmeterol,SAS40024,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40024,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC 250/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma",fluticasone propionate/salmeterol,SAS40025,,Bronchospasm,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAS40025,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria.",naratriptan,S2W20006,,Migraine Disorders and Premenstrual Syndrome,Phase 4,http://www.gsk-clinicalstudyregister.com/study/S2W20006,,,N,Y,N,Y,Y,Y,Y,"An analysis-ready dataset is not available for this study. A Clinical Study Report is not available for this study because only a draft version was located, no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures","retigabine, ezogabine",VRX-RET-E22-301,NCT00232596,Seizures,Phase 3,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-301,http://clinicaltrials.gov/show/NCT00232596,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
GSK,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures","retigabine, ezogabine",VRX-RET-E22-302,NCT00235755,Seizures,Phase 3,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-302,http://clinicaltrials.gov/show/NCT00235755,,Y,Y,Y,Y,Y,Y,Y,A follow-on study VRX-RET-E22-304 was conducted,1-Mar-2015
GSK,"A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy","retigabine, ezogabine",3065A1-216-EU/US,,Seizures,Phase 2,http://www.gsk-clinicalstudyregister.com/study/3065A1-216,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy","retigabine, ezogabine",3065A1-205,,Seizures,Phase 2/3,http://www.gsk-clinicalstudyregister.com/study/3065A1-205,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects,"retigabine, ezogabine",3065a1-123,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/3065A1-123,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers,"retigabine, ezogabine",3065A1-117,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/3065A1-117,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2),"retigabine, ezogabine",3065A1-115,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/3065A1-115,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes",rosiglitazone,049653/109,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/109,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.  A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Study to Examine the Effects of Alucol® , a Combination Magnesium/Aluminum Hydroxide-Containing Antacid, on the Pharmacokinetics of Rosiglitazone (8 mg).",rosiglitazone,49653/224,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/224,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Double-Blind Study to Assess the Effect of Rosiglitazone (RSG) on the Pharmacodynamics and Pharmacokinetics of Acenocoumerol in Healthy Male Volunteers,rosiglitazone,49653/225,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/225,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Study to Estimate the Effect of Repeat Oral Doses of Rosiglitazone (8 mg) on the Pharmacokinetics of Glimepiride (4 mg) and the Effect of a Single Oral Dose of Glimepiride (4 mg) on the Pharmacokinetics of Rosiglitazone (8 mg) in Healthy Subjects.,rosiglitazone,49653/340,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/340,,,Y,N,Y,Y,Y,Y,N,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A 24-week Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus",rosiglitazone,49653/207,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/207,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A single dose study to assess the tolerability and food effect of an enterically-coated formulation of the commercial immediate release tablet of rosiglitazone and an enterically-coated modified release tablet formulation of rosiglitazone in healthy volunteers.,rosiglitazone,BRL-049653/299,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/299,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A study to evaluate the pharmacokinetics of eight prototype formulations of rosiglitazone 8 mg in healthy volunteers.,rosiglitazone,BRL-049653/309,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/309,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A six-month double-blind, randomised, parallel-group study to compare the effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy (less than or equal to 15mg daily) on body fat distribution when administered to subjects with type 2 diabetes mellitus",rosiglitazone,BRL-049653/369,,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/369,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Study to Evaluate the Effect of Food on the Pharmacokinetics of a Modified Release Formulation of Rosiglitazone 8 mg in Healthy Volunteers After Repeat Dosing.,rosiglitazone,BRL49653/301,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/301,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Bioequivalence Study Comparing Tablets Manufactured with the 8 mg Anhydrate Form IV (ANF4) to the Commercial Anhydrate Form I (ANF1) of Rosiglitazone Maleate.,rosiglitazone,BRL49653C/300,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/300,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (4 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 4 mg and Metformin 500 mg Commercial Tablets-and a Dose Proportionality Study Comparing the 4 mg/500 mg and 1 mg/500 mg Combination Formulations.,rosiglitazone; rosiglitazone/metformin,49653/270,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/270,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,A Study to Assess the Effect of Food on the Pharmacokinetics of a Rosiglitazone 4mg and Metformin 500mg Combination Tablet Formulation and a Study Comparing the Pharmacokinetics of Rosiglitazone 4mg and Metformin 500mg Combination Tablet to Concomitant Dosing of Rosiglitazone 4mg and Metformin 500mg Commercial Tablets in the Fed State in Healthy Volunteers,rosiglitazone; rosiglitazone/metformin,49653/271,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/49653/271,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects",salmeterol,SCO20001,,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/SCO20001,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SMS40320,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40320,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A randomised, open-label, parallel group 28-day pilot study to compare the addition of inhaled salmeterol 50mcg b.i.d. (via the DISKHALER inhaler) or tulobuterol patch 2mg once daily nocte in adult asthmatic subjects symptomatic on treatment with inhaled corticosteroids.",salmeterol,SMS40332,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40332,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Single-Blind, Parallel-Group, 28-Day, Pilot Study to Compare the Addition of Inhaled Salmeterol 50µg bid (via the DISKHALER™ Inhaler) or Tulobuterol-Patch 2mg qd Nocte in Adult Asthmatic Subjects who are Symptomatic on Inhaled Corticosteroids Alone",salmeterol,SMS40329,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40329,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Compare the Systemic Pharmacodynamic Effects and Pharmacokinetics of Salmeterol Delivered by the Non-CFC Propellant (HFA-134a; GR106642X) and the CFCPropellant (Propellant 11/12) Metered Dose Inhalers in Healthy Subjects",salmeterol,SLGB10006,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SLGB1006,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A double-blind, randomised, two-period, crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects of 7 days co-administration of salmeterol (50 mcg bid) with ketoconazole (400 mg od).",salmeterol,SMS106128,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/106128,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT™ Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo Administered Via a Valved-Holding Chamber with Facemask in Subjects with Symptoms of Asthma or Reactive Airways Disease Age 6 to 23 months",salmeterol,SMS30077,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SMS30077,,,Y,Y,Y,Y,N,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"SMART: A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42mcg Twice Daily",salmeterol,SLGA5011 SMART,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SLGA5011,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma",salmeterol,SMO30006,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SMO30006,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg bd Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Children Aged 4-11 Years With Asthma",salmeterol,SMO30007,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SMO30007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced, Incomplete Block Design, Multi-Center Study of Salmeterol Inhalation Aerosol 25mcg BID, 25mcg TID, 50mcg BID and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 6 to 23 Months",salmeterol,SMS20011,,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SMS20011,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Clinical Trial of 4 Weeks Treatment With SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered via a Valved Holding Chamber With Facemask in Subjects With Asthma Aged 24 to 47 Months",salmeterol,SMS30076,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SMS30076,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Multi-Center, Cross Over Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) via the DISKUS ™ and Salmeterol Xinafoate Inhalation Aerosol (42mcg BID) via the Metered Dose Inhaler on Measures of Device Preference in Subjects with COPD",salmeterol,SMS40330,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40330,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An open, randomised, two-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects",sumatriptan,SUM10961,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM10961,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An open, randomised, four-period crossover study to investigate the bioavailability of a new orally disintegrating (melt) formulation (ODT) of sumatriptan, with and without water compared to the currently marketed sumatriptan 100mg tablet and also to investigate the effect of food on the ODT formulation, in healthy male and female subjects",sumatriptan,SUM10955,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM10955,,,N,N,N,Y,N,Y,N,"An analysis-ready dataset, a reporting and analysis plan, an annotated case report form, and a protocol are not available for this study. A Clinical Study Report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2015
GSK,"An open, randomised, three-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100mg tablet compared to the currently marketed sumatriptan 100mg tablet administered immediately after food and the fast disintegrating tablet administered in the fasted state to healthy male and female subjects",sumatriptan,SUM10954,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM10954,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An open, randomised, four-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg IMITREX† /IMIGRAN† tablets), in healthy male and female volunteers",sumatriptan,SUM10950,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM10950,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An open, randomised, single-dose, three-way crossover, pilot study investigating the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50mg tablets versus the currently marketed sumatriptan 50mg tablets in healthy volunteers",sumatriptan,SUM10948,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM10948,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"An open-label evaluation of patient satisfaction with IMITREX (sumatriptan succinate) tablets, 100mg, administered at the first sign of pain for up to three migraines in patients who are not satisfied with their current triptan therapy.",sumatriptan,SUM40301,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40301,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets,sumatriptan,SUM40294,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40294,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study of Sumatriptan 6 mg Injection In the Treatment of Moderate-to-Severe Migraine Present Upon Awakening.",sumatriptan,SUM40287,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SUM40287,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Mar-2015
GSK,"A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack.",sumatriptan,SUM30046,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SUM30046,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age)",sumatriptan,SUM30045,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SUM30045,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate The Efficacy And Tolerability Of 100mg Sumatriptan Administered As A Film-Coated, Fast Disintegrating Tablet",sumatriptan,SUM20033,,Migraine Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SUM20033,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects",zanamivir,NAI113625,NCT00989404,"Influenza A Virus, H1N1 Subtype",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113625,http://clinicaltrials.gov/show/NCT00989404,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2015
Roche,A single arm study to assess the efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folic acid regimens as first line treatment for patients with metastatic colorectal cancer.,Bevacizumab,MO18458,,metastatic colorectal cancer,Phase 4,,,,Y,Y,Y,N,Y,Y,Y,,1-Apr-2015
Lilly,The Combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic Features,"Olanzapine, Fluoxetine",F1D-MC-HGHZ,Not available,Treatment-Resistant Depression,Phase 2/Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,Olanzapine Plus Fluoxetine Combination Therapy in Treatment-Resistant Depression: A Dose Ranging Study,"Olanzapine, Fluoxetine",F1D-MC-HGIE,Not available,Treatment-Resistant Depression,Phase 2/Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,The Study of Olanzapine plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features,"Olanzapine, Fluoxetine",H6P-MC-HDAO,NCT00035321,Treatment-Resistant Depression,Phase 3,Not available,https://clinicaltrials.gov/ct2/results?term=H6P-MC-HDAO&Search=Search,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Lilly,Study to Assess the Safety and Efficacy of Olanzapine and Fluoxetine Combination versus Placebo in Patients Ages 10 to 17 in the Treatment of Major Depressive Episodes Associated with Bipolar I Disorder,"Olanzapine, Fluoxetine",H6P-MC-HDAX,NCT00844857,Bipolar Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00844857?term=H6P-MC-HDAX&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Lilly,A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression,"Olanzapine, Fluoxetine",H6P-MC-HDAY,NCT00958568,Treatment-Resistant Depression,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00958568?term=H6P-MC-HDAY&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Lilly,"Safety and Pharmacological Effects of LY333334 on Biochemical Markers of Bone Metabolism in Healthy, Postmenopausal Women",Teriparatide,B3D-MC-GHAA,Not available,Osteoporosis,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis,Teriparatide,B3D-MC-GHAC,NCT00670501,Osteoporosis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00670501?term=B3D-MC-GHAC&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Lilly,Effects of LY333334 in Postmenopausal Women on Estrogen and Progestin Therapy,Teriparatide,B3D-MC-GHAF,Not available,Osteoporosis,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,LY333334 Compared with Alendronate in Postmenopausal Women with Osteoporosis,Teriparatide,B3D-MC-GHAH,Not available,Osteoporosis,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,Effects of LY333334 in the Treatment of Men with Osteoporosis,Teriparatide,B3D-MC-GHAJ,Not available,Osteoporosis,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2015
Lilly,Effect of Teriparatide on Femoral Neck Fracture Healing,Teriparatide,B3D-MC-GHDN,NCT01473589,Femoral Neck (Hip) Fracture,Phase 3,Not available,https://clinicaltrials.gov/ct2/results?term=B3D-MC-GHDN&Search=Search,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Apr-2015
Lilly,Second Study of the Effect of Teriparatide on Femoral Neck Fracture Healing,Teriparatide,B3D-MC-GHDQ,NCT01473602,Femoral Neck (Hip) Fracture,Phase 3,Not available,https://clinicaltrials.gov/ct2/results?term=B3D-MC-GHDQ&Search=Search,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Apr-2015
Lilly,Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis,Teriparatide,B3D-US-GHBZ,NCT00051558,Osteoporosis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00051558?term=B3D-US-GHBZ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma,afatinib,1200.36,NCT00727506,Glioma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00727506?term=1200.36&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,dabigatran etexilate,1160.71,NCT00808067,Atrial Fibrillation,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00808067?term=1160.71&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV,nevirapine,1100.1414,NCT00144157,Acquired Immunodeficiency Syndrome,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00144157?term=1100.1414&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,Safety and PK Study of BIBF 1120 in Japanese Patients With IPF,nintedanib,1199.31,NCT01136174,Idiopathic Pulmonary Fibrosis,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01136174?term=1199.31&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,nintedanib,1199.32,NCT01335464,Pulmonary Fibrosis,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01335464?term=1199.32&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Boehringer Ingelheim,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,nintedanib,1199.34,NCT01335477,Pulmonary Fibrosis,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01335477?term=1199.34&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,"A Phase III, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout",febuxostat,C02-009,NCT00174915,Hyperuricemia,Phase 3,http://takedaclinicaltrials.com/browse/summary/C02-009,https://clinicaltrials.gov/show/NCT00174915,,N,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout",febuxostat,C02-010,NCT00102440,Hyperuricemia,Phase 3,http://takedaclinicaltrials.com/browse/summary/C02-010,https://clinicaltrials.gov/show/NCT00102440,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout",febuxostat,C02-021,NCT00175019,Hyperuricemia,Phase 3,http://takedaclinicaltrials.com/browse/summary/C02-021,https://clinicaltrials.gov/show/NCT00175019,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout",febuxostat,F-GT06-153,NCT00430248,Hyperuricemia,Phase 3,http://takedaclinicaltrials.com/browse/summary/F-GT06-153,https://clinicaltrials.gov/show/NCT00430248,,N,N,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,"Phase 2, Dose-Response, Safety and Efficacy Study of Oral Febuxostat (TMX-67) in Subjects With Gout",febuxostat,TMX-00-004,NCT00174967,Hyperuricemia,Phase 2,http://takedaclinicaltrials.com/browse/summary/TMX-00-004,https://clinicaltrials.gov/show/NCT00174967,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"Phase 2, Open-Label Study to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout",febuxostat,TMX-01-005,NCT00174941,Hyperuricemia,Phase 2,http://takedaclinicaltrials.com/browse/summary/TMX-01-005,https://clinicaltrials.gov/show/NCT00174941,,N,N,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,A Phase I Study to Assess the Effect of Multiple Dosing of Febuxostat on the Pharmacokinetics of Desipramine,febuxostat,C02-005,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-005,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase I, Single-Center Study to Evaluate the Safety and the Effect of Febuxostat (TMX-67) on the Pharmacokinetics of Colchicine at Steady State in Healthy Subjects",febuxostat,C02-006,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-006,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,Assessment of Potential Effect of Naproxen on the Pharmacokinetics of Febuxostat (TMX-67) and the Potential Effect of Febuxostat on the Pharmacokinetics of Naproxen at Steady State in Healthy Subjects,febuxostat,C02-013,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-013,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 1, Double-Blind Study to Evaluate the Safety and Tolerability of 300 mg of TMX-67, and a Double-Blind, Crossover Study to Evaluate the Potential Effect of TMX 67 on the QTc in Healthy Subjects After Multiple Doses Using Avelox® (moxifloxacin hydrochloride) as the Active Control Part A",febuxostat,C02-023 Part A,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-023 (Part A),Not available,,N,N,Y,Y,Y,N,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 1, Double-Blind Study to Evaluate the Safety and Tolerability of 300 mg of TMX-67, and a Double-Blind, Crossover Study to Evaluate the Potential Effect of TMX 67 on the QTc in Healthy Subjects After Multiple Doses Using Avelox® (moxifloxacin hydrochloride) as the Active Control Part B",febuxostat,C02-023 Part B,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-023 (Part B),Not available,,N,N,Y,Y,Y,N,N,,1-Apr-2015
Takeda,A Phase 1 Study to Assess the Relative Bioavailability of TMX-67 from Two 40 mg Tablets to That From an 80 mg Tablet,febuxostat,C02-033,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-033,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Study to Assess the Relative Bioavailability of TMX-67 from an 80 mg (300 L gral batch size) Tablet to that from an 80 mg (75 L gral batch size) Tablet,febuxostat,C02-034,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-034,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 1, Multiple-Dose Study of 80 mg Febuxostat (TMX-67) Comparing the Pharmacokinetics and Pharmacodynamics of Febuxostat Under Fed Conditions to Those Under Fasting Conditions in Healthy Subjects",febuxostat,C02-036,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C02-036,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,The Metabolism and Excretion of Orally Administered [14C]Febuxostat in Healthy Male Subjects,febuxostat,C03-040,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C03-040,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Study to Assess the Relative Bioavailability of 1 Febuxostat 120 mg Tablet to 1 Febuxostat 80 mg Tablet and 1 Febuxostat 40 mg Tablet,febuxostat,C03-044,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C03-044,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Study to Assess the Effect of Food on the Pharmacokinetics of Febuxostat Following a Single Dose with One 120 mg Febuxostat Oral Tablet,febuxostat,C03-054,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C03-054,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Two-way Crossover Study to Assess the Effect of Multiple Oral Doses of Febuxostat on the Pharmacokinetics and Pharmacodynamics of Warfarin Following Multiple Oral Doses of Warfarin,febuxostat,C03-057,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C03-054,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Study to Evaluate the Effect of Hydrochlorothiazide on the Pharmacokinetics and Pharmacodynamics of Febuxostat in Healthy Subjects,febuxostat,C03-059,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/C03-054,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 1, 2-way Crossover Study to Assess the Effect of Multiple Oral Doses of Febuxostat on the Pharmacokinetics and Pharmacodynamics of Warfarin Following Multiple Oral Doses of Warfarin",febuxostat,F-P107-162,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/f-p107-162,Not available,,N,N,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,Effects of Food on the Pharmacokinetics of TMX-67 in Healthy Subjects,febuxostat,TMX-00-002,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-00-002,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,The Effect of Colchicine on the Pharmacokinetic Profile of TMX-67 in Healthy Subjects,febuxostat,TMX-00-006,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-00-006,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"Safety, Pharmacokinetics, and Pharmacodynamic Study of TMX-67 in Subjects with Normal or Impaired Renal Function",febuxostat,TMX-01-008,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-008,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase I Study to Evaluate the Bioavailability of TMX-67 20 mg Tablets Manufactured at Two Different Facilities, and to Assess the Bioavailability of TMX-67 from 80 mg Tablets Relative to 4 x 20 mg Tablets",febuxostat,TMX-01-009,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-009,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase I Study to Assess the Relative Bioavailability of Different Formulations of TMX-67 Tablets Manufactured by Abbott Laboratories,febuxostat,TMX-01-010,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-010,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"Safety, Pharmacokinetics, and Pharmacodynamic Study of TMX-67 in Subjects with Normal or Impaired Hepatic Function",febuxostat,TMX-01-012,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-012,Not available,,N,N,Y,Y,Y,Y,N,,1-Apr-2015
Takeda,The Effect of an Antacid on the Pharmacokinetics of TMX-67 in Healthy Subjects,febuxostat,TMX-01-014,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-014,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"The Effect of Gender and Age on the Safety, Pharmacodynamics and Pharmacokinetics of TMX-67 in Healthy Subjects",febuxostat,TMX-01-016,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-01-016,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,Assessment of Potential Effect of Indomethacin on the Pharmacokinetics of TMX-67 and the Potential Effect of TMX-67 on the Pharmacokinetics of Indomethacin at Steady State in Healthy Subjects,febuxostat,TMX-02-017,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-02-017,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,A Phase 1 Study to Assess the Relative Bioavailability of Abbott Formulation B1 TMX-67 Coated Tablets to Teijin Tablets,febuxostat,TMX-02-018,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-02-018,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Phase 1, Double-Blind, Randomized, 2-Period Crossover Study to Evaluate the Effect of Multiple Oral Doses of Febuxostat on the Pharmacokinetics of a Single Oral Dose of Theophylline",febuxostat,TMX-67_101,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-67_101,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,"A Phase 1, Double-Blind, Randomized, 2-Period Crossover Study to Evaluate the Effect of Multiple Oral Doses of Febuxostat on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone",febuxostat,TMX-67_103,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-02-018,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2015
Takeda,"A Multiple-Dose Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TMX-67 in Healthy Volunteers",febuxostat,TMX-99-001,Not available,Hyperuricemia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TMX-99-001,Not available,,N,N,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Apr-2015
Takeda,"A Double-Blind, Dose-Response, Cross-Over Study of TAK-375 With Chronic Insomnia (Phase II Study) -- Polysomnographic Evaluation",ramelteon,TAK-375/CCT-001,NCT00915135,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-375/CCT-001,https://clinicaltrials.gov/show/NCT00915135,,Y,N,Y,Y,N,N,N,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Efficacy and Safety Study of TAK-375 in Adults and Elderly Adults with Chronic Insomnia",ramelteon,TAK-375/CCT-002,Not available,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/CCT-002,Not available,,Y,Y,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Patients with Chronic Insomnia",ramelteon,TAK-375/CCT-003,Not available,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/CCT-003,Not available,,Y,N,Y,Y,Y,N,N,Annotated case report forms are N/A. Blank case report forms will be provided. Select supporting documents are  not available in English.,1-Apr-2015
Takeda,Clinical Phase I Study of TAK-375 (Single dose study),ramelteon,TAK-375/CPH-001,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-001,Not available,,Y,N,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,TAK-375 Clinical Phase I Study (Multiple dose study),ramelteon,TAK-375/CPH-002,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-002,Not available,,Y,N,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,Placebo-Controlled Double-Blind 3-Way Crossover Study on TAK-375 in Healthy Middle Aged Male Volunteers,ramelteon,TAK-375/CPH-003,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-003,Not available,,Y,N,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,Effect of Age on the Pharmacokinetics of a Single Dose of TAK-375 in Healthy Adult Subjects,ramelteon,TAK-375/CPH-005,Not available,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-005,Not available,,Y,N,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,TAK-375 Clinical Phase I Study in Healthy Adult Male Volunteers (Single- and multiple-dose studies of 32mg),ramelteon,TAK-375/CPH-006,Not available,Insomnia,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-006,Not available,,Y,N,Y,Y,Y,N,Y,Select supporting documents are  not available in English.,1-Apr-2015
Takeda,"A Phase 3, Single Dose Study of TAK-375 in Healthy Adult Male Subjects - To Determine the Pharmacokinetic Profiles of a Finished Formulation",ramelteon,TAK-375/CPH-007,Not available,Insomnia,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375/CPH-007,Not available,,Y,N,Y,Y,Y,N,N,Select supporting documents are  not available in English.,1-Apr-2015
GSK,Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers,twinrix,100559x,NCT00289718,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100556 (Y11),http://clinicaltrials.gov/show/NCT00289718,,Y,N,Y,Y,Y,Y,N,"This is a follow on study to 208127/118. The results of this study 100559 are summarised with studies 100556, 100557, 100558, 100560, and 112266  on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.",1-Oct-2014
ViiV,"A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir once daily and GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naïve and Experienced, Pediatric Subjects 2 to 18 Years Old.",fosamprenavir,APV20003,NCT00040664,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/APV 20003,http://clinicaltrials.gov/show/NCT00040664,,Y,Y,Y,Y,Y,Y,Y,"Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.",1-May-2015
ViiV,"A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to &lt;2 years.",fosamprenavir,APV20002,NCT00071760,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/APV20002,http://clinicaltrials.gov/show/NCT00071760,,Y,Y,Y,Y,Y,Y,Y,"Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.",1-May-2015
ViiV,"A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to &lt;6 years old.",fosamprenavir,APV29005,NCT00089583,"Infection, Human Immunodeficiency Virus I",Phase 2,http://www.viiv-clinicalstudyregister.com/study/APV29005,http://clinicaltrials.gov/show/NCT00089583,,Y,Y,Y,Y,Y,Y,Y,"Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.",1-May-2015
Lilly,"A Phase 4, 8-week, Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physical Symptoms",Duloxetine hydrochloride,F1J-US-HMGR,NCT01000805,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT01000805?term=F1J-US-HMGR&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2015
Lilly,Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques,Duloxetine hydrochloride,F1J-MC-HMDG,NCT00191932,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00191932?term=F1J-MC-HMDG&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Lilly,Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms,Duloxetine hydrochloride,F1J-US-HMGU,NCT01070329,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT01070329?term=F1J-US-HMGU&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2015
Lilly,"A Phase 4, 8-week, Double-blind, Randomized Study Comparing Switching to Duloxetine or Escitalopram in Patients With Major Depressive Disorder and Residual Apathy in the Absence of Depressed Mood",Duloxetine hydrochloride,F1J-CR-HMGM,NCT00985504,Major Depressive Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00985504?term=F1J-CR-HMGM&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2015
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome",alogliptin,SYR-322_402,"NCT00968708
2009-011222-34","Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322_402,http://clinicaltrials.gov/ct2/show/NCT00968708?term=SYR-322_402&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011222-34/BE,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Takeda,"Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis – A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis",dexlansoprazole,TAK-390MR/CCT-001,Not available,Erosive Esophagitis; Gastroesophageal Reflux Disease,Phase 2,http://takedaclinicaltrials.com/browse/summary/TAK-390MR/CCT-001,Not available,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Boehringer Ingelheim,ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset,alteplase,135.312,NCT00153036,Acute Ischemic Hemispheric Stroke,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00153036?term=135.312&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,A placebo controlled trial of rt-PA (alteplase) in acute ischemic hemispheric stroke where thrombolysis is initiated 1-6 hours following onset of symptoms.,alteplase,135.63,,Acute Ischemic Hemispheric Stroke,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated up to 6 hours following the onset of symptoms (ECASS-II),alteplase,135.291,,Acute Ischemic Hemispheric Stroke,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",ipratropium bromide,244.248,NCT02236169,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02236169?term=244.2480&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",ipratropium bromide,244.2489,NCT02236182,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02236182?term=244.2489&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes",linagliptin,1218.2,NCT02183350,"Diabetes Mellitus, Type 2",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02183350?term=1218.2&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes",linagliptin,1218.3,NCT02183415,"Diabetes Mellitus, Type 2",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02183415?term=1218.3&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function",linagliptin,1218.26,NCT02191228,Renal Insufficiency,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02191228?term=1218.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients,linagliptin,1218.55,NCT00935220,"Diabetes Mellitus, Type 2",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00935220?term=1218.55&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects,nevirapine,1100.1489,NCT02194179,HIV Infections,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02194179?term=1100.1489&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.",telmisartan,502.373,NCT00153101,Cardiovascular Diseases,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00153101?term=502.373&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-May-2015
Boehringer Ingelheim,"Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD",tiotropium bromide,205.244,NCT00274040,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00274040?term=205.244&rank=1,,Y,N,Y,N,Y,Y,N,,1-May-2015
Boehringer Ingelheim,Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation,tiotropium bromide,205.32,NCT02172521,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02172521?term=205.320&rank=1,,N,N,N,N,N,Y,N,,1-May-2015
Boehringer Ingelheim,Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD),tiotropium bromide,205.133,NCT02172326,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02172326?term=205.133&rank=1,,N,N,Y,N,N,Y,N,,1-May-2015
Boehringer Ingelheim,Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.127,NCT02175342,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02175342?term=205.127&rank=1,,N,N,Y,N,N,Y,N,,1-May-2015
Boehringer Ingelheim,Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children,tipranavir,1182.14,NCT00076999,HIV Infections,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00076999?term=1182.14&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency,tipranavir,1182.32,NCT02249442,Hepatic Insufficiency,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02249442?term=1182.32&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment",tipranavir,1182.59,NCT02259855,Hepatic Insufficiency,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02259855?term=1182.59&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
Boehringer Ingelheim,Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects,tipranavir,1182.6,NCT02248883,Healthy,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02248883?term=1182.60&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long-term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus.",albiglutide,GLP112754,NCT00838916,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112754,http://clinicaltrials.gov/show/NCT00838916,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-May-2015
GSK,"A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and with Metformin plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus",albiglutide,GLP112757,NCT00839527,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112757,http://clinicaltrials.gov/show/NCT00839527,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-May-2015
GSK,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus",albiglutide,GLP108486,NCT00976391,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/108486,http://clinicaltrials.gov/show/NCT00976391,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus",albiglutide,GLP112755,NCT00849056,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112755,http://clinicaltrials.gov/show/NCT00849056,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-May-2015
GSK,"A single-site, randomized, double-blind, placebo-controlled, parallel-group, stepped glucose clamp study to assess the effects of albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.",albiglutide,GLP108372,NCT01475734,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/108372,http://clinicaltrials.gov/show/NCT01475734,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A multi-centre, randomised, double-blind, double dummy study comparing the efficacy and safety of chlorproguanil-dapsone-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in children and adolescents in Africa.",artesunate/chlorproguanil/dapsone,714703/005,NCT00344006,"Malaria, Falciparum",Phase 3,http://www.gsk-clinicalstudyregister.com/study/CDA 714703/005,http://clinicaltrials.gov/show/NCT00344006,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A multi-centre, randomised, double-blind study to compare the efficacy and safety of chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone in the treatment of acute uncomplicated Plasmodium falciparum malaria in children, adolescents and adults in Africa.",artesunate/chlorproguanil/dapsone,714703/006,NCT00371735,"Malaria, Falciparum",Phase 3,http://www.gsk-clinicalstudyregister.com/study/CDA 714703/006,http://clinicaltrials.gov/show/NCT00371735,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"An open, randomised, crossover study to assess the pharmacokinetics and tolerability of single doses of LAPDAP™, artesunate, and LAPDAP plus artesunate",artesunate/chlorproguanil/dapsone,CDA103078,,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103078,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]",casopitant,NKV105091,NCT00405080,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKV105091,http://clinicaltrials.gov/show/NCT00405080,,Y,N,Y,Y,Y,Y,Y,An annotated or blank case report form is not available as the data electronic data capture system for this study did not generate a paper version.,1-May-2015
GSK,"An open-label, randomized (with respect to different doses of casopitant), two-period parallel group study to evaluate the potential pharmacokinetic interaction of co-administered casopitant and digoxin in healthy subjects",casopitant,NKV105095,,"Nausea and Vomiting, Chemotherapy-Induced",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105095,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients",darotropium bromide,AC2103473,NCT00279019,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AC2103473,http://clinicaltrials.gov/show/NCT00279019,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A randomised, double blind, placebo-controlled, double dummy, five-way cross over dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 (20-500ug via DPI), and , tiotropium bromide (18ug via DPI) in healthy male subjects",darotropium bromide,AC2103471,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/103471,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"Multicenter, double-blind, randomized, parallel-group study, comparing 0.5 mg and 3.5 mg dutasteride daily for 4 months prior to radical prostatectomy versus radical prostatectomy alone in men with biopsy-proven and clinically localized prostate cancer",dutasteride,ARI40010,,"Neoplasms, Prostate",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ARI40010,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A single centre, randomised, double-blind, placebo-controlled,four-way cross over study to assess the safety, tolerability,pharmacokinetics and pharmacodynamics of single doses ofGSK2190915 in healthy Japanese subjects.",fiboflapon,LPA112359,NCT00955383,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112359,http://clinicaltrials.gov/show/NCT00955383,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils,fiboflapon,LPA112046,NCT00850642,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112046,http://clinicaltrials.gov/show/NCT00850642,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A single dose, crossover study in healthy female subjects to assess the regional absorption and bioavailability of 100 mg GSK2190915A",fiboflapon,LPA114604,NCT01318980,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114604,http://clinicaltrials.gov/show/NCT01318980,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A 12 week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with Tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD).",fluticasone furoate/vilanterol,HZC115247,NCT01395888,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115247,http://clinicaltrials.gov/show/NCT01395888,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A randomized, double blind, placebo-controlled three-way crossover study in mild asthmatics to evaluate the effect of smoking status on the attenuation by inhaled corticosteroids of the allergen-induced asthmatic response.",fluticasone propionate,RES114748,NCT01400906,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114748,http://clinicaltrials.gov/show/NCT01400906,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease,fluticasone propionate/salmeterol,ASQ112989,NCT00984659,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/112989,http://clinicaltrials.gov/show/NCT00984659,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization",fluticasone propionate/salmeterol,ADC113874,NCT01110200,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/113874,http://clinicaltrials.gov/show/NCT01110200,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A Phase I, Randomized, Placebo-Controlled, Crossover Clinical Trial to Assess the Safety of Oral SRT2104 and its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects with Type 2 Diabetes Mellitus",GSK2245840,SIR114089,NCT01031108,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114089,http://clinicaltrials.gov/show/NCT01031108,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A randomised, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity in healthy male subjects.",GW678007,B2B10001,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2B10001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A multi-enter, randomized, double-blind, placebo-controlled, four-way incomplete block crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20 mcg) of GSK159797",milveterol,B2E106359,NCT00358488,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2E106359,http://clinicaltrials.gov/show/NCT00358488,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia.",paroxetine,BRL-029060/676,,Social Phobia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/676,,,Y,N,Y,Y,Y,N,Y,A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder",paroxetine,29060/689,,Premenstrual Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/689,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder",paroxetine,BRL-029060/704,,Obsessive-Compulsive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/704,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression,paroxetine,BRL-029060/715,,Obsessive-Compulsive Disorder and Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/715,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder",paroxetine,TMT106386,NCT00470483,Social Phobia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/TMT106386,http://clinicaltrials.gov/show/NCT00470483,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2015
GSK,"A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD)",paroxetine,BRL-029060/716,,Obsessive-Compulsive Disorder and Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/716,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder",paroxetine,29060/677,,Premenstrual Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/677,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A double-blind, placebo-controlled, 3-arm fixed dose study of paroxetine CR continuous treatment (12.5mg and 25mg) for Premenstrual Dysphoric Disorder.",paroxetine,29060/688,,Premenstrual Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/688,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689",paroxetine,29060/711,,Premenstrual Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/711,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder",paroxetine,29060/717,,Premenstrual Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/717,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga",paroxetine,PCR111656,NCT00749359,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/PCR111656,http://clinicaltrials.gov/show/NCT00749359,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"An open label, randomised, repeat dose study to assess the pharmacokinetic performance of five ezogabine/retigabine modified release (MR) formulations at steady state compared to the immediate release (IR) formulation.","retigabine, ezogabine",RTG114552,NCT01332513,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114552,http://clinicaltrials.gov/show/NCT01332513,,Y,Y,Y,Y,Y,Y,Y,,1-May-2015
GSK,"A 12-Week, Randomized, Double-blind Study to Evaluate the Effects of Rosiglitazone 4 mg BD and Rosiglitazone 4 mg QD on Lipids in Type 2 Diabetes Mellitus Subjects Taking Statins",rosiglitazone,BRL-049653/311,,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/49653/311,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects,rosiglitazone/glimepiride,SB-797620/002,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/797620/002,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset is not available for this study. An annotated or blank case report form is not available as the data electronic data capture system for this study did not generate a paper version. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of a GSK New Chemical Entity (NCE), paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subj ...",vestipitant,NKD10020,,Social Phobia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKD10020,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder",vestipitant,NKD20006,NCT00048204,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKD20006,http://clinicaltrials.gov/show/NCT00048204,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2015
GSK,See Detailed Description,vestipitant/paroxetine,NKP102280,NCT00343707,Depressive Disorder and Anxiety Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NKP102280,http://clinicaltrials.gov/show/NCT00343707,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2015
GSK,An open label repeat dose study to investigate the effect of New Compound (X mg) and paroxetine (10 mg) given in combination for 15 days on the pharmacokinetics of Midazolam and Dextromethorphan in healthy male and female volunteers,vestipitant/paroxetine,NKP100716,,Depressive Disorder and Anxiety Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/100716,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,"A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of a new chemical entity (NCE) and paroxetine (5 or 7.5 mg) either alone or in combination, or ...",vestipitant/paroxetine,NKP100690,,Depressive Disorder and Anxiety Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/100690,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset and an annotated case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2015
GSK,A Study to Investigate the Effect of Intranasal GR121167X on Infection Rates in Healthy Male Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) virus,zanamivir,NAIA1001,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1001,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2015
GSK,A Study to Investigate the Effect of Intranasal GG167 Initiated at Various Intervals Post Inoculation on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus,zanamivir,NAIA1002,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1002,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2015
GSK,A Study to Investigate the Effect of Intranasal GG167 at Various Dosing Frequencies on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus,zanamivir,NAIA1003,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1003,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2015
GSK,A Study to Investigate the Effect of Intranasal GG167 as Nasal Drops and Nasal Spray on Infection in Healthy Volunteers Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus,zanamivir,NAIA1004,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1004,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2015
GSK,A Study to Investigate the Effect of Intranasal GG167 on Infection in Healthy Volunteers Experimentally Inoculated with Influenza B/YAMAGATA/16/88 Virus,zanamivir,NAIA1005,N/A,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/NAIA1005,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-May-2015
Roche,Thrombolytic Therapy in Acute Ischemic Stroke (Atlantis: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke),Activase,A0276G,,acute ischemic stroke,Phase 2/3,,,,Y,Y,Y,N,Y,Y,N,,1-Jun-2015
Roche,"A double-blind, randomized, stratified, placebo-controlled study of Ro 64-0796 (also known as GS4104) in children with influenza.",Oseltamivir,WV15758,,influenza,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Roche,"Safety, tolerability and activity of oral Ro 64-0796 (GS4104) for prophylaxis against experimental inoculation with human influenza virus",Oseltamivir,PV15615,,influenza,Phase 2,,,,Y,N,Y,N,Y,Y,Y,,1-Jun-2015
Roche,"Safety, Tolerability and Activity of oral GS 4104 (Ro 64-0796) in Treatment of Subjects experimentally Inoculated with Human Influenza Virus",Oseltamivir,PV15616,,influenza,Phase 2,,,,Y,N,Y,N,Y,Y,Y,,1-Jun-2015
Lilly,Phase 2 Trial of Gemcitabine Plus Cisplatin Combination Therapy in Chemonaive Patients with Metastatic Urothelial Cancer,Gemcitabine,B9E-MC-JHFY,n/a,Urothelium Cancer,Phase 2,Not available,Not Available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Randomized Phase 3 Study of Gemcitabine plus Cisplatin versus MVAC Chemotherapy in Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium.,Gemcitabine,B9E-MC-JHGA,n/a,Urothelium Cancer,Phase 3,Not available,Not Available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,"Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer",Gemcitabine,B9E-MC-JHQG,NCT00006459,Breast Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/record/NCT00006459?term=B9E-MC-JHQG&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,A Randomized Phase 3 Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients with Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy.,Gemcitabine,B9E-MC-JHQJ,n/a,Ovarian Cancer,Phase 3,Not available,Not Available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Study of Gemcitabine plus Carboplatin in Patients with Relapsed Epithelial Ovarian Carcinoma ≥6 Months after Platinum-Containing First-Line Therapy,Gemcitabine,B9E-MC-JHRW,n/a,Ovarian Cancer,Phase 2,Not available,Not Available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,First-Line Therapy with Gemcitabine and Paclitaxel in Locally Recurrent or Metastatic Breast Cancer: A Phase II Study,Gemcitabine,B9E-MC-S024,n/a,Breast Cancer,Phase 2,Not available,Not Available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer.",Pemetrexed,H3E-EW-S124,NCT00789373,Nonsquamous Non-Small Cell Lung Cancer (NSCLC).,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00789373?term=H3E-EW-S124&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Metastatic Colorectal Cancer,Pemetrexed,H3E-MC-JMAC,Not available,Colorectal Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Pancreatic Cancer,Pemetrexed,H3E-MC-JMAD,Not available,Pancreatic Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Gastric Cancer,Pemetrexed,H3E-MC-JMAF,Not available,Gastric Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Locally/Regionally Recurrent or Metastatic Breast Cancer,Pemetrexed,H3E-MC-JMAG,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Metastatic Renal Cancer,Pemetrexed,H3E-MC-JMAI,Not available,Renal Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Locally Advanced or Metastatic Head and Neck Cancer,Pemetrexed,H3E-MC-JMAJ,Not available,Head and Neck Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Advanced Bladder Cancer,Pemetrexed,H3E-MC-JMAK,Not available,Bladder Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Non-Small Cell Lung Cancer,Pemetrexed,H3E-MC-JMAL,Not available,Non-Small Cell Lung Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Cervical Cancer,Pemetrexed,H3E-MC-JMAM,Not available,Cervical Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 in Combination With Cisplatin Administered Intravenously Every 21 Days in Patients with Non-Small Cell Lung Cancer,Pemetrexed,H3E-MC-JMAY,Not available,Non-Small Cell Lung Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with 5-FU and Irinotecan-Refractory Colorectal Cancer,Pemetrexed,H3E-MC-JMBB,Not available,Colorectal Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with 5-FU-Refractory Colorectal Cancer,Pemetrexed,H3E-MC-JMBM,Not available,Colorectal Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline or Anthracenedione Containing Regimen,Pemetrexed,H3E-MC-JMBP,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Chemotherapy,Pemetrexed,H3E-MC-JMBR,Not available,Non-Small Cell Lung Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Every 21 Days in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment with an Anthracycline- (or Anthracenedione-) Containing Regimen and a Taxane,Pemetrexed,H3E-MC-JMBT,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma,Pemetrexed,H3E-MC-JMCH,NCT00005636,Mesothelioma,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00005636?term=H3E-MC-JMCH&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,"A Phase 2 Trial of MTA Administered Intravenously Every 21 Days in Patients Pretreated with an Anthracycline (or Anthracenedione), a Taxane, and Capecitabine for Advanced Breast Cancer",Pemetrexed,H3E-MC-JMDM,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 2 Trial of LY231514 Administered Intravenously Every 21 Days in Patients with Malignant Pleural Mesothelioma,Pemetrexed,H3E-MC-JMDR,Not available,Mesothelioma,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,Evaluation of the Relationship Between Clinical Response to ALIMTA and Molecular Target Levels in Patients with Advanced Breast Cancer,Pemetrexed,H3E-MC-JMDS,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,A Phase 3 Trial of ALIMTA vs Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Were Previously Treated with Chemotherapy,Pemetrexed,H3E-MC-JMEI,Not available,Non-Small Cell Lung Cancer,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Lilly,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer",Pemetrexed,H3E-MC-JMEN,NCT00102804,Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00102804?term=H3E-MC-JMEN&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,A Phase 2 Study of ALIMTA (Pemetrexed) in Patients With Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium,Pemetrexed,H3E-MC-JMEU,NCT00035061,Urothelium Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00035061?term=H3E-MC-JMEU&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,A Phase II Study of Pemetrexed in Children with Recurrent Malignancies,Pemetrexed,H3E-MC-JMHW,NCT00520936,Recurrent Cancers,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00520936?term=H3E-MC-JMHW&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,A Phase 2 Study of Pemetrexed versus Pemetrexed plus Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC,Pemetrexed,H3E-MC-S102,NCT00447057,Nonsquamous Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00447057?term=H3E-MC-S102&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,,1-Jun-2015
Lilly,"A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and
Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer",Pemetrexed,H3E-MC-S103,NCT00550173,Nonsquamous Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00550173?term=H3E-MC-S103&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jun-2015
Astellas,"A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus",ipragliflozin,1941-CL-0004,NCT01071850,"Diabetes Mellitus, Type 2",Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=1,https://clinicaltrials.gov/ct2/show/NCT01071850,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
Astellas,"Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone",ipragliflozin,1941-CL-0005,NCT01117584,"Diabetes Mellitus, Type 2",Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=2,https://clinicaltrials.gov/ct2/show/NCT01117584,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
Astellas,"Randomized, Open-label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Infections in High Risk Liver Transplant Recipients.",micafungin,9463-EC-0001,NCT01058174,Invasive Fungal Infections,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=50,https://clinicaltrials.gov/ct2/show/NCT01058174,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Astellas,"A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson",regadenoson,3606-CL-3002,NCT00826280,Myocardial Perfusion Imaging,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=49,https://clinicaltrials.gov/ct2/show/NCT00826280,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Astellas,"A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects",tacrolimus extended-release,PMR-EC-1210,NCT00717470,"Transplantation, Kidney",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=58,https://clinicaltrials.gov/ct2/show/NCT00717470,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Astellas,"A multicenter, three arm, randomized, open label clinical study to compare renal function in liver transplant recipients receiving an immunosuppressive regimen of Advagraf (immediately or delayed post-transplant) and MMF with or without a Monoclonal Anti-IL2R antibody (Basiliximab)",tacrolimus extended-release,PMR-EC-1106,NCT01011205,"Transplantation, Liver",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=57,https://clinicaltrials.gov/ct2/show/NCT01011205,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
Sanofi,Safety and Immunogenicity of DTap-IPV (Diphtheria (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age,DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed and Inactivated Poliovirus Vaccine),M5I02,NCT01346293,Tetanus; Diphtheria; Pertussis; Poliomyelitis,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/M5I02_Report_Summary.pdf,http://www.clinicaltrials.gov/ct2/show/study/NCT01346293?term=M5I02&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jun-2015
GSK,"An open, randomised, multi-centre dose-ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate.",artesunate/chlorproguanil/dapsone,714703/003,NCT00519467,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/714703/003,https://clinicaltrials.gov/ct/show/NCT00519467,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2015
GSK,"Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/049 (DTPa-HBV-IPV-049),NCT00879827,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/049,http://clinicaltrials.gov/show/NCT00879827,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2015
GSK,"Phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SB Bios' DTPa-HBV-IPV vaccine compared with Infanrix when both vaccines are co-administered with OmniHIB between 15 and 18 months of age after primary immunization at the age of 2, 4 and 6","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/061 (DTPa-HBV-IPV-061),,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/217744/061,,,N,N,Y,Y,Y,Y,Y,This is a follow-up to primary study 217744/044. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",347414/016,,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/016,,,Y,N,Y,Y,Y,Y,Y,A booster study 347414/028 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",347414/028,,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/028,,,Y,N,Y,Y,Y,Y,N,This is a booster of primary study 347414/016. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An open clinical study to assess the immunogenicity and safety of GSK Bio’s DTPa-HBV-IPV vaccine mixed in one syringe with Hib vaccine, as a primary vaccination course to pre-term infants(<37 weeks) at 2, 4 and 6 months of age in comparison with infants born after normal gestation period","Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine",217744/070 (DTPa-HBV-IPV-070),NCT00366366,Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/070,http://clinicaltrials.gov/show/NCT00366366,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV)","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/060,NCT01457560,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/060,http://clinicaltrials.gov/show/NCT01457560,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2015
GSK,"Open, clinical study to assess the safety and reactogenicity of GSK Bios’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vac. admin. with GSK Bios’ Haemophilus influenzae type b, tetanus conjugate vac. in healthy infants, before a dose of the same vac and OPV","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/063 (DTPa-HBV-IPV-063),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/063,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals’ HAV vaccine (Havrix(), in children in their second ...","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/066 (DTPa-HBV-IPV-066),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/066,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Study to assess immunogenicity, safety and reactogenicity of GSK Bio’s DTPa-IPV/Hib and HBV vaccines compared to an investigational vaccination regimen in healthy infants born to hepatitis B surface antigen negative mothers and previously primed at birth with a dose of GSK Bio’s hepatitis B vaccine","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/068,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/068,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open, randomized, multicenter, phase IIIb clinical trial to assess the incidence of high grade fever ((40.0°C) within 4 days following a booster dose in the second year of life of GSK Bios’ combined DTPa-HBV-IPV/Hib vaccine as compared to GSK Bios’ combined DTPa-IPV/Hib and HBV","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/074  (DTPa-HBV-IPV-074),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/217744/074,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Study to assess immunogenicity and reactogenicity of GSK Bio’s DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs DTPa-HBV-IPV-Hib vaccine or GSK Bio’s DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",217744/095 (DTPa-HBV-IPV-095),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/217744/095,,,Y,N,Y,Y,Y,Y,N,This is a booster to primary study 217744/086. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",347414/020,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/347414/020,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months)","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",347414/026,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/347414/026,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",759348/001,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759348/001,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",759348/003,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759348/003,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open study to assess the immunogenicity after two and three doses of GSK Bios’ Hib vaccine combined with GSK Bios’ DTPa-IPV vaccine given to Swedish infants in a 3, 5, 12 month schedule","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",213503/044 (DTPa-IPV-044),,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/213503/044,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",347414/023,,Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/023,,,Y,N,Y,Y,Y,Y,Y,A booster study 347414/036 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open, multicentric, post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine (TRITANRIX-HB) injected in healthy infants according to theprescribing information","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine",208139/053 (DTPw-HBV-053),,Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208139/053,,,N,N,Y,Y,N,Y,N,"An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,"A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine",347414/017,,Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/017,,,Y,N,Y,Y,Y,Y,Y,A booster study 347414/029 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine",763674/002,,Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/763674/002,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants,"Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",100478,NCT00290303,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100478,http://clinicaltrials.gov/show/NCT00290303,,Y,Y,Y,Y,Y,Y,Y,Follow on studies 105239 and 105245 were conducted.,1-Jun-2015
GSK,"A post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B vaccine (TRITANRIX-HB) and Haemophilus influenzae type-b tetanus-conjugate (Hib) vaccine (HIBERIX)co-administered in the same syringe in 1,000 Filipino subjects.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",213501/016 (DTPw-HBV-Hib/016),,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/213501/016,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, open, randomized study to evaluate the immunogenicity and reactogenicity of investigational vaccination regimens","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",402764/004,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/402764/004,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccinationregimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",759346/001,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759346/001,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Demonstrate non-inferiority of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",759346/007,NCT00317122,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/759346/007,http://clinicaltrials.gov/show/NCT00317122,,Y,N,Y,Y,Y,Y,Y,A follow-on study 104756 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age.","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine",763674/001,,Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/763674/001,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",213501/018 (DTPw-HBV-Hib-018),,Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213501/018,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Study to assess immunogenicity and reactogenicity of GSK Bio’s quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants","Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)",213501/019 (DTPw-HBV-Hib-019),,Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b,Phase 3,http://www.gsk-clinicalstudyregister.com/study/213501/019,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004)","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine","263855/017, 263855/030",,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/263855/017,,,N,N,Y,Y,Y,Y,N,This is a follow-on study to 263855/004 (dTpa-004). An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Open, non-randomized, phase IV study to evaluate immunogenicity and safety of GSK Biologicals’ dTpa vaccine when administered as single dose to healthy adolescents in their 11th to 18th year of life who were not previously vaccinated against pertussis and have anti-PT antibody titers < 20 EL.U/ml","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/019 (dTpa-019),,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/263855/019,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An open, phase III, single center study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ dTpa vaccine administered as a single-dose booster in healthy adults aged ≥ 18 years.","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/020 (dTpa-020),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/263855/020,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Single-blind, randomized, phase IV clinical trial to compare the immunogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) and Aventis Pasteur MSD’s tetanus toxoid vaccine (Tetavax®), ten days after vaccination of healthy adults 18 years of age and older","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/028 (dTpa-028),,Acellular pertussis; Diphtheria; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/263855/028,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Observer-blind, randomized, phase II clinical trial to assess the immunogenicity and safety of one dose of three formulations of GSK Biologicals’ dTpa vaccine containing 0.5 mg, 0.3 mg and 0.133 mg of aluminum, respectively in healthy adolescents aged 10 to 18 years","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/029 (dTpa-029),,Acellular pertussis; Diphtheria; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/263855/029,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Double-blind, randomised phase IIIb, study to compare the immunogenicity and reactogenicity of GSK Biologicals DTPa vaccine (Infanrix™) with GSK Biologicals dTpa (Boostrix™) administered to healthy children 4-6 years of age, having experienced an injection site reaction following the 4th dose of Infanrix™ vaccine","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",263855/033 (dTpa-033),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/263855/033,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",711866/001 (dTpa-IPV-001),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/711866/001,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Phase II study to assess immunogenicity and reactogenicity of GSK Biologicals dTpa-IPV vaccine compared to GSK Biologicals dTpa and Aventis Pasteur Merck Sharp Dohme’s IPV vaccines admind separately,and to assess immunogenicity and reactogenicity of GSK Biologicals DTPa-IPV vaccine, when administered to healthy adolescents","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",711866/002 (dTpa-IPV-002),,Acellular pertussis; Diphtheria; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/711866/002,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Assess immunogenicity, reactogenicity of GSK Biologicals’-dTpa-IPV vaccine versus dTpa & IPV vaccines administered separately & compared with Aventis Pasteur MSD’s Td-IPV vaccine when administered to healthy adolescents & adults","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",711866/003 (dTpa-IPV-003),NCT01277705,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/711866/003,http://clinicaltrials.gov/show/NCT01277705,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A phase 3, open, multicenter study of the safety and immunogenicity of a booster dose of SB Bios’ Diphtheria and Tetanus toxoids and acellular Pertussis vaccine and Pasteur Mérieux’s Haemophilus influenzae type b conjugate vaccine when admin intramuscularly as separate injections(12-18 mths of age)","Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed",208355/123 (APV-123),,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208355/123,,,Y,N,Y,Y,Y,Y,Y,This is a follow-up of primary study 217744/027. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma",fiboflapon,LPA112356,NCT00812773,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112356,http://clinicaltrials.gov/show/NCT00812773,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID",fiboflapon,LPA114387,NCT01248975,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114387,http://clinicaltrials.gov/show/NCT01248975,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"Absolute Bioavailability of FP, BDP, and Budesonide following single inhaled 400mcg dose and assay limits of 50pg/mL.",fluticasone propionate,FMS10031,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FMS10031,,,N,N,N,Y,N,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only a draft version was located; no final version found in archives. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ...",fluticasone propionate/salmeterol,SAS30024,,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SAS30024,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, double blind, placebo controlled, three-way cross-over study in asymptomatic patients with seasonal allergic rhinitis to compare the effect of 7 days treatment with intranasal salmeterol/fluticasone propionate combination ( 100mcg/200mcg) with 7 days treatment of fluticasone propionate (200mcg) or placebo, on nasal clinical symptoms and nasal blockage following intranasal allergen challenge.",fluticasone propionate/salmeterol,SNA10001,,Rhinitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SNA10001,,,N,Y,N,Y,N,Y,Y,An analysis-ready dataset is not available for this study. A clinical study report and a protocol are not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years.",fluticasone propionate/salmeterol,SAS10020,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SAS10020,,,N,N,N,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors",foretinib,MET111516,NCT00742261,Solid Tumours,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MET111516,http://clinicaltrials.gov/show/NCT00742261,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma,foretinib,MET111644,NCT00726323,"Carcinoma, Renal Cell",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MET111644,http://clinicaltrials.gov/show/NCT00726323,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A randomised, double-blind, three-way crossover study to investigate the effects of nebulised sterile water for injection on beta-agonist induced bronchodilation in healthy male and female volunteers.",GSK159802,B2F100819,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/100819,,,Y,N,N,Y,Y,Y,Y,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, double-blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled dry powder doses of GSK159802 in healthy male subjects and asthmatics",GSK159802,B2F104300,NCT00364273,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2F104300,http://clinicaltrials.gov/show/NCT00364273,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic pharmacokinetics of GSK159802 administered once daily for 28 days in healthy male subjects.",GSK159802,B2F104543,,"Pulmonary Disease, Chronic Obstructive",Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects with Type 2 Diabetes Mellitus",GSK2245840,SIR114010,NCT01018017,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114010,http://clinicaltrials.gov/show/NCT01018017,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers",GSK2245840,SIR113140,NCT00933062,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113140,http://clinicaltrials.gov/show/NCT00933062,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Jun-2015
GSK,"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",GSK2245840,SIR113160,NCT00937326,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113160,http://clinicaltrials.gov/show/NCT00937326,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Jun-2015
GSK,"A phase I randomized, open-label, clinical study to assess the effect of food and gender on the pharmacokinetics of SRT2104 administered as an oral suspension or capsule formulation to normal healthy volunteers",GSK2245840,SIR113261,NCT00938275,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113261,http://clinicaltrials.gov/show/NCT00938275,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Jun-2015
GSK,A Phase I study to evaluate single and multiple (seven) oral doses of SRT2104 on the endotoxin induced inflammatory response in healthy male subjects,GSK2245840,SIR114009,NCT01014117,Sepsis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114009,http://clinicaltrials.gov/show/NCT01014117,,Y,N,Y,Y,Y,N,Y,An raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days",GSK2245840,SIR113312,NCT00964340,"Atrophy, Muscular",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113312,http://clinicaltrials.gov/show/NCT00964340,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A randomised, double-blind, placebo-controlled, multi-way crossover study to assess the effects of single oral doses of SRT2104 and prednisolone on biomarkers in blood in healthy volunteers",GSK2245840,SIR113161,NCT00920660,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113161,http://clinicaltrials.gov/show/NCT00920660,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Jun-2015
GSK,"A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers",GSK2245841,SIR117041,NCT01702493,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117041,http://clinicaltrials.gov/show/NCT01702493,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"A randomised, double blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled doses of a new chemical entity in healthy male subjects.",GW597901,B2A10001,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2A10001,,,Y,Y,N,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics of single inhaled dose of a new chemical entity in asthmatic subjects.",GW597901,B2A10002,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2A10002,,,Y,Y,N,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A multi-centre, randomized, double-blind, double dummy, placebo-controlled, 5-period crossover study to examine the safety, tolerability, systemic pharmacodynamics, and systemic pharmacokinetics of single inhaled doses of a new chemical entity in asthmatic subjects.",GW678007,B2B10002,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2B10002,,,Y,Y,N,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Safety and immunogenicity of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine (GSK1562902A) in children aged 6 to 35 months,H5N1 Pre-pandemic Influenza Vaccine,109825,NCT01323946,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/109825,http://clinicaltrials.gov/show/NCT01323946,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2015
GSK,"A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects.",Haemophilus influenzae Type b Vaccine,208108/059 (Hib-059),,Haemophilus influenzae type b,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208108/059,,,Y,N,Y,Y,N,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants,Haemophilus influenzae Type b Vaccine,208108/087 (Hib-087),,Haemophilus influenzae type b,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208108/087,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals’ investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017",Haemophilus influenzae Type b Vaccine,347414/029,,Haemophilus influenzae type b,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/029,,,Y,N,Y,Y,Y,Y,N,This is a booster of primary study 347414/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023",Haemophilus influenzae Type b Vaccine,347414/036,,Haemophilus influenzae type b,Phase 3,http://www.gsk-clinicalstudyregister.com/study/347414/036,,,Y,N,Y,Y,Y,Y,N,This is a booster of primary study 347414/023. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004.",Haemophilus influenzae Type b Vaccine,371594/006,,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/371594/006,,,Y,N,Y,Y,Y,Y,N,This is a follow-up of primary study 371594/004. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase IV, open, randomized, controlled, comparative, multicenter U.S. study of the safety of GSK Bios' combination hepatitis A and hepatitis B vaccine administered on a 0-1-6 mth schedule by intramuscular injection compared with concurrently administered monovalent vaccines in healthy adults","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/091 (HAB-091),,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208127/091,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An open, randomized, monocentric study to evaluate the immunogenicity, reactogenicity and safety of GSK Bios' combined hepatitis A/hepatitis B vaccine compared to separate vaccinations with hepatitis A and hepatitis B vaccines of Chiron Behring/Aventis Pasteur in healthy adult volunteers.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/097 (HAB-097),,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208127/097,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Comparison of the immunogenicity and safety in healthy monozygotic and dizygotic twins, which have been grown up in the same environment, after having receipt three vaccinations (Mths 0-1-6) with the hepatitis A and B combination vaccine TWINRIX™ ADULT",twinrix,208127/098 (HAB-098),,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208127/098,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, open, randomized, multicenter, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bios’ combined hepatitis A/hepatitis B vac admin according to a 0-6 mth schedule by intramuscular injection versus TWINRIX™ JUNIOR admin in healthy children",twinrix,208127/120 (HAB-120),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/120,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An open study to evaluate the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A / hepatitis B vaccine (schedule 0, 1, 6 months) in healthy children aged 1 to 6 years.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/122 (Ext-HAB-039 Month 90),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/122,,,Y,N,Y,Y,Y,Y,N,This is a follow-up of primary study 208127/042. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III open study to assess the anamnestic response to a single injection of Twinrix vaccine, given approximately 44 months after primary vaccination with combined hepatitis A/ hepatitis B vac, in healthy subjects who have a previously documented seroprotective anti-HBs antibody response",twinrix,208127/123 (HAB-123),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/123,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/125 (Ext-HAB-038 Month 90),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/125,,,Y,N,Y,Y,Y,Y,N,This is a 90 month follow-up of the primary study HAB-038. A 10 year follow-up study 101040 was also conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, open, randomized, multicentric study to evaluate the immunogenicity, reactogenicity and safety of an experimental vaccine to that of Twinrix™ Adult admin following an accelerated schedule (0-7-21 days + 12 mths) in healthy adults aged more than 16 years.",twinrix,208127/126 (HAB-126),,Hepatitis A; Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208127/126,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, double-blind, controlled, multicentric randomized study, to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vac as compared to the combined hepatitis A/hepatitis B vac with preservative, admin at 0-1-6 Mth","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/129 (HAB-129),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/129,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,A phase IV open study to assess the persistence of anti-HBs and anti-HAV antibodies in older adults approximately 2 years after a primary 3-dose vaccination course with GlaxoSmithKline Biologicals’ combined hepatitis A/hepatitis B vaccine Twinrix( (720/20).,twinrix,208127/130 (EXT:HAB-098),,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208127/130,,,Y,N,Y,Y,Y,Y,N,This is a follow-up of primary study 208127/098. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase 4, open, comparative, multicenter study of the immunogenicity and safety of SB Bios' inactivated hepatitis A vaccine 720 EL.U/ 0.5 ml on a 0-6-month schedule, admin by intramuscular injection, either to children aged 15-18 mths old or 11-13 mths old, when compared to 23-25 mth-old children","Hepatitis A vaccine, Inactivated",208109/210 (HAV-210),,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208109/210,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase IV open study to assess the anamnestic response to a single intramuscular injection of GSK Bios’ hepatitis A vac, Havrix™ Junior in healthy adult subjects who have had a previously documented seropositive status following a full course of primary vaccination with GSK Bios’ hepatitis A vac","Hepatitis A vaccine, Inactivated",208109/228 (HAV-228),,Hepatitis A,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208109/228,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase IIIb, open, multicenter study of the immunogenicity and safety of one dose of GSK Bios' inactivated hepatitis A vaccine administered to healthy children who were seropositive for anti-HAV","Hepatitis A vaccine, Inactivated",208109/229 (HAV-229),,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208109/229,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Bios’ combined Vi polysaccharide typhoid vac and inactivated hepatitis A vac, to that elicited by GSK Bios’ hepatitis A vac, admin singly or concomitantly with GSK Bios’ Vi polysaccharide vac","Hepatitis A Vaccine, Inactivated","270362/006, 270362/007, 270362/008, 270362/009",NCT00197249,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/270362/006,http://clinicaltrials.gov/show/NCT00197249,,N,N,Y,Y,Y,Y,N,"The results of this primary study are summarized with studies 270362/007 (M12), 270362/008 (M24), 270362/009 (M36)  on the GSK Clinical Study Register. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jun-2015
GSK,"Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life.","Hepatitis A Vaccine, Inactivated",347414/010,NCT00119743,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/347414/010,http://clinicaltrials.gov/show/NCT00119743,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Phase II study to evaluate the immunogenicity of GSK Biologicals' preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™-B and evaluate safety and reactogenicity of each vaccine when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers","Hepatitis B Vaccine, Recombinant",103860/269 (HBV-269),,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/103860/269,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Immunogenicity and protective efficacy of GlaxoSmithKline (GSK) recombinant-DNA hepatitis B vaccine (10 (g) in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group.,"Hepatitis B Vaccine, Recombinant",103860/271 (Ext-HBV-064 Y14-Y15),,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/103860/271,,,N,N,Y,Y,N,Y,N,"This is a follow-up of primary study 103860/064. An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,Study in infants vaccinated with Engerix-B to evaluate immunogenicity and reactogenicity of following GSK Bio’s vaccines: combined DTP-HB vaccine(10g HBsAg)combined DTP-HB vaccine(5g HBsAg) simultaneous administration of Engerix-B vaccine in right thigh and whole-cell DTP vaccine in left thigh,"Hepatitis B Vaccine, Recombinant",208139/054 (DTPw-HBV-028 Ext. Y7),,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208139/054,,,N,N,Y,Y,N,Y,N,"This is a  follow-up of primary study 208139/054. An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age,"Hepatitis B Vaccine, Recombinant",347414/008,,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/347414/008,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age","Hepatitis B Vaccine, Recombinant",444563/007 (rota-007),NCT00429481,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/007,http://clinicaltrials.gov/show/NCT00429481,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease,Herpes Simplex Vaccine,208141/017,NCT00699764,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/017,http://clinicaltrials.gov/show/NCT00699764,,Y,N,Y,Y,Y,Y,Y,A follow-up study 208141/037 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Safety and reactogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received either alum-MPL or alum as placebo during one of GSK Bio’s phase III studies 208141/005, 208141/016 or 208141/017.",Herpes Simplex Vaccine,208141/037,,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/037,,,Y,N,Y,Y,Y,Y,N,"This is a follow-up of primary studies 208141/005, 208141/016 and 208141/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,"Safety, reactogenicity, and immunogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received alum-MPL or alum placebo during one of GSK Bio’s Phase III studies 208141/005, 208141/016 or 208141/017.",Herpes Simplex Vaccine,208141/038,,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/038,,,Y,N,Y,Y,Y,Y,N,"This is a follow-up of primary studies 208141/005, 208141/016 and 208141/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years.,Herpes Simplex Vaccine,208141/040,NCT00224484,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/040,http://clinicaltrials.gov/show/NCT00224484,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule.,Herpes Simplex Vaccine,208141/041,,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/041,,,Y,N,Y,Y,Y,Y,Y,This is a follow-up of primary study 208141/026. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,Study to Compare Immunogenicity & Safety of 3 comercial Lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10–17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10–17 y With Healthy HSV 1-/2- Adult Females,Herpes Simplex Vaccine,208141/042,NCT00224471,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/042,http://clinicaltrials.gov/show/NCT00224471,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,Follow-up study to evaluate the long-term immunogenicity and safety of a HPV vaccine (580299) in healthy female subjects,Human Papillomavirus Types 16 and 18 Vaccine,111375,NCT00877877,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111375,http://clinicaltrials.gov/show/NCT00877877,,Y,Y,Y,Y,Y,Y,Y,"This is a follow-up of primary study  580299/013. The results of 580299/013 are summarised with studies 104896 (M18), 104902 (M24), 104904 (M36) and 104918 (M48) on the GSK Clinical Study Register",1-Jun-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ HPV vaccine (GSK 580299) in healthy adult Chinese female subjects,Human Papillomavirus Types 16 and 18 Vaccine,114590,NCT01277042,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114590,http://clinicaltrials.gov/show/NCT01277042,,Y,N,Y,Y,Y,Y,Y,This is a follow-up of primary study 107638. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A Phase I Study of the Safety and Immunogenicity of MEDI-517, a Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers.",Human Papillomavirus Types 16 and 18 Vaccine,580299/002,,"Infections, Papillomavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/580299/002,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase I/II Study to evaluate the safety and immunogenicity of MEDI-517, a virus-like particle vaccine against human papillomavirus (HPV) types 16 and 18, in healthy adult female volunteers who are HPV-16 or HPV-18 DNA positive",Human Papillomavirus Types 16 and 18 Vaccine,580299/003,,"Infections, Papillomavirus",Phase 1/2,http://www.gsk-clinicalstudyregister.com/study/580299/003,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers",Human Papillomavirus Types 16 and 18 Vaccine,580299/004,NCT00693615,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/580299/004,http://clinicaltrials.gov/show/NCT00693615,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jun-2015
GSK,"A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers",Human Papillomavirus Types 16 and 18 Vaccine,580299/005,NCT00693966,"Infections, Papillomavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/580299/005,http://clinicaltrials.gov/show/NCT00693966,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Phase I study in elderly population aged over 65 years in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccine or a Whole virus vaccine. For both immunogenicity and safety evaluations, the commercial inactivated split vaccine Fluarix will be used as reference",Influenza Vaccine,227855/001,,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/227855/001,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase IV, open, randomised study in adults aged 18-60 and over 60 years to evaluate the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' Fluarix™ vaccine administered using two different routes","Influenza Vaccine (Split Virion, Inactivated)",684289/001,,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/684289/001,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, open, controlled, randomised study in adults aged 18-60 and elderly aged over 60 years to confirm the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' investigational influenza vaccine","Influenza Vaccine (Split Virion, Inactivated)",701464/005,,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/701464/005,,,Y,N,Y,Y,N,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151.","Measles, Mumps, Rubella Vaccine",104420,,Measles; Mumps; Rubella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104420,,,Y,N,Y,Y,Y,Y,Y,This is a two year follow-on study of primary study 209762/151. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R IIvaccine, administered to healthy children 12 to 18 months of age","Measles, Mumps, Rubella Vaccine",209762/136 (MeMuRu-136),,Measles; Mumps; Rubella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/209762/136,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.","Measles, Mumps, Rubella Vaccine",209762/147 (MeMuRu-147),NCT00388440,Measles; Mumps; Rubella,Phase 4,http://www.gsk-clinicalstudyregister.com/study/209762/147,http://clinicaltrials.gov/show/NCT00388440,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2015
GSK,"Phase II, double blind, randomized sequential study to compare immunogenicity and reactogenicity of the current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine containing human serum albumin with the modified formulations which do not contain HSA","Measles, Mumps, Rubella Vaccine",209762/148,,Measles; Mumps; Rubella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/209762/148,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Phase IV, single-blind, randomised, multicenter study to evaluate immediate post-vaccination pain, reactogenicity and tolerance of GSK Bio’s Measles-Mumps-Rubella vaccine (Priorix) administered as a second dose compared to Aventis-Pasteur-MSDs Measles-Mumps-Rubella vaccine (ROR Vax)","Measles, Mumps, Rubella Vaccine",209762/149 (MeMuRu-149),,Measles; Mumps; Rubella,Phase 4,http://www.gsk-clinicalstudyregister.com/study/209762/149,,,Y,N,N,Y,N,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan and a protocol are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Double blind, randomized sequential study to compare immunogenicity and reactogenicity of current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine to investigational vaccination regimens","Measles, Mumps, Rubella Vaccine",209762/150,,Measles; Mumps; Rubella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/209762/150,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Phase II study to evaluate immunogenicity, reactogenicity and safety of GSK Bios’ investigational vaccination regimen compared to the currently licensed GSK Bios’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months","Measles, Mumps, Rubella Vaccine",209762/151,,Measles; Mumps; Rubella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/209762/151,,,Y,N,Y,Y,Y,Y,Y,A two year follow-up study 104420 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, open, randomized, controlled study to assess the immune memory induced by an investigational vaccination regimen and the safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen in toddlers primed in study 404286/001.","Meningococcal Serogroups A, C, W-135 and Y Vaccine",404286/006,,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/404286/006,,,Y,N,Y,Y,Y,Y,N,This is a follow-up of primary study 404286/001. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase II, open, randomized, controlled study to evaluate the reactogenicity and safety of an investigational vaccination regimen in healthy toddlers aged 24-30 months.","Meningococcal Serogroups A, C, W-135 and Y Vaccine",675187/001,,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/675187/001,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus a licensed MenC vaccine or Mencevax™ ACWY when given in children aged 12 to 14 months and 3 to 5 years old","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",134612/004,,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/004,,,Y,N,Y,Y,Y,Y,Y,A follow-up study 134612/005 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus Mencevax ACWY when given in children aged 3 to 5 years old","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",134612/005,,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/005,,,Y,N,Y,Y,Y,Y,Y,This is a booster of study 134612/004. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A primary vaccination study to evaluate immunogenicity, safety & reactogenicity of 3 doses of GSK Biologicals/Finlay’s meningococcal B candidate vaccine given intramuscularly using either 0-2-4 mth or 0-1-6 mth schedule to healthy subjects aged 12-18 yrs",Meningococcal Vaccine,710158/002,NCT00137917,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/710158/002,http://clinicaltrials.gov/show/NCT00137917,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jun-2015
GSK,"Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life",Meningococcal Vaccine,711202/001,NCT00135486,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/711202/001,http://clinicaltrials.gov/show/NCT00135486,,Y,N,Y,Y,Y,Y,Y,A persistence study 711202/008 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals’ MenC-TT (1 formulation) & GSK Biologicals’ Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 mths primed in study 711202/001,Meningococcal Vaccine,711202/008,NCT00135564,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/711202/008,http://clinicaltrials.gov/show/NCT00135564,,Y,N,Y,Y,Y,Y,Y,This is a persistence study of 711202/001. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™",Meningococcal Vaccine,811936/001 (Hib-MenC-TT-001),,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/811936/001,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, double-blind, placebo-controlled, dose ascending crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled GSK159797 delivered by dry powder inhaler in mild to moderate asthmatic subjects",milveterol,B2E101312,NCT00354666,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2E101312,http://clinicaltrials.gov/show/NCT00354666,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because only a draft version was located; no final version found in archives.  There is no GSK Clinical Study Register Results Summary record for this study.,1-Jun-2015
GSK,"A randomised, double blind, placebo controlled, parallel group study to examine the safety, tolerability, and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 and COA",milveterol,B2E100529,,"Pulmonary Disease, Chronic Obstructive",Phase 1,,,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because only a draft version was located; no final version found in archives. There is no GSK Clinical Study Register entry for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jun-2015
GSK,"A randomised, double blind, placebo controlled, parallel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797",milveterol,B2E100527,,"Pulmonary Disease, Chronic Obstructive",Phase 2,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jun-2015
GSK,"An open labeled, single sequence study to investigate the safety and pharmacokinetics of oral pimozide when co-administered with repeat dosing oral paroxetine 60 mg od in healthy volunteers.",paroxetine,29060/877,,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/29060/877,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder,paroxetine,29060/650,,Post-Traumatic Stress Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/650,,,Y,N,Y,Y,Y,Y,Y,The data from this study is provided in combined datasets containing data from other paroxetine studies. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet,paroxetine,29060/653 (BRL-029060/653),,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/29060/653,,,N,N,N,Y,N,Y,N,"An analysis-ready dataset, an annotated case report form, a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,"A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of GSK Biologicals’ live attenuated human rotavirus vaccine at 2 different virus concentrations in healthy seropositive children between 1 and 3 years of age, when given as a single oral administration",Rotavirus Vaccine,444563/002 (rota-002),,"Infections, Rotavirus",Phase 1,http://www.gsk-clinicalstudyregister.com/study/444563/002,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus.",Rotavirus Vaccine,444563/003 (rota-003),,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/003,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants.",Rotavirus Vaccine,444563/004,NCT00425737,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/004,http://clinicaltrials.gov/show/NCT00425737,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Bios’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus",Rotavirus Vaccine,444563/005 (rota-005),NCT00729001,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/005,http://clinicaltrials.gov/show/NCT00729001,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib.",Rotavirus Vaccine,444563/006,NCT00385320,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/006,http://clinicaltrials.gov/show/NCT00385320,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Study of safety, reactogenicity and immunogenicity of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa",Rotavirus Vaccine,444563/014 (Rota-014),NCT00346892,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/014,http://clinicaltrials.gov/show/NCT00346892,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age",Rotavirus Vaccine,444563/020,,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/020,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals’ live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age",Rotavirus Vaccine,444563/021,,"Infections, Rotavirus",Phase 2,http://www.gsk-clinicalstudyregister.com/study/444563/021,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases",SRT501,SIR113221,NCT00920803,"Neoplasms, Colorectal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113221,http://clinicaltrials.gov/show/NCT00920803,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma",SRT501,SIR113222,NCT00920556,Multiple Myeloma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113222,http://clinicaltrials.gov/show/NCT00920556,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2015
GSK,"An open-label, randomised, two-period, crossover study to assess the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered two hours after a single IMITREX 100 mg tablet relative to two 6 mg STATdose injections administered one hour apart in healthy volunteers.",sumatriptan,SUM20040,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SUM20040,,,N,N,N,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jun-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE)",vestipitant,NKG10006,,Sleep Initiation and Maintenance Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/NKG10006,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
GSK,"An Open Label, Single-Dose, Five-Way Crossover Study Examining Relative Oral Bioavailabilty of Zanamivir With Bioenhancing Excipients Following Direct Release Into Mid-Small Intestine Using Gamma Scintigraphy and the InteliSite Companion Capsule in Healthy Subjects.",zanamivir,NAI107485,,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/107485,,,Y,Y,N,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jun-2015
Roche,"A randomized, open-label study of the effect of Herceptin plus Arimidex compared with Arimidex alone on progression-free survival in patients with HER2-positive and hormone-receptor positive metastatic breast cancer",trastuzumab,BO16216,NCT00022672,HER2-positive  metastatic  breast cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00022672?term=BO16216&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
Roche,"Chemotherapy and Antibody Response Evaluation (CARE): A phase III, multinational, randomized study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) combined with chemotherapy in patients with HER2 overexpression who have not received cytotoxic chemotherapy for metastatic breast cancer.",trastuzumab,H0648G,,HER2-positive  metastatic  breast cancer,Phase 3,,,,Y,N,Y,N,Y,Y,Y,,1-Jul-2015
Roche,A multinational open-label study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have relapsed following one or two cytotoxic chemotherapy regimens for metastatic breast cancer.,trastuzumab,H0649G,,HER2-positive  metastatic  breast cancer,Phase 2,,,,Y,N,Y,N,Y,Y,N,,1-Jul-2015
Roche,A multinational randomized single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer.,trastuzumab,H0650G,,HER2-positive  metastatic  breast cancer,Phase 2,,,,Y,N,Y,N,Y,Y,N,,1-Jul-2015
Roche,An open-label extension study with recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) for patients whose metastatic breast cancer progressed during treatment on protocol H0648g.,trastuzumab,H0659G,,HER2-positive  metastatic  breast cancer,Phase 3,,,,Y,N,Y,N,Y,Y,N,,1-Jul-2015
Roche,"A multicenter, expanded access, open-label safety study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2 overexpression who relapsed following multiple cytotoxic chemotherapy regimens for metastatic breast cancer.",trastuzumab,H0693G,,HER2-positive  metastatic  breast cancer,Phase 3,,,,Y,N,Y,N,Y,Y,N,,1-Jul-2015
Roche,"A Multicenter, Randomized Comparative Study on the Efficacy and Safety of Herceptin (Trastuzumab) Plus Docetaxel (Taxotere) Versus Docetaxel Alone as First Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer",trastuzumab,M77001,,HER2-positive  metastatic  breast cancer,Phase 2,,,,Y,Y,Y,N,Y,Y,Y,,1-Jul-2015
Roche,"An open-label, randomized phase II study of Herceptin (trastuzumab), Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere (docetaxel), in patients with advanced and/or metastatic breast cancers that overexpress HER2.",trastuzumab,MO16419,,HER2-positive  metastatic  breast cancer,Phase 2,,,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
Takeda,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes",alogliptin,SYR-322_308,NCT01289119,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322_308,https://clinicaltrials.gov/show/NCT01289119,,Y,N,Y,Y,Y,Y,Y,,1-Oct-2014
Boehringer Ingelheim,Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms,tamsulosin,527.3,NCT02245490,Prostatic Hyperplasia,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02245490?term=527.30&rank=1,,Y,Y,Y,Y,Y,Y,Y,The study was co-sponsored by Boehringer Ingelheim and Astellas,1-Jul-2015
Boehringer Ingelheim,Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms,tamsulosin,527.25,NCT02244281,Lower Urinary Tract Symptoms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02244281?term=527.25&rank=1,,Y,Y,Y,Y,Y,Y,Y,The study was co-sponsored by Boehringer Ingelheim and Astellas,1-Jul-2015
Boehringer Ingelheim,"FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)",tamsulosin,527.26,NCT02244294,Prostatic Hyperplasia,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02244294?term=527.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,The study was co-sponsored by Boehringer Ingelheim and Astellas,1-Jul-2015
GSK,"U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects with Acne",benzoyl peroxide/salicylic acid,STF114551,NCT01706263,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114551,http://clinicaltrials.gov/show/NCT01706263,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study.,1-Jul-2015
GSK,Phase 1 study of skin irritation,"calcipotriol, calcipotriene",STF114731,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114731,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).",carvedilol,COR100216,NCT00108082,"Hypertrophy, Left Ventricular",Phase 3,http://www.gsk-clinicalstudyregister.com/study/COR100216,http://clinicaltrials.gov/show/NCT00108082,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients",carvedilol,COR103561,NCT00273052,Hypertension,Phase 3,http://www.gsk-clinicalstudyregister.com/study/COR103561,http://clinicaltrials.gov/show/NCT00273052,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria",carvedilol,COR103560,NCT00123903,"Heart failure, Congestive and Microalbuminuria",Phase 3,http://www.gsk-clinicalstudyregister.com/study/COR103560,http://clinicaltrials.gov/show/NCT00123903,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa-IPV vaccine or GSK Biologicals’ dTpa (BoostrixTM) and Pasteur Mérieux’s IPV vaccine (IPV Mérieux() administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001)","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine","711866/005 (dTpa-IPV-005, one year follow-up of dTpa-IPV-001)",,Acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/711866/005,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2015
GSK,"A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects",darapladib,LPL115677,NCT01751074,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115677,http://clinicaltrials.gov/show/NCT01751074,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of the Lp-PLA2 inhibitor SB-480848 (40, 80mg od) on carotid plaque composition in patients with carotid artery disease and planned carotid endarterectomy, stratified for statin use and gender, after 14+/-4 days treatment",darapladib,LPL480848/010,NCT01916720,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/480848/010,http://clinicaltrials.gov/show/NCT01916720,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Study to Evaluate the Effect of Steady-State New Chemical Entity (NCE) on the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Warfarin in Healthy Subjects",darapladib,480848/013,,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/480848/013,,,Y,N,Y,Y,Y,Y,Y,An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2, eff",darapladib,LPL104884,NCT00269048,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/LPL104884,http://clinicaltrials.gov/show/NCT00269048,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects with Moderate Hepatic Impairment",darapladib,480848/028,NCT01154114,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/480848/028,http://clinicaltrials.gov/show/NCT01154114,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement",darapladib,DM2115403,NCT01506895,"Retinopathy, Diabetic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115403,http://clinicaltrials.gov/show/NCT01506895,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Study to Evaluate the Effect of Repeat Oral Doses of SB-480848 on Platelet Function as Compared to Placebo,darapladib,LPL101597,N/A,Atherosclerosis,Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study.,1-Jul-2015
GSK,A Study to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of SB-480848,darapladib,LPL105550,N/A,Atherosclerosis,Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study.,1-Jul-2015
GSK,Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848,darapladib,LPL107038,N/A,Atherosclerosis,Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study.,1-Jul-2015
GSK,"A Dose Rising Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Doses of the Enteric-Coated Free Base Formulation of SB-480848 in Healthy Adult Subjects",darapladib,LPL107988,N/A,Atherosclerosis,Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study.,1-Jul-2015
GSK,A Study to Assess the ADMEand Absolute Bioavailability of SB-480848 in healthy subjects (3C),darapladib,480848/015,N/A,Atherosclerosis,Phase 1,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register entry for this study.,1-Jul-2015
GSK,A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin,darapladib,480848/035,NCT00411073,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/SB 480848/035,http://clinicaltrials.gov/show/NCT00411073,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Jul-2015
GSK,"A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects",darapladib,LPL110077,NCT00551317,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LPL110077,http://clinicaltrials.gov/show/NCT00551317,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, parallel group, repeat dose study to assess the effect of SB-480848 on overall asthma control in adult subjects with persistent asthma controlled on stable, low-dose, inhaled corticosteroids",darapladib,LPL107629,NCT00368576,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LPL107629,http://clinicaltrials.gov/show/NCT00368576,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Jul-2015
GSK,A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and its Metabolites in Healthy Volunteers.,darapladib,LPL112498,NCT00743860,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LPL112498,http://clinicaltrials.gov/show/NCT00743860,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Jul-2015
GSK,"An international, multicenter, randomized, placebo controlled, parallel-group, 1 year treatment, integrated biomarkers and imaging study in subjects with angiographically documented coronary artery disease (CHD) to examine the effects of the novel lipoprotein-associated phospholipase A2 (Lp-PLA2) in",darapladib,480848/026,NCT00268996,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SB-480848/026,http://clinicaltrials.gov/show/NCT00268996,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride,dutasteride,TDC106218,,"Hypogonadism, Male",Phase 1,http://www.gsk-clinicalstudyregister.com/study/106218,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"An open label, single dose, randomized, three period crossover study to investigate the relative bioavailability of 0.5 mg of dutasteride from soft gelatin capsules (reference) vs. soft gelatin capsules containing two investigational formulations in healthy male volunteers.",dutasteride,ARI103880,,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103880,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"An open label, single dose, randomised, three period crossover study to investigate the relative bioavailability of dutasteride softgel vs. dutasteride tablet and dutasteride softgel vs. dutasteride capsule in healthy male volunteers",dutasteride,ARI19033,,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ARI19033,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study Investigating the Effects of Either 4 or 6 Weeks Dutasteride 0.5mg Daily on Peri-Operative Bleeding Following Transurethral Resection of the Prostate (TURP) in Subjects with Benign Prostatic Hyperplasia (BPH).",dutasteride,ARI40007,,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI40007,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, 5-way cross incomplete block design study to investigate the relative potency of single inhaled doses of a NCE and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients",fluticasone furoate,FFA10007,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10007,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids",fluticasone furoate,FFA115283,NCT01436071,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115283,http://clinicaltrials.gov/show/NCT01436071,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids",fluticasone furoate,FFA115285,NCT01436110,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115285,http://clinicaltrials.gov/show/NCT01436110,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability and PK of once daily inhaled GW685698 with the excipient COA administered via DISKUS in healthy subjects",fluticasone furoate,FFA10009,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10009,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of a new chemical entity (NCE) and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects.",fluticasone furoate,FFA103096,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103096,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Comparison of Fluticasone Furoate Nasal
 Spray versus Oral Fexofenadine in the Treatment of Seasonal
 Allergic Rhinitis",fluticasone furoate,FFU109045,NCT00435461,"Rhinitis, Allergic, Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/FFU109045,http://clinicaltrials.gov/show/NCT00435461,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2015
GSK,"A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects",fluticasone furoate,FFA10003,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10003,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients.",fluticasone furoate,FFA10026,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10026,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma.",fluticasone furoate,FFA20001,NCT01499446,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/FFA20001,http://clinicaltrials.gov/show/NCT01499446,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects",fluticasone furoate,FFA115441,NCT01669070,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115441,http://clinicaltrials.gov/show/NCT01669070,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects",fluticasone furoate,FFA10001,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10001,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability and systemic pharmacokinetics and pharmacodynamics of repeat doses (500, 1000 and 2000mg) of GW685698X administered once daily for fourteen da",fluticasone furoate,FFA10002,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10002,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, single dose, open label, 3-way cross-over study to assess the systemic pharmacokinetics of GW685698X (1000mg) administered via Diskhaler with or without charcoal and an intravenous dose (250mg) in healthy male subjects",fluticasone furoate,FFA10008,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/FFA10008,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and FluticasonePropionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis",Fluticasone furoate,FFU108556,,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/108556,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared to fluticasone propionate delivered twice daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy.",fluticasone furoate/vilanterol,HZA113714,NCT01498653,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113714,http://clinicaltrials.gov/show/NCT01498653,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC112352,NCT01323621,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112352,http://clinicaltrials.gov/show/NCT01323621,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,HZC113109,NCT01323634,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113109,http://clinicaltrials.gov/show/NCT01323634,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily via a Dry Powder Inhaler Compared with Placebo in Subjects of Asian Ancestry with Chronic Obstructive Pulmonary Disease,fluticasone furoate/vilanterol,HZC113684,NCT01376245,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113684,http://clinicaltrials.gov/show/NCT01376245,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,RLV116974,NCT01706328,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116974,http://clinicaltrials.gov/show/NCT01706328,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An open-label, randomised, replicate, six-way crossover, single dose study to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF / vilanterol (VI) inhalation powder administered via the novel dry powder inhaler.",fluticasone furoate; fluticasone furoate/vilanterol,FFA115440,NCT01485445,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115440,http://clinicaltrials.gov/show/NCT01485445,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS)",fondaparinux sodium,EFC3557,,"Secondary prevention of Thromboembolic events; Thrombosis, Venous",Phase 3,http://www.gsk-clinicalstudyregister.com/study/EFC3557,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS)",fondaparinux sodium,EFC4582,,"Thrombosis, Venous",Phase 3,http://www.gsk-clinicalstudyregister.com/study/EFC4582,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer,foretinib,MET111643,NCT00725712,"Neoplasms, Gastrointestinal Tract",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MET111643,http://clinicaltrials.gov/show/NCT00725712,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors,foretinib,MET111647,NCT00742131,Solid Tumours,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MET111647,http://clinicaltrials.gov/show/NCT00742131,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck,foretinib,MET111646,NCT00725764,"Neoplasms, Head and Neck",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MET111646,http://clinicaltrials.gov/show/NCT00725764,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects,GSK2239633,CC4114041,NCT01086462,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114041,http://clinicaltrials.gov/show/NCT01086462,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled, cross-over study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of GSK2239633 in healthy male subjects.",GSK2239633,CC4114660,NCT01371812,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114660,http://clinicaltrials.gov/show/NCT01371812,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomized, double-blind, placebo-controlled, parallel group study to compare GW766944 (an oral CCR3 receptor antagonist) versus placebo in patients with asthma and sputum eosinophilia.",GW766994,CRA114312,NCT01160224,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114312,http://clinicaltrials.gov/show/NCT01160224,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, placebo-controlled, four-period, crossover study of 8 days repeat dosing of a new chemical entity (NCE), fluticasone propionate (200 µg od) and placebo (blinded for NCE vs placebo) to evaluate the efficacy and safety using the Vienna Challenge Chamber in subjects with allergic rhinitis.",GW799943,ODN1003,,"Rhinitis, Allergic, Perennial",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ODN1003,,,N,N,N,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis",GW870086,SSD113434,NCT01299610,"Dermatitis, Atopic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113434,http://clinicaltrials.gov/show/NCT01299610,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind (for GW870086X), placebo-controlled study of topical GW870086X formulation to explore the potential for skin thinning in healthy adult volunteers",GW870086,SSD113435,NCT01381445,"Dermatitis, Atopic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113435,http://clinicaltrials.gov/show/NCT01381445,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis",ibandronic acid,BON103593,NCT00148915,Osteoporosis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/BON103593,http://clinicaltrials.gov/show/NCT00148915,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS",ketoconazole,STF114568,NCT00703846,"Dermatitis, Seborrheic",Phase 4,http://www.gsk-clinicalstudyregister.com/study/114568,http://clinicaltrials.gov/show/NCT00703846,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Multicenter, Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms",lamotrigine,LAM40117,,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40117,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy,lamotrigine,LAM40124,,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/LAM40124,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"Protocol SB-275833/030 – Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily…",retapamulin,275833/030,,"Skin Infections, Bacterial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/275833/030,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily",retapamulin,275833/032,,"Skin Infections, Bacterial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/275833/032,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III
 Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment versus
 Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adults and
 Paediatric Subjects with Impetigo.",retapamulin,TOC103469,NCT00133848,Impetigo,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TOC103469,http://clinicaltrials.gov/show/NCT00133848,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,See Detailed Description,retapamulin,TOC100224,NCT00133874,"Skin Infections, Bacterial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/TOC100224,http://clinicaltrials.gov/show/NCT00133874,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures","retigabine, ezogabine",PTG116878,NCT01721317,Seizures,Phase 4,http://www.gsk-clinicalstudyregister.com/study/116878,http://clinicaltrials.gov/show/NCT01721317,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS)",ropinirole,ROX104805,NCT00256854,Restless Legs Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ROX104805,http://clinicaltrials.gov/show/NCT00256854,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 101468/206 was conducted.,1-Jul-2015
GSK,"An Open-Label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169",ropinirole,101468/248,NCT00632736,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101468/248,http://clinicaltrials.gov/show/NCT00632736,,Y,Y,Y,Y,Y,Y,Y,"This is an extension study of studies 101468/165, 101468/168 and 101468/169",1-Jul-2015
GSK,"A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Sulphonylurea therapy, When Administered to Patients with Type 2 Diabetes Mellitus.",rosiglitazone,49653/015,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/015,,,Y,Y,Y,Y,Y,Y,N,Extension study 49653/009 was conducted. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus.",rosiglitazone,49653/020,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/020,,,N,N,Y,Y,Y,Y,N,Extension study 49653/009 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A 26-week Randomized, Double-Blind, Double-Dummy, Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maximal Dose (20 mg/day) of Glyburide.",rosiglitazone,49653/079,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/079,,,Y,Y,Y,Y,Y,Y,N,Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on…",rosiglitazone,49653/096,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/096,,,Y,Y,Y,Y,Y,Y,N,Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A 26-Week Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of BRL 49653C when Administered Twice Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on Insulin Monotherapy",rosiglitazone,49653/082,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/082,,,N,N,Y,Y,Y,Y,N,Extension study 49653/114 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A 26-week Randomised, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Type 2 Diabetes who are Inadequately Controlled on Insulin Monotherapy",rosiglitazone,49653/095,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/49653/095,,,N,N,Y,Y,Y,Y,N,Extension study 49653/114 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,A study to assess the effect of food and time of dosing on the pharmacokinetics of Avandamet™ (rosiglitazone maleate 8 mg/metformin HCl 1000 mg administered as 2 ' 4/500) Glucophage XR 1000 mg (given as metformin HCl 2 ' 500 mg) and Avandia™ (rosiglitazone maleate 8 mg) in healthy adult subjects.,rosiglitazone/metformin,712753/011,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/712753/011,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A 28-Week, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Formulation X in Subjects with Type 2 Diabetes Mellitus",rosiglitazone/metformin,AVM100344,,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/100344,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment.",rosiglitazone/metformin,AVT105913,NCT00386100,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/AVT105913,http://clinicaltrials.gov/show/NCT00386100,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus,rosiglitazone/metformin,712753/004,NCT00067951,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/712753/004,http://clinicaltrials.gov/show/NCT00067951,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A study to assess the steady state pharmacokinetics of repeat oral doses of AVANDAMET XR (combination formulation of rosiglitazone 8mg/metformin 1000mg) and AVANDAMET IR (rosiglitazone 4mg/metformin 500mg) in healthy subjects,rosiglitazone/metformin,712753/014,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/712753/014,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A single centre, randomised, double-blind, placebo-controlled, crossover, pilot study to determine the efficacy and safety of 400 µg and 200 µg doses of Ventolin ™ salbutamol inhaler versus placebo for the treatment of smoking related cough.",salbutamol,SBM20002,,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SBM20002,,,N,N,Y,Y,Y,Y,Y,"An analysis-ready dataset, an annotated case report form, and a blank case report form are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jul-2015
GSK,"A single centre, randomised, double blind, double dummy, cross-over study to measure the topical and systemic effects of Salbutamol delivered by the Turbuhaler inhaler compared with the Diskus dry powder inhaler at high and low flow rates in adult patients with reversible obstructive airways disease.",salbutamol,SBM40003,,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SBM40003,,,N,N,Y,Y,Y,Y,N,"An analysis-ready dataset, an annotated case report form, and a blank case report form, and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Jul-2015
GSK,A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease,salbutamol,DB2114956,NCT01691482,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/114956,http://clinicaltrials.gov/show/NCT01691482,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SMS40314,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40314,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SMS40315,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40315,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease",salmeterol,SMS40321,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40321,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomized, double-blind, placebo-controlled study in healthy volunteers to examine the safety, tolerability and pharmacokinetics of a) single, ascending and b) twice-daily repeat doses of intranasal SB-705498",SB705498,VR1111610,NCT00907933,Rhinitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111610,http://clinicaltrials.gov/show/NCT00907933,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers",SB705498,VR1111611,NCT00731250,Rhinitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111611,http://clinicaltrials.gov/show/NCT00731250,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomized, double blind, placebo controlled study to assessthe effect of intranasal single dose SB-705498 on the response tointranasal capsaicin challenge in non-allergic rhinitis patients",SB705498,VR1111925,NCT01439308,Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111925,http://clinicaltrials.gov/show/NCT01439308,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatripta ...",sumatriptan,SUM102146,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/102146,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"An open label, single dose, randomised, parallel group pharmacokinetic study to evaluate a combination product containing naproxen sodium and sumatriptan in adolescent subjects with migraine and healthy adult subjects administered at three doses.",sumatriptan,TXA108504,NCT00989625,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/108504,http://clinicaltrials.gov/show/NCT00989625,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET)",sumatriptan/naproxen,TXA107563,NCT00387881,"Migraine, Without Aura",Phase 3,http://www.gsk-clinicalstudyregister.com/study/TXA107563,http://clinicaltrials.gov/show/NCT00387881,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of MT 400 Tablets or Naproxen Sodium Tablets on Chromosomal Aberrations (CA) in Peripheral Blood Lymphocytes",sumatriptan/naproxen,TXA113014,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113014,,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers.",sumatriptan/naproxen,MT400-101 (112490),,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MT400-101 (112490),,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers.,sumatriptan/naproxen,MT400-102 (112491),,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MT400-102 (112491),,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers.,sumatriptan/naproxen,MT400-103 (112492),,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MT400-103 (112492),,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack,sumatriptan/naproxen,MT400-104 (112493),,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MT400-104 (112493),,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers.,sumatriptan/naproxen,MT400-105 (112494),,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MT400-105 (112494),,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents",sumatriptan/naproxen,TXA107979,NCT00843024,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107979,http://clinicaltrials.gov/show/NCT00843024,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents",sumatriptan/naproxen,TXA107977,NCT00488514,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TXA107977,http://clinicaltrials.gov/show/NCT00488514,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System® and a TREXIMA tablet followed by IMI",sumatriptan/naproxen,TRX103629,NCT00875784,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103629,http://clinicaltrials.gov/show/NCT00875784,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2),sumatriptan/naproxen,TRX106571,NCT00383162,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX106571,http://clinicaltrials.gov/show/NCT00383162,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2),sumatriptan/naproxen,TRX106573,NCT00382993,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX106573,http://clinicaltrials.gov/show/NCT00382993,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)*, Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks",sumatriptan/naproxen,TRX103632,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103632,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet)",sumatriptan/naproxen,TRX103635,NCT00240617,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX103635,http://clinicaltrials.gov/show/NCT00240617,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.",sumatriptan/naproxen,TRX105848,NCT00385008,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX105848,http://clinicaltrials.gov/show/NCT00385008,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea",sumatriptan/naproxen,TRX105850,NCT00329459,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX105850,http://clinicaltrials.gov/show/NCT00329459,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,See Detailed Description,sumatriptan/naproxen,TRX105852,NCT00329355,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TRX105852,http://clinicaltrials.gov/show/NCT00329355,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine",sumatriptan/naproxen,TRX101998,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101998,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine",sumatriptan/naproxen,TRX101999,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/101999,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™* in the Acute Treatment of Migraine Headaches",sumatriptan/naproxen,TXA112495,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112495,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™*in the Acute Treatment of Migraine Headaches",sumatriptan/naproxen,TXA112496,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112496,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months.",sumatriptan/naproxen,TXA112497,,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112497,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"An open-label, randomized, single-dose, 2-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™(sumatriptan 85mg and naproxen sodium 500mg)*, Tablet compared with an IMITREX® (sumatriptan) 100mg Tablet",sumatriptan/naproxen,TRX106396,,Migraine Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/106396,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,Phase II Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for subjects with Untreated Low-Grade Non Hodgkin's Lymphoma.,tositumomab,BEX104514,NCT01663714,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104514,http://clinicaltrials.gov/show/NCT01663714,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A phase I, dose-escalation, open label, multicenter study of Iodine-131 anti-B1 antibody for intermediate- and high-risk B-cell chronic lymphocytic leukemiaNote: Extensive searching has revealed that no clinical study report is available for this study.",tositumomab,BEX104510,,"Leukaemia, Lymphocytic, Chronic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/CP-98-018,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Jul-2015
GSK,"Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients with Previously Treated Non Hodgkin’s Lymphoma With More Than 25% Bone Marrow Involvement",tositumomab,BEX104512,NCT00992758,"Lymphoma, Non-Hodgkin",Phase 1,http://www.gsk-clinicalstudyregister.com/study/104512,http://clinicaltrials.gov/show/NCT00992758,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies",tositumomab,BEX104731,NCT01224821,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104731,http://clinicaltrials.gov/show/NCT01224821,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma,tositumomab,393229/023,NCT00933335,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/393229/023,http://clinicaltrials.gov/show/NCT00933335,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jul-2015
GSK,Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody,tositumomab,393229/010,NCT00938041,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/393229/010,http://clinicaltrials.gov/show/NCT00938041,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
GSK,"A single-blind, non-randomized pharmacokinetic and safety study of single dose of GSK573719 and GSK573719 + GW642444 combination in healthy subjects and in subjects with severe renal impairment",umeclidinium bromide/vilanterol,DB2114636,NCT01571999,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114636,http://clinicaltrials.gov/show/NCT01571999,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2015
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Depressive Disorder",Atomoxetine,B4Z-MC-LYAX,Not available,Attention Deficit Hyperactivity Disorder; Major Depressive Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for these studies because the studies were conducted before regulatory requirements to register studies.,1-Aug-2015
Astellas,"A Randomized, Double-blind, Parallel, Placebo-controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy",solifenacin succinate,905-UC-050,NCT01371994,Urinary Incontinence,Phase 4,Not Available,https://clinicaltrials.gov/ct2/show/NCT01371994,,Y,Y,Y,Y,Y,Y,Y,Population: subjects who are incontinent after Robotic Assisted Radical Prostatectomy,1-Aug-2015
Sanofi,"A 16-week, randomized, open-label, controlled study comparing the efficacy and safety of a new formulation of insulin glargine versus Lantus in patients with type 1 diabetes mellitus",Insulin Glargin 300 U/ml,PDY12777,NCT01658579,Diabetes Mellitus Type 1,Phase 2,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/pdy12777-summary.pdf,https://www.clinicaltrials.gov/ct2/show/study/NCT01658579?term=PDY12777&rank=1&sect=X01256,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria.,1-Feb-2017
Sanofi,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period",Insulin Glargin 300 U/ml,EFC11628,"NCT01499082
EudraCT2010-023769-23",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/efc11628_summary_V2.pdf,https://www.clinicaltrials.gov/ct2/show/NCT01499082?term=EFC11628&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023769-23,Y,Y,Y,Y,Y,Y,Y,"Datasets and document are available as per Sanofi Policy and criteria. 12-month datasets will be made available.There are 3 clinical study reports for the main 6 months, for the Substudy Comparing Adaptable Dosing Intervals with Fixed Dosing Intervals and for the 12 months",1-Aug-2015
Sanofi,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination with Oral Antihyperglycemic Drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period",Insulin Glargin 300 U/ml,EFC11629,"NCT01499095
EudraCT2010-023770-39",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/efc11629_summary.pdf,https://www.clinicaltrials.gov/ct2/show/study/NCT01499095?term=EFC11629&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023770-39,Y,Y,Y,Y,Y,Y,Y,"Datasets and document are available as per Sanofi Policy and criteria. 12-month  datasets will be made available. There are 3 clinical study reports for the main 6 months, for the Substudy Comparing Adaptable Dosing Intervals with Fixed Dosing Intervals and for the 12 months",1-Aug-2015
Sanofi,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period",Insulin Glargin 300 U/ml,EFC12347,"NCT01676220
EudraCT2012-000146-35",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/efc12347_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT01676220?term=efc12347&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=EFC12347,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria. 12-month raw datasets will be made available. There are 2 clinical study reports for the main 6 months and for the 12 months,1-Aug-2017
Sanofi,"A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period",Insulin Glargin 300 U/ml,EFC12456,NCT01683266,Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/efc12456_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT01683266?term=efc12456&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria. 12-month raw datasets will be made available. There are 2 clinical study reports for the main 6 months and for the 12 months,1-Aug-2017
GSK,"An open-label, randomized, single dose, three-way crossover study to determine the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine (5mg) and losartan (100mg) in healthy adult male and female Subjects under fasting conditions",amlodipine/losartan,AML116797,NCT01648231,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116797,http://clinicaltrials.gov/show/NCT01648231,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne",benzoyl peroxide/salicylic acid,STF115576,NCT01446237,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115576,http://clinicaltrials.gov/show/NCT01446237,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,"A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers","calcipotriol, calcipotriene",STF114739,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114739,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Aug-2015
GSK,"A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Phototoxic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers","calcipotriol, calcipotriene",STF114740,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114740,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Aug-2015
GSK,"A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , versus Vehicle Foam in Subjects with Plaque-type Psoriasis","calcipotriol, calcipotriene",STF114742,NCT00689481,Psoriasis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114742,http://clinicaltrials.gov/show/NCT00689481,,Y,N,Y,Y,Y,Y,Y,An annotated case report form and a blank case report form are not available for this study.,1-Aug-2015
GSK,A study to determine the bioequivalence of reformulated 125mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 125mg/5mL suspension at a dose of 250mg.,cefuroxime axetil,CAE10004,,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/CAE10004,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A study to determine the bioequivalence of reformulated 250mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 250mg/5mL suspension.,cefuroxime axetil,CAE10005,,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/CAE10005,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety -",darapladib,LPL110118,NCT00734032,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/LPL110118,http://clinicaltrials.gov/show/NCT00734032,,Y,Y,Y,Y,N,Y,Y,A protocol is not available for this study because an English language version was not created.,1-Aug-2015
GSK,"A 28 day, double blind, placebo-controlled, parallel-group dose-ranging phase IIA to examine the safety, tolerability and effects of SB-480848 on LP-PLA2 activity in dyslipidemic patients",darapladib,480848/005,,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/480848/005,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,The Effect of SB-480848 on the Pharmacokinietics of Digoxin in healthy subjects,darapladib,480848/014,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Dose Ranging Study to Evaluate the Pharmacokinetics of an SB480848 Freebase Enteric Coated Formulation,darapladib,LPL101582,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Study to Assess the Effects of Food and Repeat Dosing of Esomeprazole on the Pharmacokinetics of a Single Dose of Freebase Enteric Coated SB480848,darapladib,LPL101560,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Study to Assess the Effect of Steady-state Omeprazole on the Pharmacokinetics of single dose SB480848 in Healthy Adult Subjects,darapladib,480848/019,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Study to Evaluate the Single Dose Pharmacokinetics of Enteric Coated Freebase Formulations of SB480848 in Healthy Adults,darapladib,480848/904,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Repeat Dose, Dose Ranging Study to Evaluate the Safety and Pharmacokinetics of a Freebase Enteric Coated Formulation of SB480848",darapladib,480848/903,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomized, repeat-dose, dose ranging study to evaluate the safety and pharmacokinetics of the SB480848 Enteric Coated Formulation",darapladib,480848/012,,Atherosclerosis,Phase 1,,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects",darapladib,LPL111814,NCT00704431,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LPL111814,http://clinicaltrials.gov/show/NCT00704431,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. There is no GSK Clinical Study Register Results Summary record for this study.,1-Aug-2015
GSK,"Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects-",darapladib,LPL110736,NCT00622830,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/LPL110736,http://clinicaltrials.gov/show/NCT00622830,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Aug-2015
GSK,"Assessment of the Anti-Inflammatory activity, efficacy and safety of Intravenous SB-681323 in subjects at risk for development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).",dilmapimod,AL1111592,NCT00996840,"Lung Injury, Acute",Phase 2,http://www.gsk-clinicalstudyregister.com/study/111592,http://clinicaltrials.gov/show/NCT00996840,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,See Detailed Description,fluticasone propionate/salmeterol,SCO40036,NCT00361959,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO40036,http://clinicaltrials.gov/show/NCT00361959,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single dose bioequivalence study comparing a new formulation of fondaparinux sodium at 12.5 mg/mL and the reference formulation at 10 mg/mL, in healthy male subjects. Open, randomized, crossover and single center study",fondaparinux sodium,BDR4979,,Healthy Subjects,Phase 1,http://www.gsk-clinicalstudyregister.com/study/BDR4979,,,Y,N,Y,Y,Y,N,Y,A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state",glimepiride/metformin,MFG116806,NCT01725672,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116806,http://clinicaltrials.gov/show/NCT01725672,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic rhinitis",GSK1004723,HHI110159,NCT00824356,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/110159,http://clinicaltrials.gov/show/NCT00824356,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,See Detailed Description,GSK1004723,HHI110157,NCT00694993,"Rhinitis, Allergic, Seasonal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/HHI110157,http://clinicaltrials.gov/show/NCT00694993,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis",GSK1004723; GSK835726,HHI112864,NCT00972504,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112864,http://clinicaltrials.gov/show/NCT00972504,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,An adaptive PET study in healthy volunteers using [11C]GSK931145 to establish the relationship of Glycine Transporter 1 occupancy by GSK1018921 to plasma concentrations over time.,GSK1018921; GSK931145,GT1109731,NCT00945503,Schizophrenia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/109731,http://clinicaltrials.gov/show/NCT00945503,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma",GSK1059615,PIK111051,NCT00695448,Solid Tumours,Phase 1,http://www.gsk-clinicalstudyregister.com/study/PIK111051,http://clinicaltrials.gov/show/NCT00695448,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1070806 in healthy and obese subjects.",GSK1070806,A18110040,NCT01035645,Inflammatory Bowel Diseases,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110040,http://clinicaltrials.gov/show/NCT01035645,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin",GSK1292263,GPR111596,NCT00783549,Dyslipidaemias,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111596,http://clinicaltrials.gov/show/NCT00783549,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A study in type 2 diabetic subjects of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound",GSK1292263,GPR111598,NCT01119846,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/111598,http://clinicaltrials.gov/show/NCT01119846,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263",GSK1292263,GPR113132,NCT01128621,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113132,http://clinicaltrials.gov/show/NCT01128621,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,A study to investigate the interaction of GSK1292263 with rosuvastatin and simvastatin in healthy subjects,GSK1292263,GPR113506,NCT01101568,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113506,http://clinicaltrials.gov/show/NCT01101568,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects",GSK1322322,PDF111341,NCT00828867,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111341,http://clinicaltrials.gov/show/NCT00828867,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects",GSK1322322,PDF112034,NCT00924911,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112034,http://clinicaltrials.gov/show/NCT00924911,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects",GSK1322322,PDF112668,NCT00896558,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112668,http://clinicaltrials.gov/show/NCT00896558,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects",GSK1322322,PDF113376,NCT01610388,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113376,http://clinicaltrials.gov/show/NCT01610388,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An Open Label, Non-Randomized, Single dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects",GSK1322322,PDF112167,NCT01663389,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112167,http://clinicaltrials.gov/show/NCT01663389,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection",GSK1322322,PDF113414,NCT01209078,"Skin Infections, Bacterial",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113414,http://clinicaltrials.gov/show/NCT01209078,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects",GSK1322322,PDF116595,NCT01648179,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116595,http://clinicaltrials.gov/show/NCT01648179,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects",GSK1322888,MTL114422,NCT01294566,Gastroparesis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114422,http://clinicaltrials.gov/show/NCT01294566,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An open label positron emission tomography study in healthy male subjects to investigate brain DAT and SERT occupancy, pharmacokinetics and safety of single oral doses ofGSK1360707, using 11C- PE2I and 11C-DASB as PET ligands",GSK1360707,SNV112773,NCT01153802,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112773,http://clinicaltrials.gov/show/NCT01153802,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to make a preliminary assessment of the effect of food.",GSK1482160,X71111383,NCT00849134,"Pain, Inflammatory",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111383,http://clinicaltrials.gov/show/NCT00849134,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects",GSK1521498,ORA111314,NCT00857883,Obesity,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111314,http://clinicaltrials.gov/show/NCT00857883,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone.",GSK1521498,ORA111848,NCT00976066,Obesity,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111848,http://clinicaltrials.gov/show/NCT00976066,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects.",GSK1521498,ORA111849,NCT00976105,Obesity,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111849,http://clinicaltrials.gov/show/NCT00976105,,Y,N,Y,Y,Y,Y,Y,An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions.,1-Aug-2015
GSK,"A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours.",GSK1521498,ORA111850,NCT01195792,Obesity,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111850,http://clinicaltrials.gov/show/NCT01195792,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects",GSK1521498,OAA115256,NCT01366573,Alcoholism,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115256,http://clinicaltrials.gov/show/NCT01366573,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder",GSK163090,HTP109035,NCT00896363,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/109035,http://clinicaltrials.gov/show/NCT00896363,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-centre, randomized, double blind, placebo-controlled, double-dummy, dose escalating cross-over study to examine the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity and salmeterol (50 µg via DPI) in COPD patients.",GSK202405,ACH101824,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/101824,,,N,Y,N,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers",GSK2245841,SIR114011,NCT01018628,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114011,http://clinicaltrials.gov/show/NCT01018628,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects,GSK2245841,SIR115083,NCT01262911,Sepsis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115083,http://clinicaltrials.gov/show/NCT01262911,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects",GSK2245841,SIR115830,NCT01416376,Sepsis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115830,http://clinicaltrials.gov/show/NCT01416376,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A two part study to investigate the safety and tolerability, pharmacokinetics and pharmacodynamics of GSK2339345 in healthy subjects. Part A: an open label, dose escalating, rinse, gargle and spit study. Part B: a randomised, double-blind, placebo controlled, inhaled dose escalating study using nebulised lidocaine for blinding purposes.",GSK2339345,PNV115419,NCT01494636,Cough,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115419,http://clinicaltrials.gov/show/NCT01494636,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo controlled, inhaled single escalating and repeat dose study using an aqueous droplet inhaler to investigate the safety, tolerability and pharmacokinetics of GSK2339345.",GSK2339345,PNV115658,NCT01587716,Cough,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115658,http://clinicaltrials.gov/show/NCT01587716,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers",GSK2374697,EXE114403,NCT01545570,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114403,http://clinicaltrials.gov/show/NCT01545570,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease.",GSK239512,H3B110651,NCT01009255,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110651,http://clinicaltrials.gov/show/NCT01009255,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist",GSK239512,H3B109689,NCT00675090,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/H3B109689,http://clinicaltrials.gov/show/NCT00675090,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia",GSK239512,H3B113147,NCT01009060,Schizophrenia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113147,http://clinicaltrials.gov/show/NCT01009060,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics (PK), immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in healthy male subjects",GSK2434735,RES114594,NCT01563042,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114594,http://clinicaltrials.gov/show/NCT01563042,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects",GSK2485852,HBI115040,NCT01332552,Hepatitis C,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115040,http://clinicaltrials.gov/show/NCT01332552,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke",refanezumab,MAG111539,NCT00833989,"Ischaemic Attack, Transient",Phase 2,http://www.gsk-clinicalstudyregister.com/study/111539,http://clinicaltrials.gov/show/NCT00833989,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blind, single dose, placebo controlled, parallel group, first time in human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ascending IV doses of GSK249320 in healthy volunteers",refanezumab,MAG103114,NCT00622609,Cerebrovascular Accident,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MAG103114,http://clinicaltrials.gov/show/NCT00622609,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A randomized, single blind, placebo-controlled, three period crossover, dose selection study to evaluate the effect of GSK256073, an HM74A receptor agonist, on glucose and NEFA 24 hour profile in type 2 diabetic patients.",GSK256073,HMD114187,NCT01147861,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114187,http://clinicaltrials.gov/show/NCT01147861,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-center, randomized, blinded, placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in single and repeat doses, with and without food, in healthy male subjects",GSK2849466,ARM116715,NCT01696604,Cachexia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116715,http://clinicaltrials.gov/show/NCT01696604,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomized, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)",GSK315234,OSM104972,NCT00674635,"Arthritis, Rheumatoid",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104972,http://clinicaltrials.gov/show/NCT00674635,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Aug-2015
GSK,"A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects with Advanced Solid Tumor or Non-Hodgkins Lymphoma",GSK461364,PLK107427,NCT00536835,"Lymphoma, Non-Hodgkin",Phase 1,http://www.gsk-clinicalstudyregister.com/study/PLK107427,http://clinicaltrials.gov/show/NCT00536835,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects.",GSK598809,DAN109710,NCT01039454,Substance Dependence,Phase 1,http://www.gsk-clinicalstudyregister.com/study/109710,http://clinicaltrials.gov/show/NCT01039454,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward",GSK598809,DAN106593,NCT00605241,Substance Dependence,Phase 1,http://www.gsk-clinicalstudyregister.com/study/DAN106593,http://clinicaltrials.gov/show/NCT00605241,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A placebo-controlled, single blind, randomized two part study toinvestigate the tolerability, pharmacokinetics, and brainDopamine D3 receptor occupancy of increasing repeat doses ofGSK618334 for up to 21 days in healthy volunteers.",GSK618334,DBU108414,NCT01036061,Substance Dependence,Phase 1,http://www.gsk-clinicalstudyregister.com/study/108414,http://clinicaltrials.gov/show/NCT01036061,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"An open label positron emission tomography study in healthy male subjects to investigate brain Dopamine D3 receptor occupancy, pharmacokinetics and safety of single oral doses of GSK618334, using 11C-PHNO as PET ligand.",GSK618334,DBU110269,NCT00814957,Substance Dependence,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110269,http://clinicaltrials.gov/show/NCT00814957,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma",GSK679586,I13106870,NCT00843193,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106870,http://clinicaltrials.gov/show/NCT00843193,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses
 of GSK704838 and tiotropium bromide",GSK704838,AC6108697,NCT00539825,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AC6108697,http://clinicaltrials.gov/show/NCT00539825,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register Results Summary record for this study.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis",GSK835726,HH3110163,NCT00851344,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/110163,http://clinicaltrials.gov/show/NCT00851344,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,See Detailed Description,GSK835726,HH3110161,NCT00605852,"Rhinitis, Allergic, Seasonal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/HH3110161,http://clinicaltrials.gov/show/NCT00605852,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patient suffering from premature ejaculation",GSK958108,SPE111155,NCT00861484,Premature Ejaculation,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111155,http://clinicaltrials.gov/show/NCT00861484,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects",GW273225; lamotrigine,NAP107434,,Bipolar Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/107434,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects.",GW274150,RA4104917,NCT00379990,"Arthritis, Rheumatoid",Phase 2,http://www.gsk-clinicalstudyregister.com/study/RA4104917,http://clinicaltrials.gov/show/NCT00379990,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge.",GW328267,AA210012,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AA210012,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A single-centre, escalating dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a slow intravenous infusion of GW328267X in healthy volunteers",GW328267,A2L115387,NCT01640990,"Lung Injury, Acute",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115387,http://clinicaltrials.gov/show/NCT01640990,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, cross-over study to investigate the effects of pre-treatment with repeat inhaled doses of a new chemical entity on the allergen-induced late phase asthmatic response in mild asthmatic subjects.",GW328267,AA210005,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AA210005,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects.",GW328267,AA210013,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AA210013,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, 3-way cross-over study to investigate the effects of pre-treatment with single inhaled doses of an NCE and fluticasone propionate on the allergen induced late phase asthmatic response in mild asthmatic subjects.",GW559090,A4A10003,,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/A4A10003,,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"An 8-day, randomised, placebo-controlled, three-way crossover trial of repeat doses of a new chemical entity (NCE), fluticasone propionate and placebo administered intranasally, blinded for fluticasone propionate versus placebo, in an environmental exposition unit, the Vienna Challenge Chamber (VCC) in subjects with seasonal allergic rhinitis (SAR)",GW559090,A4A10008,,Rhinitis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/A4A10008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects",GW677954,ADG103440,NCT00264667,Metabolic Syndrome X,Phase 2,http://www.gsk-clinicalstudyregister.com/study/ADG103440,http://clinicaltrials.gov/show/NCT00264667,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,See Detailed Description,GW677954,ADG20001,NCT00196989,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ADG20001,http://clinicaltrials.gov/show/NCT00196989,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100 mg, 200 mg and 400 mg once daily), fluticasone propionate (200 mg once daily) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety",GW784568,BGS105049,,"Rhinitis, Allergic, Perennial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105049,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, dose escalating, 4-period design study to investigate the effects of 7-day repeat inhaled doses of GW799943X (250, 1000, 3000mcg once daily) on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge when delivered 26 hours after the last dose, in mild asthmatic patients.",GW799943,ODS10005,,Asthma,Phase 1,,,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because only a draft version was located; no final version found in archives. There is no GSK Clinical Study Register  record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics",GW870086,SIG112851,NCT00945932,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112851,http://clinicaltrials.gov/show/NCT00945932,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled, dose ascending,3-way crossover study to assess the pharmacokinetics, safety andtolerability of repeat inhaled doses of nebulised GW870086X inhealthy adult male volunteers.",GW870086,SIG113209,NCT01160003,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113209,http://clinicaltrials.gov/show/NCT01160003,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persistent Asthma",GW870086,SIG114749,NCT01245426,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114749,http://clinicaltrials.gov/show/NCT01245426,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate",ibandronic acid,743830/002,,Osteoporosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/743830/002,,,N,N,N,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate",ibandronic acid,743830/003,,"Osteoporosis, Postmenopausal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/743830/003,,,N,N,N,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy (currently untreated)",lamotrigine,LAM115376,NCT01431963,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115376,http://clinicaltrials.gov/show/NCT01431963,,N,Y,N,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Aug-2015
GSK,"A randomised, double-blind, placebo-controlled parallel group study to examine the safety, tolerability, and pharmacokinetics of repeat inhaled doses of GSK159797 in healthy subjects",milveterol,B2E101682,,"Pulmonary Disease, Chronic Obstructive",Phase 1,,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register record for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Single Dose Study to Evaluate the Dose Proportionality of the Tablet Formulation of Nabumetone Q and the Relative Bioavailability of Nabumetone Q Compared to RELAFEN in Healthy Subjects,nabumetone,14777/268,,Osteoarthritis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/14777/268,,,N,N,N,Y,N,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because because only draft versions were located; no final versions found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine.,naratriptan,S2W40027,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/S2W40027,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine.",naratriptan,S2W40024,,Migraine Disorders,Phase 4,http://www.gsk-clinicalstudyregister.com/study/S2W40024,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",omega-3-acid ethyl esters,LOV111818,NCT00903409,Hypertriglyceridemia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111818,http://clinicaltrials.gov/show/NCT00903409,,Y,N,Y,Y,Y,N,Y,This is an extension study to LOV111858. A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Aug-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation",omega-3-acid ethyl esters,LOV111820,NCT00402363,"Fibrillation, Atrial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/OM8 Afib,http://clinicaltrials.gov/show/NCT00402363,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An open-label single dose randomized, parallel group study followed by single-blind repeat dosing, to compare the relative bioavailability of GSK2212836",omega-3-acid ethyl esters,LEM113412,NCT00996268,Cardiovascular Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113412,http://clinicaltrials.gov/show/NCT00996268,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",omega-3-acid ethyl esters,LOV111858,,Hypertriglyceridemia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111858,,,Y,Y,Y,Y,Y,Y,Y,An extension study LOV111818 was conducted. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Assess the Efficacy and Safety of Adjunctive Lovaza® Therapy in Hypertriglyceridemic Subjects Treated with Antara®",omega-3-acid ethyl esters,LOV111859,,Hypertriglyceridemia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111859,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Pharmacokinetic Interaction Study Evaluating the Effect of Lovaza® on Plasma Pharmacokinetics of Zocor® in Healthy Adult Volunteers Under Fasting Conditions,omega-3-acid ethyl esters,LOV111862,,Dyslipidaemias,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111862,,,Y,N,N,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Pharmacokinetic Interaction Study Evaluating the Effect of Reliant Pharmaceuticals Inc. (Lovaza®) Omega-3-Acid Ethyl Esters Capsules on the Plasma Pharmacokinetics of Parke Davis (Lipitor®) Atorvastatin Tablets in Healthy Adult Volunteers Under Fasting Conditions,omega-3-acid ethyl esters,LOV111863,,Dyslipidaemias,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111863,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,A Pharmacokinetic Interaction Study Evaluating the Effect of Omega-3-Acid Ethyl Esters Capsules (Omacor®; Reliant Pharmaceuticals Inc.) on the Plasma Pharmacokinetics of Rosuvastatin Tablets (Crestor®; AstraZeneca) in Healthy Adult Volunteers under Fasting Conditions.,omega-3-acid ethyl esters,LOV111864,,Dyslipidaemias,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111864,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Aug-2015
GSK,"A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (propafenone hydrochloride) Manufactured at Two Different Sites",propafenone,RYT116371,NCT01956487,"Arrhythmia, Cardiac",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116371,http://clinicaltrials.gov/show/NCT01956487,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"An open-label, five-way, partially randomized crossover study to evaluate the regional gastrointestinal absorption of retigabine in healthy volunteers","retigabine, ezogabine",RTG113214,,Seizures,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113214,,,Y,Y,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Aug-2015
GSK,A single-centre open label study to investigate the effect of repeat doses of SB-649868 on the pharmacokinetics of Simvastatin and Atorvastatin in healthy male volunteers.,SB649868,OXS109652,NCT01299597,Sleep Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/109652,http://clinicaltrials.gov/show/NCT01299597,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral SB756050 administered for 6 days to Subjects with Type 2 Diabetes Mellitus",SB756050,AXO111829,NCT00733577,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111829,http://clinicaltrials.gov/show/NCT00733577,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,"A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating single dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SB756050 in healthy volunteers and in subjects with Type 2 Diabetes Mellitus",SB756050,AXO110461,NCT00607906,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AXO110461,http://clinicaltrials.gov/show/NCT00607906,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II study to determine the safety and efficacy of Coulter Clone® 131Iodine-B1 radioimmunotherapy of advanced non-Hodgkin’s Lymphoma,tositumomab,BEX104728,NCT01536561,"Lymphoma, Non-Hodgkin",Phase 1,http://www.gsk-clinicalstudyregister.com/study/104728,http://clinicaltrials.gov/show/NCT01536561,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology,tositumomab,BEX104505,NCT00950755,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104505,http://clinicaltrials.gov/show/NCT00950755,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,"Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies",tositumomab,BEX104504,NCT00989664,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104504,http://clinicaltrials.gov/show/NCT00989664,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab,tositumomab,BEX104507,NCT00996593,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104507,http://clinicaltrials.gov/show/NCT00996593,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2015
GSK,Phase II a randomized study of iodine-131 Anti-b1 Antibody versus anti-b1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL),tositumomab,BEX104515,NCT01573000,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104515,http://clinicaltrials.gov/show/NCT01573000,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Aug-2015
GSK,Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma,tositumomab,BEX104545,NCT00268203,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/BEX104545,http://clinicaltrials.gov/show/NCT00268203,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because there is no evidence in the archives that a document was authored.,1-Aug-2015
Eisai,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",lenvatinib,E7080-G000-201,"NCT00784303
EU CTR 2007-005933-12",Differentiated Thyroid Cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00784303,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005933-12,Y,Y,Y,Y,Y,Y,Y,No restrictions.,1-Aug-2015
Eisai,A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer,lenvatinib,E7080-J081-208,NCT01728623,Thyroid Cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01728623,,Y,Y,Y,Y,Y,Y,Y,No restrictions. Note: Japan is the only country participating in this study.,1-Aug-2015
Eisai,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer",lenvatinib,E7080-G000-303,"NCT01321554
EU CTR 2010-023783-41",Differentiated Thyroid Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01321554,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023783-41,Y,Y,Y,Y,Y,Y,Y,"Sharing of clinical data is prevented for the following countries; Germany, France, Sweden, Poland, due to ICF restrictions.",1-Aug-2015
GSK,"An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions",amlodipine/losartan,AML116799,NCT01797926,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116799,http://clinicaltrials.gov/show/NCT01797926,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects with Acne",benzoyl peroxide/salicylic acid,STF114553,NCT02524665,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114553,http://clinicaltrials.gov/show/NCT02524665,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study.,1-Sep-2015
GSK,Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients,carvedilol,105517/358,NCT00344513,"Heart failure, Congestive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/105517/358,http://clinicaltrials.gov/show/NCT00344513,,N,N,Y,Y,N,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and blank case report form are not available for this study. A protocol is not available for this study as there is no evidence in the archives that a document was authored. There is no GSK Clinical Study Register Results Summary for this study.,1-Sep-2015
GSK,Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",115375,NCT01358825,acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115375,http://clinicaltrials.gov/show/NCT01358825,,Y,Y,Y,Y,Y,Y,Y,This is a long-term antibody persistence follow-up study of 105539.,1-Sep-2015
GSK,"Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life","Combined Measles, Mumps, Rubella, Varicella Vaccine",104690,NCT00127010,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103388,http://clinicaltrials.gov/show/NCT00127010,,Y,N,Y,Y,Y,Y,Y,This is a follow-up study to 103388. The results of this study 104690 are summarised with primary study 103388 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,"Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admind as separate injections","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/006 (MeMuRu-OKA-006),,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208136/006,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"Study to assess immunogenicity and safety of one dose of GSK Bios’ live attenuated MMRV vaccine, co-admind with a booster dose of the GSK Bios’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/013 (MeMuRu-OKA-013),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/013,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/017 (MeMuRu-OKA-017),,Measles; Mumps; Rubella; Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208136/017,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,Study to evaluate immunogenicity and safety of GSK Bios’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios’ Priorix™ and Varilrix™ vaccines,"Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/018 (MeMuRu-OKA-018),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/018,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,Study to evaluate immunogenicity and safety of one dose of GSK Bios’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine,"Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/019 (MeMuRu-OKA-019),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/019,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,A study to evaluate immunogenicity and safety of Boostrix compared to Adacel when administered as a booster vaccination in adults aged 19 to 64 years of age,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",BTX106316,NCT00346073,acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106316,http://clinicaltrials.gov/show/NCT00346073,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,A study to evaluate immunogenicity and safety of Boostrix when co-administered with Fluarix in subjects 19 years of age and older,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",BTX106323,NCT00385255,acellular pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106323,http://clinicaltrials.gov/show/NCT00385255,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,"LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)",darapladib,LPL100601,NCT00799903,Atherosclerosis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100601,http://clinicaltrials.gov/show/NCT00799903,,Y,Y,Y,Y,Y,Y,Y,Please note that there is a Publication Steering Committee for this study.,1-Sep-2015
GSK,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).,darapladib,480848/033,NCT01000727,acute coronary syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/480848/033,http://clinicaltrials.gov/show/NCT01000727,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. Please note that there is a Publication Steering Committee for this study.,1-Sep-2015
GSK,"An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects",darapladib,LPL115678,NCT01873339,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115678,http://clinicaltrials.gov/show/NCT01873339,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,A Study to Evaluate the Effect of a High Fiber and a High Fat Meal on the Pharmacokinetics of LANOXIN† (digoxin) Elixir Pediatric in Healthy Adults,digoxin,120008/901,,"Heart failure, Congestive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/120008/901,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512,GSK239512,H3M117016,NCT01802931,Multiple Sclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117016,http://clinicaltrials.gov/show/NCT01802931,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"An open, controlled, randomized, comparative, phase IIIb study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' combined hepatitis A and hepatitis B vaccine given on an accelerated schedule compared to separate vaccine with GSK Biologicals' monovalent hepatitis A vaccine in healthy adults","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/121,,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/121,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years",twinrix,100565,,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100565,,,Y,Y,Y,Y,Y,Y,Y,"This is a 10 year follow-up study to 208127/076. Other follow-up studies 208127/111 (3 years), 208127/112 (4 years), 208127/113 (5 years), 100561 (6 years), 100562 (7 years), 100563 (8 years), 100564 (9 years) to 208127/076 were conducted. The results of this study 100565 are summarised with studies 208127/111, 208127/112, 208127/113, 100561, 100562, 100563 and 100564 on the GSK Clinical Study Register. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Sep-2015
GSK,"Assess the feasibility of an investigational vaccination regimen, compared to a 3-dose primary vaccination with GSK Bio's Infanrix hexa™ (DTPa-HBV-IPV/Hib vaccine) following hepatitis B vaccination at birth. Primary vaccination is followed in the 2nd year of life by a booster dose of Infanrix-hexa","Hepatitis B Vaccine, Recombinant",105752,NCT00289796,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/210602-002,http://clinicaltrials.gov/show/NCT00289796,,Y,N,Y,Y,Y,Y,Y,This is a booster study of 210602/002. The results of this study 105752 are summarised with primary study 210602/002 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,Immunogenicity and protective efficacy of GlaxoSmithKline (previously SmithKlineBeecham) Biologicals’ hepatitis B vaccine (10(g) in newborn of HBeAg and HBsAg positive mothers compared with a historical control group.,"Hepatitis B Vaccine, Recombinant",103860-115 (HBV-115),,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103860-115,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline (previously SmithKline Beecham and SmithKline-Rit) Biologicals’ recombinant DNA hepatitis B vaccine with or without hepatitis B immune globulins (HBIg) in newborns of HBeAg-positive mothers.,"Hepatitis B Vaccine, Recombinant",103860-143 (HBV-143),,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103860-143,,,Y,N,N,Y,N,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because there is no evidence in the archives that a document was authored. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"An observational study to investigate the incidence of influenza, downstream complications of influenza and hospitalizations, in elderly subjects vaccinated with GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly.",Influenza Vaccine,106622,NCT00306982,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106622,http://clinicaltrials.gov/show/NCT00306982,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,"An observational study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with Fluarix™",Influenza Vaccine,107564,NCT00377611,Influenza,Phase 4,http://www.gsk-clinicalstudyregister.com/study/107564,http://clinicaltrials.gov/show/NCT00377611,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,"Immunogenicity, safety and reactogenicity study of GSK Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345",Influenza Vaccine (Quadrivalent),116023,NCT01702454,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116023,http://clinicaltrials.gov/show/NCT01702454,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study of 115345.,1-Sep-2015
GSK,Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in adults aged 18 years and older,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",116664,NCT01626820,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116664,http://clinicaltrials.gov/show/NCT01626820,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure,lamivudine,NUC10901,,Hepatitis B,Phase 1,http://www.gsk-clinicalstudyregister.com/study/NUC10901,,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus",lamivudine,NUC20905,,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NUC20905,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV.",lamivudine,NUC30914,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUC30914,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment",lamivudine,NUCB3026,,"Hepatitis B, Chronic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUCB3026,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up),lamivudine,NUCB3018,,"Hepatitis B, Chronic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUCB3018,,,N,Y,Y,Y,Y,Y,N,This is a follow-on study of NUCB3009. An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies",lamivudine,NUC30926,,"Hepatitis B, Chronic",Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUC30926,,,N,Y,Y,Y,Y,Y,Y,A follow-up study NUC40040 was conducted. An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,"A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis A vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites.","Measles, Mumps, Rubella Vaccine",111870,NCT00861744,Measles; Mumps; Rubella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111870,http://clinicaltrials.gov/show/NCT00861744,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"Immunogenicity, reactogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.",Rotavirus Vaccine,RTX114351,NCT01198769,"Infections, Rotavirus",Phase 4,http://www.gsk-clinicalstudyregister.com/study/114351,http://clinicaltrials.gov/show/NCT01198769,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"A multicenter, trial comparing the efficacy and safety of Umeclidinium/Vilanterol 62.5/25 mcg once daily with Tiotropium 18 mcg once daily over 24 weeks in subjects with Chronic Obstructive Pulmonary Disease (COPD).",umeclidinium bromide/vilanterol,ZEP117115,NCT01777334,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/117115,http://clinicaltrials.gov/show/NCT01777334,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.",umeclidinium bromide; vilanterol; umeclidinium bromide/vilanterol,DB2115380,NCT01899638,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115380,http://clinicaltrials.gov/show/NCT01899638,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
GSK,"A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older.",Varicella Vaccine,208133/178,NCT00792623,Varicella,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208133/178,http://clinicaltrials.gov/show/NCT00792623,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2015
GSK,A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicals varicella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis. SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals.,Varicella Vaccine,208133/161 (OKAH-161),,Varicella,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208133/161,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Sep-2015
GSK,Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects,vercirnon,CCX116416,NCT01827631,Crohn's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116416,http://clinicaltrials.gov/show/NCT01827631,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2015
Roche,"A randomized, open-label study comparing the effect of MabThera, with and without fludarabine/ cyclophosphamide, on progression-free survival and safety in patients with previously treated B-cell chronic lymphocytic leukemia",Rituximab,BO17072,NCT00090051,lymphoid leukaemia,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00090051?term=BO17072&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, open-label, multi-center phase III trial comparing CVP + MabThera to standard CVP chemotherapy in patients with previously untreated follicular lymphoma.",Rituximab,M39021,,lymphoma,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma",Rituximab,U4391G,NCT00719472,lymphoma,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00719472?term=U4391G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, double-blind study of the effect of MabThera combined with methotrexate on treatment response in patients with active rheumatoid arthritis",Rituximab,WA17043,NCT00074438,rheumatoid arthritis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00074438?term=wa17043&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A Phase III, Randomized, Double-Blind Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Class III, IV Lupus Nephritis",Rituximab,U2970G,NCT00282347,lupus,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00282347?term=U2970g&rank=2,,Y,N,Y,N,Y,Y,N,,1-Oct-2015
Roche,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Non-Renal Systemic Lupus Erythematosis",Rituximab,U2971G,NCT00137969,lupus,Phase 2/3,,https://clinicaltrials.gov/ct2/show/NCT00137969?term=U2971G&rank=3,,Y,N,Y,N,Y,Y,N,,1-Oct-2015
Roche,"A phase II, randomized, parallel group, open-label, multicenter study to evaluate the effects of Rituximab on immune responses in subjects with active rheumatoid arthritis receiving background methotrexate",Rituximab,U3374G,NCT00282308,rheumatoid arthritis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00282308?term=U3374G&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Oct-2015
Roche,"An Open-Label, Prospective Study of the Safety of Rituximab in Combination with other Disease-Modifying Anti-Rheumatic Drugs in Subjects with Active Rheumatoid Arthritis",Rituximab,U3924G,NCT00443651,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00443651?term=U3924G&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Oct-2015
Roche,An open-label study of the efficacy and safety of re-treatments with rituximab (Mabthera/Rituxan)  in patients with active rheumatoid arthritis  (Open label extension study for DANCER and WA16291),Rituximab,WA16855,NCT02093026,rheumatoid arthritis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT02093026?term=WA16855&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A Phase IIb Randomized, Multifactorial, Double-Blind, Parallel Group, Dose Ranging Study of the Efficacy and Safety of Rituximab (MabThera/Rituxan) in Combination with Methotrexate, in Patients with active Rheumatoid Arthritis",Rituximab,WA17042,NCT00468546,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00468546?term=WA17042&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, double-blind international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.",Rituximab,WA17044,NCT00422383,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00422383?term=WA17044&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, double-blind study to evaluate the effect on treatment response of MabThera in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis",Rituximab,WA17045,NCT00299130,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00299130?term=WA17045&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,"A randomized, phase III, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX), compared with MTX alone,  in methotrexate-naive patients with active rheumatoid arthritis",Rituximab,WA17047,NCT00299104,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00299104?term=WA17047&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Roche,An open-label study of the efficacy and safety of re-treatments with rituximab (Mabthera/Rituxan) in patients with active rheumatoid arthritis who have had an inadequate response to anti-TNFα therapies  (Open label extension study for REFLEX),Rituximab,WA17531,NCT02097745,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT02097745?term=WA17531&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Eisai,An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors,lenvatinib,E7080-J081-103,NCT00280397,Solid Tumors,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT00280397,,N,Y,Y,Y,Y,Y,Y,Analysis and reporting datasets are not CDISC compliant and contain labelling in English and Japanese. Note: Japan is the only country participating in this study.,1-Sep-2015
Eisai,A Phase 1 Study of E7080 in Subjects With Solid Tumor,lenvatinib,E7080-J081-105,NCT01268293,Solid Tumors,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT01268293,,Y,Y,Y,Y,Y,Y,Y,Can only share aggregated data due to risk of re-identification. Note: Japan is the only country participating in this study.,1-Sep-2015
Boehringer Ingelheim,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,afatinib,1200.43,NCT01345682,"Head and Neck Neoplasms; Carcinoma, Squamous Cell",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01345682?term=1200.43&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours,afatinib,1200.84,NCT01214616,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01214616?term=1200.84&rank=1,,Y,Y,Y,Y,Y,N,Y,,1-Oct-2015
Boehringer Ingelheim,Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus,empagliflozin,1245.38,NCT01193218,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01193218?term=1245.38&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes,empagliflozin,1245.33,NCT01011868,"Diabetes Mellitus, Type 2",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01011868?term=1245.33&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus,empagliflozin,1245.52,NCT01368081,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01368081?term=1245.52&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus,empagliflozin,1245.35,NCT01947855,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01947855?term=1245.35&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy,linagliptin,1218.65,NCT01215097,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01215097?term=1218.65&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naÃ¯ve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control",linagliptin,1218.66,NCT01214239,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01214239?term=1218.66&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
Boehringer Ingelheim,Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control,linagliptin,1218.6,NCT01438814,"Diabetes Mellitus, Type 2",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01438814?term=1218.60&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,"Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus
 -A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus",albiglutide,GLP107865,NCT00530309,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/GLP107865,http://clinicaltrials.gov/show/NCT00530309,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,A Dose Finding Study of GSK716155 versus Placebo in the Treatment of Type 2 Diabetes Mellitus,albiglutide,GLP110932,NCT01098461,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/110932,http://clinicaltrials.gov/show/NCT01098461,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid after Topical Administration of GSK2585823 in Japanese Subjects with Acne Vulgaris,benzoyl peroxide/clindamycin,STF115959,NCT01527123,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115959,http://clinicaltrials.gov/show/NCT01527123,,Y,Y,Y,Y,N,Y,Y,A protocol is not available for this study because an English language version was not created.,1-Oct-2015
GSK,Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl peroxide 3% gel) with Healthy Japanese Male and Female Subjects,benzoyl peroxide/clindamycin phosphate,STF114849,NCT01428466,Acne Vulgaris,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114849,http://clinicaltrials.gov/show/NCT01428466,,Y,Y,N,Y,N,Y,Y,A protocol is not available for this study because an English language version was not created.,1-Oct-2015
GSK,"Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study",bupropion,AK1113351,NCT01138007,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113351,http://clinicaltrials.gov/show/NCT01138007,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study.,1-Oct-2015
GSK,"A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure  - An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study)",carvedilol,CRV110734,NCT00742508,"Heart failure, Congestive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/CRV110734,http://clinicaltrials.gov/show/NCT00742508,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because an English language version was not created.,1-Oct-2015
GSK,"Study to assess consistency of 3 production lots of GSK Bios’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/007 (MeMuRu-OKA-007),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/007,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella,"Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/014 (MeMuRu-OKA-014),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/014,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"Study to assess immunogenicity and safety of two lots of GSK Bios’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Bios’ measles-mumps-rubella vaccine as control group","Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/016 (MeMuRu-OKA-016),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/016,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine,"Combined Measles, Mumps, Rubella, Varicella Vaccine",208136/022 (MeMuRu-OKA-022),,Measles; Mumps; Rubella; Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208136/022,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"Study FFR116364, a double-blind, placebo-controlled study of GW685698X in paediatric subjects with perennial allergic rhinitis",fluticasone furoate,FFR116364,NCT01630135,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116364,http://clinicaltrials.gov/show/NCT01630135,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because English language versions were not created.,1-Oct-2015
GSK,"Study FFR116365, an open-label study of GW685698X in paediatric subjects with perennial allergic rhinitis",fluticasone furoate,FFR116365,NCT01622231,"Rhinitis, Allergic, Perennial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116365,http://clinicaltrials.gov/show/NCT01622231,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because English language versions were not created.,1-Oct-2015
GSK,A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients with Chronic Obstructive Pulmonary Disease,fluticasone propionate/salmeterol,SAM114169,NCT01254032,"Pulmonary Disease, Chronic Obstructive",N/A,http://www.gsk-clinicalstudyregister.com/study/114169,http://clinicaltrials.gov/show/NCT01254032,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study.,1-Oct-2015
GSK,CAT LOC Meta-analysis Study,fluticasone propionate/salmeterol,SAM115264,,"Pulmonary Disease, Chronic Obstructive",N/A,http://www.gsk-clinicalstudyregister.com/study/115264,,,N,N,N,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available as only a draft version was  located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Oct-2015
GSK,"A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects",GSK1034702,MAA110792,NCT00950586,Cognitive Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110792,http://clinicaltrials.gov/show/NCT00950586,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,"A double blind, randomized, placebo controlled, cross-over study to Examine the pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in nicotine abstained otherwise healthy smokers",GSK1034702,MAA113746,NCT01371799,Mental Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113746,http://clinicaltrials.gov/show/NCT01371799,,Y,N,Y,Y,Y,Y,Y,An annotated or blank case report form are not available as the electronic data capture system used for this study did not generate paper versions.,1-Oct-2015
GSK,An open label positron emission tomography (PET) study to investigate brain penetration by [11C] GSK1034702 in healthy subjects,GSK1034702,MAA110771,NCT00937846,Cognitive Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110771,http://clinicaltrials.gov/show/NCT00937846,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,"Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study",GSK424887,NSS105012,NCT01424384,Depressive Disorder and Anxiety Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/105012,http://clinicaltrials.gov/show/NCT01424384,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2015
GSK,"A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of NCE (25 μg and 50 μg) and escalating cumulative doses of salbutamol (up to 1200 μg) administered alone and in combination to healthy male smokers.",GW328267,AA210010,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/AA210010,,,N,N,N,Y,N,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because only draft versions were located; no final versions found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information.",Haemophilus influenzae Type b Vaccine,208108-083 (Hib-083),,Haemophilus influenzae type b,Phase 4,http://www.gsk-clinicalstudyregister.com/study/208108-083,,,Y,N,Y,Y,N,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A protocol is not available for this study because only a draft version was located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A phase II, open, randomised, multicentric study to compare the immunogenicity, reactogenicity and safety of experimental vaccines to that of Twinrix (administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years.",twinrix,208127/ 114 (HAB-114),,Hepatitis A; Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/208127/ 114,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A double-blind study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ high-dose combined hepatitis A/B vaccine containing 1440 EL.U of hepatitis A antigen/40 mcg of hepatitis B surface antigen to that of Twinrix™, both administered following a 0-6 month schedule in healthy adolescents",twinrix,208127/100 and 208127/101 (Ext-HAB-075),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/100 and 208127/101 (Ext-HAB-075),,,Y,N,Y,Y,Y,Y,N,This is a follow-up study of 208127/075. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A double-blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A – hepatitis B vaccine when administered in healthy adults.","Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine",208127/115 and 208127/119 (Ext-HAB-028 Month 108 and Month 120),,Hepatitis A; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208127/115 and 208127/119 (Ext-HAB-028 Month 108 and Month 120),,,Y,N,Y,Y,Y,Y,N,"This is a follow-up study of 208127/021. Follow on studies 100551,100552, 100554, 100555, and 112267 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Oct-2015
GSK,"Phase III study to evaluate the safety and consistency of 3 consecutive lots of GSK Biologicals’ thiomersal-free Engerix-B™ vaccine containing 20 µg of hepatitis B surface antigen (HbsAg) per 1 ml dose, when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers","Hepatitis B Vaccine, Recombinant",103860-270 (HBV-270),,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/103860-270,,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"Phase IV, open, multicentric, post-marketing surveillance study to monitor safety and reactogenicity of GSK Bios’ live attenuated Measles-Mumps-Rubella vaccine in Korean subjects admind according to the Prescribing Information","Measles, Mumps, Rubella Vaccine",209762-145 (MeMuRu-145),,Measles; Mumps; Rubella,Phase 4,http://www.gsk-clinicalstudyregister.com/study/209762-145,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",Meningococcal Serogroup B Vaccine,V72P13,NCT00657709,"Infections, Meningococcal",Phase 3,,http://clinicaltrials.gov/show/NCT00657709,,N,Y,Y,Y,Y,Y,Y,An extension study V12P13E1 was conducted. An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.,1-Oct-2015
GSK,"A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13",Meningococcal Serogroup B Vaccine,V72P13E1,NCT01139021,"Infections, Meningococcal",Phase 3,,http://clinicaltrials.gov/show/NCT01139021,,N,Y,Y,Y,Y,Y,Y,This is an extension study of V72P13. An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.,1-Oct-2015
GSK,"A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.",Meningococcal Serogroup B Vaccine,V72P12,NCT00721396,"Infections, Meningococcal",Phase 2,,http://clinicaltrials.gov/show/NCT00721396,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.,1-Oct-2015
GSK,"A phase-III, open, controlled, follow-up clinical trial, with Prevenar as control, to assess the safety of GSK Biologicals’ investigational vaccination regimen administered with DTPa-HBV-IPV/Hib to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study in the Netherlands",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),347414/035,,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/347414/035,,,Y,N,N,Y,N,Y,N,This is a follow-up study of 347414/020. An annotated case report form is not available. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final version found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,A placebo-controlled pharmacokinetic and safety study of twice daily SRT501 in type 2 diabetic human male subjects,resveratrol,SRT-501-006,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/SRT-501-006,,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A randomised, double-blind, triple-dummy, placebo-controlled, five-way crossover study to investigate the bronchoprotective effects against methacholine challenge and the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 µg) and salbutamol (200 µg) over a 24-hour period in at ...",salmeterol,RES11070,,"Constriction, Bronchial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/RES11070,,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A randomised, double-blind, triple-dummy, placebo-controlled, five-way cross-over study to investigate the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 mg) and salbutamol (200 mg) over a 24-h period in healthy subjects.",salmeterol,RES10988,,"Constriction, Bronchial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/RES10988,,,N,Y,N,Y,N,Y,N,An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final versions  found in archives. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2015
GSK,"A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents",sumatriptan,SUM111035,NCT00963937,Migraine Disorders,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111035,http://clinicaltrials.gov/show/NCT00963937,,Y,Y,N,Y,N,Y,Y,A clinical study report is not available for this study because an English language version was not created.,1-Oct-2015
GSK,"A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.",umeclidinium bromide/vilanterol,DB2115362,NCT01376388,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115362,http://clinicaltrials.gov/show/NCT01376388,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because English language versions were not created.,1-Oct-2015
GSK,"A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell transplantation patients",valaciclovir,HS2116100,NCT01602562,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116100,http://clinicaltrials.gov/show/NCT01602562,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because English language versions were not created.,1-Oct-2015
Lilly,"A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention-Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning",Atomoxetine,B4Z-US-LYCW,NCT00190775,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00190775?term=B4Z-US-LYCW&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Lilly,A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients with Attention-Deficit/Hyperactivity Disorder (ADHD),Atomoxetine,B4Z-JE-LYEE,NCT00962104,Attention Deficit Hyperactivity Disorder,Phase 2/Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00962104?term=B4Z-JE-LYEE&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2015
Lilly,"A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder",Atomoxetine,B4Z-MC-LYBX,NCT00191698,Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00191698?term=B4Z-MC-LYBX&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Lilly,Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults with ADHD Over an Extended Period of Time (6 months): with A Brief Evaluation of Executive Cognition,Atomoxetine,B4Z-US-LYCU,NCT00190736,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00190736?term=B4Z-US-LYCU&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2015
Lilly,"A Double-Blind, Placebo-Controlled Trial of Atomoxetine Hydrochloride to Evaluate Efficacy in the School Setting in Children Ages 8 to 12 Years with Attention-Deficit/Hyperactivity Disorder",Atomoxetine,B4Z-MC-LYAW,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2015
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Trial of Once Daily Atomoxetine Hydrochloride to Evaluate Efficacy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children Ages 6-12 with an Assessment of Evening Behavior",Atomoxetine,B4Z-US-LYBG,Not available,Attention Deficit Hyperactivity Disorder,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2015
Lilly,"A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy",Ramucirumab,I4T-IE-JVBD,NCT00917384,Gastric Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/study/NCT00917384?term=I4T-IE-JVBD&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Lilly,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine",Ramucirumab,I4T-IE-JVBE,NCT01170663,Gastric Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01170663?term=I4T-IE-JVBE&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Takeda,A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan,alogliptin,SYR-322/CCT-901,NCT01521962,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-901,http://clinicaltrials.gov/ct2/show/NCT01521962?term=SYR-322%2FCCT-901&rank=1,,Y,Y,Y,Y,N,Y,N,,1-Nov-2015
Takeda,"An Open-Label, Randomized, 4-Period Crossover Study to Determine the Bioequivalency of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) and Pioglitazone (15 and 45 mg) When Administered as Commercial Tablets and as a Combination Product",alogliptin/pioglitazone,01-06-TL-322OPI-005,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Takeda,"An Open-Label, Randomized, 4-Period Crossover Study to Determine the Bioequivalence of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) and Pioglitazone (15 and 45 mg) When Administered as Individual Tablets and as Combination Products",alogliptin/pioglitazone,SYR-322OPI_102,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYR-472 in Healthy Subjects",trelagliptin,01-05-TL-SYR-472-001,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"A Phase 1, Double-Blind Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose, Pharmacokinetic and Pharmacodynamic Single-Center Study to Evaluate the Use of SYR-472 in Healthy Subjects",trelagliptin,01-06-TL-SYR-472-002,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"An Open-Label, Randomized, Multiple-Dose, 2-Arm, 2-Period Crossover Study to Evaluate the Pharmacokinetic Drug-Drug Interaction between SYR-472 and Metformin in Healthy Adult Subjects",trelagliptin,01-06-TL-SYR-472-003,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"A Phase 1, Open-Label, Multiple-Dose Study to Assess the Drug-Drug Interaction Between SYR-472 and Caffeine, Tolbutamide, Dextromethorphan, and Midazolam, Administered Concomitantly to Healthy Adult Subjects",trelagliptin,01-06-TL-SYR-472-004,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,The Effect of Food on the Pharmacokinetics of SYR-472 in Healthy Adult Male and Female Subjects,trelagliptin,01-06-TL-SYR-472-005,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Treatment with SYR-472 in Subjects with Type 2 Diabetes",trelagliptin,01-06-TL-SYR-472-006,NCT00760344,"Diabetes Mellitus, Type 2",Phase 2,http://www.takedaclinicaltrials.com/browse/summary/01-06-TL-SYR-472-006,https://clinicaltrials.gov/show/NCT00760344,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes",trelagliptin,01-06-TL-SYR-472-007,NCT00653185,"Diabetes Mellitus, Type 2",Phase 2,http://www.takedaclinicaltrials.com/browse/summary/01-06-TL-SYR-472-007,https://clinicaltrials.gov/show/NCT00653185,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,A Phase 2 Dose-ranging Study of SYR-472,trelagliptin,SYR-472/CCT-001,Not available,"Diabetes Mellitus, Type 2",Phase 2,Not available,Not available,,Y,N,Y,Y,Y,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Nov-2015
Takeda,"A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study of SYR-472 (100 mg) Monotherapy in the Treatment of Type 2 Diabetes Mellitus",trelagliptin,SYR-472/CCT-002,NCT01632007,"Diabetes Mellitus, Type 2",Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-472/CCT-002,https://clinicaltrials.gov/show/NCT01632007,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Nov-2015
Takeda,"A Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Study to Evaluate the Effect of SYR-472 on the QT/QTc Interval in Healthy Adult Male and Female Subjects",trelagliptin,SYR-472/CPH-005,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.  Blank case report forms will be provided.,1-Nov-2015
Takeda,A Drug-interaction Study of SYR-472 in Healthy Adult Male Subjects (A Phase II Clinical Pharmacology Study),trelagliptin,SYR-472/CPH-006,Not available,"Diabetes Mellitus, Type 2",Phase 2,Not available,Not available,,Y,N,N,Y,Y,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Nov-2015
Takeda,A Long-term Phase 3 Study with SYR-472 (100 mg) of Monotherapy or Combination Therapy with an Existing Oral Anti-diabetic Drug in the Treatment of Type 2 Diabetes Mellitus,trelagliptin,SYR-472/OCT-001,NCT01431807,"Diabetes Mellitus, Type 2",Phase 3,http://www.takedaclinicaltrials.com/browse/summary/SYR-472/OCT-001,https://clinicaltrials.gov/show/NCT01431807,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Nov-2015
Takeda,An Open-Label Phase 3 Study of SYR-472 (100 mg) in Patients with Type 2 Diabetes,trelagliptin,SYR-472/OCT-002,NCT01751360,"Diabetes Mellitus, Type 2",Phase 3,http://www.takedaclinicaltrials.com/browse/summary/SYR-472/OCT-002,https://clinicaltrials.gov/show/NCT01751360,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Nov-2015
Takeda,"An Open-Label, Parallel-Group Comparison Study of Single-Dose Pharmacokinetics of SYR-472 in Subjects With Varying Degrees of Renal Impairment and Their Healthy Matched Subjects",trelagliptin,SYR-472_101,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Takeda,"An Open-Label, Parallel-Group Comparison Study of Single-Dose Pharmacokinetics of SYR-472 in Subjects With and Without Moderate Hepatic Impairment",trelagliptin,SYR-472_102,Not available,"Diabetes Mellitus, Type 2",Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Nov-2015
Astellas,"A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors",erlotinib,OSI-774-302,"NCT00373425
EudraCT 2005-001747-29",Non-small cell lung cancer,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=64,https://clinicaltrials.gov/ct2/show/NCT00373425,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001747-29,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Boehringer Ingelheim,"Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction",tenecteplase,1123.8,NCT00148460,Myocardial Infarction,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00148460?term=1123.8&rank=1,,N,N,N,N,N,Y,N,,1-Nov-2015
Boehringer Ingelheim,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,tenecteplase,1123.28,NCT00623623,Myocardial Infarction,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00623623?term=1123.28&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Boehringer Ingelheim,An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma,tiotropium bromide,205.341,NCT00365560,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00365560?term=205.341&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Boehringer Ingelheim,Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma,tiotropium bromide,205.301,NCT00152984,"Pulmonary Disease, Chronic Obstructive; Asthma",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00152984?term=205.301&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Boehringer Ingelheim,A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.,tipranavir,1182.33,NCT00144105,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00144105?term=1182.33&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Sanofi,"A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy",Semuloparin,EFC6521,"NCT00694382
EudraCT2007-007943-29",Thromboprophylaxis,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-s/,https://clinicaltrials.gov/ct2/show/NCT00694382?term=NCT00694382&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007943-29,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria.,1-Nov-2015
GSK,"Study ATG115317, a comparison of atorvastatin and glimepiride fixed dose combination and atorvastatin and glimepiride loose combination in the treatment of patients with Type 2 diabetes mellitus",atorvastatin/glimepiride,ATG115317,NCT01495013,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115317,http://clinicaltrials.gov/show/NCT01495013,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2015
GSK,"A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Potential of Topically Applied EF Calcipotriene Foam, 0.005% to Induce Contact Sensitization in Healthy Volunteers Upon Exposure to Repeated Skin Patch Applications","calcipotriol, calcipotriene",STF114738,,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114738,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2015
GSK,"An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment",darapladib,LPL115676,NCT01711723,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115676,http://clinicaltrials.gov/show/NCT01711723,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,A Study of the Efficacy and Safety of Multiple Doses of Dutasteride versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia,dutasteride,ARI114263,NCT01231607,Alopecia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114263,http://clinicaltrials.gov/show/NCT01231607,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents",fluticasone furoate/vilanterol,HZA116863,NCT01686633,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116863,http://clinicaltrials.gov/show/NCT01686633,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease,fluticasone furoate/vilanterol,HZC115805,NCT01627327,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115805,http://clinicaltrials.gov/show/NCT01627327,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A randomized, double-blind, placebo-controlled, four-way crossover study to evaluate and compare the pharmacodynamics and pharmacokinetics of fluticasone furoate /vilanterol in different dose combination (50/25mcg, 100/25mcg and 200/25mcg) after single and repeat dose administration from a novel dry powder device in healthy Chinese subjects",fluticasone furoate/vilanterol,HZA115199,NCT01711463,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115199,http://clinicaltrials.gov/show/NCT01711463,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects with Chronic Obstructive Pulmonary Disease (COPD),Fluticasone Furoate/vilanterol,HZC114156,NCT01192191,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114156,http://clinicaltrials.gov/show/NCT01192191,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A single centre, randomised, double-blind, double dummy, parallel group 3-week study to compare the effect of the salmeterol/fluticasone propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance ra ...",fluticasone propionate/salmeterol,SCO30008,,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/SCO30008,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2015
GSK,A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors,foretinib,MET111648,NCT00743067,Solid Tumours,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MET111648,http://clinicaltrials.gov/show/NCT00743067,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A Single-Blind, Randomised, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK1360707",GSK1360707,SNV111914,,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111914,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study.,1-Nov-2015
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis",GSK2245840,SIR114296,NCT01154101,Psoriasis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114296,http://clinicaltrials.gov/show/NCT01154101,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2015
GSK,"A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects with Mild to Moderate Ulcerative Colitis",GSK2245840,SIR115951,NCT01453491,"Colitis, Ulcerative",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115951,http://clinicaltrials.gov/show/NCT01453491,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A multicenter, two part, randomized, parallel group, placebo and sitagliptin controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin",GSK256073,HMD114728,NCT01376323,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114728,http://clinicaltrials.gov/show/NCT01376323,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age",lamotrigine,SCA102833,NCT00723450,Bipolar Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCA102833,http://clinicaltrials.gov/show/NCT00723450,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects.",mepolizumab,MEA115705,NCT01471327,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115705,http://clinicaltrials.gov/show/NCT01471327,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma",mepolizumab,MEA112997,NCT01000506,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112997,http://clinicaltrials.gov/show/NCT01000506,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma",mepolizumab,MEA115588,NCT01691521,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115588,http://clinicaltrials.gov/show/NCT01691521,,Y,Y,Y,Y,Y,Y,Y,A follow-on study MEA115661 was conducted. This study is available in CDISC format,1-Nov-2015
GSK,"MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma",mepolizumab,MEA115575,NCT01691508,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115575,http://clinicaltrials.gov/show/NCT01691508,,Y,Y,Y,Y,Y,Y,Y,A follow-on study MEA115661 was conducted. This study is available in CDISC format,1-Nov-2015
GSK,"A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels",mepolizumab,MEA114092,NCT01366521,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114092,http://clinicaltrials.gov/show/NCT01366521,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus",rosiglitazone/simvastatin,AVS101946,NCT00256867,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/AVS101946,http://clinicaltrials.gov/show/NCT00256867,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"An Open-Label, Randomized, Four-Period Crossover Study in Healthy Subjects to Demonstrate the Bioequivalence of a Fixed Dose Combination Tablet Formulation of Rosiglitazone and Simvastatin (8mg/80mg) to Concomitant Dosing of Rosiglitazone 8mg and Simvastatin 80mg Commercial Tablets and to Assess ...",rosiglitazone/simvastatin,AVS102130,,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/102130,,,Y,N,Y,Y,Y,Y,Y,"An annotated or blank case report form is not available for this study, as the data electronic data capture system for this study did not generate a paper version. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.",1-Nov-2015
GSK,"Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin’s Lymphoma",tositumomab,BEX104517,NCT00996996,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/104517,http://clinicaltrials.gov/show/NCT00996996,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Nov-2015
GSK,"A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma",tositumomab,393229/028,NCT00268983,"Lymphoma, Non-Hodgkin",Phase 3,http://www.gsk-clinicalstudyregister.com/study/393229/028,http://clinicaltrials.gov/show/NCT00268983,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"A 24-week randomised, double-blind and placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder compared with placebo Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide/vilanterol,DB2114634,NCT01636713,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114634,http://clinicaltrials.gov/show/NCT01636713,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"DB2114930: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD",umeclidinium bromide/vilanterol,DB2114930,NCT01817764,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114930,http://clinicaltrials.gov/show/NCT01817764,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
GSK,"DB2114951: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD",umeclidinium bromide/vilanterol,DB2114951,NCT01879410,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114951,http://clinicaltrials.gov/show/NCT01879410,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Roche,"A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus",ranibizumab,FVF4170G,NCT00473330,Diabetic Eye Disease,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00473330?term=fvf4170g&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Roche,"A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus",ranibizumab,FVF4168G,NCT00473382,Diabetic Eye Disease,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00473382?term=FVF4168G&rank=2,,Y,Y,Y,Y,N,Y,N,,1-Dec-2015
Roche,"A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration",ranibizumab,FVF4579G,NCT00891735,Neovascular Age-related Macular Degeneration,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00891735?term=FVF4579G&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Dec-2015
Roche,"A Phase IIIb, Multicenter, Randomized, Double Masked, SHAM Injection, Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) with or without Classic CNV Secondary to Age Related Macular Degeneration",ranibizumab,FVF2598G,NCT00056836,Neovascular Age-related Macular Degeneration,Phase 3,,https://clinicaltrials.gov/ct2/show?term=FVF2598G&rank=3,,Y,Y,Y,Y,Y,Y,N,,1-Dec-2015
Roche,"An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) or macular edema secondary to RETINAL VEIN OCCLUSION (RVO) who have completed a genentech sponsored RANIBIZUMAB STUDY",ranibizumab,FVF3192G,NCT00090623,Neovascular Age-related Macular Degeneration,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00090623?term=FVF3192G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Roche,"An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) or macular edema secondary to RETINAL VEIN OCCLUSION (RVO) who have completed a genentech sponsored RANIBIZUMAB STUDY",ranibizumab,FVF3426G,"cohort 1 - NCT00379795
cohort 2 - NCT01442064",Neovascular Age-related Macular Degeneration,Phase 3,,"cohort 1 - https://clinicaltrials.gov/ct2/show?term=FVF3426G&rank=2
cohort 2 - https://clinicaltrials.gov/ct2/show?term=FVF3426G&rank=1",,Y,N,Y,N,Y,Y,N,,1-Dec-2015
Roche,"A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",ranibizumab,FVF3689G,NCT00251459,Neovascular Age-related Macular Degeneration,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00251459?term=FVF3689G&rank=1,,Y,N,Y,N,Y,Y,N,,1-Dec-2015
Roche,"A Phase III, Multicenter, Randomized, Sham Injection Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion",ranibizumab,FVF4165G,NCT00486018,Retinal Vascular Occlusion,Phase 3,,https://clinicaltrials.gov/ct2/show?term=FVF4165G&rank=3,,Y,Y,Y,Y,Y,Y,N,,1-Dec-2015
Roche,"A PHASE III, MULTICENTER, RANDOMIZED, sham CONTROLLED STUDY OF THE efficacy and SAFETY OF RANIBIZUMAB compared to Sham IN SUBJECTS WITH macular edema secondary to central retinal vein occlusion",ranibizumab,FVF4166G,NCT00485836,Retinal Vascular Occlusion,Phase 3,,https://clinicaltrials.gov/ct2/show?term=FVF4166G&rank=3,,Y,Y,Y,Y,Y,Y,N,,1-Dec-2015
Roche,"A Phase III, Placebo-Controlled, Multi-Center Study to Examine theSafety and Efficacy of Multiple-Dose Intravitreal Injections of rhuFabV2 in Subjects with Age-Related Macular Degeneration who have Predominant Classic Lesion Degeneration",ranibizumab,FVF2587G,NCT00061594,Neovascular Age-related Macular Degeneration,Phase 3,,https://clinicaltrials.gov/ct2/show?term=FVF2587G&rank=3,,Y,Y,Y,Y,Y,Y,N,,1-Dec-2015
Roche,A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion,ranibizumab,FVF4967G,NCT01277302,Retinal Vascular Occlusion,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT01277302?term=FVF4967g&rank=1,,Y,N,Y,Y,N,Y,Y,,1-Dec-2015
Roche,"A phase III, double-blind, placebo-controlled study of TNKase in catheter clearance for hemodialysis catheters",tenecteplase,N3700G,NCT00396032,Catheter clearance,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00396032?term=N3700G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Roche,"A phase III, open-label study of TNKase in catheter clearance for hemodialysis catheters",tenecteplase,N3701G,NCT00396253,Catheter clearance,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00396253?term=N3701G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Roche,"A phase III, open-label study of TNKase for catheter clearance in central venous access devices",tenecteplase,N3699G,NCT00396318,Catheter clearance,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00396318?term=N3699G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin",Dulaglutide,H9X-MC-GBCF,NCT00734474,Diabetes Mellitus,Phase 2/Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00734474?term=H9X-MC-GBCF&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,The Effect of Dose Titration of LY2189265 (GLP-1 analog IV-Fc) in Overweight and Obese Patients with Type 2 Diabetes Mellitus (The EGO Study),Dulaglutide,H9X-MC-GBCJ,NCT00630825,Diabetes Mellitus,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00630825?term=H9X-MC-GBCJ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions,Dulaglutide,H9X-MC-GBCK,NCT00791479,Diabetes Mellitus,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00791479?term=H9X-MC-GBCK&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,"A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly AdministRation of LY2189265 in Diabetes-1))",Dulaglutide,H9X-MC-GBDA,NCT01064687,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01064687?term=AWARD&intr=Dulaglutide&rank=6,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,The Impact of LY2189265 versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3),Dulaglutide,H9X-MC-GBDC,NCT01126580,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01126580?term=AWARD&intr=Dulaglutide&rank=7,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,The Impact of LY2189265 versus Insulin Glargine in Combination with Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes-4)),Dulaglutide,H9X-MC-GBDD,NCT01191268,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01191268?term=AWARD&intr=Dulaglutide&rank=8,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD 6:  Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)",Dulaglutide,H9X-MC-GBDE,NCT01624259,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01624259?term=AWARD&intr=Dulaglutide&rank=2,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2015
Lilly,"The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients with Type 2 Diabetes Mellitus",Dulaglutide,H9X-MC-GBDN,NCT01149421,Diabetes Mellitus,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01149421?term=H9X-MC-GBDN&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Lilly,Phase I Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients with Advanced Solid Tumors Who Have Not Responded to Standard Therapy,Ramucirumab,I4T-IE-JVBM,NCT00793975,Advanced Solid Tumors,Phase 1,Not available,https://clinicaltrials.gov/ct2/show/NCT00793975?term=I4T-IE-JVBM&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,PK and PD data are not included and this data will not be made available.,1-Feb-2017
UCB,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1),Epratuzumab,SL0009,NCT01262365,Lupus,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT01262365?term=SL0009&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Nov-2015
UCB,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2),Epratuzumab,SL0010,NCT01261793,Lupus,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT01261793?term=SL0010&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Nov-2015
Boehringer Ingelheim,Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors,afatinib,1200.1,NCT02171637,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171637?term=1200.1&rank=3&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Boehringer Ingelheim,Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors,afatinib,1200.2,NCT02171663,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171663?term=1200.2&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Boehringer Ingelheim,Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours,afatinib,1200.3,NCT02171702,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171702?term=1200.3&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Boehringer Ingelheim,Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors,afatinib,1200.4,NCT02171728,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171728?term=1200.4&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Boehringer Ingelheim,Micardis® in Patients With Essential Hypertension,telmisartan,502.322,NCT02187705,Hypertension,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02187705?term=502.322&rank=1,,N,N,Y,N,N,Y,N,,1-Dec-2015
Boehringer Ingelheim,Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients,telmisartan,502.316,NCT02172586,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02172586?term=502.316&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Boehringer Ingelheim,"A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)",tenecteplase,1123.5,NCT02182011,Myocardial Infarction,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02182011?term=1123.5&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2015
Roche,"A randomised, double-blind, placebo controlled, multicentre, phase 3 study of OSI 774  plus chemotherapy (cisplatin and gemcitabene) vs. chemotherapy alone in patients with advanced (stage 3b or 4) non-small cell lung cancer who have not received prior chemotherapy.",erlotinib,BO16411,,malignant neoplasm of bronchus and lung,Phase 3,,,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A randomized, double-blind study to evaluate the effect of Tarceva or placebo following platinum-based CT on overall survival and disease progression in patients with advanced, recurrent or metastatic NSCLS who have not experienced disease progression or unacceptable toxicity during chemotherapy",erlotinib,BO18192,NCT00556712,malignant neoplasm of bronchus and lung,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00556712?term=BO18192&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"An open-label, randomized study to evaluate the effect of Tarceva, compared with Alimta (pemetrexed) or Taxotere (docetaxel),on survival in patients with  advanced, recurrent or metastatic non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy",erlotinib,BO18602,NCT00556322,malignant neoplasm of bronchus and lung,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00556322?term=BO18602&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A randomized, open-label study comparing the anti-tumor effect of treatment with Tarceva plus Avastin versus chemotherapy plus Avastin in patients with advanced non-small cell lung cancer",erlotinib,BO20571,NCT00531960,malignant neoplasm of bronchus and lung,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00531960?term=BO20571&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A randomized, open-label, dose-escalation to rash study to assess the effect of Tarceva in combination with gemcitabine on overall survival in patients with metastatic pancreatic cancer.",erlotinib,BO21128,NCT00652366,malignant neoplasm of pancreas,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00652366?term=BO21128&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A randomized, double blind study of biomarkers predictive of improvement in progression free survival in patients with advanced pancreatic cancer treated with Tarceva.",erlotinib,BO21129,NCT00674973,malignant neoplasm of pancreas,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00674973?term=BO21129&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A randomized, Double-BLIND, Placebo-controlled, phase IIIb trial comparing BEVACIZUMAB therapy WITH OR WITHOUT ERLotInib AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB for the first-line treatment of Locally Advanced, Recurrent, or metastatic nON SMALL CELL LUNG CANCER",erlotinib,AVF3671G,NCT00257608,malignant neoplasm of bronchus and lung,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00257608?term=AVF3671G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A Phase III, Multi-Center, Open Label, Randomized Clinical Trial to Evaluate The Efficacy of Avastin (BEVACIZUMAB) in Combination with Tarceva (Erlotinib Hydrochloride) Compared with Tarceva Alone for Treatment of Recurrent or Refractory Stage IIIB/IV Non Small Cell Lung Cancer",erlotinib,OSI3364G,NCT00130728,malignant neoplasm of bronchus and lung,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00130728?term=OSI3364G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A Phase II Randomized, Double-Blind, Multi-Center Study of Avastin Plus Docetaxel or Tarceva versus Docetaxel or Tarceva Alone in Patients with Recurrent or Refractory Non-Small Cell Lung Carcinoma",erlotinib,OSI2950G,NCT00095225,malignant neoplasm of bronchus and lung,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00095225?term=OSI2950G&rank=1,,Y,N,Y,Y,Y,Y,N,,1-Jan-2016
Roche,"Phase II, Multicenter, Open-Label Clinical Trial To Evaluate The Efficacy And Safety Of OSI-774 In Patients With Advanced Or Metastatic Breast Cancer And Disease Progression During Or Following Chemotherapy",erlotinib,OSI2288G,NCT00109265,malignant neoplasm of breast,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00109265?term=OSI2288G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"A Randomized, Double-Blind,Placebo Controlled, Multicenter, Phase III Study of OSI-774 (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) versus Chemotherapy Alone in Patients with Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy",erlotinib,OSI2298G,NCT00047736,Malignant Neoplasm Of Lung,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00047736?term=OSI2298G&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"An open-label, multicentre,dose-escalating phase I/II study, with a randomised phase II part, to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease",obinutuzumab,BO20999,NCT00517530,"Chronic Lymphocytic Leukemia;
Non-Hodgkin Lymphoma",Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00517530?term=BO20999&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"An open-label, multi-center, randomized study to evaluate the efficacy on tumor response of GA101 (RO5072759) monotherapy versus rituximab monotherapy in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma",obinutuzumab,BO21003,NCT00576758,"Chronic Lymphocytic Leukemia;
Non-Hodgkin Lymphoma",Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00576758?term=BO21003&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"An open-label, multi-center, three arm randomized study to investigate the safety and efficacy on progression-free survival of RO5072759 + chlorambucil (GClb) compared to rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients  with comorbidities.",obinutuzumab,BO21004,NCT02053610,Chronic Lymphocytic Leukemia,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT02053610?term=BO21004&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Roche,"An Open-Label, Multicenter, Randomized Phase II Trial Comparing The Efficacy, Safety, And Pharmacokinetics Of GA101 1000 Mg Versus 2000 Mg In Patients With Previously Untreated Chronic Lymphocytic Leukemia",obinutuzumab,GO25677,NCT01414205,Chronic Lymphocytic Leukemia,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01414205?term=GO25677&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Lilly,A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder,Atomoxetine,B4Z-MC-LYBV,NCT00190931,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00190931?term=LYBV&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Lilly,Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder,Atomoxetine,B4Z-US-LYDQ,NCT00190879,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00190879?term=LYDQ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Lilly,A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer,Pemetrexed,H3E-MC-JMAS,NCT00034463,Metastatic Cancer,Phase 1,Not available,https://clinicaltrials.gov/ct2/show/NCT00034463?term=H3E-MC-JMAS&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jan-2016
Lilly,A Phase 1 Pharmacokinetic Trial of LY231514 Administered Intravenously Every 3 Weeks in Advanced Cancer Patients with Varying Degrees of Renal Function,Pemetrexed,H3E-MC-JMAW,NCT00003706,Unspecified Adult Solid Tumor,Phase 1,Not available,https://clinicaltrials.gov/ct2/show/NCT00003706?term=H3E-MC-JMAW&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,BIBW 2992 in Patients With Advanced Solid Tumors,afatinib,1200.17,NCT02171650,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171650?term=1200.17&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors,afatinib,1200.6,NCT02171741,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171741?term=1200.6&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors,afatinib,1200.2,NCT02171676,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02171676?term=1200.20&rank=3,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,"Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients",nevirapine,1100.1368,NCT00273975,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00273975?term=1100.1368&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women,nevirapine,1100.1287,NCT02181933,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02181933?term=1100.1287&rank=1,,N,N,Y,N,N,Y,N,,1-Jan-2016
Boehringer Ingelheim,A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.,nevirapine,1100.1518,NCT00905489,HIV Infections,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00905489?term=1100.1518&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Evaluation of Tiotropium 5 Âµg/Day Delivered Via the RespimatÂ® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),tiotropium bromide,205.417,NCT00776984,Asthma,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00776984?term=205.417&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Evaluation of Tiotropium 5 Âµg/Day Delivered Via the RespimatÂ® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),tiotropium bromide,205.416,NCT00772538,Asthma,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00772538?term=205.417&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.226,NCT02172807,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02172807?term=205.226&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide,205.243,NCT02172469,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02172469?term=205.243&rank=1,,N,N,N,N,N,Y,N,,1-Jan-2016
Boehringer Ingelheim,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide + olodaterol,1237.5,NCT01431274,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01431274?term=1237.5&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),tiotropium bromide + olodaterol,1237.6,NCT01431287,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01431287?term=1237.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),tiotropium bromide + olodaterol,1237.25,NCT01964352,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01964352?term=1237.25&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),tiotropium bromide + olodaterol,1237.26,NCT02006732,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02006732?term=1237.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,tiotropium bromide + olodaterol,1237.2,NCT01559116,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01559116?term=1237.20&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects,tipranavir,1182.17,NCT00146328,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00146328?term=1182.17&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Boehringer Ingelheim,Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals,tipranavir,1182.52,NCT00034866,HIV Infections,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00034866?term=1182.52&rank=2,,N,N,Y,N,Y,N,N,,1-Jan-2016
Boehringer Ingelheim,Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options,tipranavir,1182.68,NCT00144287,HIV Infections,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00144287?term=1182.68&rank=1,,N,N,Y,N,Y,N,N,,1-Jan-2016
GSK,"Cultural adaptation and validation of ""COPD Assessment Test"" (CAT) into Spanish",fluticasone propionate/salmeterol,113047,N/A,"Pulmonary Disease, Chronic Obstructive",N/A,,,,N,N,N,Y,N,Y,N,This is an observational study. Only raw data is available for this study. The data labels for this study are in Spanish. The supporting documents are not in English and will not be provided. A link to the GSK Clinical Study Register entry for this study is not provided because the study was conducted before GSK policy requirements to register observational studies. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jan-2016
GSK,"A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection",GSK2336805,HAI115879,NCT01648140,"Hepatitis C, Chronic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115879,http://clinicaltrials.gov/show/NCT01648140,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2016
GSK,"An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma",GSK690693,AKT106757,NCT00493818,Cancer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/AKT106757,http://clinicaltrials.gov/show/NCT00493818,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
GSK,Evaluation of the Quality of Life in COPD patients in Europe,N/A,111749,N/A,"Pulmonary Disease, Chronic Obstructive",Phase 4,,,,Y,Y,Y,Y,Y,Y,Y,There is no GSK Clinical Study Register record for this study . A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Jan-2016
GSK,"A single-blind, randomised, placebo-controlled, parallel group study to investigate safety, tolerability, pharmacokinetics and the effects on cardiac function of repeat oral doses of SB-649868 in adult and elderly healthy volunteers",SB649868,OXS112861,NCT01030939,Sleep Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112861,http://clinicaltrials.gov/show/NCT01030939,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
GSK,"A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma",tositumomab,393229/027,NCT00315731,"Lymphoma, Follicular",Phase 2,http://www.gsk-clinicalstudyregister.com/study/393229/027,http://clinicaltrials.gov/show/NCT00315731,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-Jan-2016
Lilly,An International Observational Study Among Severe Sepsis Patients Treated in the Intensive Care Unit,Drotrecogin Alfa (Activated),F1K-MC-EVBJ,Not available,Severe Sepsis,Phase 4,Not available,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is observational and there is no regulatory requirement to register observational studies.,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Feb-2016
Astellas,Long-term Study of YM178: Long-term study of YM178 in subjects with overactive bladder.,mirabegron,178-CL-051,NCT00840645,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=88,https://clinicaltrials.gov/ct2/show/NCT00840645,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2016
Daiichi Sankyo,"Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs.",Edoxaban,DU176b-B-J306,NCT01857583,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT01857583?term=DU176b-B-J306&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation.,Edoxaban,DU176b-C-J225,NCT00829933,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2b,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00829933?term=DU176b-C-J225&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation.",Edoxaban,DU176b-C-J226,NCT00806624,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00806624?term=DU176b-C-J226&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Boehringer Ingelheim,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,empagliflozin,1245.31,NCT01289990,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01289990?term=1245.31&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2016
UCB,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Certolizumab Pegol,C87085,NCT00552058,Crohn's Disease,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00552058?term=NCT00552058&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Feb-2016
UCB,Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease,Certolizumab Pegol,CDP870037,NCT00291668,Crohn's Disease,Phase 2,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00291668?term=NCT00291668&rank=3,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Feb-2016
GSK,An Evaluation of the Bioequivalence of five 0.1 mg GI198745/dutasteride Soft Gelatin Capsules Compared to one 0.5 mg GI198745/dutasteride Gelatin Capsules in Healthy Male Volunteers,dutasteride,ARI117342,NCT01929330,Alopecia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117342,http://clinicaltrials.gov/show/NCT01929330,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2016
GSK,Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis.,GSK239512,H3M116477,NCT01772199,"Multiple Sclerosis, Relapsing-Remitting",Phase 2,http://www.gsk-clinicalstudyregister.com/study/116477,http://clinicaltrials.gov/show/NCT01772199,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2016
GSK,Feasibility  Double-blindDTPa-HBV-IPV/HIB-MenC control : DTPa-HBV-IPV + HiberixLot D21798A2;D21799B2;DCH002A46;DCH003A46;Hib400A47/MInfants 2-3 months,"Meningococcal Serogroups A, C, W-135 and Y Vaccine",404286/001,N/A,"Infections, Meningococcal",Phase 2,,,,Y,N,Y,Y,Y,Y,Y,A follow on study 404286/006 was conducted. There is no GSK Clinical Study Register record for this study . A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2016
GSK,A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment.,metformin,MTF116086,NCT01817777,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/116086,http://clinicaltrials.gov/show/NCT01817777,,Y,Y,Y,Y,Y,N,Y,This study was terminated early and only limited analysis-ready data are available. A raw dataset is not available for this study.,1-Feb-2016
Roche,"A Randomized, Double-Blind, Placebo-controlled Study of Recombinant Tissue Plasminogen Activator (rt-PA) for the Restoration of Function to Central Venous Access Devices",Activase,A2055G,,Central Venous Access Devices,Phase 3,,,,Y,Y,Y,Y,Y,Y,N,,1-Feb-2016
Roche,An Open-Label Study of the Safety of Alteplase in the Treatment of Subjects with Dysfunctional Central Venous Access Devices,Activase,A2065G,,Central Venous Access Devices,Phase 3,,,,Y,Y,Y,Y,Y,Y,N,,1-Feb-2016
Takeda,"A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes",alogliptin,SYR-322_305,NCT00856284,Type 2 Diabetes Mellitus,Phase 3,http://takedaclinicaltrials.com/browse/summary/SYR-322_305,http://clinicaltrials.gov/ct2/show/NCT00856284?term=SYR-322_305&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2016
UCB,Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis,Certolizumab Pegol,C87011,NCT00548834,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00548834?term=NCT00548834&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Mar-2016
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus",albiglutide,GLP112756,NCT00849017,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112756,http://clinicaltrials.gov/show/NCT00849017,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Mar-2016
GSK,A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: Follow-up phase.,bupropion,AK1A4013: Follow-up phase,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/AK1A4013_1,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2016
GSK,A multicenter evaluation of the effects of Zyban (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: treatment phase.ZYBAN is a registered trademark of the GlaxoSmithKline group of companies.,bupropion,AK1A4013: Treatment phase,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/AK1A4013,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2016
GSK,"A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis",solcitinib,JAK116679,NCT01782664,Psoriasis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116679,http://clinicaltrials.gov/show/NCT01782664,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Mar-2016
GSK,"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin's Lymphoma",iboctadekin,ILI105618,NCT00500058,"Lymphoma, Non-Hodgkin",Phase 1,http://www.gsk-clinicalstudyregister.com/study/ILI105618,http://clinicaltrials.gov/show/NCT00500058,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer",iboctadekin,ILI108621,NCT00659178,"Neoplasms, Ovarian",Phase 1,http://www.gsk-clinicalstudyregister.com/study/ILI108621,http://clinicaltrials.gov/show/NCT00659178,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset). A multicentre, double-blind, placebo-controlled, parallel group study.",lamotrigine,105-123,,Lennox-Gastaut Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/105-123,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2016
GSK,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients",lamotrigine,105-040,,"Epilepsy, Partial",Phase 3,http://www.gsk-clinicalstudyregister.com/study/105-040,,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2016
GSK,"Oral bioavailability study comparing OXEMET™ 1000 mg coated tablets containing metformin hydrochloride with 1000 mg of the reference product (GLAFORNIL™) administered as two 500 mg tablets, through a randomized, single-dose, open label, balanced, 2-way crossover study in healthy volunteers under fasting conditions.OXEMET (TM) is a trademark of the GlaxoSmithKline group of companies. GLAFORNIL(TM) is a trademark of Merck.",metformin,LOC117219,NCT01842620,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/117219,http://clinicaltrials.gov/show/NCT01842620,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days.",remifentanil,USA30226,,Analgesia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/USA30226,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2016
GSK,"RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures (>= 12 years old) and Subjects with Lennox-Gastaut Syndrome (>=12 years old)","retigabine, ezogabine",RTG113388,NCT01668654,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113388,http://clinicaltrials.gov/show/NCT01668654,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-Mar-2016
GSK,PHASE II MULTICENTER STUDY OF IODINE-131 ANTI-B1 ANTIBODY CONSOLIDATION FOR PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA FOLLOWING FIRST-LINE CHOP,tositumomab,393229/007,NCT01868035,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/393229/007,http://clinicaltrials.gov/show/NCT01868035,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD).",umeclidinium bromide,DB2116133,NCT01716520,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116133,http://clinicaltrials.gov/show/NCT01716520,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.",umeclidinium bromide,AC4115361,NCT01702363,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115361,http://clinicaltrials.gov/show/NCT01702363,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide,DB2116132,NCT02014480,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116132,http://clinicaltrials.gov/show/NCT02014480,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 1",umeclidinium bromide,200109,NCT01957163,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/200109,http://clinicaltrials.gov/show/NCT01957163,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
GSK,"A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 2",umeclidinium bromide,200110,NCT02119286,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/200110,http://clinicaltrials.gov/show/NCT02119286,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2016
Novartis,"A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",secukinumab,CAIN457A2211,NCT00941031,Psoriasis,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4823,https://clinicaltrials.gov/show/NCT00941031,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Novartis,"A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",secukinumab,CAIN457A2220,NCT01071252,Psoriasis,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5383,https://clinicaltrials.gov/show/NCT01071252,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Novartis,"A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",secukinumab,CAIN457A2302,NCT01365455,Psoriasis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=11643,https://clinicaltrials.gov/show/NCT01365455,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Novartis,"A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",secukinumab,CAIN457A2303,NCT01358578,Psoriasis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13605,https://clinicaltrials.gov/show/NCT01358578,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Boehringer Ingelheim,BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer,afatinib,1200.5,NCT00708214,Breast Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00708214?term=1200.5&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Boehringer Ingelheim,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,afatinib,1200.75,NCT01125566,Breast Neoplasms,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01125566?term=1200.75&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Boehringer Ingelheim,Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases,afatinib,1200.67,NCT01441596,Breast Neoplasms; Neoplasm Metastasis,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01441596?term=1200.67&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Boehringer Ingelheim,LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,afatinib,1200.42,NCT01085136,"Carcinoma, Non-Small-Cell Lung",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01085136?term=1200.42&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single and repeat inhaled doses of GSK961081 in healthy subjects.",batefenterol,MAB104865,NCT00887406,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/104865,http://clinicaltrials.gov/show/NCT00887406,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Apr-2016
GSK,A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients.,batefenterol,MAB104958,NCT00478738,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MAB104958,http://clinicaltrials.gov/show/NCT00478738,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt).",batefenterol,MAB108115,NCT00550225,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/MAB108115,http://clinicaltrials.gov/show/NCT00550225,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD.",batefenterol,MAB110123,NCT00674817,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MAB110123,http://clinicaltrials.gov/show/NCT00674817,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,A study to investigate the relative pharmacological activity of an inhaled B2-agonist/anticholinergic dual pharmacophore in healthy volunteers.,batefenterol,MAB110553,NCT00687700,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/MAB110553,http://clinicaltrials.gov/show/NCT00687700,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with Chronic Obstructive Pulmonary Disease (COPD).",batefenterol,MAB115032,NCT01319019,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115032,http://clinicaltrials.gov/show/NCT01319019,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double-blind, double-dummy, single dose, four way cross-over study to compare the pharmacokinetics and pharmacodynamics of GSK961081 and fluticasone propionate when administered alone, concurrently and as a combination blend in healthy subjects.",batefenterol,MFP113423,NCT01449799,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113423,http://clinicaltrials.gov/show/NCT01449799,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"An Open-label, Randomized, Single Dose, Two-Period Crossover study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg.",dutasteride,ARI114694,NCT01254071,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114694,http://clinicaltrials.gov/show/NCT01254071,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride/0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry.",dutasteride,ARI115708,NCT01495026,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115708,http://clinicaltrials.gov/show/NCT01495026,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 micrograms in children aged 5 to 11 years with persistent asthma.",fluticasone furoate,HZA112777,NCT01453023,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112777,http://clinicaltrials.gov/show/NCT01453023,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, double-blind, placebo controlled, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of levocabastine when administered once daily or twice daily on the symptoms of rhinitis in an allergen challenge chamber.",fluticasone furoate/levocabastine,200285,NCT01949051,"Rhinitis, Allergic, Perennial and Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/200285,http://clinicaltrials.gov/show/NCT01949051,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double-blind, placebo-controlled, 3 way, incomplete block cross over study in subjects with allergic rhinitis to assess the effect of once daily single and repeat doses of intranasal Fluticasone furoate/Levocabastine fixed dose combination (FDC) relative to Levocabastine and Fluticasone furoate alone on the onset and magnitude of symptoms of rhinitis in an allergen challenge chamber.",fluticasone furoate/levocabastine,200286,NCT01957202,"Rhinitis, Allergic, Perennial and Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/200286,http://clinicaltrials.gov/show/NCT01957202,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.",GSK1070806,A18116378,NCT01648153,Diabetes Mellitus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116378,http://clinicaltrials.gov/show/NCT01648153,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A single-blind, randomized, placebo controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1362885 in healthy normal subjects.",GSK1362885,GPA111497,NCT00823940,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111497,http://clinicaltrials.gov/show/NCT00823940,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Subjects with Type 2 Diabetes Mellitus.",GSK1362885,GPA111823,NCT01013766,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111823,http://clinicaltrials.gov/show/NCT01013766,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219).",mepolizumab,MEE103219,NCT00358449,"Oesophagitis, Eosinophilic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MEE103219,http://clinicaltrials.gov/show/NCT00358449,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.,otelixizumab,OTX115494,NCT01123083,"Diabetes Mellitus, Type 1",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115494,http://clinicaltrials.gov/show/NCT01123083,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects.",raxibacumab,HGS1021-C1063,NCT02075814,Therapeutic treatment of inhalation anthrax,Phase 3,http://www.gsk-clinicalstudyregister.com/study/HGS1021-C1063,http://clinicaltrials.gov/show/NCT02075814,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects.",vilanterol,B2C10001,,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2C10001,,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Apr-2016
GSK,"A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444.",vilanterol,B2C101762,NCT00354874,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C101762,http://clinicaltrials.gov/show/NCT00354874,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M.",vilanterol,B2C104604,NCT00381667,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C104604,http://clinicaltrials.gov/show/NCT00381667,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444.",vilanterol,B2C106093,NCT00347139,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C106093,http://clinicaltrials.gov/show/NCT00347139,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects.",vilanterol,B2C106180,NCT00711126,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2C106180,http://clinicaltrials.gov/show/NCT00711126,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers.",vilanterol,B2C106181,NCT01286831,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/106181,http://clinicaltrials.gov/show/NCT01286831,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients.",vilanterol,B2C106996,NCT00463697,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2C106996,http://clinicaltrials.gov/show/NCT00463697,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A 2-wk study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD.",vilanterol,B2C108562,NCT00372112,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C108562,http://clinicaltrials.gov/show/NCT00372112,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects.",vilanterol,B2C108784,NCT00469040,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2C108784,http://clinicaltrials.gov/show/NCT00469040,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients.",vilanterol,B2C110165,NCT00519376,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C110165,http://clinicaltrials.gov/show/NCT00519376,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD.",vilanterol,B2C111045,NCT00606684,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/B2C111045,http://clinicaltrials.gov/show/NCT00606684,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomised, single-dose, dose-ascending, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M in asthmatic patients.",vilanterol,B2C111401,NCT00702910,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/B2C111401,http://clinicaltrials.gov/show/NCT00702910,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A double-blind, placebo-controlled, randomised, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following co-administration of GW642444M with ketoconazole.",vilanterol,B2C112205,NCT00866515,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112205,http://clinicaltrials.gov/show/NCT00866515,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A randomized, double-blind, placebo-controlled, two-way crossover 7-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled GW642444 25μg (micrograms) in children aged 5-11 years with persistent asthma.",vilanterol,HZA112776,NCT01453296,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112776,http://clinicaltrials.gov/show/NCT01453296,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"Phase I, Open-label Study To Evaluate Steady-State Serum and Pulmonary Pharmacokinetics following Intravenous Administration of Zanamivir in Healthy Adult Subjects.",zanamivir,NAI106784,,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/106784,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements o register studies.,1-Apr-2016
GSK,"An Open-Label, Non-Randomized, Single-Dose Study To Evaluate Serum Zanamivir Pharmacokinetics Following Intravenous Administration to Human Subjects With Renal Impairment Compared to Subjects Without Renal Impairment.",zanamivir,NAI108127,,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/108127,,,Y,Y,Y,Y,Y,Y,N,A reporting and analysis plan is not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements o register studies.,1-Apr-2016
GSK,"An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection.",zanamivir,NAI113678,NCT01014988,"Influenza, Human",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113678,http://clinicaltrials.gov/show/NCT01014988,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) with Moxifloxacin as a Positive Control in Healthy Volunteers.",zanamivir,NAI114346,NCT01353729,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114346,http://clinicaltrials.gov/show/NCT01353729,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
GSK,"A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers.",zanamivir,NAI115096,NCT01258530,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115096,http://clinicaltrials.gov/show/NCT01258530,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2016
Lilly,Duloxetine versus Placebo in the Treatment of Patients with Diabetic PeripheralNeuropathic Pain in China,Duloxetine hydrochloride,F1J-MC-HMEQ,NCT00408993,Diabetic Peripheral Neuropathic Pain,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00408993?term=F1J-MC-HMEQ&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2016
Lilly,"The Comparative Efficacy of Olanzapine, Risperidone, and Haloperidol for Cognition in Schizophrenia",Olanzapine,F1D-MC-HGGN,Not available,Schizophrenia,Phase 4,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-May-2016
Lilly,The Acute and Long-Term Efficacy of Olanzapine in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with Haloperidol,Olanzapine,F1D-MC-HGDH,Not available,Schizophrenia,Phase 3/Phase 4,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,,1-May-2016
GSK,"An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects under Fasting Conditions",amlodipine/enalapril,ANE116798,NCT01822639,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116798,http://clinicaltrials.gov/show/NCT01822639,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions",amlodipine/rosuvastatin,200561,NCT02075619,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200561,http://clinicaltrials.gov/show/NCT02075619,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males",belimumab,BEL116119,NCT01516450,Systemic Lupus Erythematosus,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116119,http://clinicaltrials.gov/show/NCT01516450,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.",darapladib,LPL117326,NCT02000804,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117326,http://clinicaltrials.gov/show/NCT02000804,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry",dutasteride,ARI115707,NCT01471678,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115707,http://clinicaltrials.gov/show/NCT01471678,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects",GSK2256098,FAK113581,NCT00996671,Cancer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113581,http://clinicaltrials.gov/show/NCT00996671,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients with Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler",GSK2339345,PNV117270,NCT01899768,Cough,Phase 2,http://www.gsk-clinicalstudyregister.com/study/117270,http://clinicaltrials.gov/show/NCT01899768,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,"A study to evaluate the immunogenicity, safety and reactogenicity of adjuvinated influenza vaccine candidate compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly aged 60 years and older.",Influenza Vaccine,107975,NCT00363077,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107975,http://clinicaltrials.gov/show/NCT00363077,,N,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.,1-May-2016
GSK,"A study to evaluate the immunogenicity, safety and reactogenicity of adjuvinated influenza vaccine candidates compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years.",Influenza Vaccine,108656,NCT00374842,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108656,http://clinicaltrials.gov/show/NCT00374842,,N,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.,1-May-2016
GSK,"A study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the adjuvanted influenza vaccine candidate compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above.",Influenza Vaccine,108708,NCT00385840,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108708,http://clinicaltrials.gov/show/NCT00385840,,Y,N,Y,Y,Y,Y,Y,A primary study 107192 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2016
GSK,An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects,raxibacumab,HGS1021-C1069,NCT02016963,Therapeutic treatment of inhalation anthrax,Phase 2/3,http://www.gsk-clinicalstudyregister.com/study/HGS1021-C1069,http://clinicaltrials.gov/show/NCT02016963,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2016
GSK,A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers,retapamulin,RNG117151,NCT01812382,"Skin Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117151,http://clinicaltrials.gov/show/NCT01812382,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study.,1-May-2016
GSK,A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers.,salbutamol,MAB104954,NCT00549120,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/MAB104954,http://clinicaltrials.gov/show/NCT00549120,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
GSK,A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy,vilanterol,HZA106853,NCT01573767,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106853,http://clinicaltrials.gov/show/NCT01573767,,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)",ramelteon,01-04-TL-375-044,NCT00593736,Insomnia,Phase 2,http://takedaclinicaltrials.com/browse/summary/01-04-TL-375-044,https://clinicaltrials.gov/show/NCT00593736,,Y,N,N,Y,N,Y,N,,1-Apr-2015
Takeda,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose of SYR-472 in an Ascending Dose Regimen in Healthy Male Subjects.",trelagliptin,SYR-472/CPH-001,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-472/CPH-001,Not available,,N,N,Y,N,N,N,N,Only documents are available. Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-May-2016
Takeda,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose of SYR-472 in an Ascending Dose Regimen in Healthy Male Subjects",trelagliptin,SYR-472/CPH-002,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-472/CPH-002,Not available,,N,Y,Y,N,N,N,N,Only documents are available. Blank case report forms will be provided. Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-May-2016
Takeda,"A Randomized, Open-label, Crossover Study to Evaluate the Bioequivalence and the Effect of Food Following Single Oral Dose Administration of SYR-472 at a Dose of 100 mg in Healthy Adult Male Subjects",trelagliptin,SYR-472/CPH-009,Not available,"Diabetes Mellitus, Type 2",Phase 1,http://takedaclinicaltrials.com/browse/summary/SYR-472/CPH-009,Not available,,Y,N,N,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-May-2016
UCB,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Brivaracetam,NO1252,NCT00490035,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00490035?term=NCT00490035&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
UCB,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Brivaracetam,NO1253,NCT00464269,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00464269?term=NCT00464269&rank=1,,Y,Y,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
UCB,A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy,Lacosamide,SP0614,NCT00861445,Diabetic Neuropathy,Phase 2,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00861445?term=SP0614&rank=1,,Y,Y,Y,Y,Y,N,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
UCB,"Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy",Lacosamide,SP0768,NCT00135109,Diabetic Neuropathy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00135109?term=SP0768&rank=1,,Y,Y,Y,Y,Y,N,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
UCB,A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy,Lacosamide,SP0742,NCT00235469,Diabetic Neuropathy,Phase 2,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00235469?term=SP0742&rank=1,,Y,Y,Y,Y,Y,N,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
UCB,A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy,Lacosamide,SP0743,NCT00238524,Diabetic Neuropathy,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00238524?term=SP0743&rank=1,,Y,Y,Y,Y,Y,N,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jun-2016
Astellas,"A phase III, double-blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.",isavuconazonium sulfate,9766-CL-0104,"NCT00412893
EudraCT 2006-003868-59",Invasive aspergillosis / Invasive mucormycosis,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=52,https://clinicaltrials.gov/ct2/show/NCT00412893,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
Astellas,"Open-Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi",isavuconazonium sulfate,9766-CL-0103,"NCT00634049
EudraCT 2006-005003-33",Invasive aspergillosis / Invasive mucormycosis,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=51,https://clinicaltrials.gov/ct2/show/NCT00634049,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
Astellas,"A Study to Evaluate the Overall Effect of Solifenacin 5 mg and 10 mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A Double-blind, Randomized, Placebo-controlled, Parallel-group, Multi-center Study",solifenacin succinate,905-EC-007,"NCT01093534
EudraCT 2008-005215-17","Urinary Bladder, Overactive",Phase 4,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=122,https://clinicaltrials.gov/ct2/show/NCT01093534,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005215-17,Y,Y,Y,Y,Y,Y,Y,,1-May-2016
Boehringer Ingelheim,Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD),olodaterol,1237.18,NCT01040403,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01040403?term=1237.18&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Boehringer Ingelheim,Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease,tiotropium bromide,352.2046,NCT00975195,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00975195?term=352.2046&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension,brinzolamide,C-10-033,NCT01297517,Open-Angle Glaucoma; Ocular Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12971,https://clinicaltrials.gov/show/NCT01297517,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Jun-2016
Novartis,"A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension",brinzolamide,C-10-039,NCT01297920,Open-Angle Glaucoma; Ocular Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12972,https://clinicaltrials.gov/show/NCT01297920,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Jun-2016
Novartis,"Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",brinzolamide,C-10-040,NCT01310777,Open-Angle Glaucoma; Ocular Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12973,https://clinicaltrials.gov/show/NCT01310777,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Jun-2016
Novartis,"A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy",everolimus,CRAD001R2301,NCT00879333,"Cancer, Advanced Gastric",Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13505,https://clinicaltrials.gov/show/NCT00879333,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",indacaterol,CQAB149B2311,NCT00620022,Chronic Obstructive Pulmonary Disease (COPD),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2822,https://clinicaltrials.gov/show/NCT00620022,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.","indacaterol, glycopyrrolate",CQVA149A2305,NCT01294787,Chronic Obstructive Pulmonary Disease (COPD),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7504,https://clinicaltrials.gov/show/NCT01294787,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD",glycopyrronium,CNVA237A2310,NCT01154127,Chronic Obstructive Pulmonary Disease (COPD),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5183,https://clinicaltrials.gov/show/NCT01154127,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",omalizumab,Q4881g,NCT01287117,Chronic Idiopathic Urticaria (CIU),Phase 3,http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4881g,https://clinicaltrials.gov/show/NCT01287117,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.,1-Jun-2016
Novartis,"A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)",omalizumab,Q4882g,NCT01292473,Chronic Idiopathic Urticaria (CIU),Phase 3,http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4882g,https://clinicaltrials.gov/show/NCT01292473,,Y,Y,Y,Y,Y,Y,Y,Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.,1-Jun-2016
Novartis,"A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures",oxcarbazepine,CTRI476E2339,NCT00050947,Epilepsy,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1634,https://clinicaltrials.gov/show/NCT00050947,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures",oxcarbazepine,CTRI476E2340,NCT00050934,Epilepsy,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1876,https://clinicaltrials.gov/show/NCT00050934,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens",sacubitril/valsartan,CLCZ696B2228,NCT01922089,Heart Failure,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13984,https://clinicaltrials.gov/show/NCT01922089,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction",sacubitril/valsartan,CLCZ696B2314,NCT01035255,"Heart Failure, Chronic (CHF)",Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13786,https://clinicaltrials.gov/show/NCT01035255,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003 % Compared to Travatan in Patients with Open-Angle Glaucoma or Ocular Hypertension",travoprost ophthalmic solution,C-11-034,NCT01453855,Open-Angle Glaucoma; Ocular Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12951,https://clinicaltrials.gov/show/NCT01453855,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Jun-2016
Novartis,"Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction",valsartan,CVAL489E0108,Not available,Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1517,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension",amlodipine/benazepril hcl,CCIB002I2301,NCT00170950,Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2612,https://clinicaltrials.gov/show/NCT00170950,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
Novartis,"A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis",fingolimod,CFTY720D2301,NCT00289978,Multiple Sclerosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3147,https://clinicaltrials.gov/show/NCT00289978,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",fingolimod,CFTY720D2302,NCT00340834,Multiple Sclerosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2859,https://clinicaltrials.gov/show/NCT00340834,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)",rivastigmine,CENA713D1301,NCT00423085,Alzheimer's Disease,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4162,https://clinicaltrials.gov/show/NCT00423085,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)",valsartan,CDJN608B2302,NCT00097786,"Diabetes Mellitus, Type 2",Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3223,https://clinicaltrials.gov/show/NCT00097786,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",fingolimod,CFTY720D2309,NCT00355134,Multiple Sclerosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=6223,https://clinicaltrials.gov/show/NCT00355134,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
Novartis,"A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma",panobinostat,CLBH589D2308,NCT01023308,Multiple myeloma (MM); Myelodysplastic syndrome (MDS),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13623,https://clinicaltrials.gov/show/NCT01023308,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,"Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions",cefadroxil,201529,NCT02446496,Healthy Subjects,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201529,http://clinicaltrials.gov/show/NCT02446496,,N,Y,Y,Y,Y,Y,N,An analysis-ready dataset and reporting and analysis plan are not available for this study.,1-Jun-2016
GSK,"A randomised, repeat-dose, placebo-controlled, three-way crossover, double dummy study to evaluate and compare the efficacy of Fluticasone Furoate inhalation powder delivered via the single strip dry powder inhaler when administered either in the morning or in the evening, in male and female asthmatic subjects",fluticasone furoate,FFA117156,NCT01808339,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/117156,http://clinicaltrials.gov/show/NCT01808339,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease,fluticasone furoate/vilanterol,HZC113782,NCT01313676,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113782,http://clinicaltrials.gov/show/NCT01313676,,Y,Y,Y,Y,Y,Y,Y,Please note that there is a Publication Steering Committee for this study.,1-Jun-2016
GSK,"""A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation. Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and
Arterial Stiffness in Adults with Chronic Obstructive Pulmonary Disease (COPD)""",fluticasone furoate/vilanterol,HZC116601,NCT01691885,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116601,http://clinicaltrials.gov/show/NCT01691885,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,"An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler",Fluticasone Propionate/Salmeterol,200260,NCT01890863,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200260,http://clinicaltrials.gov/show/NCT01890863,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,"A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma",GSK2126458,P3K112826,NCT00972686,Solid Tumours,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112826,http://clinicaltrials.gov/show/NCT00972686,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2016
GSK,"A study to evaluate the pharmacokinetics, safety and tolerability, immunogenicity, and pharmacodynamics of GSK2800528 in healthy subjects.",GSK2800528,GZL116987,NCT01899755,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116987,http://clinicaltrials.gov/show/NCT01899755,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jun-2016
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults",mepolizumab,MEE103226,NCT00274703,"Oesophagitis, Eosinophilic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MEE103226,http://clinicaltrials.gov/show/NCT00274703,,N,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.,1-Jun-2016
GSK,"A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide,201315,NCT02236611,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/201315,http://clinicaltrials.gov/show/NCT02236611,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Jun-2016
GSK,"A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide,201316,NCT02207829,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/201316,http://clinicaltrials.gov/show/NCT02207829,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Jun-2016
Roche,"A Phase III Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma",vemurafenib,GO28141,NCT01689519,malignant melanoma of skin,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01689519,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",brinzolamide,C-10-041,NCT01309204,Open-Angle Glaucoma; Ocular Hypertension,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12974,https://clinicaltrials.gov/show/NCT01309204,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Jul-2016
Novartis,"A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)",ceritinib,CLDK378X2101,NCT01283516,Tumors Characterized by Genetic Abnormalities of ALK,Phase 1/2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12003,https://clinicaltrials.gov/show/NCT01283516,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib",ceritinib,CLDK378A2201,NCT01685060,Non-small cell lung carcinoma (NSCLC),Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=16109,https://clinicaltrials.gov/show/NCT01685060,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
Novartis,"A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma",dabrafenib,BRF113710,NCT01153763,Melanoma,Phase 2,https://www.gsk-clinicalstudyregister.com/study/113710,https://www.clinicaltrials.gov/ct2/show/NCT01153763?term=BRF113710&rank=1,,Y,Y,Y,Y,Y,Y,Y,"This study is still ongoing, however data related to the publication(s) is available.",1-Apr-2018
Novartis,"BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain",dabrafenib,BRF113929,NCT01266967,Melanoma,Phase 2,https://www.gsk-clinicalstudyregister.com/search/?study_ids=113929,https://clinicaltrials.gov/show/NCT01266967,,Y,Y,Y,Y,N,Y,Y,,1-Jun-2017
Novartis,"Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures",eltrombopag,TPL104054,NCT00678587,Liver Diseases,Phase 3,http://www.gsk-clinicalstudyregister.com/study/TPL104054,http://clinicaltrials.gov/show/NCT00678587,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2014
Novartis,Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients,everolimus,CRAD001A2309,NCT00251004,Kidney Transplantation,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3401,https://clinicaltrials.gov/show/NCT00251004,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.,everolimus,CRAD001 B201,NCT01927588,Kidney Transplantation,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2189,https://clinicaltrials.gov/show/NCT01927588,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.,everolimus,CRAD001 B251,NCT01927588,Kidney Transplantation,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2345,https://clinicaltrials.gov/show/NCT01927588,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"Two-year randomized, multi-center, doubleblind, double-dummy study of the efficacy and safety of everolimus versus azathioprine (AZA) as part of a triple immunosuppressive therapy regimen in de novo heart transplant
recipients.",everolimus,CRAD001B253,Not available,Heart transplantation,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2302,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients",everolimus,CRAD001H2304,NCT00622869,Liver Transplantation,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=8503,https://clinicaltrials.gov/show/NCT00622869,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer",lapatinib,EGF100151,NCT00078572,"Cancer, Breast",Phase 3,http://www.gsk-clinicalstudyregister.com/study/100151,http://clinicaltrials.gov/show/NCT00078572,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
Novartis,"An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens",lapatinib,EGF20008,NCT00062686,"Neoplasms, Breast",Phase 2,http://www.gsk-clinicalstudyregister.com/study/EGF20008,http://clinicaltrials.gov/show/NCT00062686,,Y,Y,Y,Y,Y,N,Y,The raw dataset is included within the analysis-ready dataset.,1-Jun-2014
Novartis,"A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens",lapatinib,EGF104900,NCT00320385,"Neoplasms, Breast",Phase 3,http://www.gsk-clinicalstudyregister.com/study/EGF104900,http://clinicaltrials.gov/show/NCT00320385,,Y,Y,Y,Y,Y,N,Y,The raw dataset is included within the analysis-ready dataset.,1-Jun-2014
Novartis,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer",lapatinib,EGF30001,NCT00075270,"Neoplasms, Breast",Phase 3,http://www.gsk-clinicalstudyregister.com/study/EGF30001,http://clinicaltrials.gov/show/NCT00075270,,Y,Y,Y,Y,Y,N,Y,The raw dataset is included within the analysis-ready dataset.,1-Jun-2014
Novartis,A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy,pazopanib,VEG110727,NCT00753688,"Sarcoma, Soft tissue",Phase 3,http://www.gsk-clinicalstudyregister.com/study/VEG110727,http://clinicaltrials.gov/show/NCT00753688,,Y,Y,Y,Y,Y,Y,Y,,1-May-2013
Novartis,"A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma",pazopanib,VEG105192,NCT00334282,"Carcinoma, Renal Cell",Phase 3,http://www.gsk-clinicalstudyregister.com/study/VEG105192,http://clinicaltrials.gov/show/NCT00334282,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
Novartis,A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma,pazopanib,VEG102616,NCT00244764,"Carcinoma, Renal Cell",Phase 2,http://www.gsk-clinicalstudyregister.com/study/VEG102616,http://clinicaltrials.gov/show/NCT00244764,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
Novartis,Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma,pazopanib,VEG20002,NCT00297258,"Sarcoma, Soft tissue",Phase 2,https://www.gsk-clinicalstudyregister.com/study/VEG20002,https://clinicaltrials.gov/show/NCT00297258,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Novartis,"A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of Rivastigmine on the Time to Clinical Diagnosis of Alzheimer’s Disease in Subjects with Mild Cognitive Impairment (MCI)",rivastigmine,CENA713 IA07,Not available,Alzheimer's Disease,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1886,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia",rivastigmine,CENA713B2311,Not available,Parkinson's Disease Dementia,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1616,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis",secukinumab,CAIN457F2306,NCT01392326,Psoriatic Arthritis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14231,https://clinicaltrials.gov/show/NCT01392326,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
Novartis,"An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor",trametinib,MEK113583,NCT01037127,Cancer,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113583,http://clinicaltrials.gov/show/NCT01037127,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2013
Novartis,"Multinational, multicenter, double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture",zoledronic acid,CZOL446H2310,NCT00046254,Osteoporosis; Hip Fracture,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2441,https://clinicaltrials.gov/show/NCT00046254,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking cal-cium and vitamin D",zoledronic acid,CZOL446H2301,NCT00049829,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2323,https://clinicaltrials.gov/show/NCT00049829,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D",zoledronic acid,CZOL446H2301E1,NCT00145327,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3662,https://clinicaltrials.gov/show/NCT00145327,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis",zoledronic acid,CZOL446H2301E2,NCT00718861,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=10323,https://clinicaltrials.gov/show/NCT00718861,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis",zoledronic acid,CZOL446H2409,NCT00439244,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2856,https://clinicaltrials.gov/show/NCT00439244,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men",zoledronic acid,CZOL446M2308,NCT00097825,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2545,https://clinicaltrials.gov/ct2/show/NCT00097825?term=CZOL446M2308&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,"A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men",zoledronic acid,CZOL446M2309,NCT00439647,"Osteoporosis, Male",Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4646,https://clinicaltrials.gov/show/NCT00439647,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Novartis,Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis,zoledronic acid,CZOL446O2306,NCT00100620,Osteoporosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2456,https://clinicaltrials.gov/show/NCT00100620,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Lilly,"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology",Pemetrexed,H3E-MC-JMIG,NCT00686959,Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/study/NCT00686959?term=H3E-MC-JMIG&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jul-2016
Lilly,A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology,Pemetrexed,H3E-MC-S104,NCT00867009,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/study/NCT00867009?term=H3E-MC-S104&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jul-2016
Novartis,"A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)",lapatinib,EGF102988,NCT00424255,"Neoplasms, Head and Neck",Phase 3,https://www.gsk-clinicalstudyregister.com/study/EGF102988,https://clinicaltrials.gov/show/NCT00424255,,Y,Y,Y,Y,Y,N,Y,The raw dataset is included within the analysis-ready dataset.,1-Feb-2017
GSK,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus",albiglutide,GLP113121,NCT01733758,"Diabetes Mellitus, Type 2",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113121,http://clinicaltrials.gov/show/NCT01733758,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2016
GSK,An Observational Study of the Adherence Behavior of Individuals Travelling to Chloroquine Resistant Plasmodium Falciparum Malarious Zones Taking Anti-Malarial Medication,atovaquone,106101,,"Malaria, Falciparum",Phase 4,http://www.gsk-clinicalstudyregister.com/study/106101,,,N,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"A Randomized, Parallel-Group, Open-Label Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Administered Subcutaneously to Healthy Subjects by Prefilled Syringe or Autoinjector",belimumab,BEL117100,NCT01894360,Systemic Lupus Erythematosus,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117100,http://clinicaltrials.gov/show/NCT01894360,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"A Multi-center, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris",benzoyl peroxide/clindamycin phosphate,200398,NCT02058628,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/200398,http://clinicaltrials.gov/show/NCT02058628,,Y,Y,Y,Y,Y,N,Y,This study is available in CDISC format,1-Jul-2016
GSK,"An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers",dutasteride,200254,NCT01957189,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200254,http://clinicaltrials.gov/show/NCT01957189,,Y,Y,Y,Y,Y,N,Y,,1-Jul-2016
GSK,"An open label, randomised, six-way crossover, single dose study to determine the pharmacokinetics of GSK961081 and fluticasone furoate when administered alone or in combination",fluticasone furoate/GSK961081,201010,NCT02064504,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201010,http://clinicaltrials.gov/show/NCT02064504,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine with Levocabastine and Fluticasone Furoate Alone,fluticasone furoate/Levocabastine,200284,NCT01962467,"Rhinitis, Allergic, Perennial and Seasonal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200284,http://clinicaltrials.gov/show/NCT01962467,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR)",fluticasone propionate,200165,NCT01916226,"Rhinitis, Allergic, Perennial and Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/200165,http://clinicaltrials.gov/show/NCT01916226,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of intravenously infused GSK1995057 in healthy subjects.",GSK1995057,TFR110951,NCT01476046,Respiratory Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110951,http://clinicaltrials.gov/show/NCT01476046,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) in children 6 to 35 months of age,GSK2282512A; Influenza Vaccine (Quadrivalent),200806,NCT01974895,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/200806,http://clinicaltrials.gov/show/NCT01974895,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"A single-blind, randomized study to evaluate the immunogenicity and reactogenicity of two production lots of GlaxoSmithKline Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine stored between 2 °C-8 °C for either 0-12 or 24-36 months and administered as a single dose to healthy adult volunteers",Haptyrix,270362/004 (TypHA-004),,Hepatitis A,Phase 3,http://www.gsk-clinicalstudyregister.com/study/270362/004,,,Y,N,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. An analysis-ready dataset is not available for this study.,1-May-2016
GSK,"Phase III study to compare immunogenicity, safety and reactogenicity of GSK Bios’ novel adjuvanted hepatitis B vaccine admind intramuscularly, according to a 0, 6 month schedule, to Engerix™-B 20 mcg admind according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype","Hepatitis B Vaccine, Recombinant",208129/034 (HBV-MPL-034),NCT00697749,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208129/034,http://clinicaltrials.gov/show/NCT00697749,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"Study to compare the immunogenicity and safety of GSK Biologicals’ novel adjuvanted HBV vaccine (0, 21-day schedule) to a double dose of Engerix™ -B (0, 7, 21-day schedule), in pre-liver transplant patients ≥ 18 y, boosted at month 6-12","Hepatitis B Vaccine, Recombinant",208129/036 (HBV-MPL-036),NCT00697554,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208129/036,http://clinicaltrials.gov/show/NCT00697554,,Y,N,Y,Y,Y,Y,N,A RAP is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"Evaluating the consistency of 3 consecutive lots of GSK Biologicals' novel adjuvanted HBV vaccine with single-blind safety evaluation using Engerix™-B as a control, administered according to a 0, 1, 2-month schedule in healthy volunteers (15-50y).","Hepatitis B Vaccine, Recombinant",208129/037,NCT00697866,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208129/037,http://clinicaltrials.gov/show/NCT00697866,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2016
GSK,A study to evaluate antibody responses to 10 and 20 µg of licensed recombinant hepatitis B vaccine among elderly patients,"Hepatitis B Vaccine, Recombinant",103860/128 (HBV-128),,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/103860/128,,,Y,N,Y,Y,N,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study.,1-May-2016
GSK,Demonstrate the lot-to-lot consistency of 3 consecutive production lots of an adjuvinated influenza vaccine candidate and evaluate the safety of an adjuvinated influenza vaccine candidate versus Fluarix™ administered intramuscularly in elderly,Influenza Vaccine,107192,NCT00321763,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107192,http://clinicaltrials.gov/show/NCT00321763,,Y,N,Y,Y,Y,Y,N,A follow on study 107214 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-May-2016
GSK,"A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above",Influenza Vaccine,107022,NCT00321373,Influenza,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107022,http://clinicaltrials.gov/show/NCT00321373,,Y,N,Y,Y,Y,Y,N,A follow on study 107191 was conducted.  An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-May-2016
GSK,"Study in an elderly population aged over 65 years (>= 65 years-old) in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccines, administered intramuscularly as compared to Fluarix vaccine",Influenza Vaccine,103304-001,,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/103304-001,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2016
GSK,"Double-blind randomised, multicentre, comparative phase III vaccination study to determine the immunogenicity and reactogenicity of an investigational influenza vaccine formulation versus the standard formulation of Influsplit SSW® 2004/2005 in subjects at least 18 years old.","Influenza Vaccine (Split Virion, Inactivated)",102500-060,,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/102500-060,,,Y,N,Y,Y,Y,Y,Y,A link to clincialtrials.gov and a NCT ID number are not available for this study because the study was conducted before the regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals live attenuated Measles-Mumps-Rubella vaccine (Priorix) given to healthy children at the age of 12 to 15 months or 4- 6 years","Measles, Mumps, Rubella Vaccine",209762/146 (MMR-146),,"Measles, Mumps, Rubella",Phase 3,http://www.gsk-clinicalstudyregister.com/study/209762/146,,,Y,N,Y,Y,N,Y,N,A link to clincialtrials.gov and a NCT ID number are not available for this study because the study was conducted before the regulatory requirements to register studies. A RAP and Protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2016
GSK,DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study,otelixizumab,OTX115496,,"Diabetes Mellitus, Type 1",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115496,,,Y,N,Y,Y,Y,Y,Y,This study was not originally sponsored by GSK. A link to clincialtrials.gov and a NCT ID number are not available for this study. This is a follow up study to OTX115495. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder",paroxetine,PCR112810,NCT00866294,Depressive Disorder,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112810,http://clinicaltrials.gov/show/NCT00866294,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because an English language version was not created.,1-Jul-2016
GSK,"Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) injected in healthy children and adults according to the Indian prescribing information.Typherix™: GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (Typh)",Polysaccharide Typhoid Vaccine,219550/012,,Typhoid Fever,Phase 4,http://www.gsk-clinicalstudyregister.com/study/219550/012,,,Y,N,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-May-2016
GSK,"Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium",Rotavirus Vaccine,111426,NCT01177826,"Infections, Rotavirus",Phase 4,http://www.gsk-clinicalstudyregister.com/study/111426,http://clinicaltrials.gov/show/NCT01177826,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2016
GSK,"A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD",umeclidinium bromide,AC4116135,NCT01772134,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116135,http://clinicaltrials.gov/show/NCT01772134,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2016
GSK,"A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD.",umeclidinium bromide,AC4116136,NCT01772147,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116136,http://clinicaltrials.gov/show/NCT01772147,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD",umeclidinium bromide/vilanterol,DB2116134,NCT01822899,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116134,http://clinicaltrials.gov/show/NCT01822899,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
GSK,"A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD",umeclidinium bromide/vilanterol,201211,NCT02152605,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/201211,http://clinicaltrials.gov/show/NCT02152605,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2016
Lilly,A Controlled Trial of Olanzapine Versus Quetiapine in the Treatment of Schizophrenic and Schizoaffective Subjects with Prominent Negative Symptoms,Olanzapine,FID-US-HGJB,Not available,Schizophrenia,Phase 4,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Aug-2016
Lilly,A Controlled Trial of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression,Olanzapine,F1D-US-HGJU,Not available,Schizophrenia,Phase 4,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Aug-2016
Lilly,Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia,Olanzapine,F1D-MC-HGHJ,NCT00036088,Schizophrenia,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00036088?term=F1D-MC-HGHJ&rank=1,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Aug-2016
Lilly,Quality of Life in Asian Patients with Schizophrenia:  Comparing Olanzapine with Haloperidol,Olanzapine,F1D-SN-S010,Not available,Schizophrenia,Phase 4,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Aug-2016
Sanofi,Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer,Oxaliplatin,EFC3313,NCT00275210,Colonic Neoplasms,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-o/,https://clinicaltrials.gov/ct2/show/NCT00275210?term=00275210&rank=1,Not available,Y,Y,Y,Y,Y,N,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Aug-2016
Lilly,"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Galrgine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimeperide (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 2)",Dulaglutide,H9X-MC-GBDB,NCT01075282,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01075282?term=H9X-MC-GBDB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
Lilly,"A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)",Dulaglutide,H9X-MC-GBDG,NCT01769378,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01769378?term=H9X-MC-GBDG&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Sep-2016
Takeda,"An Open-Label, Randomized, 3-Period Crossover Study to Evaluate the Relative Bioavailability of TAK-491 and Chlorthalidone in Fixed-Dose Combination Following Oral Administration to Healthy Subjects",azilsartan medoxomil/chlorthalidone,TAK-491CLD_102,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_102,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Randomized, Open-Label, 2-Period Crossover Study to Determine the Relative Bioavailability of the TAK-491CLD High-Dose Formulation of Fixed-Dose Combination Tablets Compared to Coadministration of Individual TAK-491 and Chlorthalidone Tablets in Healthy Adult Subjects",azilsartan medoxomil/chlorthalidone,TAK-491CLD_103,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_103,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Randomized, Open-Label, 2-Period Crossover, Parallel Group Study to Determine the Effect of Food on the Pharmacokinetics of Scaled-up Fixed-Dose Combination Formulation of TAK-491 and Chlorthalidone in Healthy Subjects",azilsartan medoxomil/chlorthalidone,TAK-491CLD_104,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_104,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"An Open-Label, Randomized, 2-Cohort, 2-Period Crossover Study to Evaluate the Relative Bioavailability of Two TAK-491CLD Fixed-Dose Combination Tablets Compared to Individual TAK-491 and Chlorthalidone Tablets in Healthy Subjects",azilsartan medoxomil/chlorthalidone,TAK-491CLD_105,Not available,Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_105,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Randomized, Open-Label, 2-Period Crossover Study to Determine the Relative Bioavailability of TAK-491CLD Fixed-Dose Combination Tablet Compared to Coadministration of Individual TAK-491 and Chlorthalidone Tablets in Healthy Adult Subjects",azilsartan medoxomil/chlorthalidone,TAK-491CLD_106,"NCT00818883
2010-020752-61",Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_106,https://clinicaltrials.gov/show/NCT00818883,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020752-61,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Phase 3, Double-blind, Randomized, Factorial, Efficacy and Safety Study of TAK-491 Plus Chlorthalidone Fixed-Dose Combination in Subjects with Moderate to Severe Hypertension",azilsartan medoxomil/chlorthalidone,TAK-491CLD_302,"NCT00847626 
2008-004218-28",Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_302,"https://clinicaltrials.gov/show/NCT00847626,",https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004218-28,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension",azilsartan medoxomil/chlorthalidone,TAK-491CLD_303,NCT01033071,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_303,https://clinicaltrials.gov/show/NCT01033071,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
Takeda,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension",azilsartan medoxomil/chlorthalidone,TAK-491CLD_306,NCT00818883,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_306,https://clinicaltrials.gov/show/NCT00818883,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2016
GSK,Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment,alitretinoin,ATN117221,NCT01245140,Psoriasis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/117221,http://clinicaltrials.gov/show/NCT01245140,,N,Y,Y,Y,Y,Y,Y,A raw dataset is not available for this study.,1-Sep-2016
GSK,A two-part crossover study to assess the pharmacokinetics of amoxicillin after administration with clavulanate of pharmacokinetically enhanced formulations of amoxicillin in healthy volunteers.,amoxicillin/clavulanic acid,25000/552,,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/552,,,N,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis and reporting dataset is not available for this study. A reporting and analysis plan is not available for this study.,1-Sep-2016
GSK,"An open, randomised, balanced, three period, single dose crossover study to investigate the effect of food on the bioavailability of pharmacokinetically enhanced (PE) oral Augmentin® in healthy male and female volunteers.",amoxicillin/clavulanic acid,25000/553,,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/25000/553,,,N,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis and reporting  dataset is not available for this study. A reporting and analysis plan is not available for this study.,1-Sep-2016
GSK,"A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",103488,NCT00169481,acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/103488,http://clinicaltrials.gov/show/NCT00169481,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A Reporing and tanalysis plan is not available for this study,1-Sep-2016
GSK,"A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022",danirixin,201022,NCT02169583,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201022,http://clinicaltrials.gov/show/NCT02169583,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A single-centre, double-blind, placebo-controlled study to evaluate the safety, tolerabilty, pharmacokinetics, and pharmacodynamics of single, oral, ascending doses and repeat oral doses of GSK1325756 in healthy male subjects.",danirixin,CX3112483,NCT01209052,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112483,http://clinicaltrials.gov/show/NCT01209052,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A single-dose, open, randomized, crossover investigation of age, gender, food-effect and proton-pump interaction on the pharmacokinetics of GSK1325756 in healthy adult subjects and a single-dose, double blind, parallel-group, placebo- controlled investigation of the pharmacokinetics of GSK1325756",danirixin,CX3113722,NCT01209104,Nutritional Status,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113722,http://clinicaltrials.gov/show/NCT01209104,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized cross-over study to evaluate the pharmacokinetics and pharmacodynamics of twice daily oral administration of GSK1325756, compared to placebo, in healthy subjects; and the pharmacokinetic profile of twice daily oral administration of GSK1325756 in healthy fed and fasted elderly subjects",danirixin,CX3114922,NCT01267006,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114922,http://clinicaltrials.gov/show/NCT01267006,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bio enhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion",danirixin,CX3115550,NCT01453478,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115550,http://clinicaltrials.gov/show/NCT01453478,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,Bioequivalence Study of Dutasteride Capsules-An evaluation of the bioequivalence of dutasteride capsule manufactured at GSK compared to dutasteride capsule manufactured at Catalent in healthy Japanese male subjects,dutasteride,204646,NCT02578953,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/204646,http://clinicaltrials.gov/show/NCT02578953,,Y,N,N,Y,N,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Sep-2016
GSK,"A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with low to mid-strength inhaled corticosteroid or low-strength combination therapy.",fluticasone furoate/vilanterol trifenatate,HZA113719,NCT01498679,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113719,http://clinicaltrials.gov/show/NCT01498679,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Sep-2016
GSK,"A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and ADOAIR 50/250mcg alone) in the treatment of Japanese subjects with COPD",fluticasone propionate/salmeterol,SCO116572,NCT01751113,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/116572,http://clinicaltrials.gov/show/NCT01751113,,Y,N,N,Y,Y,Y,N,A clinical study report is not available for this study because an English language version was not created. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided,1-Sep-2016
GSK,"SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma",fluticasone propionate/salmeterol,SAS115359,NCT01475721,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115359,http://clinicaltrials.gov/show/NCT01475721,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666),gepotidacin,BTZ116666,NCT01934205,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116666,http://clinicaltrials.gov/show/NCT01934205,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Sep-2016
GSK,"A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.",gepotidacin,BTZ115198,NCT01615796,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115198,http://clinicaltrials.gov/show/NCT01615796,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)",gepotidacin,BTZ116778,NCT01706315,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116778,http://clinicaltrials.gov/show/NCT01706315,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil),daprodustat,PHI113634,NCT01376232,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113634,http://clinicaltrials.gov/show/NCT01376232,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A multi-center, placebo-controlled study to evaluate the safety and efficacy of GSK1278863 vs. placebo in subjects with peripheral artery disease (PAD).",daprodustat,PVD114272,NCT02135848,"Vascular Disease, Peripheral",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114272,http://clinicaltrials.gov/show/NCT02135848,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A",daprodustat,PHI114703,NCT01319006,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114703,http://clinicaltrials.gov/show/NCT01319006,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects",daprodustat,PHI115385,NCT02348372,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115385,http://clinicaltrials.gov/show/NCT02348372,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized, placebo-controlled, study to evaluate the effects of GSK1278863A on pulmonary artery pressure in healthy volunteers",daprodustat,PHI116008,NCT01673555,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116008,http://clinicaltrials.gov/show/NCT01673555,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis",daprodustat,PHI116581,NCT01587898,Anaemia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116581,http://clinicaltrials.gov/show/NCT01587898,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease",daprodustat,PHI116582,NCT01587924,Anaemia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116582,http://clinicaltrials.gov/show/NCT01587924,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,Cancer immunotherapeutic GSK1572932A as adjuvant therapy for patients with MAGE-A3-positive Non-Small Cell Lung cancer,GSK1572932A,107240,NCT00455572,"Lung Cancer, Non-Small Cell",Phase 1,http://www.gsk-clinicalstudyregister.com/study/107240,http://clinicaltrials.gov/show/NCT00455572,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomised, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and efficacy against allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies",GSK2245035,TL7116392,NCT01607372,Asthma and Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116392,http://clinicaltrials.gov/show/NCT01607372,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhinitis",GSK2445053,TL7114450,NCT01480271,"Rhinitis, Allergic, Seasonal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114450,http://clinicaltrials.gov/show/NCT01480271,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A First Time in Human study to assess the safety, tolerability and pharmacokinetics of GSK356278 (PDE4 inhibitor) in healthy volunteers",GSK356278,POD113324,NCT01031186,Depressive Disorder and Anxiety Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113324,http://clinicaltrials.gov/show/NCT01031186,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278",GSK356278,POD115719,NCT01573819,Huntington Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115719,http://clinicaltrials.gov/show/NCT01573819,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"An open label positron emission tomography study in healthy male subjects to investigate brain PDE4 engagement, pharmacokinetics and safety of single oral doses of GSK356278, using 11C-(R)-rolipram as a PET ligand(s)",GSK356278,POD116038,NCT01602900,Huntington Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116038,http://clinicaltrials.gov/show/NCT01602900,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.",lamotrigine,LAM115207,NCT01879423,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115207,http://clinicaltrials.gov/show/NCT01879423,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects",lamotrigine,200697,NCT02064465,Epilepsy,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200697,http://clinicaltrials.gov/show/NCT02064465,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents",lamotrigine,LAM115377,NCT01431976,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115377,http://clinicaltrials.gov/show/NCT01431976,,Y,Y,N,Y,Y,Y,Y,A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Sep-2016
GSK,"A randomized, placebo-controlled, single-blind study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of otelixizumab in rheumatoid arthritis subjects",otelixizumab,RAO111601,NCT01077531,"Arthritis, Rheumatoid",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111601,http://clinicaltrials.gov/show/NCT01077531,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomised, comparator controlled, two part, open-label study to evaluate the safety, tolerability and pharmacodynamics of multiple doses of otelixizumab in patients with thyroid orbitopathy",otelixizumab,GOO112480,NCT01114503,Graves Ophthalmopathy,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112480,http://clinicaltrials.gov/show/NCT01114503,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomised, single-blind, placebo-controlled, study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat subcutaneous administration of otelixizumab in subjects with rheumatoid arthritis",otelixizumab,RAO113299,NCT01101555,"Arthritis, Rheumatoid",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113299,http://clinicaltrials.gov/show/NCT01101555,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized, single blind, placebo-controlled, single ascending dose/repeat dose cohort study to assess safety, tolerability, pharmacokinetics and immunogenicity of GSK1223249 in patients with relapsing forms of multiple sclerosis.",ozanezumab,NGM114840,NCT01435993,"Multiple Sclerosis, Relapsing-Remitting",N/A,http://www.gsk-clinicalstudyregister.com/study/114840,http://clinicaltrials.gov/show/NCT01435993,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"An open label, randomized, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of the controlled-release paroxetine tablets at the dose levels of 12.5, 25 and 50mg in healthy Japanese male subjects",paroxetine,PCR112811,NCT00938184,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112811,http://clinicaltrials.gov/show/NCT00938184,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Sep-2016
GSK,"A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled-release paroxetine tablet (25 mg) with that of the standard immediate-release paroxetine tablet (20 mg) in healthy Japanese male subjects",paroxetine,PCR112812,NCT01000857,Depressive Disorder,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112812,http://clinicaltrials.gov/show/NCT01000857,,Y,Y,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because an English language version was not created.,1-Sep-2016
GSK,"Impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112595,NCT00839254,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112595,http://clinicaltrials.gov/show/NCT00839254,,Y,Y,Y,Y,Y,Y,Y,This study is linked to 111442,1-Sep-2016
GSK,"To evaluate the pharmacokinetics, safety and tolerability of Retosiban (GSK221149) co-administered with EFAVIRENZ",retosiban,OTA116073,NCT01867996,"Obstetric Labour, Premature",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116073,http://clinicaltrials.gov/show/NCT01867996,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Sep-2016
GSK,"A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, with Moxifloxacin as a Positive Control in Healthy Volunteers",retosiban,OTA113789,NCT01702376,"Obstetric Labour, Premature",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113789,http://clinicaltrials.gov/show/NCT01702376,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A two cohort, open-label study to evaluate the pharmacokinetics of GSK2847065, the metabolite of Retosiban (GSK221149) after single and repeat oral doses, the pharmacokinetics of GSK221149 coadministered with a high fat meal, and the pharmacokinetics of GSK221149 coadministered with an inhibitor of CYP3A4 (Ketoconazole)",retosiban,OTA115893,NCT01627587,"Obstetric Labour, Premature",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115893,http://clinicaltrials.gov/show/NCT01627587,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks’ gestation",retosiban,OTA105256,NCT00404768,"Obstetric Labour, Premature",Phase 2,http://www.gsk-clinicalstudyregister.com/study/OTA105256,http://clinicaltrials.gov/show/NCT00404768,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD",umeclidinium bromide/vilanterol,DB2116961,NCT02257385,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116961,http://clinicaltrials.gov/show/NCT02257385,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
GSK,"Phase I study of GW642444M- A randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects",vilanterol,DB1112017,NCT00964249,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/112017,http://clinicaltrials.gov/show/NCT00964249,,Y,Y,Y,Y,N,Y,N,A reporting and analysis plan is not available for this study.,1-Sep-2016
GSK,"Phase1 study of GR121167- A double blind, placebo controlled, randomized, dose ascending, single and multiple dose study to investigate the safety and pharmacokinetics following intravenous administration of GR121167 in healthy Japanese males",zanamivir,NAI115070,NCT01428479,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115070,http://clinicaltrials.gov/show/NCT01428479,,Y,Y,N,Y,Y,Y,Y,A Clinical Study Report is not available for this study .,1-Sep-2016
GSK,"An open-label, multi-center, single arm study to evaluate the safety and efficacy of intravenous zanamivir in the treatment of hospitalized patients with confirmed influenza infection (NAI115215)",zanamivir,NAI115215,NCT01527110,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115215,http://clinicaltrials.gov/show/NCT01527110,,Y,Y,Y,Y,N,Y,Y,A protocol is not available for this study because an English language version was not created.,1-Sep-2016
Roche,"A multiple ascending dose study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of RO4389620 in patients with type 2 diabetes mellitus",GK Activator (2),NP17752,,Type 2 Diabetes Mellitus,Phase 1,,,,Y,N,Y,N,Y,Y,N,,1-Oct-2016
Roche,"A Randomized Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.",GK Activator (2),BM18249,NCT00266253,Type 2 Diabetes Mellitus,Phase 2,,https://clinicaltrials.gov/ct2/show?term=BM18249&rank=2,,Y,N,Y,Y,Y,Y,Y,,1-Oct-2016
Roche,"A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of Herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer",Pertuzumab,WO20697,NCT00545688,malignant neoplasm of breast,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00545688?term=WO20697&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Lilly,A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes,Atomoxetine,B4Z-US-LYDZ,NCT00510276,Attention Deficit Hyperactivity Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00510276?term=B4Z-US-LYDZ&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of IC351 (LY450190) Administered “On Demand” to Patients with Male Erectile Dysfunction",Tadalafil,H6D-CA-LVAC,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks Followed by an Open-Label Extension to Evaluate the Long-Term Safety and Efficacy of Tadalafil in Japanese Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-JE-LVIA,NCT00783094,Benign Prostatic Hyperplasia,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00783094?term=H6D-JE-LVIA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Lilly,An Open Label Study of “On Demand” Therapy with IC351 for the Treatment of Male Erectile Dysfunction,Tadalafil,H6D-MC-LVBD,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,An Open-label Continuation Study of “On Demand” Therapy with IC351 for the Treatment of Male Erectile Dysfunction,Tadalafil,H6D-MC-LVBE,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Double-blind, Placebo-Controlled Safety and Efficacy Study of “On Demand” Therapy with IC351 for the Treatment of Male Erectile Dysfunction",Tadalafil,H6D-MC-LVBF,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Double-blind, Placebo-controlled, Safety and Efficacy Study of Twenty-one Days of Once Daily Treatment with IC351 in Patients with Mild to Moderate Erectile Dysfunction",Tadalafil,H6D-MC-LVBG,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A 2x2 Crossover Study to Evaluate the Acute Tolerability, Safety, and Efficacy of IC351 in Patients with Male Erectile Disorder",Tadalafil,H6D-MC-LVBI,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,Onset and Duration of Response to IC351: A Penile Plethysmography Study,Tadalafil,H6D-MC-LVBJ,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of IC351 (LY450190) Administered “On Demand” to Male Diabetics with Erectile Dysfunction",Tadalafil,H6D-MC-LVBK,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Two-Year, Open Label Study of “On Demand” Therapy with IC351 for the Treatment of Male Erectile Dysfunction",Tadalafil,H6D-MC-LVBL,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered “On Demand” to Patients with Male Erectile Dysfunction",Tadalafil,H6D-MC-LVBN,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of IC351 (LY450190) Compared with Sildenafil for the Treatment of Patients with Male Erectile Dysfunction",Tadalafil,H6D-MC-LVBO,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,An Evaluation on Effect of IC351 on Sperm Concentration in Normal Healthy Subjects or Subjects with Mild Erectile Dysfunction,Tadalafil,H6D-MC-LVCD,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered “On Demand” to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVCE,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Comparison Study of IC351 (LY450190) and Sildenafil Administered “On Demand” to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVCF,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,Switching from Sildenafil Citrate to IC351 (LY450190) in Oral Treatment of Erectile Dysfunction: A Multicenter Open-Label Study of Treatment Preference,Tadalafil,H6D-MC-LVCG,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil (IC351, LY450190) Administered “On Demand” to Patients with Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Retropubic Prostatectomy",Tadalafil,H6D-MC-LVCI,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,Time of Response to IC351,Tadalafil,H6D-MC-LVCK,Not available,Erectile Dysfunction,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered “On Demand” to Patients with Erectile  Dysfunction in Taiwan",Tadalafil,H6D-MC-LVCO,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered over 6 Months “On Demand” to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVCQ,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered “On Demand” to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVCR,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, 4-week, Two-Period Crossover Study to Evaluate Patient Preference for IC351 (LY450190) Versus Sildenafil Citrate During the Initial Treatment Period for Erectile Dysfunction",Tadalafil,H6D-MC-LVCU,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind,
Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (IC351) (5 mg and 10 mg) Administered Once Daily to Men with Erectile Dysfunction",Tadalafil,H6D-MC-LVCV,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Lilly,"A Randomized, Double-Blind, Crossover Study of IC351 (LY450190) Compared with Sildenafil Citrate for the Treatment of Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVCY,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Oct-2016
Astellas,Phase III Study of YM178: A double-blind group comparison study in patients with overactive bladder,mirabegron,178-CL-048,NCT00966004,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=193,https://clinicaltrials.gov/ct2/show/NCT00966004,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
Astellas,"A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder",mirabegron,178-CL-008,NCT01604928,"Urinary Bladder, Overactive",Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=194,https://clinicaltrials.gov/ct2/show/NCT01604928,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
Astellas,"A randomized, double-blind, parallel-group, placebo and active controlled, multi-center dose ranging study with beta-3 agonist YM178 in patients with symptomatic overactive bladder (DRAGON)",mirabegron,178-CL-044,"NCT00337090
EudraCT 2005-002256-17","Urinary Bladder, Overactive",Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=195,https://clinicaltrials.gov/ct2/show/NCT00337090,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002256-17,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2016
Boehringer Ingelheim,BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery,dabigatran etexilate,1160.19,NCT01225822,Venous Thromboembolism,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01225822?term=1160.19&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.,dabigatran etexilate,1160.5,NCT00246025,"Arthroplasty, Replacement, Knee; Venous Thrombosis",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00246025?term=1160.50&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,dabigatran etexilate,1160.24,NCT00152971,"Arthroplasty, Replacement, Knee; Thromboembolism",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00152971?term=1160.24&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery,dabigatran etexilate,1160.48,NCT00168818,"Thromboembolism; Arthroplasty, Replacement, Hip",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00168818?term=1160.48&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery,dabigatran etexilate,1160.25,NCT00168805,"Arthroplasty, Replacement, Knee; Thromboembolism",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00168805?term=1160.25&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,dabigatran etexilate,1160.64,NCT00657150,Venous Thromboembolism,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00657150?term=1160.64&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate,dabigatran etexilate,1160.86,NCT01184989,"Arthroplasty, Replacement; Prevention of Venous Thromboembolism; Moderate Renal Impairment (CrCl 30-50 mL/Min)",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01184989?term=1160.86&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery,dabigatran etexilate,1160.11,NCT02170701,Venous Thromboembolism,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02170701?term=1160.11&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.,olodaterol,1222.5,NCT00452400,"Pulmonary Disease, Chronic Obstructive; Asthma",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00452400?term=1222.5&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I,olodaterol,1222.37,NCT01040130,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01040130?term=1222.37&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma,olodaterol,1222.6,NCT00467740,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00467740?term=1222.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.,olodaterol,1222.27,NCT01013753,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01013753?term=1222.27&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma,olodaterol,1222.29,NCT01311661,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01311661?term=1222.29&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD,olodaterol,1222.22,NCT00824382,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00824382?term=1222.22&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II,olodaterol,1222.38,NCT01040793,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01040793?term=1222.38&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD,olodaterol,1222.26,NCT00846768,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00846768?term=1222.26&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication,tiotropium bromide,205.441,NCT01696071,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01696071?term=205.441&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Japan Long-term Safety for Tiotropium Plus Olodaterol,tiotropium bromide + olodaterol,1237.22,NCT01536262,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01536262?term=1237.22&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients with Gastroparesis",camicinal,MOT111809,NCT00861809,Gastroparesis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111809,http://clinicaltrials.gov/show/NCT00861809,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A double-blind, randomized, placebo controlled Phase II study to evaluate the pharmacodynamics, safety, tolerability, and pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in critically ill male and female patients with enteral feed intolerance",camicinal,MOT112571,NCT01039805,Gastroparesis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112571,http://clinicaltrials.gov/show/NCT01039805,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A single dose, open label, nonrandomized, study to evaluate the pharmacokinetics and absolute bioavailability of GSK962040 given as an oral dose simultaneously with an intravenous micro tracer dose of [14C]-GSK962040 in healthy volunteers",camicinal,MOT114136,NCT01267071,Gastroparesis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114136,http://clinicaltrials.gov/show/NCT01267071,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects",camicinal,MOT107043,NCT00562848,Gastroparesis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MOT107043,http://clinicaltrials.gov/show/NCT00562848,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers",camicinal,MOT109681,NCT00733551,Gastroparesis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/MOT109681,http://clinicaltrials.gov/show/NCT00733551,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2016
GSK,"A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis.",elubrixin,CF2110399,NCT00903201,Cystic Fibrosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110399,http://clinicaltrials.gov/show/NCT00903201,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis.",elubrixin,CUC111342,NCT00748410,"Colitis, Ulcerative",Phase 2,http://www.gsk-clinicalstudyregister.com/study/CUC111342,http://clinicaltrials.gov/show/NCT00748410,,N,N,Y,Y,Y,Y,Y,An analysis and reporting dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2016
GSK,"A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation",epelsiban,OTB109059,NCT01021553,Premature Ejaculation,Phase 2,http://www.gsk-clinicalstudyregister.com/study/109059,http://clinicaltrials.gov/show/NCT01021553,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers after Single and Repeat Dosing",epelsiban,IVF116741,NCT01669083,Embryo Transfer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116741,http://clinicaltrials.gov/show/NCT01669083,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma",fluticasone furoate/umeclidinium bromide,ILA115938,NCT01573624,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/115938,http://clinicaltrials.gov/show/NCT01573624,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects",fluticasone furoate/umeclidinium bromide,ILA116524,NCT01725685,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116524,http://clinicaltrials.gov/show/NCT01725685,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison with FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).",fluticasone furoate/vilanterol/umeclidinium bromide,200587,NCT01894386,"Pulmonary disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200587,http://clinicaltrials.gov/show/NCT01894386,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomized, double-blind, single dose, four way cross-over study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol following single inhaled doses of Umeclidinium/Vilanterol blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in healthy subjects",fluticasone furoate/vilanterol/umeclidinium bromide,CTT116415,NCT01691547,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116415,http://clinicaltrials.gov/show/NCT01691547,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate from FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol from SERETIDE™ 250/25 HFA pMDI when given with the VENTOLIN Mini-Spacer Compared to the Aero chamber Plus Spacer in Healthy Subjects",fluticasone propionate,201092,NCT02045953,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201092,http://clinicaltrials.gov/show/NCT02045953,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin",GSK2330672,200185,NCT01929863,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/200185,http://clinicaltrials.gov/show/NCT01929863,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A first time in human, single blind, randomized, placebo-controlled, dose escalating crossover study to evaluate the safety,tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in healthy volunteers",GSK2330672,BAT114985,NCT01416324,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114985,http://clinicaltrials.gov/show/NCT01416324,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients with Relapsing Remitting Multiple Sclerosis",GSK2618960,I7R116702,NCT01808482,"Multiple Sclerosis, Relapsing-Remitting",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116702,http://clinicaltrials.gov/show/NCT01808482,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers",GSK2862277,TFR116343,NCT01818024,Respiratory Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116343,http://clinicaltrials.gov/show/NCT01818024,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers",GSK933776,BA1116891,NCT02033668,"Atrophy, Geographic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116891,http://clinicaltrials.gov/show/NCT02033668,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Oct-2016
GSK,"A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with Alzheimer's Disease.",GSK933776,BA1106006,NCT00459550,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/106006,http://clinicaltrials.gov/show/NCT00459550,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Oct-2016
GSK,Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer’s disease or mild cognitive impairment,GSK933776,BA1113043,NCT01424436,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113043,http://clinicaltrials.gov/show/NCT01424436,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects,losmapimod,PM1116628,NCT01756495,Acute Coronary Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116628,http://clinicaltrials.gov/show/NCT01756495,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation",losmapimod,PM1111810,NCT00910962,Acute Coronary Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111810,http://clinicaltrials.gov/show/NCT00910962,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury",losmapimod,KIP112967,NCT00969059,"Pain, Neuropathic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112967,http://clinicaltrials.gov/show/NCT00969059,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,A Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).,losmapimod,MKI113006,NCT01218126,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113006,http://clinicaltrials.gov/show/NCT01218126,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A six week randomized, double-blind, multi-center, placebo-controlled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder",losmapimod,PKI113009,NCT00976560,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113009,http://clinicaltrials.gov/show/NCT00976560,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous dose(s) and a single oral dose of GW856553 in healthy volunteers",losmapimod,PM1113022,NCT01039961,Cardiovascular Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113022,http://clinicaltrials.gov/show/NCT01039961,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy",losmapimod,KIP113049,NCT01110057,"Pain, Neuropathic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113049,http://clinicaltrials.gov/show/NCT01110057,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects.",losmapimod,PM1116681,NCT01648192,Acute Coronary Syndrome,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116681,http://clinicaltrials.gov/show/NCT01648192,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Oct-2016
GSK,"A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD)",losmapimod,MKI102428,NCT00642148,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/MKI102428,http://clinicaltrials.gov/show/NCT00642148,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 month, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis",losmapimod,PM1111138,NCT00633022,Atherosclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/PM1111138,http://clinicaltrials.gov/show/NCT00633022,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) Losmapimod to Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome (LATITUDE)-TIMI 60.,losmapimod,PM1116197,NCT02145468,Acute Coronary Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116197,http://clinicaltrials.gov/show/NCT02145468,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg from Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions",montelukast,200107,NCT02322671,Respiratory Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200107,http://clinicaltrials.gov/show/NCT02322671,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,Characterization of Exposure from Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects,umeclidinium bromide,LHH117157,NCT01934153,Hyperhidrosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117157,http://clinicaltrials.gov/show/NCT01934153,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
GSK,"A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma",umeclidinium bromide,ALA116402,NCT01641692,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116402,http://clinicaltrials.gov/show/NCT01641692,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Novartis,Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer,lapatinib,LPT109096,NCT00524303,"Cancer, Breast",Phase 2,http://www.gsk-clinicalstudyregister.com/search/?study_ids=lpt109096,https://clinicaltrials.gov/show/NCT00524303,,Y,Y,Y,Y,Y,N,Y,The raw dataset is included within the analysis-ready dataset.,1-Nov-2016
Novartis,"A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model",olopatadine hydrochloride,C-10-126,NCT01479374,Allergic conjunctivitis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12984,https://clinicaltrials.gov/show/NCT01479374,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Nov-2016
Novartis,"A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily",olopatadine hydrochloride,C-12-028,NCT01698814,Allergic conjunctivitis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12985,https://clinicaltrials.gov/show/NCT01698814,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Nov-2016
Novartis,"Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model",olopatadine hydrochloride,C-12-053,NCT01743027,Allergic conjunctivitis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12986,https://clinicaltrials.gov/show/NCT01743027,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Nov-2016
Lilly,Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis UNCOVER-A,Ixekizumab,I1F-MC-RHBL,NCT01777191,Psoriasis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01777191?term=I1F-MC-RHBL&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis,Ixekizumab,I1F-MC-RHAJ,NCT01107457,Psoriasis,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01107457?term=I1F-MC-RHAJ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Study is ongoing. Datasets available up to 32 weeks,1-Nov-2016
Lilly,"A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis UNCOVER-1",Ixekizumab,I1F-MC-RHAZ,NCT01474512,Psoriasis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01474512?term=I1F-MC-RHAZ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Study is ongoing. Datasets available up to 60 weeks,1-Nov-2016
Lilly,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis. UNCOVER-2",Ixekizumab,I1F-MC-RHBA,NCT01597245,Psoriasis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01597245?term=I1F-MC-RHBA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Study is ongoing. Datasets available up to 60 weeks,1-Nov-2016
Lilly,"A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period  UNCOVER-3",Ixekizumab,I1F-MC-RHBC,NCT01646177,Psoriasis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01646177?term=iXEKIZUMAB+and+Uncover&rank=2,Not available,Y,Y,Y,Y,Y,Y,Y,Study is ongoing. Datasets available up to 12 weeks,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess Duration of Responsiveness to IC351 (LY450190) in Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVDG,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered “On Demand” to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVDJ,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Six-Month, Open-Label Study of “On Demand” Therapy with IC351 for the Treatment of Male Erectile Dysfunction",Tadalafil,H6D-MC-LVDR,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled Study of IC351 (LY450190) Provided to Patients with Erectile Dysfunction",Tadalafil,H6D-MC-LVDU,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy and Safety of IC351 Administered “On Demand” to Men with Erectile Dysfunction in Korea",Tadalafil,H6D-MC-LVDW,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, 12-Week, Two-Period Crossover Study to Evaluate Patient Preference for IC351 (LY450190) Versus Sildenafil Citrate for the Treatment of Erectile Dysfunction",Tadalafil,H6D-MC-LVEB,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel, Placebo-Controlled Study To Evaluate The Efficacy And Safety of IC351 Administered “On Demand” To Men With Erectile Dysfunction",Tadalafil,H6D-MC-LVEF,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of IC351 Administered “On Demand” to Men with Erectile Dysfunction",Tadalafil,H6D-MC-LVEG,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel, Placebo-Controlled Study To Evaluate The Efficacy And Safety of IC351 Administered “On Demand” To Men With Erectile Dysfunction",Tadalafil,H6D-MC-LVEL,Not available,Erectile Dysfunction,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel, Placebo-Controlled Study in Men With Erectile Dysfunction to Evaluate the Efficacy and Safety of Tadalafil When Sexual Attempts Occur at Specific Time Points After Dosing",Tadalafil,H6D-MC-LVFD,NCT00547508,Erectile Dysfunction,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00547508?term=H6D-MC-LVFD&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Effects of 5 mg Tadalafil (IC351, LY450190) and 50 mg Sildenafil Administered Once Daily for 6 Months on Visual Function in Healthy Subjects or Subjects With Mild Erectile Dysfunction",Tadalafil,H6D-MC-LVGO,NCT00333281,Erectile Dysfunction,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00333281?term=H6D-MC-LVGO&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension,Tadalafil,H6D-MC-LVGX,NCT00549302,"Hypertension, Pulmonary",Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00549302?term=H6D-MC-LVGX&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension",Tadalafil,H6D-MC-LVGY,NCT00125918,"Hypertension, Pulmonary",Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00125918?term=H6D-MC-LVGY&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHB,NCT00861757,Benign Prostatic Hyperplasia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00861757?term=H6D-MC-LVHB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHG,NCT00384930,Benign Prostatic Hyperplasia,Phase 2/Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00384930?term=H6D-MC-LVHG&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Phase 3, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHJ,NCT00827242,Benign Prostatic Hyperplasia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00827242?term=H6D-MC-LVHJ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHK,NCT00386009,Benign Prostatic Hyperplasia,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00386009?term=H6D-MC-LVHK&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men With Both Erectile Dysfunction and Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHR,NCT00855582,"Erectile Dysfunction, 
Benign Prostatic Hyperplasia",Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00855582?term=H6D-MC-LVHR&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy",Tadalafil,H6D-MC-LVHS,NCT00848081,Benign Prostatic Hyperplasia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00848081?term=H6D-MC-LVHS&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVHT,NCT00540124,Benign Prostatic Hyperplasia,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00540124?term=H6D-MC-LVHT&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Lilly,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors",Tadalafil,H6D-MC-LVHX,NCT00836693,Erectile Dysfunction,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00836693?term=H6D-MC-LVHX&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2016
Lilly,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVID,NCT00970632,Benign Prostatic Hyperplasia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00970632?term=H6D-MC-LVID&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2016
Lilly,"A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",Tadalafil,H6D-MC-LVIR,NCT01152190,Benign Prostatic Hyperplasia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01152190?term=H6D-MC-LVIR&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Nov-2016
Astellas,"A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron (YM178) in Asian Patients with Symptoms of Overactive Bladder",mirabegron,178-CL-090,NCT01043666,"Urinary Bladder, Overactive",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=168,https://clinicaltrials.gov/ct2/show/NCT01043666,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Astellas,"YM178 Phase II study - A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder",mirabegron,178-CL-045,NCT00527033,"Urinary Bladder, Overactive",Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=166,https://clinicaltrials.gov/ct2/show/NCT00527033,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Boehringer Ingelheim,Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer,afatinib,1200.89,NCT01325428,Breast Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01325428?term=1200.89&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Boehringer Ingelheim,Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery,dabigatran etexilate,1160.85,NCT00846807,"Arthroplasty, Replacement;   Thromboembolism",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00846807?term=1160.85&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Boehringer Ingelheim,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,empagliflozin,1276.1,NCT01719003,"Diabetes Mellitus, Type 2;   Hyperglycemia",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01719003?term=1276.1&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 8mg tablet formulation of candesartan cilexetil (GW615775) relative to one 8mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions",candesartan,200956,NCT02006589,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200956,http://clinicaltrials.gov/show/NCT02006589,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions",candesartan cilexetil/hydrochlorothiazide,200957,NCT02094924,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200957,http://clinicaltrials.gov/show/NCT02094924,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma",fluticasone furoate/vilanterol,HZA116592,NCT01837316,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116592,http://clinicaltrials.gov/show/NCT01837316,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma",fluticasone propionate/salmeterol,SAS115358,NCT01462344,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115358,http://clinicaltrials.gov/show/NCT01462344,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,A study to evaluate GSK Biologicals’ candidate formulations of pneumococcal vaccines (GSK2189241A) in elderly subjects.,GSK2189241A,111652,NCT00756067,"Infections, Streptococcal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111652,http://clinicaltrials.gov/show/NCT00756067,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Nov-2016
GSK,A study to evaluate GSK Biologicals’ candidate formulations of pneumococcal vaccines (GSK2189242A) in young adults.,GSK2189242A,111651,NCT00707798,"Infections, Streptococcal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111651,http://clinicaltrials.gov/show/NCT00707798,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.The results of this study 111651 are related to 112993,1-Nov-2016
GSK,A study to evaluate safety and immunogenicity of a booster dose of two formulations of GSK Biologicals’ pneumococcal candidate vaccine in healthy young adults,GSK2189242A,112993,NCT00896064,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112993,http://clinicaltrials.gov/show/NCT00896064,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 112993 are related to 111651,1-Nov-2016
GSK,"Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in children aged 12-23 months at the time of first vaccination.",GSK2189242A,113171,NCT00985751,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/113171,http://clinicaltrials.gov/show/NCT00985751,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Nov-2016
GSK,"Impact of GSK Biologicals’ 2189242A vaccine on nasopharyngeal carriage, safety and immunogenicity when co-administered with routine EPI vaccines in infants following safety assessment in children aged 2-4 years in The Gambia",GSK2189242A; Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),114174,NCT01262872,"Infections, Streptococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/114174,http://clinicaltrials.gov/show/NCT01262872,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,"A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers",GSK2256294,SEH114068,NCT01762774,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114068,http://clinicaltrials.gov/show/NCT01762774,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Nov-2016
GSK,"A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study will also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294",GSK2256294,SEH117023,NCT02006537,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117023,http://clinicaltrials.gov/show/NCT02006537,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately,1-Nov-2016
GSK,A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions,GSK2256294,201402,NCT02262689,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201402,http://clinicaltrials.gov/show/NCT02262689,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A single-centre double-blind, placebo controlled three part study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and repeat doses of nebulised GSK2269557 in healthy male subjects",GSK2269557,PII115117,NCT01462617,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115117,http://clinicaltrials.gov/show/NCT01462617,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A Randomized, Placebo Controlled, Repeat Dose, Double Blind (sponsor unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered with Metformin to Type 2 Diabetes Patients",GSK2330672,201351,NCT02202161,"Diabetes Mellitus, Type 2",Phase 2,http://www.gsk-clinicalstudyregister.com/study/201351,http://clinicaltrials.gov/show/NCT02202161,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK2789869A and GSK2789868A administered in adults 21 to 64 years of age,GSK2789869A,115415,NCT01934127,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115415,http://clinicaltrials.gov/show/NCT01934127,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,"An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.",twinrix,110699,NCT00875485,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/110699,http://clinicaltrials.gov/show/NCT00875485,,Y,N,Y,Y,Y,Y,N,"An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 110699 are summarized with 110700, 110701,110702, 110703, 110704 on GSK register",1-Nov-2016
GSK,An open-label study to assess the immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine Engerix™-B (103860) in adults with or without type 2 diabetes mellitus,"Hepatitis B Vaccine, Recombinant",115918,NCT01627340,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115918,http://clinicaltrials.gov/show/NCT01627340,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9 - 14 year old females,Human Papillomavirus Types 16 and 18 Vaccine,114700,NCT01381575,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114700,http://clinicaltrials.gov/show/NCT01381575,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,Follow-up study to evaluate the long-term immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV (580299) vaccine in healthy female subjects,Human Papillomavirus Types 16 and 18 Vaccine,112772,NCT00947115,"Infections, Papillomavirus",Phase 4,http://www.gsk-clinicalstudyregister.com/study/112772,http://clinicaltrials.gov/show/NCT00947115,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 112772 are related to103514.,1-Nov-2016
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 year old females,Human Papillomavirus Types 16 and 18 Vaccine,115411,NCT01462357,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115411,http://clinicaltrials.gov/show/NCT01462357,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,"MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects who participated in the MEA115588 or MEA115575 trials",mepolizumab,MEA115661,NCT01842607,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115661,http://clinicaltrials.gov/show/NCT01842607,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to MEA115588 and MEA115575. This study is available in CDISC format,1-Nov-2016
GSK,"Impact of immediate or delayed prophylactic antipyretic treatment on the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ pneumococcal vaccine 1024850A and the co-administered DTPa-combined vaccines",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),112921,NCT01235949,"Infections, Streptococcal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/112921,http://clinicaltrials.gov/show/NCT01235949,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Nov-2016
GSK,"A Two-Period, Randomized, Open-Label, Parallel group, Multiple-Probe Drug Interaction Study to Determine the Effects of NCE on the metabolism of CYP450 Probe Substrates in Healthy Postmenopausal Female Subjects",relacatib,462795/007,,Osteoarthritis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/462795/007,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Nov-2016
GSK,"A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures.","retigabine, ezogabine",RTG114855,NCT01648101,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114855,http://clinicaltrials.gov/show/NCT01648101,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A single-blind, randomized, placebo-controlled study to investigate the safety, tolerability, and potential effects on betamethasone pharmacokinetics of a co-administered infusion of the new chemical entity (NCE) in healthy female subjects.",retosiban,OTA105036,,"Obstetric Labour, Premature",Phase 1,http://www.gsk-clinicalstudyregister.com/study/105036,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Nov-2016
GSK,A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease,rilapladib,LPZ114458,NCT01428453,Alzheimer's Disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114458,http://clinicaltrials.gov/show/NCT01428453,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
GSK,"A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) with Focus on Cardiac Repolarization (QTc duration) in Healthy Subjects",tafenoquine,TAF114582,NCT01928914,"Malaria, Vivax",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114582,http://clinicaltrials.gov/show/NCT01928914,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2016
Bayer,"Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal female adolescents under 18 years of age for 1 year, and an optional 2-year extension phase",Levonorgestrel,14371,NCT01434160,Contraception,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=14371&search=14371&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT01434160,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,"Multi-center, open label, single arm study to assess efficacy, safety, bleeding pattern and pharmacokinetics of the ultra low dose levonorgestrel intrauterine contraceptive system (LCS) for a maximum of 3 years in women 18 to 40 years of age",Levonorgestrel,91775,NCT00884260,Contraception,Phase 3,http://pharma.bayer.com/en/in#novation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=91775&search=91775&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT00884260,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,"A Multicenter, Open-Label, Non-Randomized Study of SH G 00650 A (Levonorgestrel Intrauterine System) in Parous Women Seeking Contraception to Evaluate its Efficacy, Safety, and Pharmacokinetic Profile When Inserted for 12 months",Levonorgestrel,90870,Not available,Contraception,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=90870&search=90870&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,Not available,,N,Y,Y,N,Y,Y,Y,,1-Dec-2016
Bayer,"Multi-center, open, randomized, dose finding phase II study to investigate ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing different amounts of levonorgestrel compared to MIRENA in nulliparous and parous women in need of contraception.",Levonorgestrel,91412,NCT00185380,Contraception,Phase 2,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=91412&search=91412&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT00185380,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,"Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day initial in vitro release rate (LCS12) in comparison to a combined oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone (Yasmin®) in young women (18-29 years) over 18 months of use",Levonorgestrel,13362,NCT01254292,Contraception,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=13362&search=13362&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT01254292,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,"Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonorgestrel subdermal implant over 12 months of use in women 18 to 35 years of age",Levonorgestrel,13363,NCT01397097,Contraception,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=13363&search=13363&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT01397097,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,"Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age and an extension phase of the 16µg/24h dose group (LCS16 arm) up to 5 years",Levonorgestrel,91665,NCT00528112,Contraception,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=91665&search=91665&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT00528112,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Bayer,Five-year Clinical Performance of the New Formulation of the Levonorgestrel Intrauterine System and Serum Levonorgestrel Concentration with the New Formulation Compared to That with the Original One.,Levonorgestrel,B078,Not available,Contraception,Phase 3,Not available,Not available,,N,N,Y,N,Y,N,Y,There are substantial practical constraints to provide technical access to this legacy study data from 1996.,1-Dec-2016
Lilly,"A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)  (SQUIRE)",Necitumumab,14X-IE-JFCC,NCT00981058,Squamous Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00981058?term=jfcc&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Lilly,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",Necitumumab,14X-MC-JFCK,NCT01788566,Squamous Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01788566?term=JFCK&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Lilly,"Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed",Olanzapine,F1D-JE-HGMS,NCT00618748,Bipolar Disorder,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00618748?term=NCT00618748&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2016
Lilly,Bipolar Depression Assessment Study on Treatment Response,"Olanzapine, Fluoxetine",F1D-SU-HGMA,NCT00191399,Bipolar Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00191399?term=NCT00191399&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2016
Lilly,Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression,"Olanzapine, Fluoxetine",H6P-US-HDAQ,NCT00485771,Bipolar Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00485771?term=NCT00485771&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2016
Lilly,"An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer",Ramucirumab,I4T-IE-JVBH,NCT00862784,Colorectal Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00862784?term=I4T-IE-JVBH&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Lilly,"A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer",Ramucirumab,I4T-IE-JVBJ,NCT00735696,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00735696?term=I4T-IE-JVBJ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Lilly,"A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)",Ramucirumab,I4T-MC-JVBA,NCT01168973,Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01168973?term=I4T-MC-JVBA&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,PK and PD data are not included and this data will not be made available.,1-Dec-2016
Lilly,"A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE)",Ramucirumab,I4T-MC-JVBB,NCT01183780,Colorectal Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01183780?term=I4T-MC-JVBB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Boehringer Ingelheim,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,afatinib,1200.125,NCT01523587,"Carcinoma, Non-Small-Cell Lung",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01523587?term=1200.125&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Boehringer Ingelheim,Ventilator Adapters for Combivent Respimat,ipratropium bromide + salbutamol,1012.65,NCT01969539,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01969539?term=1012.65&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Boehringer Ingelheim,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,linagliptin,1275.1,NCT01422876,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01422876?term=1275.1&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Boehringer Ingelheim,Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine,telmisartan,1348.2,NCT01911780,Hypertension,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01911780?term=1348.2&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2016
Roche,"A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",Pirfenidone,PIPF-004,NCT00287716,idiopathic Pulmonary Fibrosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00287716?term=pipf-004&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Roche,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",Pirfenidone,PIPF-006,NCT00287729,idiopathic Pulmonary Fibrosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00287729?term=pipf-006&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Roche,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)",Pirfenidone,PIPF-016,NCT01366209,idiopathic Pulmonary Fibrosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01366209?term=pipf-016&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Roche,A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer,trastuzumab emtansine,BO22589,NCT01120184,Breast Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01120184?term=BO22589&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Roche,"A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy",trastuzumab emtansine,BO25734,NCT01419197,Breast Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01419197?term=BO25734&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Novartis,"A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salbutamol (200 μg) and Salmeterol/Fluticasone (50/500 μg) as Active Controls",indacaterol,CQAB149B2307,NCT00669617,Chronic Obstructive Pulmonary Disease (COPD),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2745,https://clinicaltrials.gov/show/NCT00669617,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Novartis,"A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)",rivastigmine,CENA713B2315,NCT00623103,Parkinson's Disease Dementia,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4686,https://clinicaltrials.gov/show/NCT00623103,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Boehringer Ingelheim,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,tamsulosin,527.51,NCT00796614,"Bladder, Neurogenic",Phase 2/Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00796614?term=527.51&rank=2&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
Boehringer Ingelheim,"PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder",tamsulosin,527.66,NCT00340704,"Bladder, Neurogenic",Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00340704?term=527.66&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector that Administers Belimumab Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE),belimumab,200339,NCT02124798,Systemic Lupus Erythematosus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/200339,http://clinicaltrials.gov/show/NCT02124798,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jan-2017
GSK,"201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily with Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down from a Maintenance Therapy with RELVAR® inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects",fluticasone furoate,201135,NCT02094937,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/201135,http://clinicaltrials.gov/show/NCT02094937,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jan-2017
GSK,A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis,fluticasone furoate,201474,NCT02397915,"Rhinitis, Allergic, Perennial and Seasonal",Phase 4,http://www.gsk-clinicalstudyregister.com/study/201474,http://clinicaltrials.gov/show/NCT02397915,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma,fluticasone furoate,HZA106855,NCT01563029,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106855,http://clinicaltrials.gov/show/NCT01563029,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone furoate/vilanterol,200301,NCT02184624,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/200301,http://clinicaltrials.gov/show/NCT02184624,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents with Asthma",fluticasone propionate/salmeterol,ASR115645,NCT01978119,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115645,http://clinicaltrials.gov/show/NCT01978119,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided,1-Jan-2017
GSK,"A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 after Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design",GSK1399686,MCA111406,NCT00721812,Inflammatory Bowel Diseases,Phase 1,http://www.gsk-clinicalstudyregister.com/study/111406,http://clinicaltrials.gov/show/NCT00721812,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,Safety and immunogenicity study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A when administered subcutaneously versus intramuscularly in adults aged 50 years or older,GSK1437173A,116760,NCT01777321,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116760,http://clinicaltrials.gov/show/NCT01777321,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235",GSK2330672,BSC116511,NCT01607385,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116511,http://clinicaltrials.gov/show/NCT01607385,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine Engerix™-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy","Hepatitis B Vaccine, Recombinant",106793,NCT02052661,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106793,http://clinicaltrials.gov/show/NCT02052661,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents,Human Papillomavirus Types 16 and 18 Vaccine,106636,NCT00534638,"Infections, Papillomavirus",Phase 4,http://www.gsk-clinicalstudyregister.com/study/106636,http://clinicaltrials.gov/show/NCT00534638,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,A Phase III study for the evaluation of the immunogenicity and reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 season Southern Hemisphere) in adults 18 years of age and above,Influenza Vaccine (Quadrivalent),201959,NCT02369341,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/201959,http://clinicaltrials.gov/show/NCT02369341,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",102252,NCT00196950,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/003,http://clinicaltrials.gov/show/NCT00196950,,Y,N,Y,Y,Y,Y,Y,"This is a year 1 follow-up study to 134612/003. The results of this study 102252 are summarised with studies 134612/003, 102254, and 102253 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jan-2017
GSK,"Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs","Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine",102253,NCT00196950,"Infections, Meningococcal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/134612/003,http://clinicaltrials.gov/show/NCT00196950,,Y,N,Y,Y,Y,Y,Y,"This is a year 2 follow-up study to 134612/003. The results of this study 102253 are summarised with studies 134612/003, 102254, and 102252 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jan-2017
GSK,"Open-label, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with partial onset seizures or Lennox-Gastaut syndrome","retigabine, ezogabine",RTG113284,NCT01494584,Epilepsy,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113284,http://clinicaltrials.gov/show/NCT01494584,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine 257049 in the sporozoite challenge model in healthy malaria-naïve adults",SB257049,117014,NCT01857869,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/117014,http://clinicaltrials.gov/show/NCT01857869,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2017
GSK,"An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus",solicitinib,JAK115919,NCT01777256,Systemic Lupus Erythematosus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/115919,http://clinicaltrials.gov/show/NCT01777256,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jan-2017
GSK,"A multi-centre, double-blind, randomised, parallel-group, active controlled study to evaluate the efficacy, safety and tolerability of tafenoquine (SB-252263, WR238605) in subjects with Plasmodium vivax malaria.",tafenoquine,TAF112582,NCT01376167,"Malaria, Vivax",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112582,http://clinicaltrials.gov/show/NCT01376167,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jan-2017
GSK,Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine,Varicella Vaccine,104105,NCT00226499,Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100388,http://clinicaltrials.gov/show/NCT00226499,,Y,N,Y,Y,Y,Y,Y,"This is a follow-up study to 100388.  The results of this study 104105 are summarised with studies 100388, 104106, and 103494 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jan-2017
GSK,Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine,Varicella Vaccine,104106,NCT00226499,Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100388,http://clinicaltrials.gov/show/NCT00226499,,Y,Y,Y,Y,Y,Y,Y,"This is a follow-up study to 100388. The results of this study 104106 are summarised with studies 100388, 104105, and 103494 on the GSK Clinical Study Register.",1-Feb-2018
GSK,Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine,Varicella Vaccine,103494,NCT00226499,Varicella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100388,http://clinicaltrials.gov/show/NCT00226499,,Y,N,Y,Y,Y,Y,Y,"This is a follow-up study to 100388. The results of this study 103494 are summarised with studies 100388, 104106, and 104105 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.",1-Jan-2017
Novartis,"A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",fingolimod,CFTY720D2306,NCT00731692,Multiple Sclerosis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=15030,https://clinicaltrials.gov/show/NCT00731692,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
Novartis,"A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).","indacaterol, glycopyrrolate",CQVA149A2318,NCT01782326,Chronic Obstructive Pulmonary Disease (COPD),Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14907,https://clinicaltrials.gov/show/NCT01782326,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
Novartis,"Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery","nepafenac ophthalmic suspension, 0.3%",C-12-067,NCT01853072,Cataract,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14887,https://clinicaltrials.gov/show/NCT01853072,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Feb-2017
Novartis,"Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery","nepafenac ophthalmic suspension, 0.3%",C-12-071,NCT01872611,Cataract,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14930,https://clinicaltrials.gov/show/NCT01872611,,Y,Y,Y,Y,Y,Y,Y,Alcon is a division of Novartis,1-Feb-2017
Astellas,Long-term Study of ASP1941 — Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) —,ipragliflozin,1941-CL-0072,NCT01316094,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=91,https://clinicaltrials.gov/ct2/show/NCT01316094,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"Phase III Study of ASP1941 –A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus–",ipragliflozin,1941-CL-0105,NCT01057628,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=99,https://clinicaltrials.gov/ct2/show/NCT01057628,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone,ipragliflozin,1941-CL-0106,NCT01135433,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=100,https://clinicaltrials.gov/ct2/show/NCT01135433,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone",ipragliflozin,1941-CL-0107,NCT01225081,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=101,https://clinicaltrials.gov/ct2/show/NCT01225081,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an α-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an α-Glucosidase Inhibitor Alone",ipragliflozin,1941-CL-0108,NCT01242202,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=102,https://clinicaltrials.gov/ct2/show/NCT01242202,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Sulfonylurea in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone",ipragliflozin,1941-CL-0109,NCT01242215,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=103,https://clinicaltrials.gov/ct2/show/NCT01242215,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with a Dipeptidyl Peptidase-4 Inhibitor Alone -",ipragliflozin,1941-CL-0110,NCT01242228,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=104,https://clinicaltrials.gov/ct2/show/NCT01242228,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with Nateglinide in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Nateglinide Alone -",ipragliflozin,1941-CL-0111,NCT01316107,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=105,https://clinicaltrials.gov/ct2/show/NCT01316107,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Astellas,"Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus -",ipragliflozin,1941-CL-0121,NCT01054092,"Diabetes Mellitus, Type 2",Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=106,https://clinicaltrials.gov/ct2/show/NCT01054092,,Y,Y,Y,N,N,Y,Y,Formats available for datasets without specifications,1-Jan-2017
Eisai,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",fycompa,E2007-G000-332,"NCT01393743
EU CTR 2011-000265-12",Primary Generalised Tonic Clonic Seizures,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01393743,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000265-12,Y,Y,Y,Y,Y,Y,Y,"Sharing of clinical data is prevented for the following countries; Netherlands, Thailand, Czech, Poland, France, Lithuania, Korea, Serbia, Greece, China, Australia, Germany, Austria, Latvia and Hungary, due to ICF restrictions.",1-Jun-2016
Eisai,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",fycompa,E2007-G000-332EXT,"NCT01393743
EU CTR 2011-000265-12",Primary Generalised Tonic Clonic Seizures,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01393743,,Y,Y,Y,Y,Y,Y,Y,"Sharing of clinical data is prevented for the following countries; Netherlands, Thailand, Czech, Poland, France, Lithuania, Korea, Serbia, Greece, China, Australia, Germany, Austria, Latvia and Hungary, due to ICF restrictions.",1-Jun-2016
GSK,"A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)",adefovir/lamivudine,LAF114957,NCT01353742,"Hepatitis B, Chronic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114957,http://clinicaltrials.gov/show/NCT01353742,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
GSK,"A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus",albiglutide,GLP116170,NCT01777282,Diabetes Mellitus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116170,http://clinicaltrials.gov/show/NCT01777282,,Y,N,Y,Y,Y,Y,Y,"This study is available in CDISC format.
An annotated case report form is not available for this study. A blank case report form will be provided.",1-Feb-2017
GSK,Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India,"Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",111157,NCT01353703,Poliomyelitis; Tetanus; Acellular Pertussis; Haemophilus influenzae type b; Diphtheria; Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111157,http://clinicaltrials.gov/show/NCT01353703,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,Safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix-IPV+HibTM) in healthy Vietnamese toddlers,"Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine",115389,NCT01577732,Acellular Pertussis; Haemophilus influenzae type b; Tetanus; Poliomyelitis; Diphtheria,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115389,http://clinicaltrials.gov/show/NCT01577732,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease (COPD)",fluticasone furoate/vilanterol,HZC115151,NCT01551758,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115151,http://clinicaltrials.gov/show/NCT01551758,,Y,Y,Y,Y,Y,Y,Y,Medical record information for patients who participated in this study will not be provided as this information is held in a third party database which is not owned by GSK.,1-Feb-2017
GSK,A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD).,fluticasone furoate/vilanterol,HZC113108,NCT01336608,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/113108,http://clinicaltrials.gov/show/NCT01336608,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
GSK,A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,200820,NCT02105974,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/200820,http://clinicaltrials.gov/show/NCT02105974,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-Feb-2017
GSK,An open-label study investigating critical and overall errors following 14 days of treatment with SERETIDE Metered Dose Inhaler (EVOHALER) in adult subjects with controlled asthma currently using the SERETIDE DISKUS Inhaler,fluticasone propionate/salmeterol,201909,NCT02416180,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201909,http://clinicaltrials.gov/show/NCT02416180,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"A randomized, double-blind, placebo-controlled, crossover study to evaluate the influence of the A118G polymorphism in the mu opioid receptor gene (OPRM1) on effects of GSK1521498 and naltrexone on physiological and behavioral markers of brain function in healthy social drinkers",GSK1521498,OAA116753,NCT01738867,Alcoholism,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116753,http://clinicaltrials.gov/show/NCT01738867,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2017
GSK,"A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV",lamivudine,NUC30935,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUC30935,,,N,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  An analysis-ready dataset is not available for this study.,1-Feb-2017
GSK,A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis,lamivudine,NUCB4006,,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/NUCB4006,,,N,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset and a reporting and analysis plan are not available for this study.,1-Feb-2017
GSK,"Adjuvant justification study of candidate malaria vaccines (257049), administered according to a 0, 1, 2 months schedule .",SB257049,107731,NCT00443131,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/107731,http://clinicaltrials.gov/show/NCT00443131,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"Bridging Safety & Immunogenicity study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years",SB257049,105874,NCT00307021,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/105874,http://clinicaltrials.gov/show/NCT00307021,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"A Phase I/IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine in infants living in a malaria-endemic region",SB257049,103967,NCT00197028,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/103967,http://clinicaltrials.gov/show/NCT00197028,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,A partially-blind (observer-blind) study to evaluate the safety and immunogenicity of 3 different vaccination schedules with 2 GSK Biologicals candidate Plasmodium falciparum vaccines in children aged 5 to 17 months living in Ghana,SB257049,106367,NCT00360230,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106367,http://clinicaltrials.gov/show/NCT00360230,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"A study of the efficacy against episodes of clinical malaria due to P. falciparum infection of GSK Biologicals candidate vaccine RTS,S/AS01, administered according to a 0,1,2-months schedule in children aged 5 to 17 months living in Tanzania & Kenya",SB257049,106464,NCT00380393,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106464,http://clinicaltrials.gov/show/NCT00380393,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes DTPw/Hib in infants living in a malaria-endemic region.",SB257049,104298,NCT00289185,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104298,http://clinicaltrials.gov/show/NCT00289185,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"Safety and immunogenicity study of GSK Biologicals investigational vaccination regimen Malaria Vaccine 257049, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes Tritanrix HepB/Hib, OPV, measles and yellow fever vaccination in infants",SB257049,106369,NCT00436007,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/106369,http://clinicaltrials.gov/show/NCT00436007,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,Consistency of immunogenicity and non inferiority of three production lots of GSK Biologicals candidate malaria vaccine in children,SB257049,113398,NCT01323972,Malaria,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113398,http://clinicaltrials.gov/show/NCT01323972,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"Safety, immunogenicity and efficacy against malaria in the sporozoite challenge model of one dose of Ad35.CS.01 malaria vaccine followed by two doses of malaria 257049 vaccine in healthy malaria-naïve adults",SB257049,114460,NCT01366534,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114460,http://clinicaltrials.gov/show/NCT01366534,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,Safety and immunogenicity study of GSK Biologicals Plasmodium falciparum malaria vaccine 257049 administered to HIV infected infants and children,SB257049,112745,NCT01148459,Malaria,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112745,http://clinicaltrials.gov/show/NCT01148459,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,Efficacy of GSK Biologicals’ candidate malaria vaccine (257049) against malaria disease caused by P. falciparum infection in infants and children in Africa,SB257049,110021,NCT00866619,Malaria,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110021,http://clinicaltrials.gov/show/NCT00866619,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2017
GSK,"An open label, experimental medicine investigation of the safety and tolerability of 400 mg b.i.d. GSK2586184 in patients with moderate to severely active ulcerative colitis.",solcitinib,200208,NCT02000453,"Colitis, Ulcerative",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200208,http://clinicaltrials.gov/show/NCT02000453,,Y,Y,Y,Y,Y,Y,Y,This study was terminated early. Data from only 2 subjects is available and additional steps may be required to protect participant data privacy before these data can be shared,1-Feb-2017
Novartis,"An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma",fluticasone propionate,CQAE397A2202,NCT00411567,Asthma,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14396,https://clinicaltrials.gov/show/NCT00411567,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2017
GSK,"An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 with Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers",daprodustat,200229,NCT02371603,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200229,http://clinicaltrials.gov/show/NCT02371603,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"Single-blind, randomised, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2647544 and its potential pharmacokinetic interaction with simvastatin in healthy volunteers",GSK2647544,200592,NCT01978327,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200592,http://clinicaltrials.gov/show/NCT01978327,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2017
GSK,An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3206641A and GSK3206640A administered in adults 18 to 64 years of age,GSK3206641A,201072,NCT01999842,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201072,http://clinicaltrials.gov/show/NCT01999842,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2017
GSK,A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials.,lamivudine,NUCB3017,,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/NUCB3017,,,N,Y,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A report and analysis plan is not available for this study.,1-Mar-2017
GSK,"An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment",lamivudine,NUC40040,,"Hepatitis B, Chronic",Phase 4,http://www.gsk-clinicalstudyregister.com/study/NUC40040,,,N,Y,Y,Y,Y,Y,Y,This is a follow-up study to NUC30926. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.,1-Mar-2017
GSK,"An Open-Label Extension Study to Study MHE100185, to Evaluate Long-term Safety, Efficacy and Optimal Dosing Frequency of 750 mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndromes",mepolizumab,MHE100901,NCT00097370,Hypereosinophilic Syndrome,Phase 3,http://www.gsk-clinicalstudyregister.com/study/100901,http://clinicaltrials.gov/show/NCT00097370,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to MHE100185.,1-Mar-2017
GSK,"A Multicenter, Double-blind, Placebo-controlled, Study to  Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES",mepolizumab,MHE100185,NCT00086658,Hypereosinophilic Syndrome,Phase 2,http://www.gsk-clinicalstudyregister.com/study/100185,http://clinicaltrials.gov/show/NCT00086658,,Y,Y,Y,Y,Y,Y,Y,A follow-up study MHE100901 was conducted.,1-Mar-2017
GSK,Immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ IPV (PoliorixTM) in healthy Chinese toddlers,Poliomyelitis Vaccine (Inactivated),114306,NCT01323647,Poliomyelitis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114306,http://clinicaltrials.gov/show/NCT01323647,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided. This study is a booster of study IPV-018 (112679),1-Mar-2017
GSK,"A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease",ropinirole,ROP111662,NCT01485172,Parkinson Disease,Phase 4,http://www.gsk-clinicalstudyregister.com/study/111662,http://clinicaltrials.gov/show/NCT01485172,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson’s disease",ropinirole,ROP111569,NCT01494532,Parkinson Disease,Phase 4,http://www.gsk-clinicalstudyregister.com/study/111569,http://clinicaltrials.gov/show/NCT01494532,,Y,N,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose,Rotavirus Vaccine,103792,NCT00289172,"Infections, Rotavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/103792,http://clinicaltrials.gov/show/NCT00289172,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"An open-label, randomised, cross-over, two cohort, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the delivery of salbutamol and to compare the pharmacokinetic profile with the MDI and Diskus presentations.",salbutamol,200921,NCT01984086,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200921,http://clinicaltrials.gov/show/NCT01984086,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2017
GSK,"Staggered study to evaluate safety and immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to a 0,1,3-month schedule in semi-immune children aged 6 to 11 years in Gambia, a malaria endemic region",SB257049,257049/015,,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/257049/015,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"A phase I, double-blind, randomized, controlled, study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate vaccine, administered intramuscularly according to a 0, 1, 2-month vaccination schedule in children aged 1 through 4",SB257049,257049/025,,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/257049/025,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"Double-blind, randomized phase I/IIa human challenge study, to evaluate the safety, reactogenicity, immunogenicity, and preliminary efficacy after primary sporozoite challenge and rechallenge, of GSK Biologicals’ candidate malaria vaccines containing the antigen RTS,S adjuvanted with either AS02A or AS01B and administered intramuscularly at months 0, 1, 2 in healthy malaria-naive volunteers aged 18 - 45 years",SB257049,257049/027,,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/257049/027,,,Y,N,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
GSK,"A single arm, open-label, multicentre, phase II study of Tositumomab and Iodine 131-Tositumomab in subjects with indolent non-Hodgkin's Lymphoma who have previously received Rituximab.",tositumomab,393229/032,NCT00240565,"Lymphoma, Non-Hodgkin",Phase 2,http://www.gsk-clinicalstudyregister.com/study/393229/032,http://clinicaltrials.gov/show/NCT00240565,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Mar-2017
Novartis,An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192,pazopanib,VEG107769,NCT00387764,"Carcinoma, Renal Cell",Phase 3,https://www.gsk-clinicalstudyregister.com/study/VEG107769,https://clinicaltrials.gov/show/NCT00387764,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Novartis,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,rivastigmine,CENA713D2320,NCT00099242,Alzheimer's Disease,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2353,https://clinicaltrials.gov/show/NCT00099242,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Novartis,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase",rivastigmine,CENA713D2340,NCT00506415,Alzheimer's Disease,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=6023,https://clinicaltrials.gov/show/NCT00506415,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Lilly,"A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia",Olanzapine,F1D-MC-HGMX,NCT00982020,Bipolar Disorder,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT00982020?term=F1D-MC-HGMX&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Lilly,The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS),Somatropin,B9R-EW-GDFC,NCT01088412,"Dwarfism, Growth Hormone Deficiency;
Turner Syndrome;
Infant, Small for Gestational Age;
SHOX Protein, Human",Not applicable,Not available,https://clinicaltrials.gov/ct2/show/NCT01088412?term=B9R-EW-GDFC&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).,BI 54903,1248.7,NCT01396278,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01396278?term=1248.7&rank=1&submit_fld_opt=,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy,BI 54903,1248.5,NCT01397162,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01397162?term=1248.5&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS),BI 54903,1248.6,NCT01397201,Asthma,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01397201?term=1248.6&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy,budesonide,1047.16,NCT02181335,Asthma,Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02181335?term=1047.16&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit,BI 2536 BS,1216.2,NCT02211859,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02211859?term=1216.2&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,"Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)",BI 2536 BS,1216.3,NCT00243087,Lymphoma,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00243087?term=1216.3&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,BI 811283 in Various Solid Tumours,BI 811283,1247.1,NCT00701324,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00701324?term=1247.1&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Phase I Study of BI 831266 in Patients With Advanced Solid Tumours,BI 831266 Cl,1257.1,NCT00756223,Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00756223?term=1257.1&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer,bivatuzumab,1191.3,NCT02254031,Breast Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02254031?term=1191.3&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer,bivatuzumab,1191.1,NCT02254005,Breast Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02254005?term=1191.1&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Boehringer Ingelheim,Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck,bivatuzumab,1191.2,NCT02254018,Head and Neck Neoplasms,Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02254018?term=1191.2&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Sanofi,"A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-X",Lixisenatide,EFC6019,"NCT00707031
EudraCT2007-005883-28",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00707031?term=NCT00707031&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005883-28,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea / GETGOAL-S",Lixisenatide,EFC6015,"NCT00713830
EudraCT2007-005881-11",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00713830?term=NCT00713830&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005881-11,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes / GETGOAL-MONO Japan LTS",Lixisenatide,LTS10888,NCT00905255,Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/LTS10888_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT00905255?term=NCT00905255&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"Pharmacodynamics, safety, tolerability and pharmacokinetics following dose titration of
subcutaneously administered AVE0010 in patients with type 2 diabetes mellitus in a double-blind,
randomized, placebo-controlled Phase IIa study",Lixisenatide,ACT6011,Not available,Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/ACT6011_summary.pdf,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 µg AVE0010 single doses and the efficacy, safety and pharmacokinetics of AVE0010 administered for 5 or 6 weeks, either once or twice daily, following dose escalation from 5 to 30 µg in Japanese and Caucasian type 2 diabetic patients not adequately controlled with sulfonylurea or sulfonylurea and metformin",Lixisenatide,PDY6797,EudraCT2006-003138-13,Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,Not available,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003138-13,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin",Lixisenatide,PDY12625,"NCT01596504
EudraCT2012-000027-40",Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/pdy12625-summary.pdf,https://clinicaltrials.gov/ct2/show/NCT01596504?term=NCT01596504&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000027-40,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus",Lixisenatide,DRI6012,"NCT00299871
EudraCT2006-002847-96",Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00299871,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002847-96,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin",Lixisenatide,PDY10931,"NCT01175473
EudraCT2009-017666-23",Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT01175473?term=NCT01175473&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017666-23,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin / GetGoal Duo1",Lixisenatide,EFC10781,"NCT00975286
EudraCT2008-007335-40",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00975286?term=NCT00975286&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007335-40,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin",Lixisenatide,EFC12261,"NCT01517412
EudraCT2011-002416-85",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT01517412?term=NCT01517412&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002416-85,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin  / GetGoal Duo-2",Lixisenatide,EFC12626,"NCT01768559
EudraCT2012-004096-38",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/efc12626_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT01768559?term=NCT01768559&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004096-38,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents / GETGOAL-MONO",Lixisenatide,EFC6018,"NCT00688701
EudraCT2007-005887-29",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00688701?term=NCT00688701&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005887-29,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea / GETGOAL-L-Asia",Lixisenatide,EFC10887,NCT00866658,Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00866658?term=NCT00866658&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-F1",Lixisenatide,EFC10743,"NCT00763451
EudraCT2008-001002-16",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00763451?term=NCT00763451&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001002-16,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin  / GETGOAL-L",Lixisenatide,EFC6016,"NCT00715624

EudraCT2007-005886-36",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00715624?term=NCT00715624&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005886-36,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-M",Lixisenatide,EFC6014,"NCT00712673
EudraCT2007-005880-80",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00712673?term=NCT00712673&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005880-80,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin",Lixisenatide,EFC10780,"NCT00976937
EudraCT2008-007334-22",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00976937?term=NCT00976937&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007334-22,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone / GETGOAL-P",Lixisenatide,EFC6017,"NCT00763815
EudraCT2007-005884-92",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT00763815?term=NCT00763815&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005884-92,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period / GetGoal-M-Asia",Lixisenatide,EFC11321,NCT01169779,Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/EFC1132_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT01169779?term=NCT01169779&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
Sanofi,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA",Lixisenatide,EFC11319,"NCT01147250
EudraCT2009-012852-26",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-l/,https://clinicaltrials.gov/ct2/show/NCT01147250?term=NCT01147250&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012852-26,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Apr-2017
GSK,"Efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) two times a day compared to clindamycin (150mg) four times a day for 5-7 days in treatment of acute odontogenic infection with or without abscess",amoxicillin/clavulanic acid,AUG117044,NCT02141217,"Focal Infection, Dental",Phase 4,http://www.gsk-clinicalstudyregister.com/study/117044,http://clinicaltrials.gov/show/NCT02141217,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Apr-2017
GSK,"A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis",amoxicillin/clavulanic acid,AUG117150,NCT01934231,"Sinusitis, Acute",Phase 3,http://www.gsk-clinicalstudyregister.com/study/117150,http://clinicaltrials.gov/show/NCT01934231,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
GSK,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, One-Year Study to Evaluate the Efficacy and Safety of Bupropion Hydrochloride (SR) (Sustained-Release Tablets) for the Treatment of Nicotine Dependence as an Aid to Smoking Cessation.",bupropion,ZYB40017,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40017,,,N,N,N,Y,N,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A clincial study report, protocol, and reporting and analysis plan are not available for this study.",1-Apr-2017
GSK,"An open-label, single dose, randomized, two-period crossover study to investigate the bioavailability of a novel dosage form of dutasteride in healthy male subjects",dutasteride,ARI115148,NCT01577693,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115148,http://clinicaltrials.gov/show/NCT01577693,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
GSK,"A randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2330672 administration in patients with primary biliary cirrhosis (PBC) and symptoms of pruritus",GSK2330672,BAT117213,NCT01899703,"Cholestasis, Intrahepatic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/117213,http://clinicaltrials.gov/show/NCT01899703,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
GSK,An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects,GSK2894512,IPS117191,NCT01984775,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117191,http://clinicaltrials.gov/show/NCT01984775,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Apr-2017
GSK,A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B,lamivudine,NUC20912,,"Hepatitis B, Chronic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NUC20912,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.,1-Apr-2017
GSK,"A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period",losmapimod,PKI108574,NCT00569062,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/PKI108574,http://clinicaltrials.gov/show/NCT00569062,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Apr-2017
GSK,"DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a fixed combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects with COPD Who Continue To Have Symptoms on Tiotropium",umeclidinium bromide/vilanterol,DB2116960,NCT01899742,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116960,http://clinicaltrials.gov/show/NCT01899742,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-Apr-2017
GSK,"A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza",zanamivir,NAI114373,NCT01231620,"Influenza, Human",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114373,http://clinicaltrials.gov/show/NCT01231620,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2017
Roche,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus",rontalizumab,IFN4575g,NCT00962832,systemic lupus erythematosus,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00962832?term=IFN4575g&rank=1,,Y,N,Y,N,Y,Y,N,,1-May-2017
Novartis,"A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",rivastigmine,CENA713DUS44,NCT00948766,Alzheimer's Disease,Phase 4,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7723,https://clinicaltrials.gov/show/NCT00948766,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Novartis,"A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia",zoledronic acid,CZOL446N2312,NCT00132808,Osteopenia,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2621,https://clinicaltrials.gov/show/NCT00132808,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Lilly,"Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach",Ramucirumab,I4T-MC-JVBT,NCT01246960,Stomach Cancer;  Esophageal Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01246960?term=I4T-MC-JVBT&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Lilly,Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC),Semagacestat,H6L-MC-LFBF,NCT01035138,Alzheimer's Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01035138?term=H6L-MC-LFBF&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2017
Lilly,Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo,Semagacestat,H6L-MC-LFAN,NCT00594568,Alzheimer's Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01035138?term=H6L-MC-LFAN&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2017
Lilly,LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease,Semagacestat,H6L-MC-LFAJ,NCT00244322,Alzheimer's Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00244322?term=H6L-MC-LFAJ&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2017
Lilly,"Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo",Semagacestat,H6L-MC-LFBC,NCT00762411,Alzheimer's Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01035138?term=H6L-MC-LFBC&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-May-2017
UCB,A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Certolizumab Pegol,C87028,NCT00175877,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00175877?term=C87028&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-May-2017
UCB,A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Certolizumab Pegol,C87051,NCT00160641,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00160641?term=C87051&rank=1,,Y,Y,Y,Y,Y,Y,Y,"AD and ADaM are available for Analysis and Reporting Dataset

Datasets are available in English only",1-May-2017
Sanofi,"A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients",Insulin Glargine/Lixisenatide Fixed Ratio Combination,ACT12374,"NCT01476475
EudraCT2011-002090-36",Diabetes Mellitus Type 2,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i/,https://clinicaltrials.gov/ct2/show/study/NCT01476475?term=act12374&rank=1&show_locs=Y,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002090-36,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) / LixiLan-O",Insulin Glargine/Lixisenatide Fixed Ratio Combination,EFC12404,"NCT02058147
EudraCT2013-003131-30",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/EFC12404_summary.pdf,https://clinicaltrials.gov/ct2/show/study/NCT02058147?term=efc12404&rank=1&show_locs=Y,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003131-30+,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) / LixiLan-L",Insulin Glargine/Lixisenatide Fixed Ratio Combination,EFC12405,"NCT02058160
EudraCT2013-003132-79",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/EFC12405_summary_V2.pdf,https://clinicaltrials.gov/ct2/show/NCT02058160?term=efc12405&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003132-79+,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC",Vandetanib,D4200C00036,"NCT00418886 
Eudract2006-003695-35",Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00418886?term=00418886&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003695-35,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.","Vandetanib, Docetaxel",D4200C00006,NCT00047840,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00047840?term=00047840&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC","Vandetanib, Docetaxel",D4200C00032,"NCT00312377
EudraCT2005-004749-32",Non-Small Cell Lung Cancer,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00312377?term=00312377&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004749-32,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2017
Sanofi,"A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients with Symptomatic Osteoarthritis of the Knee",Hylan G-F 20,SYNV00704,NCT00131352,Pain in osteoarthritis of the knee,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-h/,https://clinicaltrials.gov/ct2/show/NCT00131352?term=NCT00131352&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jun-2017
GSK,"An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fasting conditions",acetylsalicylic acid/pantoprazole,APP116480,NCT01847404,"Ulcers, Duodenal and Gastric",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116480,http://clinicaltrials.gov/show/NCT01847404,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2017
GSK,"An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fed conditions",acetylsalicylic acid/pantoprazole,APP116498,NCT01847417,"Ulcers, Duodenal and Gastric",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116498,http://clinicaltrials.gov/show/NCT01847417,,N,N,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2017
GSK,"A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure",albiglutide,GHF112670,NCT01357850,"Heart failure, Congestive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/112670,http://clinicaltrials.gov/show/NCT01357850,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"An open-label, randomized, single sequence, two period study to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of GSK962040 in healthy volunteers",camicinal,MOT112648,NCT01039974,Gastroparesis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112648,http://clinicaltrials.gov/show/NCT01039974,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,A double blind randomised placebo controlled two way cross over study to determine the effect of GSK962040 on oesophageal function and gastric emptying in healthy male volunteers.,camicinal,MOT114639,NCT01366560,Gastrointestinal Motility,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114639,http://clinicaltrials.gov/show/NCT01366560,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease",daprodustat,PHI116099,NCT02019719,Anaemia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116099,http://clinicaltrials.gov/show/NCT02019719,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-May-2017
GSK,"An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).",darapladib,LPL115679,NCT01852565,Atherosclerosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115679,http://clinicaltrials.gov/show/NCT01852565,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)",fluticasone propionate/salmeterol,ASR115646,NCT01978145,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115646,http://clinicaltrials.gov/show/NCT01978145,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A comparative bioavailability study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Fluticasone propionate and Salmeterol delivered by Fluticasone propionate/ Salmeterol combination in a capsule-based inhaler and a multi-dose dry powder inhaler, in moderate asthma patients and moderate to severe Chronic obstructive pulmonary disease (COPD) patients.",fluticasone propionate/salmeterol,ASR114334,NCT01494610,Asthma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114334,http://clinicaltrials.gov/show/NCT01494610,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects with Hepatocellular Carcinoma",foretinib,MET111645,NCT00920192,"Carcinoma, Hepatocellular",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111645,http://clinicaltrials.gov/show/NCT00920192,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-May-2017
GSK,"An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)",gepotidacin,BTZ115774,NCT02000765,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115774,http://clinicaltrials.gov/show/NCT02000765,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2017
GSK,"A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers",gepotidacin,BTZ115775,NCT02257398,"Infections, Respiratory Tract",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115775,http://clinicaltrials.gov/show/NCT02257398,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2017
GSK,"A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction with Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects",gepotidacin,BTZ117349,NCT02045849,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117349,http://clinicaltrials.gov/show/NCT02045849,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2017
GSK,"A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects",GSK1322322,PDF116266,NCT01818011,"Infections, Bacterial",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116266,http://clinicaltrials.gov/show/NCT01818011,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,Immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults with a prior episode of herpes zoster,GSK1437173A,ZOS116796,NCT01827839,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116796,http://clinicaltrials.gov/show/NCT01827839,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer,GSK1572932A,109493,NCT00480025,"Lung Cancer, Non-Small Cell",Phase 3,http://www.gsk-clinicalstudyregister.com/study/109493,http://clinicaltrials.gov/show/NCT00480025,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects who Smoke Cigarettes",GSK2269557,PII116617,NCT01762878,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116617,http://clinicaltrials.gov/show/NCT01762878,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) compared to Fluzone® Quadrivalent in children 6 to 35 months of age,GSK2282512A,201234,NCT02242643,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/201234,http://clinicaltrials.gov/show/NCT02242643,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects",GSK2894512,200920,NCT02637206,"Dermatitis, Atopic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200920,http://clinicaltrials.gov/show/NCT02637206,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine",lamivudine,NUC20904,,"Hepatitis B, Chronic",Phase 2,http://www.gsk-clinicalstudyregister.com/study/NUC20904,,,N,Y,Y,Y,Y,Y,Y,A Follow up study NUC20917 was conducted.  A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  An analysis-ready dataset is not available for this study.,1-May-2017
GSK,"A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904",lamivudine,NUC20917,,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/NUC20917,,,N,Y,Y,Y,Y,Y,Y,This is a follow-up study to NUC20904. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  An analysis-ready dataset is not available for this study.,1-May-2017
GSK,"A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint",lamivudine,NUC40021,,"Hepatitis B, Chronic",Phase 4,http://www.gsk-clinicalstudyregister.com/study/NUC40021,,,N,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  An analysis-ready dataset is not available for this study.,1-May-2017
GSK,"Primary and booster vaccination course in human immunodeficiency virus (HIV) infected infants, HIV exposed uninfected infants and unexposed uninfected infants receiving the pneumococcal vaccine GSK 1024850A.",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),111634,NCT00829010,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111634,http://clinicaltrials.gov/show/NCT00829010,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients",refanezumab,MAG104615,NCT01808261,Cerebrovascular Accident,Phase 2,http://www.gsk-clinicalstudyregister.com/study/104615,http://clinicaltrials.gov/show/NCT01808261,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,"A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg when Co-administered with the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP)",tafenoquine,200951,NCT02184637,"Malaria, Vivax",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200951,http://clinicaltrials.gov/show/NCT02184637,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2017
GSK,"A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD",umeclidinium bromide,201314,NCT02257372,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/201314,http://clinicaltrials.gov/show/NCT02257372,,Y,Y,Y,Y,Y,Y,Y,The raw data are included within the analysis-ready data for this study and are not provided separately.,1-May-2017
Roche,"(AVAGAST) A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer",bevacizumab,AVF4200G/BO20904,NCT00548548,gastric cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00548548?term=BO20904&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jun-2017
Roche,"(AVATAR) A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.",bevacizumab,ML22367,NCT00887822,gastric cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00887822?term=ML22367&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jun-2017
Roche,(ACT-RAY) Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients,tocilizumab,MA21488,NCT00810199,rheumatoid arthritis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00810199?term=MA21488&rank=2,,Y,N,Y,N,Y,Y,Y,,1-Jun-2017
Novartis,"A multicenter, double-blind, randomized, placebo-controlled, crossover study evaluating the efficacy and safety of methylphenidate hydrocholoride in female adolescents diagnosed with attention deficit/hyperactivity disorder",methylphenidate,CRIT124DUS02,,Attention deficit hyperactivity disorder (ADHD),Phase 4,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1624,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Lilly,"A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus:  The ELEMENT 1 Study",Insulin glargine injection,I4L-MC-ABEB,NCT01421147,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01421147?term=I4L-MC-ABEB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Lilly,"A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients with Type 2 Diabetes Mellitus:  The ELEMENT 2 Study",Insulin glargine injection,I4L-MC-ABEC,NCT01421459,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01421459?term=I4L-MC-ABEC&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Lilly,Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized Double-Blind Comparison with Placebo,Olanzapine,F1D-MC-HGKK,NCT00088036,Borderline Personality Disorder,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00088036?term=HGKK&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jun-2017
Lilly,"Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized, Flexible-Dose, Double-Blind Comparison with Placebo",Olanzapine,F1D-MC-HGKL,NCT00091650,Borderline Personality Disorder,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00091650?term=HGKL&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Jun-2017
Lilly,A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma,Olaratumab,I5B-IE-JGDG,NCT01185964,Soft Tissue Sarcoma,Phase 1/Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01185964?term=I5B-IE-JGDG&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets are only available for phase 2 of the study,1-Jun-2017
Astellas,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors",certolizumab pegol,CDP870-275-11-001,NCT01451203,Rheumatoid Arthritis,Phase 3,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=66,https://clinicaltrials.gov/ct2/show/NCT01451203,,Y,N,Y,N,Y,Y,Y,,1-Jun-2017
Astellas,"A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to Enzalutamide (MDV3100) and Monitor Its Safety in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy",enzalutamide,9785-CL-0401,NCT01606982,Castration-resistant prostate cancer,Phase 4,https://www.astellasclinicalstudyresults.com/study.aspx?ID=23,https://clinicaltrials.gov/ct2/show/NCT01606982,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Astellas,"Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 2 Diabetes Mellitus -",ipragliflozin,1941-CL-0131,NCT02175784,"Diabetes Mellitus, Type 2",Phase 4,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=171,https://clinicaltrials.gov/ct2/show/NCT02175784,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Astellas,"A Phase 3b, Open-label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)",regadenoson,3606-CL-3004,NCT01618669,Myocardial Perfusion Imaging,Phase 3,https://www.astellasclinicalstudyresults.com/study.aspx?ID=86,https://clinicaltrials.gov/ct2/show/NCT01618669,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Takeda,A Phase 2 Dose-ranging Study of TAK-875,fasiglifam,TAK-875/CCT-002,NCT01433406,"Diabetes Mellitus, Type 2",Phase 2,https://www.takedaclinicaltrials.com/browse/summary/TAK-875/OCT-002,http://clinicaltrials.gov/show/NCT01433406,,Y,N,Y,Y,Y,Y,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"A Randomized, Double-blind, Placebo-controlled, Phase 3, Multicenter, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of Once Daily TAK-875 25 mg and 50 mg Orally Administered in Type 2 Diabetic Patients with Inadequate Glycemic Control Despite Diet Therapy and/or Exercise Therapy",fasiglifam,TAK-875/CCT-003,NCT01433393,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875/CCT-003,http://clinicaltrials.gov/show/NCT01433393,,Y,N,Y,N,Y,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"A Phase 1, Double-blind, Randomized Placebo-controlled, Parallel-group, Ascending Single-dose and Multiple-dose Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics and Food Effect of TAK-875 in Japanese Healthy Male Subjects",fasiglifam,TAK-875/CPH-001,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,Y,N,Y,N,Y,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"An Open-Label, Randomized, 2-Period Crossover Study to Determine the Bioequivalence of TAK-875 25 mg (Old) and 50 mg (New) Tablet, or TAK-875 25 mg (New) and 50 mg (New) Tablet, and to Determine the Effect of Food on the Pharmacokinetics of TAK-875 25 mg (New) or 50 mg (New) Tablet in Healthy Japanese Male Subjects",fasiglifam,TAK-875/CPH-020,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,Y,N,Y,N,Y,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Postprandial Blood Glucose Profiles of TAK-875 25 mg and 50 mg Administered Orally Once Daily in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Despite Diet and/or Exercise Therapies",fasiglifam,TAK-875/CPH-030,NCT01585792,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875/CPH-030,https://clinicaltrials.gov/show/NCT01585792,,Y,N,N,N,N,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"An Open-Label, Phase 3, Multicenter, Long-Term Study to Evaluate the Safety and Efficacy of Once Daily TAK-875 25 mg and 50 mg Orally Administered in Type 2 Diabetic Patients with Inadequate Glycemic Control despite Diet Therapy and/or Exercise Therapy Alone or Diet Therapy and/or Exercise Therapy in Combination with One of the Existing Oral Hypoglycemic Agent",fasiglifam,TAK-875/OCT-002,NCT01433406,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875/OCT-002,https://clinicaltrials.gov/show/NCT01433406,,Y,N,Y,N,Y,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"An Open-label, Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of Once Daily TAK-875 25 mg and 50 mg Orally Administered in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Diet Therapy and/or Exercise Therapy",fasiglifam,TAK-875/OCT-003,NCT01433419,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875/OCT-003,http://clinicaltrials.gov/show/NCT01433419,,Y,N,Y,N,Y,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sequential Ascending Single Doses of TAK-875 and the Effect of Food on TAK-875 Pharmacokinetics and Pharmacodynamics in Healthy Volunteers",fasiglifam,TAK-875_101,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes",fasiglifam,TAK-875_102,NCT00949091,"Diabetes Mellitus, Type 2",Phase 1,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_102,http://clinicaltrials.gov/show/NCT00949091,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Sequence Crossover Interaction Study Investigating the Effect of TAK-875 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Adult Subjects",fasiglifam,TAK-875_103,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of TAK-875 on the Pharmacokinetics of a Single Oral Dose of Repaglinide in Healthy Adult Subjects",fasiglifam,TAK-875_104,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of TAK-875 in Healthy Adult Subjects",fasiglifam,TAK-875_105,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of Pioglitazone on the Pharmacokinetics of a Single Oral Dose of TAK-875 in Healthy Subjects",fasiglifam,TAK-875_107,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1 Study to Assess the Absorption, Distribution, Metabolism and Excretion of Orally Administered [14C]TAK-875 in Healthy Male Subjects",fasiglifam,TAK-875_108,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Sequence Crossover Interaction Study Investigating the Effect of TAK-875 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Adult Subjects",fasiglifam,TAK-875_109,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,N,Y,N,Y,N,,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Arm Parallel- Group Study to Evaluate the Effect of TAK-875 on the Electrocardiogram in Healthy Subjects",fasiglifam,TAK-875_110,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,Y,Y,N,Y,N,,1-May-2017
Takeda,"A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of TAK-875 50 mg in Subjects with Normal or Varying Degrees of Impaired Renal Function",fasiglifam,TAK-875_111,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,N,Y,N,Y,N,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of TAK-875 25 mg in Subjects with Normal or Varying Degrees of Impaired Hepatic Function",fasiglifam,TAK-875_112,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,N,N,Y,N,Y,N,,1-May-2017
Takeda,"A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effects of Age and Gender on the Pharmacokinetics of TAK-875 in Healthy Adult Subjects",fasiglifam,TAK-875_113,not available,"Diabetes Mellitus, Type 2",Phase  1,not available,not available,,Y,N,N,Y,N,Y,N,,1-May-2017
Takeda,"A Phase 1, Open-Label, Multiple-Dose, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of TAK-875 on the Steady-State Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel in Healthy Adult Female Subjects",fasiglifam,TAK-875_114,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Drug Interaction Potential Between Metformin and TAK-875 in Healthy Subjects",fasiglifam,TAK-875_115,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of TAK-875 in Healthy Adult Subjects",fasiglifam,TAK-875_116,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Single-Blind, Placebo-Controlled, Sequential Design Study to Evaluate the Drug Interaction Potential Between Glimepiride and TAK-875 in Subjects With Type 2 Diabetes Mellitus",fasiglifam,TAK-875_118,NCT01496443,"Diabetes Mellitus, Type 2",Phase 1,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_118,http://clinicaltrials.gov/show/NCT01496443,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Drug Interaction Potential Between Alogliptin and TAK-875 in Healthy Subjects",fasiglifam,TAK-875_120,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Drug Interaction Potential of TAK-875 on Digoxin in Healthy Subjects",fasiglifam,TAK-875_121,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, 2-Period Crossover Design Study to Evaluate the Bioavailability of Over-Coated 100 mg Sitagliptin Tablets Relative to Unaltered 100 mg Sitagliptin Tablets in Healthy Subjects",fasiglifam,TAK-875_122,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Open-Label, Sequential Design Study to Evaluate the Drug Interaction Potential Between Simvastatin and TAK-875, and Pravastatin and TAK-875 in Healthy Subjects",fasiglifam,TAK-875_124,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 1, Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Assess the Relative Bioavailability of Two Formulation Strengths of TAK-875 and Metformin HCl (US Sourced Glucophage) When Administered as a Fixed-Dose Combination Tablet Compared With Individually Administered Tablets in Healthy Adult Subjects",fasiglifam,TAK-875_126,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Phase 1, Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Determine the Absolute Bioavailability of Fasiglifam (TAK-875) in Healthy Adult Subjects",fasiglifam,TAK-875_132,not available,"Diabetes Mellitus, Type 2",Phase 1,not available,not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects with Type 2 Diabetes Mellitus",fasiglifam,TAK-875_201,NCT01007097,"Diabetes Mellitus, Type 2",Phase 2,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_201,http://clinicaltrials.gov/show/NCT01007097,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double- Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination with Sitagliptin 100 mg in Subjects with Type 2 Diabetes Mellitus",fasiglifam,TAK-875_202,NCT01414920,"Diabetes Mellitus, Type 2",Phase 2,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_202,http://clinicaltrials.gov/show/NCT01414920,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",fasiglifam,TAK-875_301,NCT01456195,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_301,http://clinicaltrials.gov/show/NCT01456195,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK 875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes",fasiglifam,TAK-875_302,NCT01549964,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_302,http://clinicaltrials.gov/show/NCT01549964,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin in Subjects With Type 2 Diabetes",fasiglifam,TAK-875_304,NCT01481116,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_304,http://clinicaltrials.gov/show/NCT01481116,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50 mg Compared With Placebo in Asia Pacific Subjects With Type 2 Diabetes",fasiglifam,TAK-875_307,NCT01647542,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_307,http://clinicaltrials.gov/show/NCT01647542,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Randomized, Open-Label Study to Assess the Pharmacokinetics of a TAK-375 (Ramelteon) Tablet for Sublingual Administration and its Bioavailability Relative to Approved Ramelteon Tablets in Healthy Subjects",ramelteon,TAK-375_111,Not available,Insomnia,Phase 1,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,An Open-Label Sensory Evaluation of Ramelteon Sublingual (SL) Formulations in Healthy Subjects,ramelteon,TAK-375SL-11_101,Not available,Insomnia,Phase 1,Not available,Not available,,Y,N,Y,Y,Y,Y,N,Annotated case report forms are N/A. Blank case report forms will be provided.,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects",ramelteon,TAK-375SL_201,NCT01467700,Bipolar Disorder,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375SL_201,https://clinicaltrials.gov/show/NCT01467700,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects",ramelteon,TAK-375SL_203,NCT01467713,Bipolar Disorder,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375SL_203,https://clinicaltrials.gov/show/NCT01467713,,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 and 0.4 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects",ramelteon,TAK-375SL_301,"NCT01677182
2012-001357-10",Bipolar Disorder,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-375SL_301,https://clinicaltrials.gov/show/NCT01677182,https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001357-10/results,Y,Y,Y,Y,Y,Y,Y,,1-May-2017
GSK,Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects with Androgenetic Alopecia,dutasteride,ARI114264,NCT01831791,Alopecia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114264,http://clinicaltrials.gov/show/NCT01831791,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
GSK,"A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid Tumors",GSK2256098,FAK113517,NCT01138033,Cancer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113517,http://clinicaltrials.gov/show/NCT01138033,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2017
GSK,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control",mepolizumab,200862,NCT02281318,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/200862,http://clinicaltrials.gov/show/NCT02281318,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jun-2017
GSK,Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects,rosiglitazone,EMI112684,NCT00964106,Healthy Subjects,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112684,http://clinicaltrials.gov/show/NCT00964106,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
GSK,A study in patients with Crohn's Disease to evaluate the effect of AVANDIA™ on inflammatory activity mediated by monocytes/macrophages.,rosiglitazone,999910/150,,Multiple Sclerosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/999910/150,,,Y,N,Y,Y,Y,N,Y,Raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2017
Lilly,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.",Prasugel,H7T-MC-TADO,NCT01794000,Sickle Cell Disease,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01794000?term=TADO&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
Sanofi,"A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety and Efficacy of Three
Docetaxel-Based Chemotherapy Regimens plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of
Patients with Node Positive and High-Risk Node-Negative Breast Cancer (DOCET_L_00714)",Docetaxel,DOCET_L_00714,NCT00365365,Breast Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-d/,https://clinicaltrials.gov/ct2/show/NCT00365365?term=NCT00365365&rank=1,Not available,Y,Y,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2017
Sanofi,A randomized double-blind placebo-controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4 mg at 2–week intervals on amputation or any death in critical limb ischemia patients with skin lesions,Riferminogene Pecaplasmid,EFC6145,"NCT00566657
EudraCT2006-006277-24","Prevention of major amputation above the ankle of the treated leg or of death from any cause, in critical limb ischemia patients with skin lesions",Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-r/,https://clinicaltrials.gov/ct2/show/NCT00566657?term=NCT00566657&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006277-24,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2017
Novartis,"A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",fingolimod,CFTY720D1201,NCT00537082,Multiple Sclerosis,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3963,https://clinicaltrials.gov/show/NCT00537082,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
Novartis,"An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",fingolimod,CFTY720D1201E1,NCT00670449,Multiple Sclerosis,Phase 2,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=8343,https://clinicaltrials.gov/show/NCT00670449,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
Astellas,"An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-blind Study",micafungin,9463-EC-0002,"NCT01122368
EudraCT 2008-006409-18",Mycoses,Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=211,https://clinicaltrials.gov/ct2/show/NCT01122368,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006409-18,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
Astellas,"A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects with Overactive Bladder (OAB)",mirabegron,178-MA-1001,NCT02138747,"Urinary Bladder, Overactive",Phase 4,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=184,https://clinicaltrials.gov/ct2/show/NCT02138747,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
Astellas,"A multicenter, 2-arm, randomized, open-label clinical study investigating renal function in an Advagraf®-based immunosuppressive regimen with or without sirolimus in kidney transplant patients",tacrolimus,PMR-EC-1212,"NCT01363752
EudraCT 2010-019639-37","Transplantation, Kidney",Phase 4,,https://clinicaltrials.gov/ct2/show/NCT01363752,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019639-37,Y,Y,N,Y,Y,Y,Y,,1-Aug-2017
Astellas,"Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids – A Multicenter, Two Arm, Randomized, Open Label Clinical Study",tacrolimus,PMR-EC-1211,"NCT01304836
EudraCT 2010-019638-28","Transplantation, Kidney",Phase 4,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=212,https://clinicaltrials.gov/ct2/show/NCT01304836,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019638-28,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
Boehringer Ingelheim,Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis,nintedanib,1199.3,NCT00514683,Pulmonary Fibrosis,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00514683?term=1199.30&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Aug-2017
GSK,"A multicenter, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SeretideTM) at a dose of 50/100µg twice daily and fluticasone propionate (FlixotideTM) at a dose of 200µg twice daily, both delivered via a dry powder inhaler (DiskusTM) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose",fluticasone propionate/salmeterol,SAM104926,NCT00353873,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM104926,http://clinicaltrials.gov/show/NCT00353873,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
GSK,"A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections",gepotidacin,BTZ116704,NCT02045797,"Infections, Bacterial",Phase 2,http://www.gsk-clinicalstudyregister.com/study/116704,http://clinicaltrials.gov/show/NCT02045797,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2017
GSK,"A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitis",GSK1399686,MCA111407,NCT01036022,"Colitis, Ulcerative",Phase 2,http://www.gsk-clinicalstudyregister.com/study/111407,http://clinicaltrials.gov/show/NCT01036022,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
GSK,"A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",GSK2647544,LPC116698,NCT01702467,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116698,http://clinicaltrials.gov/show/NCT01702467,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
GSK,An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects,GSK2647544,LPC117155,NCT01924858,Alzheimer's Disease,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117155,http://clinicaltrials.gov/show/NCT01924858,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2017
GSK,"Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study",lamotrigine,200776,NCT02100644,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/200776,http://clinicaltrials.gov/show/NCT02100644,,Y,Y,N,Y,Y,Y,Y,A clinical study report is not available for this study because an English language version was not created.,1-Jul-2017
GSK,A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo,paroxetine,29060/274,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/29060/006,,,Y,N,Y,Y,Y,N,N,The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-May-2014
GSK,"Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions",rabeprazole,201527,NCT02446483,Gastrointestinal Diseases,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201527,http://clinicaltrials.gov/show/NCT02446483,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jul-2017
GSK,"Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Raperazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fed conditions",rabeprazole,201528,NCT02605395,Gastrointestinal Diseases,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201528,http://clinicaltrials.gov/show/NCT02605395,,N,N,Y,Y,N,Y,N,"An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A protocol, and reporting and analysis plan are not available for this study.",1-Jul-2017
GSK,"A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)","retigabine, ezogabine",VRX-RET-E22-304,NCT00310388,Epilepsy,Phase 3,http://www.gsk-clinicalstudyregister.com/study/VRX-RET-E22-304,http://clinicaltrials.gov/show/NCT00310388,,Y,Y,Y,Y,Y,Y,Y,This is a follow-up study to VRX-RET-E22-302,1-Jul-2017
GSK,"A Study ROP116991, Clinical Evaluation of 18 to 24mg/day Ropinirole CR for Parkinson’s disease.",ropinirole,ROP116991,NCT01929317,Parkinson Disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116991,http://clinicaltrials.gov/show/NCT01929317,,Y,N,N,Y,N,Y,N,"A clinical study report, protocol, reporting and analysis plan and annotated or blank CRF are not available for this study because English language versions were not created.",1-Jul-2017
GSK,"A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.",SB705498,VRA107438,NCT00461682,Irritable Colon,Phase 2,http://www.gsk-clinicalstudyregister.com/study/VRA107438,http://clinicaltrials.gov/show/NCT00461682,,N,N,Y,Y,Y,Y,N,An analysis-ready dataset is not available for this study.  An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Jul-2017
Sanofi,"A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen",Cabazitaxel,EFC6193,NCT00417079,"Prostatic Neoplasm, Prostate Cancer",Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/,https://clinicaltrials.gov/ct2/show/NCT00417079?term=00417079&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Aug-2017
Sanofi,"Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen",Cabazitaxel,EFC11785,"NCT01308580
EudraCT2010-022163-35","Prostatic Neoplasm, Prostate Cancer",Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/,https://clinicaltrials.gov/ct2/show/NCT01308580?term=01308580&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022163-35,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Aug-2017
Sanofi,"Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy","Cabazitaxel, Docetaxel",EFC11784,"NCT01308567
EudraCT2010-022064-12","Prostatic Neoplasm, Prostate Cancer",Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/,https://clinicaltrials.gov/ct2/show/NCT01308567?term=01308567&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022064-12+,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Aug-2017
Sanofi,A multicenter phase III randomized trial comparing Taxotere administered either weekly or every three weeks in combination with prednisone versus Mitoxantrone in combination with prednisone for metastatic hormone-refractory prostate cancer,Docetaxel,RP56976-V-327,Not available,"Prostatic Neoplasm, Prostate Cancer",Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,N,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Aug-2017
Takeda,"A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Control in Subjects With Type 2 Diabetes (TERMINATED)",fasiglifam,TAK-875_203,NCT01982253,"Diabetes Mellitus, Type 2",Phase 2,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_203,http://clinicaltrials.gov/show/NCT01982253,,Y,Y,Y,Y,Y,Y,Y,"10 of 400 planned subjects randomized; none completed, no statistical comparisons performed. Annotated case report forms are N/A. Blank case report forms will be provided.",1-Aug-2017
Takeda,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes (TERMINATED)",fasiglifam,TAK-875_303,NCT01829464,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_303,http://clinicaltrials.gov/show/NCT01829464,,Y,N,N,Y,N,Y,N,"90 of 390 planned  subjects randomized; 7 completed, no statistical comparisons performed.",1-Aug-2017
Takeda,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes (TERMINATED)",fasiglifam,TAK-875_309,NCT01829477,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_309,http://clinicaltrials.gov/show/NCT01829477,,Y,N,N,Y,N,Y,N,"33 of 206 planned  subjects randomized; 2 completed, no statistical comparisons performed.",1-Aug-2017
Takeda,"A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With  Type 2 Diabetes (TERMINATED)",fasiglifam,TAK-875_310,NCT01834274,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_310,http://clinicaltrials.gov/show/NCT01834274,,Y,N,N,Y,N,Y,N,96 of 620 planned  subjects randomized; 8 completed; no meaningful efficacy results exist.,1-Aug-2017
Boehringer Ingelheim,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,empagliflozin,1245.49,NCT01306214,"Diabetes Mellitus, Type 2; Obesity",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01306214?term=1245.49&rank=1,,Y,Y,Y,Y,Y,Y,Y,,Sept 2017
Lilly,Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China,Duloxetine hydrochloride,F1J-MC-HMGS,NCT01931475,Osteoarthritis Pain,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01931475?term=HMGS&intr=duloxetine&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Sep-2017
Lilly,"A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",Necitumumab,I4X-MC-JFCL,NCT01769391,Squamous Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01769391?term=JFCL&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
Lilly,"An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)",Ramucirumab,I4T-IE-JVBL,NCT01160744,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/study/NCT01160744?term=I4T-IE-JVBL&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,PK and PD data are not included and this data will not be made available.,1-Sep-2017
GSK,"An Open-label, Randomized, Single Dose, three-way Crossover study to determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg tablets in Healthy Male Subjects in the fed and fasted states",dutasteride,ARI117057,NCT02184585,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/117057,http://clinicaltrials.gov/show/NCT02184585,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"An Open-label, Randomized, Single Dose, Two-way Crossover study to Determine the Bioavailability of one Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of one Dutasteride 0.5 mg capsule and one Tamsulosin Hydrochloride 0.2 mg tablet in Healthy Male Subjects in the Fed and Fasted States",dutasteride,201897,NCT02509104,Prostatic Hyperplasia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201897,http://clinicaltrials.gov/show/NCT02509104,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects,exenatide,200016,NCT01857895,Obesity,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200016,http://clinicaltrials.gov/show/NCT01857895,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma",fluticasone furoate,HZA107112,NCT02502734,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/107112,http://clinicaltrials.gov/show/NCT02502734,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (with an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning via a Dry Powder Inhaler with Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily via a Reservoir Inhaler in Subjects with Chronic Obstructive Pulmonary Disease",fluticasone furoate/vilanterol/umeclidinium bromide,CTT116853,NCT02345161,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116853,http://clinicaltrials.gov/show/NCT02345161,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Sep-2017
GSK,Steroid-sparing management of the salmeterol/fluticasone 50/100µg b.i.d. combination compared to fluticasone 200µg b.i.d. in children and adolescents with moderate asthma,fluticasone propionate/salmeterol,SAM102318,NCT00315744,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/102318,http://clinicaltrials.gov/show/NCT00315744,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2017
GSK,Long term immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy subjects,GSK1437173A,114825,NCT01295320,Herpes Zoster,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114825,http://clinicaltrials.gov/show/NCT01295320,,Y,Y,Y,Y,Y,Y,Y,This is an extension study to 108494,1-Sep-2017
GSK,Immunogenicity and safety study of different formulations of GSK Biologicals’ herpes zoster vaccine 1437173A when administered twice in adults aged 50 years and older,GSK1437173A,112077,NCT00802464,Herpes Zoster,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112077,http://clinicaltrials.gov/show/NCT00802464,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE with AS01B adjuvant in healthy elderly subjects, aged 60 to 69 years and 70 years and above.",GSK1437173A,108494,NCT00434577,Herpes Zoster,Phase 2,http://www.gsk-clinicalstudyregister.com/study/108494,http://clinicaltrials.gov/show/NCT00434577,,Y,Y,Y,Y,Y,Y,Y,"Follow-on studies 108516,108518,108520 were conducted. Extension study 114825 was conducted",1-Sep-2017
GSK,Safety and immunogenicity of GlaxoSmithKline Biologicals’ herpes zoster vaccine 1437173A in adult HIV-infected subjects,GSK1437173A,112673,NCT01165203,Herpes Zoster,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112673,http://clinicaltrials.gov/show/NCT01165203,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma,GSK2132231A,111476,NCT00942162,Melanoma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111476,http://clinicaltrials.gov/show/NCT00942162,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers",GSK2245851,SIR115444,NCT01340911,"Diabetes Mellitus, Type 2",Phase 1,http://www.gsk-clinicalstudyregister.com/study/115444,http://clinicaltrials.gov/show/NCT01340911,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2017
GSK,"A double-blind [sponsor unblinded], randomized, placebo-controlled, staggered-parallel study to investigate the safety, tolerability, and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes",GSK2890457,SMP116623,NCT01725126,Obesity,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116623,http://clinicaltrials.gov/show/NCT01725126,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A single-centre, masked, placebo-controlled four part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of the CC-chemokine receptor 3 (CCR3) antagonist, GW824575, coadministered with or without food in healthy male subjects",GW824575,CA3115802,NCT01551771,Retinal Diseases,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115802,http://clinicaltrials.gov/show/NCT01551771,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma",mapatumumab,200149,NCT01258608,"Carcinoma, Hepatocellular",Phase 2,http://www.gsk-clinicalstudyregister.com/study/200149,http://clinicaltrials.gov/show/NCT01258608,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2017
GSK,TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD),otelixizumab,OTX115493,NCT00451321,"Diabetes Mellitus, Type 1",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115493,http://clinicaltrials.gov/show/NCT00451321,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A single centre, single blind study to investigate the safety, tolerability and pharmacokinetics of single doses of oxytocin (GR121619) administered via an inhaled route in healthy female volunteers",oxytocin,201558,NCT02542813,Postpartum Hemorrhage,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201558,http://clinicaltrials.gov/show/NCT02542813,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"Immunogenicity, safety and reactogenicity of GSK Biologicals’ pneumococcal vaccine 1024850A when administered to children between 8 weeks and 2 years of age",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),114056,NCT01175083,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114056,http://clinicaltrials.gov/show/NCT01175083,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection",SB249553,249553/004,NCT00290355,"Lung Cancer, Non-Small Cell",Phase 2,http://www.gsk-clinicalstudyregister.com/study/249553/004,http://clinicaltrials.gov/show/NCT00290355,,Y,Y,Y,Y,Y,Y,Y,,1-Sep-2017
GSK,"A multicenter, open-label Phase I/II trial of the safety and efficacy of the dHER2 recombinant protein combined with immunological adjuvant AS15 in patients with metastatic breast cancer overexpressing HER2/neu",SB719125,100633,NCT00140738,"Neoplasms, Breast",Phase 1,http://www.gsk-clinicalstudyregister.com/study/100633,http://clinicaltrials.gov/show/NCT00140738,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Sep-2017
GSK,An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.,twinrix,112266,NCT01037114,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/112266,http://clinicaltrials.gov/show/NCT01037114,,Y,Y,Y,Y,Y,Y,Y,"This is a follow on study to 208127/118. The results of this study 112266 are summarised with studies 100556,100557, 100558, 100559, and 100560 on the GSK Clinical Study Register.",1-Sep-2017
GSK,An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.,twinrix,112267,NCT01000324,Hepatitis A; Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/112267,http://clinicaltrials.gov/show/NCT01000324,,Y,Y,Y,Y,Y,Y,Y,"This is a follow on study to 208127/119. The results of this study 112267 are summarised with studies 100551, 100552, 100553, 100554, and 100555 on the GSK Clinical Study Register.",1-Sep-2017
Bayer,"A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib (RESORCE)",Regorafenib,15982,NCT01774344,Hepatocellular carcinoma,Phase 3,http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/trial-finder-details/?trialid=15982&search=15982&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&btnSubmit=submit&num=10&show=1,https://clinicaltrials.gov/ct2/show/NCT01774344?term=NCT01774344&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung,afatinib,1200.123,NCT01466660,Lung Neoplasms,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01466660?term=1200.123&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib,afatinib,1200.7,NCT00993499,"Carcinoma, Non-Small-Cell Lung",Phase 1,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00993499?term=1200.70&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Safety and Tolerability of Dabigatran Etexilate in Adolescents,dabigatran,1160.88,NCT00844415,Venous Thromboembolism,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00844415?term=1160.88&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation,dabigatran,1160.13,NCT01491178,Atrial Fibrillation,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01491178?term=1160.130&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation,dabigatran,1160.149,NCT02433366,Atrial Fibrillation,Phase 4,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/results/NCT02433366?term=1160.149&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa,dabigatran,1160.2,NCT02149303,Atrial Fibrillation;   Hemorrhage,N/A,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02149303?term=1160.200&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan,dabigatran,1160.254,NCT02631057,Atrial Fibrillation,N/A,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02631057?term=1160.254&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,linagliptin,1275.9,NCT01734785,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01734785?term=1275.9&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",linagliptin,1218.89,NCT01792518,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01792518?term=1218.89&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,linagliptin,1275.1,NCT01778049,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01778049?term=1275.10&rank=2,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
Boehringer Ingelheim,Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients,linagliptin,1288.18,NCT01708902,"Diabetes Mellitus, Type 2",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01708902?term=1288.18&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
GSK,"An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 16mg tablet formulation of candesartan cilexetil (GW615775) relative to one 16mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions",candesartan,201011,NCT02006602,Hypertension,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201011,http://clinicaltrials.gov/show/NCT02006602,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
GSK,"An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions",candesartan,201713,NCT02254447,Respiratory Disorders,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201713,http://clinicaltrials.gov/show/NCT02254447,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
GSK,Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’ seasonal influenza vaccine GSK2321138A in adults aged 50 years and older,GSK1437173A,ZOS117036,NCT01954251,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/117036,http://clinicaltrials.gov/show/NCT01954251,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
GSK,"A randomized, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and effect on allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies",GSK2245035,TL7116958,NCT01788813,Mild Asthma and Allergic Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116958,http://clinicaltrials.gov/show/NCT01788813,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 204509 was  conducted.,1-Oct-2017
GSK,"A single-centre, follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects who completed treatment in study TL7116958 in 2014",GSK2245035,204509,NCT02446613,Asthma and Rhinitis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/204509,http://clinicaltrials.gov/show/NCT02446613,,Y,Y,Y,Y,Y,N,Y,This study is a follow up study to TL7116958. A Raw dataset is not avaiable for this study.,1-Oct-2017
GSK,Neisseria meningitidis carriage study,GSK2647155A,BEP114991,NCT01808365,"Infections, Meningococcal",N/A,http://www.gsk-clinicalstudyregister.com/study/114991,http://clinicaltrials.gov/show/NCT01808365,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2017
GSK,"Efficacy and safety of long-term inhaled salmeterol and beclomethasone dipropionate in corticosteroid-naïve children with mild to moderate, chronic, stable asthma.",salmeterol,SMS40065 (521/120 [SLPT10]),,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SMS40065,,,N,N,Y,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A Raw dataset related to efficacy data is not available for this study. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study.  A protocol is not available for this study.,1-Oct-2017
Novartis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis",secukinumab,CAIN457F2305,NCT01358175,Ankylosing Spondylitis,Phase 3,https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14387,https://clinicaltrials.gov/show/NCT01358175,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
Lilly,"A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine (AWARD-9)",Dulaglutide,H9X-MC-GBDI,NCT02152371,Diabetes Mellitus,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT02152371?term=H9X-MC-GBDI&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
Lilly,"Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma",Gemcitabine,B9E-US-S302,NCT00191646,Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00191646?term=NCT00191646&rank=1,Not available,Y,Y,N,N,Y,Y,Y,"A Clinical Study Report is not available for this study.  The citation for the study publication is listed here:  Gordon AN, Teneriello M, Janicek MF, et al. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecologic Oncology. 2011;123(3):479-485.",1-Nov-2017
Lilly,"An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",Ramucirumab,I4T-IE-JVCD,NCT01427933,Breast Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01427933?term=NCT01427933&rank=1,Not available,Y,N,Y,N,Y,Y,Y,"The annotated case report form is not available. A blank case report form will be provided.
A dataset specification document is available for the raw datasets. The dataset specification document is not available for the analysis-ready datasets.",1-Nov-2017
UCB,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Brivaracetam,N01358,NCT01261325,Epilepsy,Phase 3,http://www.ucb.com/rd/data-transparency,https://www.clinicaltrials.gov/ct2/show/NCT01261325?term=N01358&cond=Epilepsy&cntry1=NA%3AUS&rank=1,,Y,Y,Y,Y,Y,Y,Y,"ADaMs are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Nov-2017
UCB,A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis,Certolizumab Pegol,C87027,NCT00152386,Rheumatoid Arthritis,Phase 3,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/study/NCT00152386?term=NCT00152386&rank=1,,Y,N,Y,Y,Y,Y,Y,"Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only",1-Jul-2014
UCB,"A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures",Lacosamide,SP0847,NCT00938431,Epilepsy,Phase 2,http://www.ucb.com/rd/data-transparency,https://clinicaltrials.gov/ct2/show/NCT00938431?term=SP0847&rank=1,,Y,Y,Y,Y,Y,Y,Y,"ADaMs are available for Analysis and Reporting Dataset

Datasets are available in English only",1-Nov-2017
Sanofi,"An intergroup phase III trial to evaluate the activity of Docetaxel, given either sequentially or in combination with doxorubicin, followed by cmf, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by cmf, in the adjuvant treatment of node-positive breast cancer patients",Docetaxel,RP56976_PR_315,NCT00174655,Breast Cancer,Phase 3,"https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/RP56976_PR_315_summary.pdf

https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/RP56976_V-315_summary.pdf",https://clinicaltrials.gov/ct2/show/NCT00174655?term=NCT00174655&rank=1,Not available,Y,Y,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Nov-2017
GSK,"A randomized, double-blind, single-dose, placebo controlled, 2-way cross-over study evaluating effect of albiglutide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects",albiglutide,201834,NCT02496221,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/201834,http://clinicaltrials.gov/show/NCT02496221,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,"A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation",bupropion,ZYB AK1A405,,Smoking Cessation,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AK1A4005,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study.,1-Nov-2017
GSK,A multicenter dose response evaluation of Wellbutrin† (Bupropion hydrochloride) sustained release versus placebo as an aid to smoking cessation,bupropion,AK1A403,,Smoking Cessation,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AK1A403,,,N,N,Y,N,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Nov-2017
GSK,A multicenter comparison of bupropion hydrochloride sustained-release versus placebo for the prevention of relapse in patients who quit smoking while taking bupropion sustained-release,bupropion,ZYB AK1A406,,Smoking Cessation,Phase 3,http://www.gsk-clinicalstudyregister.com/study/AK1A406,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Nov-2017
GSK,"A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation",bupropion,SMK20001,,Smoking Cessation,Phase 2,http://www.gsk-clinicalstudyregister.com/study/SMK20001,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Nov-2017
GSK,"A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor",bupropion,ZYB 30011,,Smoking Cessation,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ZYB 30011,,,N,N,N,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol are not available for this study. A clinical study report is not available for this study because  there is no evidence in the archives that a document was authored.,1-Nov-2017
GSK,"A multi-centre, randomised, double-blind, placebo controlled, 6 month study to evaluate the efficacy and tolerability of bupropion hydrochloride sustained release tablets for the treatment of nicotine dependence as an aid to smoking cessation in a healthcare professionals and hospital staff population at hospitals in Denmark",bupropion,ZYB30009,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB30009,,,N,N,N,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol are not available for this study. A clinical study report is not available for this study because  there is no evidence in the archives that a document was authored.,1-Nov-2017
GSK,"A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban",bupropion,ZYB40001,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40001,,,N,Y,N,Y,N,Y,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A reporting and analysis plan and protocol is not available for this study. A clinical study report is not available for this study because  there is no evidence in the archives that a document was authored.,1-Nov-2017
GSK,"A multi-centre, randomised, double-blind, placebo-controlled, one-year study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in population of healthcare professionals",bupropion,ZYB40011,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40011,,,N,N,N,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol is not available for this study. A clinical study report is not available for this study because  there is no evidence in the archives that a document was authored.,1-Nov-2017
GSK,"Evaluation of efficacy of safety of ZybanTM (bupropion hydrochloride extended release tablet) in smoking cessation aid in nicotine-dependent patients. Multicentre, randomized, double blind, placebo-controlled study, 6 months length",bupropion,ZYBF4001,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYBF4001,,,N,N,N,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol is not available for this study. A clinical study report is not available for this study because  there is no evidence in the archives that a document was authored.,1-Nov-2017
GSK,Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy ethnic Japanese adults,GSK1437173A,113819,NCT01086449,Herpes Zoster,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113819,http://clinicaltrials.gov/show/NCT01086449,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier,GSK1437173A,201198,NCT02581410,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/201198,http://clinicaltrials.gov/show/NCT02581410,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,Contribution of infectious pathogens to acute respiratory illness in adults and elderly,GSK2231395A,BEP114378,NCT01360398,Respiratory Disorders,N/A,http://www.gsk-clinicalstudyregister.com/study/114378,http://clinicaltrials.gov/show/NCT01360398,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,GSK2302032A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer,GSK2302032A,116389,NCT01853878,"Lung Cancer, Non-Small Cell",Phase 2,http://www.gsk-clinicalstudyregister.com/study/116389,http://clinicaltrials.gov/show/NCT01853878,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,Immunogenicity and safety study of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) when co-administered with Pneumovax™ 23 in adults 50 years of age and older,Influenza Vaccine (Quadrivalent),117276,NCT02218697,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/117276,http://clinicaltrials.gov/show/NCT02218697,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,"A Two-Part, Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis",mepolizumab,MPP111782,NCT01362244,"Polyps, Nasal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/111782,http://clinicaltrials.gov/show/NCT01362244,,Y,Y,Y,Y,Y,Y,Y,,1-Nov-2017
GSK,"An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older",valaciclovir,123-005,,Herpes Zoster,Phase 3,,,,Y,Y,Y,Y,Y,N,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  A raw dataset is not available for this study. A single analysis and reporting dataset is available for the primary efficacy endpoints.,1-Nov-2017
GSK,"A multicenter, double-blind, placebo-controlled trial evaluating oral 256U87 for the treatment of herpes zoster in immunocompetent patients less than 50 years old",valaciclovir,123-006,,Herpes Zoster,Phase 3,,,,Y,Y,Y,Y,Y,N,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.  A raw dataset is not available for this study. A single analysis and reporting dataset is available for the primary efficacy endpoints,1-Nov-2017
ViiV,"A DOUBLE BLIND (3rd PARTY OPEN), PLACEBO CONTROLLED, DOSE ESCALATING, CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF SINGLE ORAL DOSES (SOLUTION) OF UK-427,857 IN HEALTHY MALE VOLUNTEERS IN THE FED AND FASTED STATES",maraviroc,A4001001,N/A,"Infection, Human Immunodeficiency Virus",Phase 1,,,,Y,N,Y,Y,Y,Y,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated and a blank case report form are not available for this study.,1-Nov-2017
ViiV,"A DOUBLE BLIND (3RD PARTY OPEN), PARALLEL GROUP, PLACEBO CONTROLLED SINGLE DOSE AND MULTIPLE ESCALATING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF UK-427,857 IN HEALTHY MALE SUBJECTS",maraviroc,A4001002,N/A,"Infection, Human Immunodeficiency Virus",Phase 1,,,,Y,N,Y,Y,Y,Y,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated and a blank case report form are not available for this study.,1-Nov-2017
Takeda,"An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",ixazomib,C16003,NCT00932698,Multiple myeloma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C16003,https://clinicaltrials.gov/show/NCT00932698,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2017
Takeda,"An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma",ixazomib,C16004,NCT00963820,Multiple myeloma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C16004,https://clinicaltrials.gov/show/NCT00963820,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2017
Takeda,"A Phase 1 Study of Oral Ixazomib (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction with Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients with Advanced Nonhematologic Malignancies or Lymphoma",ixazomib,C16009,NCT01454076,Multiple myeloma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C16009,https://clinicaltrials.gov/show/NCT01454076,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2017
Takeda,Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients with Normal Renal Function or Severe Renal Impairment,ixazomib,C16015,NCT01830816,Multiple myeloma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C16015,https://clinicaltrials.gov/show/NCT01830816,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2017
Takeda,A Phase 1 Pharmacokinetic Study of Oral Ixazomib (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction,ixazomib,C16018,NCT01912222,Multiple myeloma,Phase 1,http://takedaclinicaltrials.com/browse/summary/C16018,https://clinicaltrials.gov/show/NCT01912222,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Nov-2017
Astellas,"A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)",regadenoson,3606-CL-2001,NCT01334918,Coronary Artery Disease,Phase 2,https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=225,https://clinicaltrials.gov/ct2/show/NCT01334918,,Y,N,Y,Y,Y,Y,Y,,1-Dec-2017
Eisai,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma",eribulin mesIlate,E7389-G000-309,"NCT01327885
EU CTR 2010-024483-17",Soft Tissue Sarcoma,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01327885,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024483-17,Y,Y,Y,Y,Y,N,Y,"No restrictions. Note: In the ICF for Brazil there is a reference for the requirements of the local law only - but as Eisai is sharing data with the researchers based on a contract with confidentiality requirements, it is fine.",1-Nov-2017
Eisai,Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma,eribulin mesIlate,E7389-E044-207,"NCT00413192 
EU CTR 2005-004272-20",Soft Tissue Sarcoma,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00413192,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004272-20,Y,Y,Y,Y,Y,Y,Y,No restrictions.,1-Nov-2017
Eisai,"An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma",eribulin mesIlate,E7389-J081-217,NCT01458249,Soft Tissue Sarcoma,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01458249,,Y,Y,Y,Y,Y,Y,Y,No restrictions. Note: Japan is the only country participating in this study.,1-Nov-2017
Eisai,"An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment",lenvatinib,E7080-G000-205 Ph1b,"NCT01136733
EU CTR 2010-019484-10",Renal Cell Carcinoma,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT01136733,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10,Y,Y,Y,Y,N,Y,N,No restrictions. Note: The Protocol and Statistical Analysis Plan are part of the phase 2 study documents.,1-Nov-2017
Eisai,"An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment",lenvatinib,E7080-G000-205 Ph2,"NCT01136733  
EU CTR 2010-019484-10",Renal Cell Carcinoma,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01136733,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10,Y,Y,Y,Y,Y,Y,N,Sharing of clinical data is prevented for the following countries; Czech Republic.,1-Nov-2017
Eisai,"A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome",rufinamide,E2080-G000-303,"NCT01405053
EU CTR 2010-023505-36",Lennox-Gastaut Syndrome,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01405053,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023505-36,Y,Y,Y,Y,Y,Y,Y,No restrictions.,1-Nov-2017
Lilly,ADORE – Attention-Deficit Hyperactivity Disorder Observational Research in Europe,Atomoxetine,B4Z-EW-S006,Not available,Attention Deficit Hyperactivity Disorder,Not applicable,Not available,Not available,Not available,Y,N,N,N,N,Y,N,"A link to Clinicaltrials.gov and a NCT ID number are not available because this is a non-interventional trial. The publication citation presents the results of the study.  A CSR, protocol, reporting and analysis plan and aCRF are not available. 
Publication citation:  Ralston, S.J., Lorenzo, M.J.M. & and the ADORE study group European Child & Adolescent Psychiatry (2004) 13(Suppl 1): i36. https://doi.org/10.1007/s00787-004-1004-8",1-Dec-2017
Lilly,"A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis (IXORA-S)",Ixekizumab,I1F-MC-RHBS,NCT02561806,Plaque Psoriasis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT02561806?term=I1F-MC-RHBS&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2017
Lilly,"A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)",Necitumumab,I4X-IE-JFCB,NCT00982111,Non-Small Cell Lung Cancer,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00982111?term=I4X-IE-JFCB&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Dec-2017
Lilly,"A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC",Pemetrexed,H3E-EW-S125,NCT01004250,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01004250?term=H3E-EW-S125&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2017
Lilly,A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations,Pemetrexed,H3E-CR-JMIT,NCT01469000,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01469000?term=NCT01469000&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,The annotated case report form is not available. A blank case report form will be provided.,1-Dec-2017
Lilly,"A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy",Ramucirumab,I4T-JE-JVCG,NCT01703091,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT01703091?term=jvcg&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,PK and PD data are not included and this data will not be made available.,1-Dec-2017
Lilly,A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment),Tadalafil,H6D-JE-LVJK,NCT02431754,Benign Prostatic Hyperplasia,Phase 4,Not available,https://clinicaltrials.gov/ct2/show/NCT02431754?term=H6D-JE-LVJK&rank=1,Not available,Y,N,N,N,Y,N,N,"The analysis-ready dataset contains some data in Japanese. The CSR, blank case report form, dataset specifications and reporting analysis plan will not be provided because the documents are in Japanese; the documents have not been translated to review for company confidential information and the documents have not been anonymized for patient privacy.",1-Dec-2017
Roche,"A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy",herceptin,BO16348,NCT00045032,breast Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00045032,,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2018
Roche,"A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma","Oxaliplatin
Capecitabine",MO17527/L_9570,NCT02560974,gastric cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/study/NCT02560974?term=mo17527&rank=1,,Y,N,Y,N,Y,Y,Y,This trial is a collaboration of Sanofi & Roche and is listed under both companies.,1-Aug-2016
Lilly,"Pharmacokinetic Characterization of Intramuscular Olanzapine Depot as a
Function of Particle Size Distribution",Olanzapine,F1D-EW-LOBS,Not available,Schizophrenia,Phase 1,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jan-2018
Sanofi,"Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Months after the Initial Dose Versus HAVRIX 720 Vaccine","Hepatitis A vaccine, Inactivated",HAF78,"NCT00483470
EudraCT2015-005191-18",Active immunisation against Hepatitis A infection,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pasteur/,https://clinicaltrials.gov/ct2/show/NCT00483470?term=NCT00483470&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005191-18,Y,Y,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Dec-2017
Lilly,Fluoxetine Versus Placebeo in Posttraumatic Stress Disorder,Fluoxetine,B1Y-MC-HCJK,Not available,Posttraumatic Stress Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Feb-2018
Lilly,Fluoxetine Versus Placebo in Posttraumatic Stress Disorder,Fluoxetine,B1Y-MC-HCJL,Not available,Posttraumatic Stress Disorder,Phase 3,Not available,Not available,Not available,Y,N,Y,Y,Y,Y,N,The annotated case report form is not available. A blank case report form will be provided.,1-Feb-2018
GSK,Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects,benzoyl peroxide/clindamycin phosphate,201884,NCT02557399,Acne Vulgaris,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201884,http://clinicaltrials.gov/show/NCT02557399,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A multi-centre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with Chronic Obstructive Pulmonary Disease.",bupropion,ZYB40030,,Smoking Cessation,Phase 4,http://www.gsk-clinicalstudyregister.com/study/ZYB40030,,,N,N,N,Y,N,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form is not available for this study. A reporting and analysis plan is not available for this study. A Protocol is not available for this study because an English language version was not created. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.,1-Feb-2018
GSK,A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402),bupropion,ZYBAKIA402,,"Depressive Disorder, Major",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ZYBAKIA402,,,N,Y,Y,Y,Y,Y,Y,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2018
GSK,"A Single Centre, Open-label, 5-Period, Cross over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets",danirixin,201037,NCT02453022,"Pulmonary Disease, Chronic Obstructive",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201037,http://clinicaltrials.gov/show/NCT02453022,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Feb-2018
GSK,"A randomized, open-label, parallel-group study, to assess the pharmocodynamic effect on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner, of 0.5mg and 3.5mg dutasteride administered orally once daily, for one year in men with symptomatic benign prostatic hyperplasia and during a two month period between baseline and radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer",dutasteride,104274,NCT00375765,Prostatic Hyperplasia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/104274,http://clinicaltrials.gov/show/NCT00375765,,N,N,N,Y,Y,Y,N,An analysis-ready dataset is not available for this study. An annotated and a blank case report form is not available for this study. A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because an English language version was not created.,1-Feb-2018
GSK,"An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V)",dutasteride,106377,NCT00441116,Alopecia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/106377,http://clinicaltrials.gov/show/NCT00441116,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Feb-2018
GSK,A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia,dutasteride,200209,NCT02014584,Alopecia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/200209,http://clinicaltrials.gov/show/NCT02014584,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A randomized, double-blind, placebo-controlled, six-month parallel-group study to assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH), followed by a 12-month open-label treatment phase",dutasteride,ARI108898,NCT00527605,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/ARI108898,http://clinicaltrials.gov/show/NCT00527605,,Y,N,N,Y,N,N,N,A raw dataset is not available for this study. An annotated and a blank case report form is not available for this study. A reporting and analysis plan  is not available for this study. A Protocol is not available for this study because an English language version was not created. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.,1-Feb-2018
GSK,"A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent",dutasteride,ARI109924,NCT00558363,"Neoplasms, Prostate",Phase 2,http://www.gsk-clinicalstudyregister.com/study/ARI109924,http://clinicaltrials.gov/show/NCT00558363,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism",dutasteride,TDC106220,NCT00398580,"Hypogonadism, Male",Phase 2,http://www.gsk-clinicalstudyregister.com/study/TDC106220,http://clinicaltrials.gov/show/NCT00398580,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin (0.2mg) with tamsulosin (0.2mg) monotherapy, administered once daily for 2 years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia",dutasteride/tamsulosin,ARI114265,NCT02058368,Prostatic Hyperplasia,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114265,http://clinicaltrials.gov/show/NCT02058368,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A pivotal, open-label trial assessing the safety and efficacy of the 0.5 mg dutasteride and 0.4 mg tamsulosin combination once daily for six months in patients with benign prostatic hyperplasia",dutasteride/tamsulosin,FDC114785,NCT01673490,Prostatic Hyperplasia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114785,http://clinicaltrials.gov/show/NCT01673490,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,A prospective study of sexual function in sexually active men treated for BPH,dutasteride/tamsulosin,FDC116115,NCT01777269,Prostatic Hyperplasia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/116115,http://clinicaltrials.gov/show/NCT01777269,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Comparative efficacy of Dutasteride plus tamsulosin with lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men with moderately symptomatic benign prostatic hyperplasia and prostate enlargement.,dutasteride/tamsulosin,FDC114615,NCT01294592,Prostatic Hyperplasia,Phase 4,http://www.gsk-clinicalstudyregister.com/study/114615,http://clinicaltrials.gov/show/NCT01294592,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 10 years after the first booster immunization with Tick Borne Encephalitis vaccine in adults who received 1 of 3 different primary vaccination schedules",encepur adults,205335,NCT01562444,Tick borne encephalitis,Phase 4,http://www.gsk-clinicalstudyregister.com/study/205335,http://clinicaltrials.gov/show/NCT01562444,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"An open-label, randomised, cross-over, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) with four different formulations for the delivery of fluticasone fuorate and to compare the pharmacokinetic profile with the fluticasone fuorate ELLIPTA presentation",fluticasone furoate,200939,NCT02218723,Asthma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200939,http://clinicaltrials.gov/show/NCT02218723,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component,fluticasone furoate/umeclidinium bromide,200699,NCT02164539,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/200699,http://clinicaltrials.gov/show/NCT02164539,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Feb-2018
GSK,Open-label study to evaluate the safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older,GSK1437173A,116697,NCT01751165,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116697,http://clinicaltrials.gov/show/NCT01751165,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Comparison of the immunogenicity and safety of various investigational and licensed formulations of Hepatitis B surface antigen (HBsAg) vaccines.,GSK2231392A,112115,NCT00805389,Hepatitis B,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112115,http://clinicaltrials.gov/show/NCT00805389,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in patients with metastatic melanoma,GSK2302025A,113173,NCT01149343,Melanoma,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113173,http://clinicaltrials.gov/show/NCT01149343,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,A Single Dose First in Human Study of GSK2398852 Co-Administered with GSK2315698 in Patients with Systemic Amyloidosis,GSK2315698/GSK2398852,SAP115570,NCT01777243,Amyloidosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115570,http://clinicaltrials.gov/show/NCT01777243,,Y,Y,Y,Y,Y,Y,Y,The informed consent for this study allows for further research into the medicine studied but not the disease.,1-Feb-2018
GSK,An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccines GSK2654911A and GSK2654909A administered to adults 18 to 64 years of age,GSK2654911A,116358,NCT01659086,Influenza,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116358,http://clinicaltrials.gov/show/NCT01659086,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects",GSK2881078,200181,NCT02045940,Cachexia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200181,http://clinicaltrials.gov/show/NCT02045940,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"Phase III, partially double-blind study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals' Hib conjugate vaccine 208108 versus ActHIB and Pentacel at 2, 4, 6 and 15-18 months of age in healthy infants",Haemophilus influenzae Type b Vaccine,112957,NCT01000974,Haemophilus influenzae type b,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112957,http://clinicaltrials.gov/show/NCT01000974,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK580299) in female American and Canadian subjects who had received control vaccine in study 580299/008,Human Papillomavirus Types 16 and 18 Vaccine,111955,NCT00799825,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/111955,http://clinicaltrials.gov/show/NCT00799825,,Y,Y,Y,Y,Y,Y,Y,This is a follow up study to 580299/008,1-Feb-2018
GSK,Gynaecological follow-up of a subset of 580299/008 study subjects,Human Papillomavirus Types 16 and 18 Vaccine,112024,NCT00937950,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/112024,http://clinicaltrials.gov/show/NCT00937950,,Y,Y,Y,Y,Y,Y,Y,This is a follow up study to 580299/008,1-Feb-2018
GSK,Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female control subjects from the GSK HPV-023 study,Human Papillomavirus Types 16 and 18 Vaccine,114379,NCT01418937,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/114379,http://clinicaltrials.gov/show/NCT01418937,,Y,Y,Y,Y,Y,Y,Y,This is a safety follow up study of the placebo cohort from study 580299/001 (HPV-001).,1-Feb-2018
GSK,Immunogenicity and safety study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra® (2013/2014 season) in adults 18 years of age and older,Influenza Vaccine (Quadrivalent),200188,NCT01878812,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/200188,http://clinicaltrials.gov/show/NCT01878812,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,An efficacy study of GSK Biologicals’ quadrivalent influenza vaccine GSK2321138A (FLU D-QIV) when administered in children,Influenza Vaccine (Quadrivalent),115345,NCT01439360,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115345,http://clinicaltrials.gov/show/NCT01439360,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Study for evaluation of immunogenicity and reactogenicity of Fluarix/Influsplit SSW 2013/2014 in people 18 years of age and above,"Influenza Vaccine (Split Virion, Inactivated)",200160,NCT01884519,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/200160,http://clinicaltrials.gov/show/NCT01884519,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in adults aged 18 years and older,"Influenza Vaccine (Split Virion, Inactivated, Fluviral)",200190,NCT01878825,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/200190,http://clinicaltrials.gov/show/NCT01878825,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered concomitantly with Routine Vaccines to Healthy Infants in Taiwan.","Meningococcal group-B vaccine (rDNA, component, adsorbed) rMenB+OMV NZ",205249,NCT02173704,Meningococcal disease,Phase 3,http://www.gsk-clinicalstudyregister.com/study/205249,http://clinicaltrials.gov/show/NCT02173704,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection",Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),115884,NCT01746108,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115884,http://clinicaltrials.gov/show/NCT01746108,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infants,Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed),200799,NCT02447432,"Infections, Streptococcal",Phase 3,http://www.gsk-clinicalstudyregister.com/study/200799,http://clinicaltrials.gov/show/NCT02447432,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
GSK,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) When Added to Their Usual Treatment Regimen",salmeterol,SMS40026,,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SMS40026,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.,1-Feb-2018
GSK,Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa,SB257049,BEP114001,NCT01190202,Malaria,N/A,http://www.gsk-clinicalstudyregister.com/study/114001,http://clinicaltrials.gov/show/NCT01190202,,Y,Y,Y,Y,Y,Y,Y,,1-Feb-2018
Daiichi Sankyo,"Phase III Clinical Study of DU-176b (non-valvular atrial fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients with non-valvular atrial fibrillation and Severe Renal Impairment",Edoxaban,DU176b-C-J307,JapicCTI-111716,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-111716,Not available,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)",Edoxaban,DU176b-C-U301,"NCT00781391
EudraCT 2008-004522-16
JapicCTI-090775",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090775,https://www.clinicaltrials.gov/ct2/show/NCT00781391?term=DU176b-C-U301&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004522-16,N,Y,Y,Y,Y,Y,Y,0,1-Nov-2015
Daiichi Sankyo,"A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).",Edoxaban,DU176b-D-U305,"NCT00986154
EudraCT 2009-014290-40",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00986154?term=DU176b-D-U305&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014290-40,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"Exploratory Study of DU-176b (Phase II) - A Multi-center, Open-label, Dose-escalation Study in Patients with Nonvalvular Atrial Fibrillation.",Edoxaban,DU176b-J03,DU176b-J03,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,Not available,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging, Multi-center Study of DU-176b in Patients Undergoing Total Knee Replacement",Edoxaban,DU176b-J04,DU176b-J04,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2b,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,Not available,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"Exploratory Study of DU-176b (Phase II) - A Multi-center, Open-label, Dose-escalation Study in Patients with Nonvalvular Atrial Fibrillation (Low Doses).",Edoxaban,DU176b-J05,DU176b-J05,Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,Not available,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 2a, Multi-Center, Multi-National, Open-label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Subjects Undergoing Total Hip Arthroplasty.",Edoxaban,DU176b-PRT007,"NCT00107900
EudraCT 2004-004415-29",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2a,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00107900?term=DU176b-PRT007&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004415-29,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,DU-176b Phase IIb Clinical Study (Venous Thromboembolism) Japan–Taiwan Multicenter Randomized Double-blind Dose-finding Study Using Enoxaparin as a Reference in Patients Undergoing Total Hip Replacement.,Edoxaban,DU176b-B-J209,"NCT01203098
JapicCTI-090827",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090827,https://www.clinicaltrials.gov/ct2/show/NCT01203098?term=DU176b-B-J209&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)",Edoxaban,DU176b-B-J302,"NCT01181102
JapicCTI-090727",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090727,https://www.clinicaltrials.gov/ct2/show/NCT01181102?term=DU176b-B-J302&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)",Edoxaban,DU176b-B-J303,"NCT01181141
JapicCTI-090798",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090798,https://www.clinicaltrials.gov/ct2/show/NCT01181141?term=DU176b-B-J303&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)",Edoxaban,DU176b-B-J304,"NCT01181167
JapicCTI-090771",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 3,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090771,https://www.clinicaltrials.gov/ct2/show/NCT01181167?term=DU176b-B-J304&rank=1,Not available,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation",Edoxaban,DU176b-PRT018,"NCT00504556
EudraCT 2007-001271-11",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00504556?term=DU176b-PRT018&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001271-11,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Daiichi Sankyo,"A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement",Edoxaban,DU176b-PRT011,"NCT00398216
EudraCT 2006-000758-29",Venous Thromboembolism;  Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE):  Thromboembolism;  Venous Thrombosis; Non-Valvular Atrial Fibrillation;Cancer associated venous thromboembolism,Phase 2b,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,https://www.clinicaltrials.gov/ct2/show/NCT00398216?term=DU176b-PRT011&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000758-29,N,Y,Y,Y,Y,Y,Y,,1-Nov-2015
Sanofi,"A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma",Oxaliplatin /Capecitabine,MO17527/L_9570,NCT00411229,Gastric cancer/Stomach neoplasms,Phase 3,https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/clinical-study-results/l_9570_summary.pdf,https://clinicaltrials.gov/ct2/show/NCT00411229?term=00411229&rank=1,Not available,Y,N,Y,N,Y,Y,Y,This trial is a collaboration of Sanofi & Roche and is listed under both companies.,1-Aug-2016
Sanofi,"Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Comparative Safety Extension Period",Insulin lispro,EFC12619,"NCT02273180
EudraCT2013-002945-12",Diabetes Mellitus Type 1,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i/,https://clinicaltrials.gov/ct2/show/NCT02273180?term=EFC12619&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=EFC12619,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Mar-2018
Sanofi,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analogue SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine",Insulin lispro,EFC13403,"NCT02294474
EudraCT2014-002844-42",Diabetes Mellitus Type 2,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-i/,https://clinicaltrials.gov/ct2/show/NCT02294474?term=EFC13403&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=EFC13403,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Mar-2018
Takeda,"A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan",alogliptin,SYR-322/CCT-001,NCT01263470,"Diabetes Mellitus, Type 2",Phase 2,http://takedaclinicaltrials.com/browse/summary/SYR-322/CCT-001,https://clinicaltrials.gov/show/NCT01263470,,Y,N,Y,Y,N,Y,N,Select supporting documents are N/A in English and as such are N/A for sharing at this time.,1-Oct-2014
Takeda,Early Phase II Study of TAK-875,fasiglifam,TAK-875/CCT-001,not available,"Diabetes Mellitus, Type 2",Phase 2,not available,not available,,Y,N,Y,N,Y,N,N,Select supporting documents are  N/A in English and as such are N/A for sharing at this time.,1-May-2017
Takeda,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events (TERMINATED)",fasiglifam,TAK-875-306,NCT01609582,"Diabetes Mellitus, Type 2",Phase 3,https://www.takedaclinicaltrials.com/browse/summary/TAK-875_306,https://clinicaltrials.gov/show/NCT01609582,,Y,Y,Y,Y,Y,Y,Y,Blank case report forms will be provided.,1-Mar-2018
Roche,"A randomized study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy, as neoadjuvant therapy for patients with HER2-positive breast cancer.",Pertuzumab,BO22280,NCT00976989,malignant neoplasm of breast,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00976989?term=BO22280&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Oct-2016
Roche,"A multicenter, open-label, randomized Phase III study to evaluate the efficacy and safety of Erlotinib (Tarceva®) versus gemcitabine/cisplatin as the first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine  kinase domain of epidermal growth factor receptor (EGFR) in their tumors.",erlotinib,YO25121,NCT01342965,non-small cell lung cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01342965,,Y,N,Y,N,Y,Y,Y,,1-Mar-2018
Roche,"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in ""Triple Negative"" Breast Cancer.",bevacizumab,BO20289 (Beatrice),NCT00528567,breast Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT00528567?term=BO20289&rank=1,,Y,N,Y,Y,N,Y,Y,,1-Mar-2018
Roche,"Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology",bevacizumab,ML21217,NCT02596958,non-small cell lung cancer,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT02596958?term=ML21217&rank=1,,Y,N,Y,N,N,Y,N,,1-Mar-2018
Roche,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors,cobimetinib,MEK4592G/GO01329/XL518-001,NCT00467779,neoplasms,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT00467779?term=MEK4592G&rank=1,,Y,N,Y,N,N,Y,N,,1-Mar-2018
Roche,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission",vismodegib,SHH4489G,NCT00739661,malignant neoplasm of ovary,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00739661?term=SHH4489G&rank=1,,Y,N,Y,N,N,Y,N,,1-Mar-2018
Roche,"A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)",vismodegib,SHH4812G/GS01354,NCT01201915,malignant melanoma of skin,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01201915?term=SHH4812G&rank=1,,Y,N,Y,N,N,Y,N,,1-Mar-2018
Roche,"A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma",vismodegib,SHH4476G/GO01541,NCT00833417,malignant melanoma of skin,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00833417?term=SHH4476G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Roche,"An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists",vismodegib,SHH3925G,NCT00607724,neoplasms,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT00607724?term=SHH3925G&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-Mar-2018
Roche,"A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction",trastuzumab emtansine,BO27952,NCT01641939,"neoplasm, stomach",Phase 2/3,,https://clinicaltrials.gov/ct2/show/NCT01641939?term=BO27952&rank=1,,Y,N,Y,N,N,Y,Y,,1-Mar-2018
Roche,"A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer",pertuzumab,TOC2572G,NCT00063154,Malignant Neoplasm Of Lung,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00063154?term=TOC2572G&rank=1,,Y,N,Y,N,N,Y,N,,1-Mar-2018
Roche,"An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine",vemurafenib,NO25530,NCT01286753,neoplasms,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01286753?term=NO25530&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-Mar-2018
Roche,"An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases",vemurafenib,MO25743,NCT01378975,malignant melanoma of skin,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01378975?term=MO25743&rank=1,,Y,N,Y,Y,N,Y,Y,,1-Mar-2018
Roche,"A Single Arm, Open Label, Expanded Access Study Of RG7204 In Previously Treated Patients With Metastatic Melanoma",vemurafenib,ML25597,NCT01248936,malignant melanoma of skin,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01248936?term=ML25597&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Roche,Randomized Phase III Open-Label Study Comparing the Efficacy and Safety of Crizotinib and CH5424802 in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer,alectinib,JO28928,,non-small cell lung cancer,Phase 3,,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132316,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Roche,A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy,bevacizumab,YO25404,NCT01364012,non-small cell lung cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01364012?term=YO25404&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Mar-2018
Roche,An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology),bevacizumab,AVF3991n,NCT00388206,metastatic colorectal cancer,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT00388206?term=AVF3991n&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Mar-2018
GSK,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)",belimumab,HGS1006-C1115,NCT01484496,Systemic Lupus Erythematosus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/112341,http://clinicaltrials.gov/show/NCT01484496,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2017
GSK,"Long-term persistence of hepatitis B antibodies and immune response to a challenge dose of GSK Biologicals’ Hepatitis B Virus vaccine, Engerix™-B Kinder (SKF103860), in 15-16 years old adolescents, vaccinated in infancy with Engerix™-B Kinder","Hepatitis B Vaccine, Recombinant",116722,NCT01847430,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/116722,http://clinicaltrials.gov/show/NCT01847430,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,Safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) in healthy Vietnamese children,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",115739,NCT01988857,Diphtheria; Tetanus; Acellular Pertussis,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115739,http://clinicaltrials.gov/show/NCT01988857,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,"A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of Salmeterol/Fluticasone propionate combination product (Seretide®) 50/100 mcg with Fluticasone propionate (Flixotide® ) 200 mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6-12 years with symptomatic asthma",fluticasone propionate/salmeterol,SAM101667,NCT00197106,Asthma,Phase 4,http://www.gsk-clinicalstudyregister.com/study/SAM101667,http://clinicaltrials.gov/show/NCT00197106,,N,Y,Y,Y,Y,Y,Y,An analysis-ready dataset is not available for this study. Only limited raw data are available for this study.,1-Mar-2018
GSK,"A Phase 1, Randomized, Double-Blind (sponsor open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (anti-CCL20 monoclonal antibody) in Healthy Male Volunteers",GSK3050002,200784,NCT01984047,"Colitis, Ulcerative",Phase 1,http://www.gsk-clinicalstudyregister.com/study/200784,http://clinicaltrials.gov/show/NCT01984047,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,"Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin",epelsiban,IVF116828,NCT02213029,Embryo Transfer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116828,http://clinicaltrials.gov/show/NCT02213029,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,"A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency",GSK2636771,P3B115717,NCT01458067,Cancer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/115717,http://clinicaltrials.gov/show/NCT01458067,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD),losmapimod,201496,NCT02299375,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/201496,http://clinicaltrials.gov/show/NCT02299375,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects with Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium vivax Malaria Patients with Glucose-6-phosphate Dehydrogenase Deficiency,tafenoquine,TAF110027,NCT01205178,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/110027,http://clinicaltrials.gov/show/NCT01205178,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
GSK,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Measure the Efficacy and Safety of Nicotine Lozenges (2 mg and 4 mg) in Smoking Cessation",Nicotine Polacrilex Lozenge 2 mg and 4 mg,209357,N/A,Smoking Cessation,Phase 3,,,,Y,Y,Y,Y,Y,Y,Y,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.,1-Mar-2018
Daiichi Sankyo,A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate (MTX) to Validate Inhibitory Effect on Bone Erosion (Phase II).,Denosumab,DS-AMG162-D-J201,JapicCTI-101263,Rheumatoid Arthritis,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101263,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III).,Denosumab,DS-AMG162-D-J301,"NCT01973569
JapicCTI-132277",Rheumatoid Arthritis,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,"https://www.clinicaltrials.gov/ct2/show/NCT01973569?term=NCT01973569&rank=1
http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132277",Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,CS-747S PhaseIII trial - Double-blinded comparative study for evaluation of efficacy and safety of CS-747S versus clopidogrel bisulfate in subject with acute coronary syndromes who are to undergo percutaneous coronary intervention.,Prasugrel,DS-CS0747S-B-J301,JapicCTI-101339,Acute Coronary Syndromes who are to undergo Percutaneous Coronary Intervention (PCI),Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101339,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,CS-747S PhaseIII trial - Double-blinded study for evaluation of efficacy and safety of CS-747S in reference to clopidogrel bisulfate in subject with coronary arterial disease who are to undergo elective percutaneous coronary intervention.,Prasugrel,DS-CS0747S-B-J302,JapicCTI-111550,CAD patients who are to undergo elective PCI,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-111550,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,"A Phase 3 Study of CS-8958 (Prophylaxis for children) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy for the prevention of influenza virus infection in children under 10 years.",Laninamivir,DS-CS8958-A-J308,JapicCTI-142678,Postexposure prophylaxis of influenza A or B virus infection,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142678,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,"A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy of single dose administration for the prevention of influenza virus infection.",Laninamivir,DS-CS8958-A-J309,JapicCTI-142679,Postexposure prophylaxis of influenza A or B virus infection,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142679,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,Phase III clinical study of DQ-2466 - Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillation.,Carvedilol,DS-DQ2466-A-J301,JapicCTI-132201,Persistent or permanent atrial fibrillation,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132201,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,DS-7113b phase II study - A DS-7113b potency ratio assessment study in patients with cancer pain.,Hydromorphone,DS-DS7113-A-J201,JapicCTI-132166,Moderate to severe cancer pain,Phase 2,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132166,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,DS-7113b phase III study A randomized double-blind comparison study with immediate release (IR) oxycodone in opioid-naive patients with cancer pain.,Hydromorphone,DS-DS7113-A-J301,JapicCTI-132338,Moderate to severe cancer pain,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132338,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,DS-7113b phase III study A DS-7113b immediate release (IR) tablet long-term study in patients with cancer pain.,Hydromorphone,DS-DS7113-A-J302,JapicCTI-132288,Moderate to severe cancer pain,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132288,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,DS-7113b extended-release (ER) tablet phase III study - A randomized double-blind comparison study with extended-release oxycodone in opioid-naive patients with cancer pain.,Hydromorphone,DS-DS7113-B-J303,JapicCTI-142666,Moderate to severe cancer pain,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142666,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Daiichi Sankyo,DS-7113b extended-release (ER) tablet phase III study - A DS-7113b extended-release tablet long-term study in patients with cancer pain.,Hydromorphone,DS-DS7113-B-J304,JapicCTI-142667,Moderate to severe cancer pain,Phase 3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142667,Not available,N,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Lilly,A Study of Tadalafil for Duchenne Muscular Dystrophy,Tadalafil,H6D-MC-LVJJ,Not available,"Muscular Dystrophy, Duchenne",Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT01865084?term=LVJJ&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"An observer-blind study to assess the safety, reactogenicity and immunogenicity of different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), in healthy women",GSK3003891A,201510,NCT02360475,Respiratory Syncytial Virus Infections,Phase 2,http://www.gsk-clinicalstudyregister.com/study/201510,http://clinicaltrials.gov/show/NCT02360475,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Immunogenicity of the hepatitis B antigen of the GSK Biologicals’ candidate malaria vaccine (257049),"Hepatitis B Vaccine, Recombinant",113681,NCT01345240,Hepatitis B,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113681,http://clinicaltrials.gov/show/NCT01345240,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,An observer-blind safety and reactogenicity study to assess GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women,GSK3003891A,204813,NCT02753413,Respiratory Syncytial Virus Infections,Phase 2,http://www.gsk-clinicalstudyregister.com/study/204813,http://clinicaltrials.gov/show/NCT02753413,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Evaluation of the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (Tuberculosis) vaccine GSK 692342 in healthy adults,SB692342,116777,NCT01669096,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/116777,http://clinicaltrials.gov/show/NCT01669096,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine 257049 when administered on different schedules to infants in Africa,SB257049,111315,NCT01231503,Malaria,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111315,http://clinicaltrials.gov/show/NCT01231503,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"Efficacy, safety, and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older",GSK1437173A,110390,NCT01165177,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110390,http://clinicaltrials.gov/show/NCT01165177,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"Efficacy, safety and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 70 years or older",GSK1437173A,113077,NCT01165229,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/113077,http://clinicaltrials.gov/show/NCT01165229,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"Consistency, immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults 50 years of age or older",GSK1437173A,117177,NCT02075515,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/117177,http://clinicaltrials.gov/show/NCT02075515,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 3 and 4-year-old children,"Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine",111763,NCT01245049,acellular pertussis; Diphtheria; Poliomyelitis; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111763,http://clinicaltrials.gov/show/NCT01245049,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",759348/002,,acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759348/002,,,Y,N,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank will be provided.The analysis plan is not available for this study.,1-Apr-2018
GSK,"A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",759348/007,,acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/759348/007,,,Y,N,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank will be provided.The analysis plan is not available for this study.,1-Apr-2018
GSK,"A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age.","Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine",101853,,acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus,Phase 2,http://www.gsk-clinicalstudyregister.com/study/101853,,,Y,N,Y,Y,Y,Y,N,A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies. An annotated case report form is not available for this study. A blank will be provided.The analysis plan is not available for this study.,1-Apr-2018
GSK,"A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers",daprodustat,PHI113635,NCT02293148,Anaemia,Phase 1,http://www.gsk-clinicalstudyregister.com/study/113635,http://clinicaltrials.gov/show/NCT02293148,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women",retosiban,OTA117168,NCT02377414,"Obstetric Labour, Premature",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117168,http://clinicaltrials.gov/show/NCT02377414,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (belimumab; HGS1006) on Vaccine Responses in Subjects with Systemic Lupus Erythematosus (SLE)",belimumab,BEL115470,NCT01597492,Systemic Lupus Erythematosus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/115470,http://clinicaltrials.gov/show/NCT01597492,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults",GSK2878175,H5B116973,NCT01879462,"Hepatitis C, Chronic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116973,http://clinicaltrials.gov/show/NCT01879462,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects with Chronic Hepatitis C.",GSK2878175,H5B116976,NCT02014571,"Hepatitis C, Chronic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/116976,http://clinicaltrials.gov/show/NCT02014571,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Study MEA117106: Mepolizumab vs. placebo as add-on treatment for frequently exacerbating COPD patients,mepolizumab,MEA117106,NCT02105948,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/117106,http://clinicaltrials.gov/show/NCT02105948,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level,mepolizumab,MEA117113,NCT02105961,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/117113,http://clinicaltrials.gov/show/NCT02105961,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma",fluticasone furoate/vilanterol,HZA115150,NCT01706198,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115150,http://clinicaltrials.gov/show/NCT01706198,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Estimation of Skeletal Muscle Mass with Deuterium Labeled d3 Creatine in Subjects with Chronic Disease,CCI21130,RES117245,,"Atrophy, Muscular",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117245,,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",umeclidinium bromide/vilanterol,204990,NCT02799784,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/204990,http://clinicaltrials.gov/show/NCT02799784,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects with COPD",umeclidinium bromide/vilanterol,201317,NCT02275052,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/201317,http://clinicaltrials.gov/show/NCT02275052,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,An open label study to evaluate the effects of ezogabine/retigabine added to existing anti-epileptic drug(s) on urinary voiding function in subjects with partial onset seizures,"retigabine, ezogabine",RTG116158,NCT01607346,Epilepsy,Phase 4,http://www.gsk-clinicalstudyregister.com/study/116158,http://clinicaltrials.gov/show/NCT01607346,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination with Methotrexate Therapy, in Japanese Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate",GSK3196165,201789,NCT03028467,"Arthritis, Rheumatoid",Phase 2,http://www.gsk-clinicalstudyregister.com/study/201789,http://clinicaltrials.gov/show/NCT03028467,,Y,N,N,Y,N,Y,Y,A clinical study report and a protocol are not available for this study because an English language version was not created. An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,An open-label study to evaluate the preference attributes of the ELLIPTA™ dry powder inhaler (DPI) compared to the HandiHaler™ DPI in subjects with Chronic Obstructive Pulmonary Disease (COPD),fluticasone furoate/vilanterol,204983,NCT02786927,"Pulmonary Disease, Chronic Obstructive",Phase 4,http://www.gsk-clinicalstudyregister.com/study/204983,http://clinicaltrials.gov/show/NCT02786927,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects with Primary Axillary Hyperhidrosis",umeclidinium bromide,202093,NCT02563899,Hyperhidrosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/202093,http://clinicaltrials.gov/show/NCT02563899,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A multicenter, randomized, single blind, active controlled, parallel group study to determine efficacy and safety of nebulized fluticasone propionate 1mg BID compared with nebulized budesonide 2mg BID administered for 12 weeks in Chinese adult and adolescent patients with severe persistent asthma",fluticasone,LOC114219,NCT01687283,Asthma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/114219,http://clinicaltrials.gov/show/NCT01687283,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"An open-label, fixed sequence study to evaluate pharmacokinetics, safety and tolerability of single and repeated dose of extended-release bupropion hydrochloride (bupropion XL) tablets 150 mg and 300 mg once daily in Chinese healthy volunteers",bupropion,LOC114883,NCT02698553,"Depressive Disorder, Major",Phase 1,http://www.gsk-clinicalstudyregister.com/study/114883,http://clinicaltrials.gov/show/NCT02698553,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Randomised, Double-blind (Sponsor Unblind), Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects",GSK2793660,200186,NCT02058407,Bronchiectasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200186,http://clinicaltrials.gov/show/NCT02058407,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD)",fluticasone furoate/vilanterol/umeclidinium bromide,200812,NCT02729051,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/200812,http://clinicaltrials.gov/show/NCT02729051,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 monoclonal Antibody (mAb) GSK2849330 and Characterize its Dose-receptor Occupancy Relationship in Subjects with Advanced HER3-Positive Solid Tumors,GSK2849330,200980,NCT02345174,Cancer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200980,http://clinicaltrials.gov/show/NCT02345174,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Phase 1 double-blind, randomised, placebo-controlled, dose escalating study to assess the safety and tolerability of single and multiple oral doses of CHR-5154 and the effect of the fasted and fed state on pharmacokinetics of CHR-5154 and CHR-5426 in healthy male volunteers",GSK3117391,201302,NCT01934101,"Arthritis, Rheumatoid",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201302,http://clinicaltrials.gov/show/NCT01934101,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban",epelsiban,201691,NCT02257359,Embryo Transfer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201691,http://clinicaltrials.gov/show/NCT02257359,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban",epelsiban,201752,NCT02703181,Embryo Transfer,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201752,http://clinicaltrials.gov/show/NCT02703181,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Apr-2018
GSK,"An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide with Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers",albiglutide,201840,NCT02802514,Diabetes Mellitus,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201840,http://clinicaltrials.gov/show/NCT02802514,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,A Microdose Study to Describe the Intravenous Pharmacokinetics of GSK3191607 in Healthy Male Subjects Following Administration of [14C]-GSK3191607,GSK3191607,204853,NCT02737007,"Malaria, Falciparum",Phase 1,http://www.gsk-clinicalstudyregister.com/study/204853,http://clinicaltrials.gov/show/NCT02737007,,Y,N,Y,Y,Y,Y,Y,This study is available in CDISC format. An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2 Diabetes Mellitus",albiglutide,204879,NCT02793154,"Diabetes Mellitus, Type 2",Phase 4,http://www.gsk-clinicalstudyregister.com/study/204879,http://clinicaltrials.gov/show/NCT02793154,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A randomised, open, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).",GSK256066,IPR109764,NCT00464568,"Rhinitis, Allergic, Seasonal",Phase 2,http://www.gsk-clinicalstudyregister.com/study/IPR109764,http://clinicaltrials.gov/show/NCT00464568,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"Single-blind, placebo-controlled, randomized study testing single ascending doses of GSK369796 in healthy subjects",GSK369796,ISO105774,NCT00675064,Malaria,Phase 1,http://www.gsk-clinicalstudyregister.com/study/ISO105774,http://clinicaltrials.gov/show/NCT00675064,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,"A Double-Blind (sponsor unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response using Sputum Biomarkers",nemiralisib,PII115119,NCT02130635,"Pulmonary Disease, Chronic Obstructive",Phase 2,http://www.gsk-clinicalstudyregister.com/study/115119,http://clinicaltrials.gov/show/NCT02130635,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-Apr-2018
GSK,"A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects",dutasteride,ARI116897,NCT02052713,Urologic Diseases,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116897,http://clinicaltrials.gov/show/NCT02052713,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,"A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects",dutasteride,ARI116108,NCT02058576,Urologic Diseases,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116108,http://clinicaltrials.gov/show/NCT02058576,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-Apr-2018
GSK,Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in patients with resectable Non-Small Cell Lung Cancer,GSK2302032A,113174,NCT01159964,"Lung Cancer, Non-Small Cell",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113174,http://clinicaltrials.gov/show/NCT01159964,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
GSK,Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 when administered to adults with TB disease,SB692342,114886,NCT01424501,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/114886,http://clinicaltrials.gov/show/NCT01424501,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Sanofi,"A multicenter phase II randomized trial comparing XRP6258 administered either weekly (D1, D8, D15, D22 every 5 weeks) or every three weeks versus XRP9881 every three weeks in Taxoid resistant metastatic breast cancer patients",Cabazitaxel,ARD6191,Not available,Breast Cancer,Phase 2,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2018
Sanofi,Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy,Cabazitaxel,ARD12166,"NCT01500720
EudraCT2011-003415-31",Small Cell Lung Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-c/,https://clinicaltrials.gov/ct2/show/NCT01500720?term=ARD12166&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=ARD12166,Y,N,Y,Y,Y,N,Y,Datasets and document are available as per Sanofi Policy and criteria,1-May-2018
Daiichi Sankyo,DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (intravenous administration),Hydromorphone,DS-DS7113-B-J305,JapicCTI-142735,Moderate to severe cancer pain,Phase 2/3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142735,Not available,N,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Daiichi Sankyo,DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (subcutaneous injection),Hydromorphone,DS-DS7113-B-J306,JapicCTI-142736,Moderate to severe cancer pain,Phase 2/3,https://www.daiichisankyo.com/rd/our_approach/clinical_studies/result/index.html,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-142736,Not available,N,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Novartis,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Letrozole,CFEM345D2411,NCT00248170,Breast Cancer,Phase 3,https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CFEM345D2411,https://www.clinicaltrials.gov/ct2/show/NCT00248170?term=CFEM345D2411&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Novartis,"A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly",Pasireotide,CSOM230C2305,NCT00600886,Acromegaly,Phase 3,https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CSOM230C2305,https://www.clinicaltrials.gov/ct2/show/NCT00600886?term=CSOM230C2305&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Novartis,"A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research",Everolimus,CRAD001JDE49,NCT01626222,Metastatic Breast Cancer,Phase 3,https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CRAD001JDE49,https://www.clinicaltrials.gov/ct2/show/NCT01626222?term=CRAD001JDE49&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Novartis,"A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane",Everolimus,CRAD001JUS226,NCT02069093,Advanced Breast Cancer,Phase 2,https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CRAD001JUS226,https://www.clinicaltrials.gov/ct2/show/NCT02069093?term=CRAD001JUS226&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Lilly,"A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia",Olanzapine pamoate,F1D-MC-HGLQ,NCT00320489,Schizophrenia,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT00320489?term=NCT00320489&rank=1,Not available,Y,N,Y,Y,Y,Y,Y,,1-Apr-2018
Astellas,A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain,ASP8477,8477-CL-0020,"NCT02065349
EudraCT 2013-002521-27",Peripheral Neuropathic Pain,Phase 2,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=217,https://clinicaltrials.gov/ct2/show/NCT02065349,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002521-27,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
Roche,An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer,erlotinib,MO18109,NCT00949910,non-small cell lung cancer,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT00949910?term=MO18109&rank=1,,Y,Y,Y,Y,Y,Y,N,,1-Mar-2018
Roche,MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients,erlotinib,BO18279,NCT02774278,non-small cell lung cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT02774278?term=BO18279&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Mar-2018
Roche,An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers,erlotinib,MO18660,NCT02013206,non-small cell lung cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT02013206?term=MO18660&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-Mar-2018
Roche,"An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy",alectinib,ML29453,NCT02271139,non-small cell lung cancer,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT02271139?term=ML29453&rank=1,,Y,N,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"An Open-label, Multi-center Phase I/II Study of the Safety And Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) with Docetaxel, and Potentially Pertuzumab, for Treatment for Patients with Advanced Breast Cancer.",trastuzumab emtansine,BP22572,NCT00934856,breast Cancer,Phase1/2,,https://clinicaltrials.gov/ct2/show/NCT00934856,,Y,N,Y,Y,Y,Y,Y,,1-May-2018
Roche,A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1),atezolizumab,GO29293,NCT02951767,bladder Cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT02951767?term=GO29293&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
Roche,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,atezolizumab,GO28915,NCT02008227,non-small cell lung cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT02008227?term=GO28915&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR],atezolizumab,GO28625,NCT01846416,non-small cell lung cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01846416?term=GO28625&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
Roche,A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,atezolizumab,GO28754,NCT02031458,non-small cell lung cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT02031458?term=GO28754&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
Roche,"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""POPLAR""",atezolizumab,GO28753,NCT01903993,non-small cell lung cancer,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT01903993?term=GO28753&rank=1,,Y,Y,Y,N,Y,Y,Y,,1-May-2018
ViiV,A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance,fosdevirine,113399,NCT01199731,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/113399,http://clinicaltrials.gov/show/NCT01199731,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
ViiV,Phase 2b study to select a once daily oral dose of GSK2248761 administered with tenofovir/emtricitabine or abacavir/lamivudine in HIV-1 infected antiretroviral therapy naive adult subjects,fosdevirine,113404,NCT01231555,"Infection, Human Immunodeficiency Virus",Phase 2,http://www.viiv-clinicalstudyregister.com/study/113404,http://clinicaltrials.gov/show/NCT01231555,,Y,Y,Y,Y,Y,Y,Y,,1-Apr-2018
Astellas,"A randomized, double-blind, double-dummy, placebo-controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10 mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity",solifenacin succinate,905-EC-005,"NCT00629642
EudraCT 2006-005523-42",Neurogenic detrusor overactivity,Phase 4,https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=213,https://clinicaltrials.gov/ct2/show/NCT00629642,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005523-42,Y,N,Y,Y,Y,Y,Y,,1-Jun-2018
Boehringer Ingelheim,Lume Lung 2 : Nintedanib Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,nintedanib,1199.14,NCT00806819,"Carcinoma, Non-Small-Cell Lung",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00806819?term=1199.14&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Boehringer Ingelheim,LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer,nintedanib,1199.13,NCT00805194,"Carcinoma, Non-Small-Cell Lung",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT00805194?term=1199.13&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Boehringer Ingelheim,Follow on Study From RE-ALIGN,dabigatran etexilate,1160.138,NCT01505881,Thromboembolism,Phase 2,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT01505881?term=1160.138&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse",bevacizumab,AVF3708G,NCT00345163,glioblastoma,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00345163?term=AVF3708G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis",rituximab,U2786G,NCT00087529,multiple Sclerosis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00087529?term=U2786G&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis",ocrelizumab,WA21092,NCT01247324,multiple Sclerosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01247324?term=WA21092&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis",ocrelizumab,WA21093,NCT01412333,multiple Sclerosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01412333?term=WA21093&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",ocrelizumab,WA25046,NCT01194570,multiple Sclerosis,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01194570?term=WA25046&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Roche,"Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS",ocrelizumab,WA21493,NCT00676715,multiple Sclerosis,Phase 2,,https://clinicaltrials.gov/ct2/show/NCT00676715?term=WA21493&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
GSK,"A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia",SB649868,OXS107714,NCT00426816,Sleep Initiation and Maintenance Disorders,Phase 2,http://www.gsk-clinicalstudyregister.com/study/OXS107714,http://clinicaltrials.gov/show/NCT00426816,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
GSK,"A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center study to Evaluate the Dose Response Relationship of GSK1278863 over the first 4 weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 over 24 weeks in Hemodialysis-Dependent Subjects with Anemia associated with Chronic Kidney Disease who Switch from Recombinant Human Erythropoietin",daprodustat,PHI113633,NCT01977482 2009-018001-51,Anaemia,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113633,http://clinicaltrials.gov/show/NCT01977482,https://www.clinicaltrialsregister.eu/show/2009-018001-51,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
GSK,"A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum",nicotine,S2111378,NCT01476202,Smoking Cessation,Phase 2,,http://clinicaltrials.gov/show/NCT01476202,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
Takeda,"A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults",azilsartan medoxomil,TAK-491_109,"NCT01078376
2009-013165-25",Hypertension,Phase 1,http://takedaclinicaltrials.com/browse/summary/TAK-491_109,https://clinicaltrials.gov/show/NCT01078376,https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013165-25,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Randomized, Open-Label, 2-Period Crossover Study to Determine the Relative Bioavailability of 2 TAK-491 10 mg Tablets Compared to a TAK-491 20 mg Tablet in Healthy Adult Subjects",azilsartan medoxomil,TAK-491_113,Not available,Hypertension,Phase 1,Not available,Not available,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes",azilsartan medoxomil,TAK-491_304,NCT01496430,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491_304,https://www.clinicaltrials.gov/ct2/show/NCT01496430,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension",azilsartan medoxomil/chlorthalidone,TAK-491CLD_301,NCT00846365,Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_301,https://www.clinicaltrials.gov/ct2/show/NCT00846365,,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy",azilsartan medoxomil/chlorthalidone,TAK-491CLD_307,"NCT01456169
2011-000220-16",Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_307,https://www.clinicaltrials.gov/ct2/show/NCT01456169,https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000220-16,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension",azilsartan medoxomil/chlorthalidone,TAK-491CLD_308,"NCT00996281
2008-008260-28",Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_308,https://www.clinicaltrials.gov/ct2/show/NCT00996281,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008260-28,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
Takeda,"A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment",azilsartan medoxomil/chlorthalidone,TAK-491CLD_309,"NCT01309828
2010-023098-21",Hypertension,Phase 3,http://takedaclinicaltrials.com/browse/summary/TAK-491CLD_309,https://www.clinicaltrials.gov/ct2/show/NCT01309828,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023098-21,Y,Y,Y,Y,Y,Y,Y,Annotated case report forms are N/A. Blank case report forms will be provided.,1-Jun-2018
GSK,"A Phase 2, open-label, controlled, multi-center extension study to evaluate 4-year antibody persistence and booster response following MenABCWY vaccination in healthy adolescents and young adults who previously participated in studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)",GSK3536819A,205213,NCT02451514,Meningococcal disease,Phase 2,http://www.gsk-clinicalstudyregister.com/study/205213,http://clinicaltrials.gov/show/NCT02451514,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank will be provided. A reporting and analysis plan is not available for this study.,1-May-2018
GSK,GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma,GSK2132231A,111482,NCT00796445,Melanoma,Phase 3,http://www.gsk-clinicalstudyregister.com/study/111482,http://clinicaltrials.gov/show/NCT00796445,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,Safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy female children 4-6 years old,Human Papillomavirus Types 16 and 18 Vaccine,115887,NCT01627561,"Infections, Papillomavirus",Phase 3,http://www.gsk-clinicalstudyregister.com/study/115887,http://clinicaltrials.gov/show/NCT01627561,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,"Evaluation of immunogenicity and safety of GSK Biologicals' Tdap booster vaccine (Boostrix™) in young adults, administered 10 years after previous Tdap boosting","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",116570,NCT01738477,Acellular Pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116570,http://clinicaltrials.gov/show/NCT01738477,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,Safety and immunogenicity study of GSK Biologicals’ Quadrivalent Influenza Candidate Vaccine (GSK23211381A) manufactured with a new process in adults and children,Influenza Vaccine (Quadrivalent),201251,NCT02207413 2010-020735-39,Influenza,Phase 3,http://www.gsk-clinicalstudyregister.com/study/201251,http://clinicaltrials.gov/show/NCT02207413,https://www.clinicaltrialsregister.eu/show/2010-020735-39,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,"Long term immunogenicity and safety study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A and assessment of re-vaccination with 2 additional doses, in healthy subjects aged 60 years of age and older",GSK1437173A,204926,NCT02735915,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/204926,http://clinicaltrials.gov/show/NCT02735915,,Y,N,N,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided. The finalized CSR is not yet available.,1-May-2018
GSK,"Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma",GSK2132231A,111473,NCT00896480 2015-000841-22,Melanoma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111473,http://clinicaltrials.gov/show/NCT00896480,https://www.clinicaltrialsregister.eu/show/2015-000841-22,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23™ in adults aged 50 years and older,GSK1437173A,116889,NCT02045836 2009-018106-21,Herpes Zoster,Phase 3,http://www.gsk-clinicalstudyregister.com/study/116889,http://clinicaltrials.gov/show/NCT02045836,https://www.clinicaltrialsregister.eu/show/2009-018106-21,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,"Persistence of hepatitis B antibodies, immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy",INFANRIX PENTA/INFANRIX HEXA / PEDIARIX,106794,NCT02798952,Hepatitis B,Phase 4,http://www.gsk-clinicalstudyregister.com/study/106794,http://clinicaltrials.gov/show/NCT02798952,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,Immunogenicity and safety study of GSK Biologicals’ combined measles-mumps-rubella vaccine in subjects seven years and older (209762),"Measles, Mumps, Rubella Vaccine",115231,NCT02058563,Measles; Mumps; Rubella,Phase 3,http://www.gsk-clinicalstudyregister.com/study/115231,http://clinicaltrials.gov/show/NCT02058563,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank will be provided.,1-May-2018
GSK,"An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects with Pulmonary Arterial Hypertension (PAH)",epoprostenol,201614,NCT02705807,Cardiovascular Disease,Phase 4,http://www.gsk-clinicalstudyregister.com/study/201614,http://clinicaltrials.gov/show/NCT02705807,,Y,Y,Y,Y,Y,N,Y,A raw dataset is not available for this study.,1-May-2018
Sunovion,"A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia",Lurasidone hydrochloride,D1050229,NCT00549718  EudraCT 200700381931,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/show/NCT00549718,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D1050229,Y,Y,Y,Y,Y,Y,Y,The raw dataset is combined for D1050229 and D1050229E,1-Jun-2018
Sunovion,"A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia (6-month Open-Label Extension)",Lurasidone hydrochloride,D1050229E,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,The raw dataset is combined for D1050229 and D1050229E,1-Jun-2018
Sunovion,"A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia",Lurasidone hydrochloride,D1050231,NCT00615433 EudraCT 200700382040,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/show/NCT00615433,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D1050231,Y,Y,Y,Y,Y,Y,Y,The raw dataset is combined for D1050231 and D1050231E,1-Jun-2018
Sunovion,"A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia (6-month Open-Label Extension)",Lurasidone hydrochloride,D1050231E,Not available,Schizophrenia,Phase 3,Not available,Not available,Not available,Y,Y,Y,Y,Y,Y,Y,The raw dataset is combined for D1050231 and D1050231E,1-Jun-2018
Sunovion,"A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)",Lurasidone hydrochloride,D1050233,NCT00790192 EudraCT 2008003984-38,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/show/NCT00790192,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D1050233,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Sunovion,"A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)",Lurasidone hydrochloride,D1050234,NCT00789698,Chronic Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/show/NCT00789698,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Sunovion,"A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia",Lurasidone hydrochloride,D1050238,NCT01435928 EudraCT 201100171131,Schizophrenia,Phase 3,Not available,http://clinicaltrials.gov/show/NCT01435928,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D1050238,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Sunovion,"A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents",Lurasidone hydrochloride,D1050289,NCT011443077,Schizophrenia; Schizoaffective disorder,Phase 3,Not available,http://clinicaltrials.gov/show/NCT01143077,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
Sunovion,"A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder",Lurasidone hydrochloride,D1050290,NCT01143090,Schizophrenia; Schizoaffective disorder,Phase 3,Not available,http://clinicaltrials.gov/show/NCT01143090,Not available,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
ViiV,"A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination with the Abacavir/Lamivudine Fixed Dose Combination Tablet over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects",dolutegravir,ING116070,NCT01499199,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/116070,http://clinicaltrials.gov/show/NCT01499199,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
ViiV,"A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo over 7 Days in HIV-1-infected Subjects with RAL/ELV resistance, Followed by an Open-label Phase with an Optimized Background Regimen",dolutegravir,ING116529,NCT01568892,"Infection, Human Immunodeficiency Virus",Phase 3,http://www.viiv-clinicalstudyregister.com/study/116529,http://clinicaltrials.gov/show/NCT01568892,,Y,Y,Y,Y,Y,Y,Y,,1-May-2018
GSK,Long-term follow-up of participants from studies evaluating the HIV vaccine 732462,SB732462,114083,NCT01092611,HIV Infections,Phase 1,http://www.gsk-clinicalstudyregister.com/study/114083,http://clinicaltrials.gov/show/NCT01092611,,Y,Y,Y,Y,Y,Y,Y,This is a follow up  study to 111679 and 112353.,1-Jun-2018
GSK,"Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110084,NCT00489970  2005-005825-75,Acellular Pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110080,http://clinicaltrials.gov/show/NCT00489970,https://www.clinicaltrialsregister.eu/show/2005-005825-75,Y,Y,Y,Y,Y,Y,N,"This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110082, 110086 and posted under 110080 on the GSK Study Register. A reporting and analysis plan is not available for this study. The statistical analysis plan is not available for this study",1-Jun-2018
GSK,"Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110086,NCT00489970     2005-005825-75,Acellular Pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110080,http://clinicaltrials.gov/show/NCT00489970,https://www.clinicaltrialsregister.eu/show/2005-005825-75,Y,Y,Y,Y,Y,Y,Y,"This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110084, 110086 and posted under 110080 on the GSK Study Register.",1-Jun-2018
GSK,"Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110082,NCT00489970     2005-005825-75,Acellular Pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110080,http://clinicaltrials.gov/show/NCT00489970,https://www.clinicaltrialsregister.eu/show/2005-005825-75,Y,Y,Y,Y,Y,Y,Y,"This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110084, 110086 and posted under 110080 on the GSK Study Register.",1-Jun-2018
GSK,"Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9","Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine",110080,NCT00489970    2005-005825-75,Acellular Pertussis; Diphtheria; Tetanus,Phase 3,http://www.gsk-clinicalstudyregister.com/study/110080,http://clinicaltrials.gov/show/NCT00489970,https://www.clinicaltrialsregister.eu/show/2005-005825-75,Y,Y,Y,Y,Y,Y,Y,"This is a follow-up study to 106316. Follow-on studies were conducted: 110082, 110084, 110086 and posted under 110080 on the GSK Study Register.",1-Jun-2018
GSK,"A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis",GSK3536852A,205494,NCT02676895,Shigella sonnei infection,Phase 2,http://www.gsk-clinicalstudyregister.com/study/205494,http://clinicaltrials.gov/show/NCT02676895,,Y,N,Y,Y,Y,Y,N,An annotated case report form is not available for this study. A blank case report form will be provided.The reporting and analysis plan is not available for this study.,1-Jun-2018
GSK,Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in adult Acute Myeloid Leukemia patients with a suboptimal clinical response to induction chemotherapy,GSK2130579A,111727,NCT01051063,"Leukaemia, Myelocytic, Acute",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111727,http://clinicaltrials.gov/show/NCT01051063,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
GSK,Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as post-consolidation therapy in adult patients with Acute Myeloid Leukemia,GSK2130579A,111444,NCT00725283   2006-001281-16,"Leukaemia, Myelocytic, Acute",Phase 1,http://www.gsk-clinicalstudyregister.com/study/111444,http://clinicaltrials.gov/show/NCT00725283,https://www.clinicaltrialsregister.eu/show/2006-001281-16,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
GSK,Efficacy and safety of HIV Vaccine 732462 in ART-naïve HIV-1 infected persons,SB732462,111679,NCT01218113,HIV Infections,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111679,http://clinicaltrials.gov/show/NCT01218113,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 114083 was conducted,1-Jun-2018
GSK,Study to evaluate the safety and reactogenicity of the HIV Vaccine 732461 in HIV infected subjects aged 18 to 55 years old,SB732462,112353,NCT00814762,HIV Infections,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112353,http://clinicaltrials.gov/show/NCT00814762,,Y,Y,Y,Y,Y,Y,Y,A follow-on study 114083 was conducted,1-Jun-2018
GSK,"A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586184 following a single dose of 800mg and repeat oral tablet doses of 800mg b.d and the effect of food and gender on the pharmacokinetics of oral GSK2586184 in healthy subjects",solicitinib,JAK116439,NCT01687309,Systemic Lupus Erythematosus,Phase 1,http://www.gsk-clinicalstudyregister.com/study/116439,http://clinicaltrials.gov/show/NCT01687309,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,"A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir after Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults",zanamivir,NAI117104,NCT02377401,"Influenza, Human",Phase 1,http://www.gsk-clinicalstudyregister.com/study/117104,http://clinicaltrials.gov/show/NCT02377401,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
GSK,A comparison of the effects of AVANDIA® on arterial stiffness in obese subjects and healthy non-obese control subjects,rosiglitazone,999910/189,,Insulin Resistance,Phase 1,http://www.gsk-clinicalstudyregister.com/study/999910/189,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.The Reporting and analysis plan is not available for this study.,1-Jun-2018
GSK,"A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease",fluticasone furoate/vilanterol/umeclidinium bromide,CTT116855,NCT02164513,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://www.gsk-clinicalstudyregister.com/study/116855,http://clinicaltrials.gov/show/NCT02164513,,Y,Y,Y,Y,Y,Y,Y,,1-Jun-2018
GSK,"A Multicenter, Double–Blind, Placebo–Controlled, Flexible Dose (100–400mg) 10 Week Evaluation Of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Bipolar Disorder",lamotrigine,SCAA2010,2016-002294-35,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCAA2010,,https://www.clinicaltrialsregister.eu/show/2016-002294-35,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2018
GSK,"A Multicenter, Double–Blind, Placebo–Controlled, Fixed Dose (50 or 200mg per day) 7 Week Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar Disorder",lamotrigine,SCAB2001,,"Depressive Disorder, Major",Phase 3,http://www.gsk-clinicalstudyregister.com/study/SCAB2001,,,N,N,Y,Y,Y,Y,N,A link to clinical trials.gov and a NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jun-2018
Boehringer Ingelheim,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,tiotropium bromide + olodaterol,1237.16,NCT02085161,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02085161?term=1237.16&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
Boehringer Ingelheim,"A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]",tiotropium bromide + olodaterol,1237.19,NCT02296138,"Pulmonary Disease, Chronic Obstructive",Phase 3,http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview.html,https://clinicaltrials.gov/ct2/show/NCT02296138?term=1237.19&rank=1,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
Roche,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",bevacizumab,GO25632,NCT01663727,Breast Cancer,Phase 3,,https://clinicaltrials.gov/ct2/show/NCT01663727?term=GO25632&rank=1,,Y,N,Y,N,Y,Y,Y,,1-Jul-2018
Sanofi,A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma,Vandetanib,"D4200C00004
6474IL/0004",NCT00047788,Multiple Myeloma,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00047788?term=6474IL%2F0004&rank=1,Not available,Y,Y,N,Y,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).",Vandetanib,D4200C00002 (6474IL/0002),NCT00034918,"Breast Neoplasms
Metastases, Neoplasm",Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00034918?term=6474IL%2F0002&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.",Vandetanib,D4200C00003 (6474IL/0003),NCT00059722,"Carcinoma, Non-Small Cell Lung Cancer",Phase 2,Not available,https://clinicaltrials.gov/ct2/show/study/NCT00059722?term=6474IL%2F0003&rank=1&show_locs=Y,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy,Vandetanib,D4200C00005 (6474IL/0005),NCT00066313,Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00066313?term=6474IL%2F0005&rank=1,Not available,N,Y,N,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",Vandetanib,D4200C00007,NCT00071188,Locally Advanced or Metastatic NSCLC,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/record/NCT00071188?term=D4200C00007&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.",Vandetanib,D4200C00008 (LPS14954),NCT00098345,Unresectable Locally Advanced Cancer or  Medullary Thyroid Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/study/NCT00098345?term=d4200c00008&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]",Vandetanib,D4200C00039,NCT00252746,Non-Small Cell Lung Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/record/NCT00252746?term=d4200c00039&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with Arimidex vs. Arimidex alone in patients with hormone sensitive (ER+ve and/or PR+ve) tumours as 2nd line treatment for advanced breast cancer (ABC)",Vandetanib,D4200C00045,EudraCT2005-003591-38,Advanced Breast Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,Not available,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D4200C00045,Y,N,N,Y,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).","Vandetanib, Docetaxel",D4200C00046,"NCT004944812
EudraCT2005-003592-20",Advanced Breast Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00494481?term=D4200C00046&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003592-20,Y,N,N,Y,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen",Vandetanib,D4200C00047 (LPS15025),"NCT00500292
EudraCT2006-005022-23",Colorectal Cancer,Phase 2,Not available,https://clinicaltrials.gov/ct2/show/NCT00500292?term=D4200C00047&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005022-23,Y,N,N,N,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Oxaliplatin and Fluoropyrimidine Containing Regimen",Vandetanib,D4200C00048,"NCT00454116
EudraCT2006-005023-42",Colorectal Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00454116?term=D4200C00048&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005023-42,Y,Y,N,N,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)",Vandetanib,D4200C00055,"NCT00358956
EudraCT2006-001354-28","Prostate Cancer, Metastatic, Hormone Refractory",Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/results/NCT00358956?term=D4200C00068&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001354-28,Y,Y,N,Y,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",Vandetanib,D4200C00068,"NCT00358956
EudraCT2006-001354-28",Unresectable Locally Advanced Cancer or  Medullary Thyroid Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/results/NCT00358956?term=D4200C00068&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001354-28,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)",Vandetanib,D4200C00072,NCT00508001,"Carcinoma, Hepatocellular",Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/record/NCT00508001?term=D4200C00072&rank=1,Not available,N,N,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.",Vandetanib,D4200C00075,"NCT00597116
EudraCT2007-003633-16",Mesothelioma,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/study/NCT00597116?term=D4200C00075&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003633-16+,N,N,Y,N,Y,N,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy",Vandetanib,D4200C00077,NCT00777179,Non-Small Cell Lung Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/study/NCT00777179?term=D4200C00077&rank=1,Not available,N,N,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized, Double-blind Phase II Trial to Assess the Efficacy and Safety of Bicalutamide (Casodex® ) Associated to ZD6474 (Zactima™ ) or to Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression",Vandetanib,D4200C00080,"NCT00659438
EudraCT2007-001891-35",Prostate Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00659438?term=D4200C00080&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001891-35,N,Y,N,N,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients (ZELIG)",Vandetanib,D4200L00012,"NCT00753714
EudraCT2007-004521-22",Non-Small Cell Lung Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00753714?term=D4200L00012&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004521-22,N,N,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestrant (Loading Dose)in Postmenopausal Advanced BC Patients (ZACFAST)",Vandetanib,D4200L00009,"NCT00752986
EudraCT2008-000579-12",Breast Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/study/NCT00752986?term=D4200L00009&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000579-12,N,N,N,N,Y,Y,N,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy",Vandetanib,D4200L00010,NCT00686036,Prostate Cancer,Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00686036?term=D4200L00010&rank=1,Not available,N,N,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)(VANGOGH)",Vandetanib,D4200L00007,"NCT00753675
EudraCT2007-003056-12","Biliary Tract Cancer
Gallbladder Cancer
Cancer, Extrahepatic Bile Duct
Ampullary Carcinoma",Phase 2,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/NCT00753675?term=D4200L00007&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=D4200L00007,N,N,Y,N,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI),Vandetanib,D4200C00044,"NCT0404924
EudraCT2006-002384-12",Locally Advanced or Metastatic NSCLC,Phase 3,https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/letter-v/,https://clinicaltrials.gov/ct2/show/record/NCT00404924?term=d4200c00044&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=d4200c00044,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Sanofi,"A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy",Vandetanib,D4200C00057,"NCT00364351
EudraCT2006-000259-16",Locally Advanced or Metastatic NSCLC,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/record/NCT00364351?term=d4200c00057&rank=1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000259-16,Y,Y,Y,Y,Y,Y,Y,Datasets and document are available as per Sanofi Policy and criteria,1-Jul-2018
Lilly,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis (SPIRIT-P2)",Ixekizumab,I1F-MC-RHBE,NCT02349295,Psoriatic Arthritis,Phase 3,Not available,https://clinicaltrials.gov/ct2/show/NCT02349295?term=RHBE&rank=1,Not available,Y,Y,Y,Y,Y,Y,Y,The 52 week publication is pending. Datasets available up to 24 weeks.,1-Jul-2018
Academic Research Funders,Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer,ipilimumab in combination with carboplatin and etoposide (ICE),ICE,"NCT01331525
EudraCT 2010-021863-34",extensive stage small cell lung cancer,Phase 2,,http://clinicaltrials.gov/show/NCT01331525,https://eudract.ema.europa.eu/2010-021863-34,Y,N,Y,Y,Y,Y,Y,An Annotated CRF is not available however a spreadsheet showing what each raw variable means and question it maps to from the CRF is available,1-Jul-2018
GSK,Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in association with chemotherapy in patients with unresectable and progressive metastatic cutaneous melanoma,GSK2132231A,111714,NCT00849875   2007-005303-18,Melanoma,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111714,http://clinicaltrials.gov/show/NCT00849875,https://www.clinicaltrialsregister.eu/show/2007-005303-18,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,Safety and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to HIV-positive adults living in a Tuberculosis endemic region,SB692342,113935,NCT01262976,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/113935,http://clinicaltrials.gov/show/NCT01262976,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,"A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who are HSV-1 and -2 Seronegative",SB208141,208141/039,NCT00057330,Herpes Simplex,Phase 3,http://www.gsk-clinicalstudyregister.com/study/208141/039,http://clinicaltrials.gov/show/NCT00057330,,Y,N,Y,Y,Y,Y,Y,An annotated case report form is not available for this study. A blank case report form will be provided.,1-Jul-2018
GSK,A study to evaluate GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in healthy young adults,"Hepatitis B Vaccine, Recombinant",112076,NCT00814489 2010-024564-17,Hepatitis B,Phase 1,http://www.gsk-clinicalstudyregister.com/study/112076,http://clinicaltrials.gov/show/NCT00814489,https://www.clinicaltrialsregister.eu/show/2012-000282-20,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,"A partially blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Staphylococcal 4-component investigational vaccine (GSK2392102A) in healthy adults",GSK2392102A,113949,NCT01160172  2010-024564-17,"Infections, Staphylococcal",Phase 1,http://www.gsk-clinicalstudyregister.com/study/113949,http://clinicaltrials.gov/show/NCT01160172,https://www.clinicaltrialsregister.eu/show/2010-024564-17,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,Dose range study evaluating safety and immunogenicity study of GSK Biologicals' candidate tuberculosis vaccines (692342) when administered to healthy adults aged 18 to 45 years.,SB692342,110345,NCT00621322  2005-005682-11,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/110345,http://clinicaltrials.gov/show/NCT00621322,https://www.clinicaltrialsregister.eu/show/2005-005682-11,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy HIV-negative adolescents living in a TB endemic region,SB692342,112898,NCT00950612,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112898,http://clinicaltrials.gov/show/NCT00950612,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,Safety and immunogenicity of a candidate tuberculosis (TB) vaccine (692342) in HIV-positive adults.,SB692342,111517,NCT00707967   2006-004777-10,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/111517,http://clinicaltrials.gov/show/NCT00707967,https://www.clinicaltrialsregister.eu/show/2006-004777-10,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants,SB692342,112899,NCT01098474,Tuberculosis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/112899,http://clinicaltrials.gov/show/NCT01098474,,Y,Y,Y,Y,Y,Y,Y,,1-Jul-2018
GSK,"A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease exhibiting delayed gastric emptying",camicinal,MOT115816,NCT01602549,Gastroparesis,Phase 2,http://www.gsk-clinicalstudyregister.com/study/115816,http://clinicaltrials.gov/show/NCT01602549,,N,Y,Y,Y,Y,N,Y,Awaiting Olu's confirmation if both raw and AR datasets not available will not list this study,1-Jul-2018
GSK,A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically applied GSK2894512 Cream in Subjects with Atopic Dermatitis,tapinarof,201851,NCT02466152 2010-021569-58,"Dermatitis, Atopic",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201851,http://clinicaltrials.gov/show/NCT02466152,https://www.clinicaltrialsregister.eu/show/2010-021569-58,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2018
GSK,A FTIH study with GSK3008348 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis,GSK3008348,200262,NCT02612051,Idiopathic Pulmonary Fibrosis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/200262,http://clinicaltrials.gov/show/NCT02612051,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2018
GSK,"A randomized, open-label, single-period, parallel-group study in healthy subjects to determine the effects of dissolution profile on the pharmacokinetics (via both venous and peripheral micro-samples) of single oral 300 mg doses of Tafenoquine (SB-252263) tablets + 30 mg Tafenoquine stable isotope labelled (SIL) solution",tafenoquine,201780,NCT02751294,"Malaria, Vivax",Phase 1,http://www.gsk-clinicalstudyregister.com/study/201780,http://clinicaltrials.gov/show/NCT02751294,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2018
GSK,A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test,GSK2981278,201465,NCT02548052,Psoriasis,Phase 1,http://www.gsk-clinicalstudyregister.com/study/201465,http://clinicaltrials.gov/show/NCT02548052,,Y,Y,Y,Y,Y,Y,Y,This study is available in CDISC format,1-Jul-2018
